JACQUES R. SIMARD, PhD, FCAHS, C.Dir

ADDRESS

Genomics Centre
CHU de Québec - Université Laval Research Centre
2705, Laurier Blvd, R-4720 - Quebec (Quebec) G1V 4G2
Tel.: (418) 654-2264
E-mail: jacques.simard@crchudequebec.ulaval.ca
Website: http://www.crchudequebec.ulaval.ca/en/research/researchers/jacques-simard/

CURRENT POSITIONS

- Vice-Dean of Research and Graduate Studies, Faculty of Medicine, Université Laval, Quebec
- Chairholder of the Canada Research Chair in Oncogenetics (Tier 1)
- Full Professeur, Department of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec
- Director, Cancer Genomics Laboratory, CHU de Québec-Université Laval Research Centre, Quebec

ACADEMIC TRAINING AND DEGREES

2010	C.Dir, Certification in Governance of corporations, *Collège des administrateurs de sociétés (CAS)* (Directors College) of the Université Laval, with a joint venture between The Conference Board of Canada and the Degroote School of Business at McMaster University. Director : Jacques Grisé.
08/86-03/90	Post-doctoral Fellow, Laboratory of Molecular Endocrinology, CHUL Research Centre, Quebec. Director : Manjapra Variath Govindan.
02/83-07/86	PhD, Physiology (Molecular Endocrinology), Université Laval, Quebec. Subject : Modulation of growth hormone secretion and characterization of the effects of adrenal C-19 steroids and atrial natriuretic factor in the anterior pituitary. Director : Fernand Labrie.
05/81-01/83	MSc, Biology (Type B, Fundamental Genetics), Université Laval, Quebec. Subject : Utilization of unstable genetic mutations in the fungi *Ascobolus immersus* for the study of the molecular mechanism of genetic recombination. Director : Normand Paquette.
08/78-05/81	BSc, Biology, Université Laval, Quebec.

ACADEMIC POSITIONS

07/2018-	Vice-Dean of Research and Graduate Studies, Faculty of Medicine, Université Laval, Québec (July 2018-)
01/2001-	Chairholder of the Canada Research Chair in Oncogenetics, Tier 1.
06/2001-	Full Professor, Department of Anatomy and Physiology (2001-2009) / Departement of Molecular Medicine (2009-), Faculty of Medicine, Université Laval, Quebec.
06/1997-05/2001	Associate Professor, Department of Anatomy-Physiology, Faculty of Medicine, Université Laval, Quebec.
06/1990-06/1997	Assistant Professor, Department of Anatomy-Physiology, Faculty of Medicine, Université Laval, Quebec.

INTERNAL PROFESSIONAL PARTICIPATION

01/2014-	Director, Next Generation Sequencing Platform, Genomics Center, CHU de Québec-Université Laval Research Centre, Quebec.
04/1997-	Director, Cancer Genomics Laboratory, CHUQ Research Centre (1997-2012), CHU de Québec Research Centre (2013-2015), CHU de Québec-Université Laval Research Centre (2015-), Quebec.
06/2012-07/2018	Deputy Director Basic Research, CHUQ Research Centre (May 2012-March 2013) / CHU de Québec Research Centre (March 2013-March 2015) / CHU de Québec-Université Laval Research Centre (March 2015-July 2018), Québec.
06/2008-05/2012	Director, Endocrinology and Genomics Axis, CHU de Québec Research Centre, Quebec.

DISTINCTIONS & AWARDS

05/2019	*Prix Grands diplômés 2019 de l'Université Laval,* recipient of the *« Gloire de l'Escolle »* medal
04/2018	Scientific, Medical and Research Excellence Award*,* conferred by the Quebec Breast Cancer Foundation.
01/2018	*Grand Lauréat 2017*, Le Soleil/Radio Canada
11/2017	*Lauréat de la Semaine*, Le Soleil/Radio Canada
11/2017	*Léo-Pariseau - sciences biologiques et sciences de la santé* awarded by l'Association francophone pour le savoir (ACFAS).
11/2012	« *Les Grands Prix Sirius 2011-2012 du CHU de Québec* », « Fundamental Research » award recipient.
11/2009	«Researcher of the month» awarded by Canadiens for Health Research, Science in the Service of Health.
2006-	Fellow, Canadian Academy of Health Sciences.
2004	«*Prix d'Excellence 2004*», awarded by Foundation for Research into Children's Diseases.
2003	« *Mérites du CQLC 2003* », awarded to INHERIT BRCAs by « *le Conseil québécois de lutte contre le cancer du Ministère de la santé du gouvernement du Québec ».*
2000-	Canada Who's Who.
1999	Young Investigator Richard E. Weitzman Memorial Award conferred by The Endocrine Society for Young Researchers (less than 40 years old).
1997	"André Dupont Young Investigator Award", *Club de recherches cliniques du Québec.*
1991	"Antoni Nalecz Award" for the best presentation at the Annual Meeting of the Canadian Society of Endocrinology and Metabolism.
1989	"New Investigator Award" conferred by The Endocrine Society, Seattle, USA.
1985	Student Award conferred by the Canadian Society for Clinical Investigation, Vancouver.
1985	Student Prize awarded by Upjohn Company at the "Eastern Student Research Forum", Miami, Florida, USA.

SCHOLARSHIPS, FELLOWSHIPS & STUDENTSHIPS

03/2015-02/2022	Renewal 2 - Chairholder of the Canada Research Chair in Oncogenetics, Tier 1.
03/2008-02/2015	Renewal 1 - Chairholder of the Canada Research Chair in Oncogenetics, Tier 1.
2001-2008	Chairholder of the Canada Research Chair in Oncogenetics, Tier 1.
1998-2001	Research Scholar (Senior), Fonds de la Recherche en Santé du Québec (FRSQ).
1996-1998	Research Scholar (Junior II), FRSQ.
1991-1996	Research Scholar, Medical Research Council of Canada (MRCC).
1991-1994	Research Scholar (Junior I), FRSQ.
1987-1990	Postdoctoral Fellowship, FRSQ.
1985-1986	Studentship for graduate studies at the Ph.D. level, awarded by the Fonds pour la formation de chercheurs et l'aide à la recherche (Fonds F.C.A.R.).
1981-1983	Studentship for graduate studies at the M.Sc. level, awarded by the Fonds F.C.A.R.

COMMITTEES

1. Board of Directors / Advisory Boards

01/2020-	President, Research coordination committee of the Québec Molecular Diagnostic Network, *Ministère de la santé et des service sociaux du Québec*
05/2019-	Member, Scientific Advisory Committee, Québec Breast Cancer Foundation (FCSQ)
09/2018-	Member, Scientific Steering Committee, CONFLUENCE
01/2018-	Member, Scientific Advisory Board, MyPeBS (Personalising Breast Screening) project and clinical trials, Unicancer National Breast Cancer Group
10/2016-	Member, Scientific Advisory Committee, CARTaGENE.
2013-	Member, Data Access Coordinating Committee, BCAC (Breast Cancer Association Consortium).
2010-	Member, Data Access Coordinating Committee, CIMBA (The Consortium of Investigators of Modifiers of *BRCA1/2*).
1999-	Member, *Conseil sectoriel, Investissements technologiques* (1999-2009) / *Conseil sectoriel, Nouvelle Économie* (2009-2015) / *Comité d'Investissement Nouvelle Économie* (2015-2018) / *Innovation et capital de risque* (2019-), Fonds de Solidarité FTQ.
2014 -2017	Member, *Conseil scientifique international, Site de recherche intégrée sur le cancer* (SIRIC) ONCOLille.
2016-2018	« *Co-champion* », Merck-FRQS Collaboration Initiative, Towards the Consolidation of a Competitive Cancer Research and Innovation Technopole in Quebec « Oncopole ».
2013-2017	Member, External Advisory Committee, *Regroupement en Soins de Santé Personnalisés au Québec (RSSPQ)*.
2010-2016	President, Science and Industry Advisory Committee (SIAC), Genome Canada.
2010-2016	*Ex officio Member*, Board of Directors, Genome Canada.
2000-2019	Member, Board of Directors, *Réseau de médecine génétique appliquée du FRSQ* (RMGA).
2010-2011	Member, FRSQ Advisory Committee "*Développement d'une stratégie québécoise concertée de médecine personnalisée*".

2007-2009	Chairman, Users' Board, CARTaGENE.
2009-2010	Member, Transition Team, Genome Canada
2005-2010	Chairman (2008-2010), Member (2005-2008), Corporate Governance Committee, Genome Canada.
2006-2008	Chairman (2007-2008), Member (2006-2007), Investistment Committee, Genome Canada.
2005-2010	Member, Board of Directors, Genome Canada.
2005-2012	Member, Ministerial Science Advisory Board, Health Canada.
2005-2006	Member, Oncogenetic Scientific Board of the *Institut national du cancer de France*.
2002-2007	Member Research Policy Advisory Committee of the Canadian Association of Provincial Cancer Agencies.
2001-2012	Member, Member, Planning and Priorities Committee: From Gene to Genomic Medicine, Institute of Genetics, Canadian Institutes for Health Research (CIHR)
2001-2004	Member, Institute of Gender and Health Advisory Board, Canadian Institutes of Health Research (CIHR).
1998-2000	Member, Governing Council, Medical Research Council of Canada.
1997-2001	Member, Canadian Breast Cancer Research Initiative Management Committee.

3. Editorial Board of Scientific Journals

2001-2009	Member, Editorial Board, Molecular and Cellular Endocrinology.
2002-2006	Member, Editorial Board, Journal of Endocrinology.
2001-2004	Member, Editorial Board, Endocrinology.
1996-2004	North American Reviews Editor, Journal of Molecular Endocrinology.
1994-1999	Member, Editorial Board, The Journal of Clinical Endocrinology & Metabolism.

4. Peer Review Panels

09-10/01/2018	Member, Ontario Research Fund – Research Excellence Program Round 9, Health Sciences Panel
05-07/04/2017	Member, Comité d'évaluation multidisciplinaire, Concours 2017 du Fonds d'innovation de la Fondation canadienne pour l'innovation (FCI).
2015	Member, Canadian Cancer Society Research Institute (CCSRI), Toronto, Ontario, Canada, September 29-30, 2015.
2013	Chairman, Multidisciplinary Assessment Committee, Canada Foundation for Innovation (CFI), Ottawa, Ontario, Canada, September 24-25, 2013.
2012	Member, PSR-SIIRI Program Evaluation Committee, *Fonds de recherche du Québec - Santé (FRQS)*, 23 October 2012.
2011	Member, Ontario Research Fund – Research Excellence Program Round 5, Genomics Panel.
2010	Member, Ontario Research Fund-Global Leadership in Genomics and Life Sciences (GL2 competition) Cancer & Stem Cells Panel.
2009	Chairman, Multidisciplinary Assessment Committee (Number 8), Canada Foundation for Innovation (CFI).

2008	Chairman, *Jury de sélection de Prix du Québec Wilder-Penfield*.
2007-2008	Chairman, Assessment Committee of the CHUM, *Fonds de la recherche en santé du Québec (FRSQ)*.
2004-2005	Member, IDEA Grant Applications, Canadian Breast Cancer Research Alliance (CBCRA).
2003-2004	Chairman, Assessment Committee, Canada Foundation for Innovation (CFI).
2001-2004	Member, *Comité des cancers héréditaires, Conseil de lutte contre le cancer du Québec, Gouvernement du Québec.*
2003-2004	Member, Assessment Committee, Alberta Cancer Board.
2003	Chairman, *Groupe de recherche en cancer de McGill, Fonds de la recherche en santé du Québec (FRSQ).*
2002-2003	Member for the CBCRA's Translation Acceleration Grants, Canadian Breast Cancer Research Alliance (CBCRA).
2002-2003	Member, Assessment Committee, Ontario Cancer Research Network.
2001	Member, Assessment Committee, *Fonds de la recherche en santé du Québec (FRSQ)* / Canada Foundation for Innovation (CFI).
2001-2003	Chairman, Assessment Committee of the Lady Davis Research Centre, *Fonds de la recherche en santé du Québec (FRSQ)*.
1999-2000	Member, *Comité d'évaluation des performances des centres de recherche et de leurs chercheurs, Fonds de la recherche en santé du Québec (FRSQ).*
1999-2000	Member, Committee for the Michael Smith Award, Medical Research Council of Canada (MRCC).
1997	Member, Molecular Genetics, Department of Defense Breast Cancer Research Program.
1993-1994	Vice President, Advisory Committee on the Science Citation Index, *FRSQ*.
1993	Member, Data Base and Registry on Medical Research in Canada, MRC/PMAC Advisory Committee.
1992-1997	Member (7/92-6/95) and Scientific Officer (7/95-7/97), Peer Review Panel, Endocrinology, Medical Research Council of Canada (MRCC).
1991-1994	Chairman (1993-1994), Vice-chairman (1992-1993) and Member (1991-1992), Postdoctoral Fellowship Committee, FRSQ.
1990	Member, MSc Studentship Committee, FRSQ.

5. Organizing Committees for Conferences

02/2019	Member, Scientific Steering Committee for the European Commission Joint Research Centre Conference, *Integrating genomics into personalised healthcare: a science-for-policy perspsective. My Genome: our future,* Brussels, Belgium, February 12-13, 2019.
09/2018	Member, Scientific Program Committee, 2nd International Congress on Personnalized Healthcare (ICPH), Montreal, QC, Canada, September 23-26 ,2018.
04/2018	Co-organiser, *Rendez-Vous Génome Québec 2018*, Quebec, QC, Canada, April 20, 2018.
10/2016	Co-organiser, *Rendez-Vous Génome Québec 2016*, Quebec, QC, Canada, September 30, 2016.

05/2016	President of the PERSPECTIVE (Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer) - CPAC (Canadian Partnership Against Cancer) / CBCSN (Canadian Breast Cancer Screening Network) joint meeting, Montréal, QC, Canada, May 9, 2016.
2015-2016	Member, Scientific Program Committee, 1st International Congress on Personnalized Healthcare (ICPH), Montreal, QC, Canada, June 12-14, 2016.
2014-2015	Member, Scientific Program Committee of the 2015 Canadian Cancer Research Conference (CCRC), Montreal, QC, Canada, November 8-10, 2015.
2014	Co-organiser, *Rendez-Vous Génome Québec 2014*, Quebec, QC, Canada, May 26, 2014.
2013	Member, Genome Canada, Disruptive Technologies Workshop, Toronto, ON, Canada, May 9-10, 2013.
2012-2013	Membre, Scientific Program Committee for the 2013 Canadian Cancer Research Conference, Toronto, ON, Canada, November 3-6, 2013.
2012	President of the organization committee of the international « COGS 2012 », *Joint Meeting Collaborative Oncological Gene-Environment Study / CIHR Team in Familial Risks of Breast Cancer,* Loews Hôtel Le Concorde, Quebec, QC, Canada, September 18-26, 2012. International Consortia Meetings: IBCCS (*International BRCA1/2 Carrier Cohort Study*), September 18, 2012. CIMBA (*Consortium of Investigators of Modifiers of BRCA1/2*), September 18-20, 2012. BCAC (*Breast Cancer Association Consortium*), September 20-22, 2012. COMPLEXO (*Consortium of Massively Parallel Breast Cancer Exome Sequencing*), September 21, 2012. ENIGMA (*Evidence-based Network for the Interpretation of Germline Mutant Alleles*), September 21-22, 2012. PRACTICAL (*Prostate cancer AssoCiation group To Investigate Cancer Associated altérations in the genome*), September 24-25, 2012. OCAC (*Ovarian Cancer Association Consortium*), September 24-26, 2012. CEC (*Clinical ELLIPSE (ELucidating Loci Involved in Prostate cancer SuscEptibility) Consortium*), September 26, 2012.
2011	President and organization of the 2011 Annual meeting of the CIHR Team in Familial Risks of Breast Cancer, Quebec, QC, Canada, March 21-22, 2011.
2010	Member, *Journées scientifiques du Centre de Recherche en Endocrinologie Moléculaire et Oncologique et en Génomique Humaine (CREMOGH) et de l'Axe Endocrinologie et Génomique*, Quebec, QC, Canada, October 28-29, 2010.
2009	President and organization of the 2009 Annual Meeting of the CIHR Team in Familial Risks of Breast Cancer, Quebec, QC, Canada, April 14-15, 2009.
2008	Member, Local Organizing Committee, International Congress on Hormonal Steroids and Hormones and Cancer, Quebec, QC, Canada, September 2008.
2008	Member, Organizing Committee, *Journées Génétiques 2008: 400 ans de "brassage de gènes" au Québec - Qu'en résulte-t-il?* Quebec, QC, Canada, May 2008.
2006-2007	Member, HGM2007 Local Organizing Committee, 12th International Congress. The Human Genome Organisation (HUGO), Montreal, QC, Canada, May 2007.
2004	Member, Organization Committee, *Dix-septièmes Entretiens du Centre Jacques Cartier 2004* (EJC) Oncogenetics: Achievements and Challenges, Montreal, QC, Canada, October 2004.

2002	Co-Chairman, Joint Conference on Inherited Susceptibility to Breast and Ovarian Cancers - Second Annual INHERIT BRCAs Meeting & First National Hereditary Cancer Task Force, Quebec, QC, Canada, November 2002.
2001	President, First Annual meeting of the Interdisciplinary Health Research International Team on Breast Cancer susceptibility Quebec, QC, Canada, October 2001.
2000-2001	President, Canadian Breast Cancer Research Initiative 2nd Scientific Conference «Reasons for Hope», Quebec, QC, Canada, May 2001.
2000	Member, International Workshop: Recent progress in research on 17β–hydroxysteroid dehydrogenases: Impact on medicine, Elmau Castle, Germany.
2000	Abstract Reviewer, 50th Annual Meeting of the American Society of Human Genetics, Philadelphia, PA, USA.
2000	Secretary, 14th International Symposium of the Journal of Biochemistry and Molecular Biology, Quebec, QC, Canada.
1998	Secretary, Xth International Congress on Hormonal Steroids, Quebec, QC, Canada.
1998	Director, Endocrinology Section, 66th Annual Meeting of the "Association Canadienne Française pour l'Avancement des Sciences".
1995	Secretary, Fifth International Congress on Hormones and Cancer, Quebec, QC, Canada.
1995	Secretary, International Symposium on DHEA Transformation into Androgens and Estrogens in Target Tissues: Intracrinology, Quebec, QC, Canada.

GRADUATE STUDENTS – DIRECTION

- Keiko Sugimoto, MSc (September 1991-September 1993).
- Marie-Claude Carrière, MSc (May 1992-December 1993).
- Nathalie Laflamme, MSc (May 1992-September 1993).
- Martine Poulin, MSc (May 1990-March 1994, in the meantime as her M.D.).
- Rocio Sanchez, PhD (May 1991-May 1995).
- Francine Durocher, PhD (January 1992-December 1996).
- Yves Blais, PhD (January 1992-June 1996).
- Patrick Couture, PhD (May 1990-December 1997).
- Sébastien Gingras, PhD (May 1994-May 1999).
- Stéphanie Coté, MSc (September 1998-2001).
- Caroline Manhes, MSc (September 2000-December 2001).
- Jessyka Fortin, MSc (January 2003-September 2004).
- Anne-Marie Moisan, MSc (September 1997-1999) and PhD (2001-2006).
- Marie Plourde, PhD (September 2000-November 2007).
- Denis Mathon, MSc (September 2003-July 2008).
- Alexandra Ferland, MSc (September 2006-August 2008).
- Anne-Laure Renault, MSc (September 2011-March 2014).
- Steffany Grondin, MSc (September 2014-May 2015).
- Yosr Hamdi, PhD (September 2008-May 2017).
- Mandy Ducy, MSc (May 2014-accelerated passage to PhD) and PhD (January 2016-April 2019)

GRADUATE STUDENTS – CO-DIRECTION

- Hui-Fen Zhao, PhD (September 1987-November 1991) (with Fernand Labrie).
- Éric Rhéaume, PhD (May 1989-June 1994) (with Fernand Labrie).
- Nathalie Breton, MSc (May 1990-June 1992) (with Fernand Labrie).

- Yvan Labrie, PhD (May 1991-May 1996) (with Fernand Labrie).
- Nancy Brochu, MSc (May 1992-December 1993) (with Fernand Labrie).
- Martin Leclerc, MSc (September 2010-April 2012) and PhD in Mathematics (January 2012-February 2016) (Director: M'Hamed Lajmi Lakhal-Chaieb).
- Audrey Lemaçon, PhD (January 2015 – May 2019) (Director: Arnaud Droit)

POST-GRADUATE AND POSTDOCTORAL FELLOWS DIRECTION

- Dr. Yvan de Launoit (January 1990-December 1991) (Director: Fernand Labrie, Co-Director Jacques Simard) Belgium.
- Dr. Thierry Normand (January 1992-September 1993), France.
- Dr. Didier Monté (November 1994-April 1995), France.
- Dr. Farida Mébarki (September 1994-March 1995), France.
- Dr. Jean-Louis Carsol (April 1998-July 2001), France.
- Dr. Marie-Louise Ricketts (September 1998- 2000), United Kingdom.
- Dr. Maxime Vallée, Post-doctoral fellow (December 2014 - May 2015) (Director: Jacques Simard, Co-director, Arnaud Droit), France.
- Dr. Guillaume Margaillan, Post-doctoral Fellow (November 14, 2016 - September 30, 2018), France.
- Dr. Gemma Montalban Canudas, Post-doctoral Fellow (April 2019-) (Director: Jacques Simard, Co-director, Jean-Yves Masson), Spain.

FUNDING

Canada Foundation for Innovation (CFI): 2020-2025 – $19 978 909
SecureData4Health
Principal Investigators: Guillaume Bourque & Vincent Ferreti / Co-investigators: Brudno M, Gingras A-C, Goldenberg A, Haibe-Kains B, Hussin J, Jacques P-E, Knoppers BM, **Simard J**.

Cancer Research Society 2020 Operating Grant: 2020-2022 – $120 000
The influence of occupational and genetic risk factors in breast cancer etiology
Principal Investigator: Vikki Ho / Co-investigators: **Simard J**, Goldberg M, Labrèche F.

Génome Canada – 2017 Large-Scale Applied Research Project (LSARP) Competition: Genomics and Precision Health: 2018-2022 – $15 217 973
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)
Principal Investigators: **Jacques Simard (Lead)** and Anna Chiarelli (co-leader)
Co-investigators: Andrulis I; Antoniou A; Brooks J; Chiquette J; Devilee P; Dorval M; Droit A; Easton D; Eisen A; Eloy L; Goldgar D; Joly Y; Kamel-Reid S; Knoppers BM; Masson J-Y; Mittmann N; Nabi H; Pashayan N; Schmutzler R; Stockley T; Tavtigian S; van Attikum H; Walker M; Wolfson M

Social Sciences and Humanities Research Council of Canada - Insight Grants: Societal Implications of Genomics Research: 2017-2020 – $255 000
Impacts of Evolving Demography and Socio-Economic Status on Assessment of Genetic Risks
Principal Investigator: Michael Wolfson / Co-Investigators: Bélanger A, **Simard J**, McCabe C

Ministère de l'Économie, Science et Innovation - Programme de soutien à la recherche, PSR-SIIRI-949, volet 4 : soutien à des initiatives internationales de recherche et d'innovation: 2016-2016 – $1 499 900
Prédisposition, Prédiction et Prévention du cancer du sein (PRÉ^{3}VENTION)
Principal Investigator: **Jacques Simard /** International Co-Investigators: Devilee P, Easton D, Antoniou A, Goldgar D, Schmutzler R / Canadian Co-Investigators: Lakhal Chaieb L, Masson J-Y, Knoppers BM, Droit A, Loiselle C, Amara N, Chiquette J

Fondation du CHU de Québec-Université Laval, Fondation du Cancer du Sein du Québec: 2016-2017 – $280 000
Connaître et communiquer son histoire familiale pour mieux lutter contre le cancer du sein au Québec : Mise en place d'une campagne d'information
Principal Investigator: **Jacques Simard /** Co-Investigators: Amara N, Loiselle C, Knoppers B-M

Genome Alberta, Genome Canada, Genome Quebec: 01/2016-12/2018 – $1 996 945
GE^{3}LS Network in Genomics and Personalized Health
Principal Investigators: Christopher McCabe, François RousseauCo-Investigators: Wilson B, Wolfson M, Bubela T, Knoppers BM, Laberge A-M, Regier D, Lévesque E, Légaré F, Bartlett G, **Simard J**, Lachaine J, Kimmelman J, Bonter K, O'Doherty K, Votova K, Zawati M, Beauger N, Gold R, Veilleux S, Caulfield T, Ravitsky V, Ungar W, Joly Y

The Cancer Research Society (CRS) - 2015 Operating Grant: 09/2015-08/2017 – $120 000
Inherited chromosomally-integrated human herpesvirus 6 as a risk factor for breast cancer development
Principal Investigator: Louis Flamand / Co-Investigators: **Simard J**; Spineli J; Aronson K

European Commission, Research - Horizon 2020: 09/2015-12/2020 – 6 200 000EU
Breast Cancer Risk after Diagnostic Gene Sequencing (BRIDGES)
Principal Investigator (Coordinator): Peter Devilee / Co-Investigators: Easton D; Benitez J; Borg Å; Engel C; de la Hoya M; Stoppa-Lyonnet D; Schmutzler R; Hall P; Bojesen S; Vroling B; Blavier A; Southey M; Goldgar D; Spurdle A; Couch F; **Simard J**

European Commission, Research - Horizon 2020: 09/2015-12/2020 – 5 983 356 EU
Breast CAncer Stratification: understanding the determinants of risk and prognosis of molecular subtypes (B-CAST) Principal Investigator (Coordinator): Marjanka Schmid t/ Co-Investigators: Easton D; Pharoah P; Carracedo Á; Chang-Claude J; García-Closas M; Hall P; Antoniou A; Burton H; Gut I; Lambrechts D; Chenevix-Trench G; **Simard J**; Kraft P

Canadian Institutes of Health Research (CIHR): 03/2015-03/2022 – $1 400 000
Canada Research Chair in Oncogenetics (Tier 1) Renewal 2
Principal Investigator: **Jacques Simard**

Canadian Breast Cancer Foundation - Ontario Chapter, Fall 2013 CBCF-CIHR Breast Cancer in Young Women Competition: 04/2014-03/2016 – $194 500
Discovering genetic susceptibility factors for breast cancer in an innovative international consortium
Principal Investigator: Kristan J. Aronson / Co-Investigators: Spinelli JJ; **Simard J**; Grundy A; Brooks-Wilson A

Fonds de recherche Québec-Santé (FRQS) - Réseau thématique de recherche: 2014-2018 – $3 060 000
Réseau de Médecine Génétique Appliquée (RMGA), Regroupement Stratégique 3 du RMGA, Génomique intégrée
Network Director: Guy A. Rouleau / Co-Investigators: Puymirat J; Shoubridge E; Dupré N; Labuda D; Vézina H; Pastinen T; **Simard J**; Sinnett D; Rousseau F; Laberge A-L; Knoppers BM; Joly Y

Genome Canada - 2012 Large-Scale Applied Research Project Competition Genomics and Personalized Health / Canadian Institutes of Health Research (CIHR) / Genome Québec / Quebec Breast Cancer Foundation / NIH: 04/2013-03/2017 – $11 761 269
Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE)
Principal Investigators: **Jacques Simard (Lead**) Bartha-Maria Knoppers (co-lead)
Co-Investigators: Andrulis I; Antoniou A; Bader G; Chiarelli A; Chiquette J; de Marcellis-Warin N; Dorval M; Droit A; Easton D; Evans G; Foulkes W; Goldgar D; Jbilou J; Joly Y; Kamel-Reid S; Meindl A; Mittmann N; Pashayan N; Schmidt M; Schmutzler R; Tavtigian S; Wolfson M

Canada Foundation for Innovation (CFI), 2012 Leading Edge Fund:
2013-2016 Equipment/Infrastructure – $7 512 147
Human and Microbial Integrative Genomics
Principal Investigator: **Jacques Simard** / Co-Investigators: Barbier O; Bergeron M G; Corbeil J; Droit A; Durocher F; Guillemette C; Ouellette M; Papadopoulou B; Poirier G

Leading Edge Fund Infrastructure Operating Fund (IOF) / Canada Foundation for Innovation (CFI)
04/2013-07-2016 – $862 000
Human and Microbial Integrative Genomics
Principal Investigator: **Jacques Simard** / Co-Investigators: Barbier O; Bergeron M G; Corbeil J; Droit A; Durocher F; Guillemette C; Ouellette M; Papadopoulou B; Poirier G

Ministère du développement économique, Innovation et Exportation (MDEIE) (Research Support Soutien à des initiatives internationales de recherche et d'innovation, volet 3): 10/2011-02/2014 – $998 047
Genetic Susceptibility to Breast Cancer: Identification, Predication and Communication
Principal Investigator in Quebec: **Jacques Simard /** Co-Investigators in Quebec: Amara N; Avard D; Dorval M; Droit A; Goldberg M; Jbilou J; Joly Y; Knoppers BM; Lakhal Chaieb MHL; Landry R; Sinnett D
Foreign Principal Investigator: Per Hall / Foreign Co-Partner: Easton, Douglas
Foreign Co-Investigators: Antoniou A; Benitez-Ortiz J; Burton H; Chenevix-Trench G; Czene K; Goldgar D; Rookus MA; Sinilnikova O; Tavtigian S

Quebec Breast Cancer Foundation (QBCF): 01/2012-12/2015 – $442 976
Identification of an alternative splicing signature in BRCA1/2 mutation carriers from French Canadian families with high risk of breast cancer
Principal Investigator: Francine Durocher / Co-Investigators: Abou-Elela S; Klinck R; **Simard J**

Quebec Breast Cancer Foundation (QBCF): 01/2012-12/2015 – $759 040
Cancer screening practices of non-carriers from BRCA1/2 mutation-positive families: Extent, determinants and psychosocial impact of over-screening
Principal Investigator: Michel Dorval / Co-Investigators: Foulkes W; Hamet P; Chiquette J; **Simard J**

Canadian Innovation Foundation (CFI): 04/2011-12/2011 – $950 000
Nextgen sequencing for monitoring genomic health and disease states
Principal Investigator: Jacques Corbeil / Co-investigators: **Simard J**; Ouellette M

Fondation Canadienne pour l'Innovation (FCI): 12/2010-12/2011 – $604 469
A Two-Photon Laser Scanning Confocal Microscope to study Cellular Response to DNA Damage in Mammalian Cells and for Functional Proteomics
Principal Investigator: Guy Poirier / Co-investigators: **Simard J**; Tremblay

Network of Applied Genetic Medicine and the Health Research Fund in Quebec (FRSQ): 2010-2014 – $1 500 000
Next Generation Integrative Genomics (RS3) of RMGA
Strategic group: Sinnett D; **Simard J**; Pastinen T

Canadian Institutes of Health Research (CIHR): 04/2009-03/2015 – $1 281 761
Subvention de formation des IRSC-FRSQ en médecine génétique appliquée
Principal Investigator: Guy A. Rouleau / Co-Investigators: Bouchard G; Brais B; Knoppers B-M; Michaud J; Puymirat J; Rousseau F; **Simard J**; Vézina H

Canadian Breast Cancer Research Alliance (CBCRA): 07/2009-06/2010 – $49 905
Exploring the potential of administrative databases to evaluate the quality and cost of medical monitoring of people tested for BRCA1/2
Principal Investigator: Michel Dorval / Co-Investigators: Chiquette J; Desbiens C; Plante M; **Simard J**

Université Laval, In support of Jacques Simard's grant application to the Canadian Institutes of Health Research (CIHR): 10/2008-09/2013 – $125 000
CIHR Team in Familial Risks of Breast Cancer
Principal Investigator: **Jacques Simard** / Co-Investigators: Amara N; Andrulis I; Antoniou A; Avard D; Bridge P; Chiquette J; Dorval M; Durocher F; Easton D; Glendon G; Goldberg MS; Goldgar D; Jbilou J; Jolly Y; Kim-Sing C; Knoppers BM; Laframboise R; Landry R; Lespérance B; Maugard C; Ouimet M; Plante M; Sinilnikova O; Sinnett D; Tavtigian SV

Canadian Institutes of Health Research (CIHR): 10/2008-03/2015 – $5 379 534
CIHR Team in Familial Risks of Breast Cancer
Principal Investigator: **Jacques Simard** / Co-Investigators: Amara N; Andrulis I; Antoniou A; Avard D; Bridge P; Chiquette J; Dorval M; Durocher F; Easton D; Glendon G; Goldberg MS; Goldgar D; Jbilou J; Joly Y; Kim-Sing C; Knoppers BM; Laframboise R; Landry R; Lespérance B; Maugard C; Ouimet M; Plante M; Sinilnikova O; Sinnett D; Tavtigian SV

Canadian Institutes of Health Research (CIHR): 07/2008-06/2013 – $1 492 810
A research and knowledge network on genetic health services and policy : building on the Apogee-Net and CanGene test experiences
Principal Investigator: François Rousseau / Co-Investigators: Amara N; Batttista R; Blancquaert I; Cassiman J-J; Cole D; Drouin R; Forest J-C; Foulkes W; Freidman J; Gaudet D; Giguère Y; Godard B; Knoppers B-M; Laberge

A-M; Laberge C; Labrecque M; Laflamme N; Lamothe L; Landry R; Leduc N; Légaré F; Marra C; Matthijs G; Mitchell G; Reinharz D; **Simard J**

Canadian Breast Cancer Research Alliance (CBCRA): 07/2008-06/2011 – $583 305
Genetic modifiers of cancer risk in BRCA1/2 mutation carriers: Role of functional promoter polymorphisms in candidate genes
Principal Investigator: **Jacques Simard** / Co-Investigators: Sinnett D; Goldgar DE; Sinilnikova O

Network of Applied Genetic Medicine and the Fund for Health Research in Quebec (FRSQ):
07/2008-06/2010 – $110 000
Évaluation de l'impact de la variation inter-individuelle comme déterminants du risque de cancer
Principal Investigators: **Jacques Simard**, Daniel Sinnett / Co-Investigators: Awadalla P; Durocher F; Krajinovic M; Labuda D; Maugard C; Michaud J; Roy-Gagnon M-H

Canadian Institutes of Health Research (CIHR): 03/2008-03/2015 – $1 400 000
Canada Research Chair in Oncogenetics (Tier 1) - Renewal 1
Principal Investigator: **Jacques Simard**

Canadian Breast Cancer Research Alliance (CBCRA): 04/2007-03/2010 – $574 425
Localisation and identification of novel breast cancer susceptibility loci/genes in high-risk French-Canadian families
Principal Investigators: Francine Durocher, **Jacques Simard**
Co-Investigators: Vézina H; Goldgar DE; Easton DF

Canadian Institutes of Health Research (CIHR): 04/2007-03/2010 – $254 583
Family communication following BRCA1/2 genetic testing
Principal Investigator: Michel Dorval / Co-Investigators: Godard B; **Simard J**

CURE Foundation - Breast Cancer: 10/2007-09/2008 – $64 625
Programme interdisciplinaire INHERIT BRCAs
Principal Investigator: **Jacques Simard**

Canadian Institutes of Health Research (CIHR): 04/2006-03/2007 – $420 000
CIHR team in familial breast cancer risk: Assessment, communication and management
Principal Investigator: **Jacques Simard /** Co-Investigators: Allanson J; Andrulis I; Avard D; Berman N; Bridge P; Carroll J; Chiquette J; Dorval M; Durocher F; Easton D; Eisinger F; Godard B; Goldberg MS; Goldgar D; Green JS; Grimshaw J; Horsman D; Houde L; Knoppers BM; Laframboise R; Landry R; Lespérance B; Little J; Miller FA; Plante M; Provencher L; Sinilnikova O; Sinnett D; Tavtigian SV; Vézina H; Wilson BJ

Quebec Breast Cancer Foundation (QBCF): 07/2004-12/2010 – $1 500 000
Gene-Environment interactions in postmenopausal breast cancer: A case-control study »
Principal Investigator: Mark Goldberg / Co-Investigators: **Simard J**; Durocher F; Labrèche F; Parent M-É; Langholz B; Sinnett D

Fund for Health Research in Quebec (FRSQ): 07/2004-06/2008 – $320 000
Réseau de médecine génétique et appliquée du FRSQ, Axe oncogénétique
Unit Manager: **Jacques Simard** / Co-Investigators: Sinnett D; Labuda D; Durocher F; Dorval M; Laframboise R

Canadian Institutes of Health Research (CIHR): 03/2003-03/2008 – $1 000 000
Translating genetics discoveries into appropriate health policy and services: Enhancing research capacity and developing an interdisciplinary approach
Principal Investigator: Brenda Wilson / Co-Investigators: Caulfield T; Avard D; Wells G; Graham I; **Simard J**; Grimshaw J; Allanson J; Carroll J; Bouchard L; Lemyre L; Cappelli M; Gold R; Coyle D

Canadian Institutes of Health Research (CIHR): 03/2002-02/2009 – $2 075 514
Génomique fonctionnelle, hormones et santé
Principal Investigator: Fernand Labrie / Co-Investigators: Barden N; Luu-The V; Morissette J; Raymond V; Bélanger A; Labrie C; St-Amand J; Poirier G; Rivest S; Poirier D; Lin SX, Guillemette C; Durocher F; Pelletier G; Tchernof A; **Simard J**

Canada Foundation for Innovation (CFI): 08/2002-08/2006 – $30 000 000
Centre de génomique fonctionnelle et humaine
Principal Investigator: Fernand Labrie / Co-Investigators: Barden N; Morissette J; Raymond V; Rivest S; **Simard J**; Tremblay JP; Poirier GG; Tanguay R

Genome Canada/Genome Quebec: 2002-2008 – $20 676 000
Atlas of Genomic Profiles of Steroid Action
Principal Investigators: Fernand Labrie, Thomas J. Hudson / Co-investigators: Barden N, De Belle I, Faure R, Hallett M, Julien JP, Labrie C, Luu-The V, Morissette J, Pelletier G, Poirier G, Raymond V, Rigault P, Rivest S, **Simard J**, St-Amand J, White J

Canadian Institutes of Health Research (CIHR): 2001-2008 – $1 400 000
Canada Research Chair in Oncogenetics (Tier 1)
Principal Investigator: **Jacques Simard**

Canadian Institutes of Health Research (CIHR): 01/2001-03/2006 – $7 385 233
INterdisciplinary HEalth Research International Team on BReast CAncer susceptibility (INHERIT BRCAs)
Principal Investigator: **Jacques Simard** / Co-Investigators: Avard D; Bridge PJ; Chiquette J; Dorval M; Dugas MJ; Durocher F; Easton D; Goldgar D; Green JS; Knoppers BM; Laframboise R; Lespérance B; Plante M; Sinnett D; Vézina H

Fund for Health Research in Quebec (FRSQ): 07/2000-06/2004 – $340 000
Réseau de médecine génétique et appliquée du FRSQ, Axe oncogénétique
Unit Manager: **Jacques Simard** / Co-Investigators: Sinnett D; Labuda D; Durocher F; Dorval M; Laframboise R

Canadian Breast Cancer Research Alliance (CBCRA): 07/2000-06/2003 – $678 000
Génétique et épidémiologie moléculaire des cancers héréditaires du sein chez les Canadiennes françaises
Principal Investigator: **Jacques Simard** / Co-Investigators: Durocher F; Easton D; Provencher L; Bridge P; Plante M; Laframboise R; Vézina H; Lespérance B; Jacob S

Canada Foundation for Innovation (CFI): 06/2001-05/2002 – $586 278
Plateformes de génomique et de bio-informatique de la Chaire de recherche du Canada en oncogénétique
Principal Investigator: **Jacques Simard**

Régie régionale de la santé et des services sociaux du Québec - Allocation régionale : 2000-2001 – $120 000
Infrastructure de recherche en génomique **(décodage et compréhension de l'information génétique contenue dans un organisme)**
Principal Investigators: **Jacques Simard**; Vincent Raymond

Valorisation recherche Québec (VRQ): 2000 – $10 000
Demande d'actions de concertation INterdisciplinary HEalth Research International Team on Breast Cancer susceptibility (INHERIT BRCAs)
Principal Investigator: **Jacques Simard**

Medical Research Council of Canada, Canadian Institutes of Health Research (CIHR): 1996-2001$492 000
Biologie moléculaire des enzymes de la famille 3β-hydroxystéroïde-déshydrogénases/isomérases
Principal Investigator: **Jacques Simard /** Co-Investigators: Bélanger A; Labrie F; Lin SX; Luu-The V; Pelletier G

Medical Research Council of Canada: 06/1996-07/2001 – $1 500 000
Groupe du CRM en endocrinologie moléculaire (operating budget) »
Principal Investigator: Fernand Labrie / Co-Investigators: **Simard J**; Luu-The V; Lin SX; Bélanger A

Canadian Institutes of Health Research (CIHR), Development grant: 2000 – $10 000
INterdisciplinary HEalth Research International Team on Breast Cancer susceptibility (INHERIT BRCAs)
Principal Investigator: **Jacques Simard**

Régie régionale de la santé et des services sociaux - Allocation régionale: 06/1999-06/2000 – $120 000
Infrastructure de recherche clinique sur le cancer du sein et de l'ovaire
Principal Investigator: **Jacques Simard**

Canada Foundation for Innovation (CFI) - *Ministère de la santé et des services sociaux:* 1999-2000 – $1 045 000
Création d'une unité de séquençage et de génotypage à haut débit
Principal Investigator: Vincent Raymond / Co-Investigators: Barden N; Brown J; Laframboise R; Morissette J; **Simard J**

Canada Foundation for Innovation (CFI) - Ministère de la santé et des services sociaux: 1999-2000 – $2 626 307
Formation et mécanismes d'action des hormones stéroïdiennes
Principal Investigator: Fernand Labrie / Co-Investigators: **Simard J;** Bélanger A; Pelletier G; Luu-The V; Rivest S; Poirier D; Lin SX; Di Paolo T; Labrie C

Fondation du CHUQ : 04/1998 – $35 000
Infrastructure de recherche pour les cancers héréditaires

Medical Research Council of Canada (MRSC): 07/1990-06/1996 – $2 118 770
Groupe du CRM en endocrinologie moléculaire
Principal Investigator: Fernand Labrie / Co-Investigators: Bélanger A; Lin SX; Luu-The V; Pelletier G; **Simard J**

Medical Research Council of Canada (MRC): 01/1996-12/1996 – $135 000
High Performance Elite ESP Cell Sortin System »
Principal Investigator: Jean Gosselin / Co-Investigators: Borgeat P; Naccache PH; **Simard J;** Mourad W; Bourgoin SG; Poirier GG; Hébert J; Tremblay M; Poubelle PE

Fonds de la recherche en santé du Québec: 07/1991-06/1994 – $25 000
Établissement de jeunes chercheurs

Direction de la coopération, Ministère de l'Enseignement supérieur et de la science: 01/1991-12/1992 – $5000
Caractérisation des mutations responsables des dysfonctions congénitales de l'activité 17β-HSDet 3β-HSD

Téléthon des étoiles : 10/1989-06/1992 $55 000
Identification et caractérisation des mutations responsables des dysfonctions congénitales de l'activité 17β-HSD et 3β-HSD
Principal Investigator: **Simard J**

Medical Research Council of Canada (MRC): 1991 $15 000
Établissement de chercheurs-boursiers
Principal Investigator: **Simard J.**

RESEARCH CONTRACTS

Projet mobilisateur Université - Industrie dans le cadre du Fonds de développement technologique du Gouvernement du Québec (F. Labrie)

(1994-2000) Total amount awarded/Year: **500 000$**

Pharmacia (Canada) Inc.
Étude de la structure et du contrôle de l'expression de la protéine GCDFP-24: nouveau marqueur potentiel dans le cancer de la prostate et le cancer du sein

(07/1990-12/1992) Total amount awarded: **150 000$**

Applied Biosystems Canada
Chercheur principal en collaboration avec le Dr Van Luu-The (équipements)

(05/1990-04/1993) Total amount awarded: **274 161**$

PATENTS Application Date

Chromosome 17p-linked prostate cancer susceptibility gene and a paralog and orthologous genes

United States Patent: no 6,333,403 2000/05/05

Inventors: Sean V. Tavtigian, David F. Teng, Jacques Simard, Johanna M. Rommens

Chromosome 17p-linked prostate cancer susceptibility gene

United States Patent: no 6,844,189 1999/11/05

Inventors: Sean V. Tavtigian, David F. Teng, Jacques Simard, Johanna M. Rommens, Lisa A. Cannon Albright, Susan L. Neuhausen

Chromosome 13-linked breast cancer susceptibility gene

United States Patent: no 5,837,492 1998/11/17

United States Patent: no 6,033,857 2000/03/07

Canadian Patent: no 2,239,733 2001/04/03

Inventors: Sean V. Tavtigian, Alexander Kamb, Jacques Simard, Fergus Couch, Johanna M, Rommens, Barbara L.Weber

Linked breast and ovarian cancer susceptibility gene

United States Patent: no 5,693,473 1997/12/02

United States Patent: no 5,709,999 1998/01/20

Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Francine Durocher, Mitsuuru Emi, Yusuke Nakamura

In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene

Canadian application number: no 2,196,797 22/02/1996

Inventors: Donna M. Shattuck-Eidens, Jacques Simard, Mitsuru Emi, Yusuke Nakamura, Francine Durocher

INVITED SPEAKER

1. **Control of Gross Cystic Disease Fluid Protein-15 Gene Expression by Androgens, Estrogen Progestins and Glucocorticoids in the ZR-75-1 Human Breast Cancer Cell Line**. *Workshop on Human Breast Cyst Fluid and Cancer Risk,* New York, NY, USA, December 1988.
2. **La régulation de l'expression de l'apolipoprotéine D est inversement correllée à la prolifération cellulaire dans les cellules humaines du cancer du sein et de la prostate**. *Institut de Recherches Cliniques de Montréal,* Montreal, QC, Canada, March 1991.
3. **Molecular basis of reproductive endocrinology. Structure and control of expression of the 3β-HSD and 17β-HSD genes in classical steroidogenic and peripheral tissues: Their role in intracrinology**. *Serono Symposium*, Vancouver, BC, Canada, July 1991.
4. **Molecular characterization of sex steroid formation in normal and neoplastic cells**. *The 2nd Eastern Canadian Conference on Development and Cancer,* Montreal, QC, Canada, October 1991.
5. **Régulation de l'expression de l'apolipo-protéine D par les stéroïdes dans les cellules humaines du cancer du sein et de la prostate**. *Université du Québec à Montréal*, Montreal, QC, Canada, April 1992.
6. **Regulation of apolipoprotein D gene expression by steroids human in breast and prostate cancer cells**. *Gordon Research Conference on Lipid Metabolism,* Meriden, NH, USA, June 1992.
7. **Structure et expression des gènes encodant les enzymes de la stéroïdogénèse ovarienne et périphérique**. *XXXIVe Congrès de la Fédération des Gynécologues et Obstétriciens,* Quebec, QC, Canada, June 1992.
8. **Molecular basis of congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency**. *Fourth Joint Lawson Wilkins Pediatric Endocrine Society and European Society for Paediatric Endocrinology,* San Francisco, CA, USA, June 1993.
9. **The 3β-hydroxysteroid dehydrogenase gene family: Structure, function, regulation of tissue-specific gene expression and molecular basis of human 3β-HSD deficiency**. *International Conference on Molecular Endocrinology*, Athens, Greece, October 1993.
10. **La famille des 3β-hydroxystéroïde déshydrogénases: structure, fonction et génétique moléculaire du déficit enzymatique chez l'humain**. *Centre de Recherche, Hôpital Maisonneuve-Rosemont,* Montreal, QC, Canada, November 1993.
11. **The 3β-hydroxysteroid dehydrogenase gene family: Structure, function, regulation of tissue-specific gene expression and molecular basis of human 3β-HSD deficiency**. *Loeb Medical Research Institute,* Ottawa, ON, Canada, February 1994.
12. **Hereditary breast and ovarian cancer**. *Colloque SOREP sur la génétique du cancer: recherche et société,* Montreal, QC, Canada, May 1994.
13. **Biologie moléculaire de la formation des stéroïdes sexuelles dans les tissus périphériques: cancer du sein et cancer de la prostate**. *Institut du Cancer de Montréal*, Montreal, QC, Canada, May 1994.
14. **Molecular Basis of 3β-hydroxysteroid dehydrogenase deficiency**. *IX International Congress on Hormonal Steroids,* Dallas, Texas, USA, September 1994.
15. **Base moléculaire de la formation des stéroïdes sexuels dans les tissus périphériques: intracrinologie**. *19ième Réunion des Endocrinologues de Langue Française*, Montreal, QC, Canada, September 1994.
16. **Genetics aspects of breast and ovarian cancers**. *Contact Québec 94*, Quebec, QC, Canada, October 1994.
17. **Relation between molecular defect and phenotypic manifestation of human 3β-hydroxysteroid dehydrogenase deficiency.** Where Phenotype does not Match Genotype. *Serono Symposium*, Volterra, Italy, October 1994.

18. **Génétique moléculaire des cancers du sein et de l'ovaire**. *Mercredi d'oncologie, Hôtel-Dieu de Québec*, Quebec, QC, Canada, January 1995.
19. **Génétique du cancer du sein et de l'ovaire**. *Centre de Recherche de l'Hôtel-Dieu de Québec*, Quebec, QC, Canada, March 1995.
20. **Génétique des cancers du sein et de l'ovaire**. *Conférence de Médecine du CHUL*, Quebec, QC, Canada, April 1995.
21. **Molecular basis of 3β-hydroxysteroid dehydrogenase/Δ^4-Δ^5 isomerase congenital deficiency: A structure-function relationship**. *Workshop on the Molecular and Cell Biology of Hydroxysteroid Dehydrogenases, Max-Planck-Institute for Experimental Endocrinology*, Hannover, Germany, April 1995.
22. **Caractérisation des mutations dans le gène *BRCA1* prédisposant au cancer du sein et de l'ovaire chez les familles nord-américaines**. *Université Claude Bernard Lyon I*, Lyon, France, April 1995.
23. **Molecular genetics and regulation of tissue-specific expression of the 3β-hydroxysteroid dehydrogenase gene family**. *The Endocrine Society, 77th Annual Meeting*, Washington, DC, USA, June 1995.
24. **Hormonal and interleukin modulation properties of cystic disease proteins**. *Satellite Symposium of the Fifth International Congress on Hormones and Cancer entitled: Gross Cystic Disease Fluid Proteins: Hormonal Modulation, Biological Function, Clinical Utility,* Quebec, QC, Canada, September 1995.
25. **3β-HSD dehydrogenase superfamily**. *International Symposium on DHEA Transformation into Androgens and Estrogens in Target Tissues: Intracrinology,* Quebec, QC, Canada, September 1995.
26. **Inhibition of breast cancer cell growth**. *Fifth International Congress on Hormones and Cancer*, Quebec, QC, Canada, September 1995.
27. **Aspects génétiques du cancer du sein et de l'ovaire**. *Institut de Recherches Cliniques de Montréal, Conférence Pfizer*, Montreal, QC, Canada, September 1995.
28. **Molecular Biology of Sex Steroid Formation**. *Sir Mortimer B. Davis - Jewish General Hospital*, Montreal, QC, Canada, November 1995.
29. **Molecular biology of sex steroid biosynthesis in peripheral tissues**. *Hôpital Royal Victoria*, Montreal, QC, Canada, May 1996.
30. **Androgen receptor research**. *Eulexin Speaker's Update Meeting*, Aspen, CO, Montreal, September 1996.
31. **Genetic aspects of breast cancer**. *Biocontact Québec 96*, Quebec, QC, Canada, October 1996.
32. ***BRCA2*: un gène de prédisposition au cancer du sein**. *Unité d'Oncologie Moléculaire INSERM U186 - Institut Pasteur de Lille*, Lille, France, October 1996.
33. **Clonage positionnel du gène de prédisposition au cancer du sein *BRCA2* et détection de mutations chez les familles et chez des hommes atteints d'un cancer du sein**. *Matinée des chercheurs-boursiers du Club de Recherches Cliniques du Québec*, Quebec, QC, Canada, October 1996.
34. **Structure of mouse and rat *BRCA2* gene**. *Consortium for Hereditary Breast Cancer Linkage*, Lyon, France, October 1996.
35. **Importance de l'intracrinologie dans la formation des stéroïdes sexuels dans les tissus périphériques**. *Centre de Recherche de l'Hôpital Ste-Justine*, Montreal, QC, Canada, November 1996.
36. **La génétique moléculaire du cancer du sein**. *Centre de Recherche des Sciences de la Vie*, November 1996.
37. **Génétique moléculaire du cancer du sein**. *Centre Hospitalier Universitaire de Sherbrooke*, Sherbrooke, QC, Canada, November 1996.
38. **Génétique et cancer du sein**. *Colloque sur le cancer du sein, Centre Hospitalier Jonquière*, Jonquière, QC, Canada, January 1997.

39. **Les cancers du sein et de l'ovaire héréditaires: où en sommes-nous?** *Conférence dans le cadre des mercredis d'oncologie du Pavillon Hôtel-Dieu du CHUQ,* Quebec, QC, Canada, April 1997.
40. **Key role of cytokines in estrogen bioavailability in breast cancer cells**. *Workshop Mechanisms of Action of Estrogens and Physiological Needs*, Chantilly, France, April 1997.
41. **Structure and expression of mammalian homologues of the breast cancer susceptibility gene, *BRCA2***. *Terry Fox Workshop on Cancer genetics*, Toronto, ON, Canada, May 1997.
42. **Crucial role of cytokines in sex steroid formation in breast cancer cells**. *13th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology*, Monaco, May 1997.
43. **Hérédité et cancer du sein: certitude ou prédisposition**. *Club de Recherches Cliniques du Québec*, Bécancour, QC, Canada, October 1997.
44. **The Breast Cancer Susceptibility Gene, *BRCA2*: Basic and Clinical Aspects**. *Département de Physiologie, Université McGill*, Montreal, QC, October 1997.
45. **Genetics of breast and prostate cancer**. *Biocontact Québec 97*, Quebec, QC, October 1997.
46. **Facteurs génétiques et considérations éthiques**. *Université de Montréal*, Montreal, QC, October 1997.
47. **Leadership of the CHUL Research Centre of the Laval University Medical Centre in the discovery of new therapies against prostate and breast cancers**. *Cuban-Canadian Workshop on Cancer Immunotherapy*, Havane, Cuba, February 1998.
48. **Hérédité et cancer du sein: Conduite à tenir avec les patientes porteuses de mutations des gènes *BRCA1* et *BRCA2***. *Colloque de la Fondation québécoise du cancer: Cancer du sein: 100 ans de progrès*, Montreal, QC, Canada, April 1998.
49. **Rôle de *BRCA1* et *BRCA2* dans les Cancers du Sein Familiaux**. *Association de Cytogénétique du Québec*, Quebec, QC, Canada, April 1998.
50. **Genetics of breast cancer**. *The Endocrine Society, 80th Annual Meeting*, New Orleans, USA, June 1998.
51. **Crucial role of cytokines in DHEA transformation in target tissues**. *VIIIth Adrenal Cortex Conference,* Mont-Orford, QC, Canada, June 1998.
52. **Molecular biology of sex steroid biosynthesis in peripheral target tissues: Crucial role of cytokines in intracrinology**. *Trans-Pacific Symposium, Japan Endocrine Society, 71st Annual Meeting*, Fukuoka, Kyushu, Japan, June 1998.
53. **Génétique et épidémiologie des cancers du sein et de l'ovaire**. *Centre Universitaire de Santé de l'Estrie*, Sherbrooke, QC, Canada, June 1998.
54. **Molecular Biology of Sex Steroid formation and action in breast cancer cell**. *Canadian Breast Cancer Research Initiative*, Toronto, ON, Canada, September 1998.
55. **Crucial role of interleukin-4 in sex steroid formation in breast and prostate cells**. *Breast and Prostate Cancer.* University of Calgary, Calgary, AB, Canada, December 1998.
56. **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire chez les Canadiennes françaises**. *Les Journées Scientifiques de l'IREP*, Montreal, QC, Canada, January 1999.
57. **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire: quel est l'impact des gènes *BRCA1* et *BRCA2* mutés chez les Canadiennes françaises?** *Colloque d'obstétrique-gynécologie, Université de Montréal*, Montreal, QC, Canada, April 1999.
58. **Crucial Role of Cytokines in Sex Steroid Synthesis in Breast Cancer Cells**. *Satellite Conference on Breast Cancer*, Ottawa, ON, Canada, July 1999.
59. **Heredity and Breast Cancer, *BRCA1* and *2***. *Médecine et Génétique: La double Hélice s'élève, Collège Royal des médecins et chirurgiens du Canada*, Montreal, QC, Canada, September 1999.
60. **Genetic Mutation in French Canadian Families**. *Pourquoi le «bogue» dans la santé du sein: Réseau québécois pour la santé du sein*, Montreal, QC, Canada, October 1999.

61. **Hérédité et Cancer du Sein**. *Semaine de la sensibilisation de la recherche en santé*, Quebec, QC, Canada, October 1999.

62. **Genetic and Endocrine Mechanisms as a Cause of Breast and Prostate Cancers**. *Symposium sur l'héritage scientifique du Conseil de recherches médicales du Canada*, Ottawa, ON, Canada, March 2000.

63. **Multiple signaling pathways involved cytokine-induced in transcriptional activation 3β-hydroxysteroid dehydroge-nases**. *International Workshop: Recent progress in research on 17β-hydroxysteroid dehydrogenases: impact on medicine*, Elmau Castle, Germany, April 2000.

64. **Importance du DHEA dans la Production intracellulaire d'estrogènes et androgènes dans les tissus périphériques cibles: intracrinologie**. *T.H.S. et alternatives au traitement hormonal substitutif de la ménopause*, Marseille, France, April 2000.

65. **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire chez les Canadiennes françaises**. *Colloque: Écogénétique: interaction entre la génétique et l'environnement (ACFAS)*, Montreal, QC, Canada, May 2000.

66. **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire chez les Canadiennes françaises**. *Troisième Journées Génétiques (RMGA),* Quebec, QC, Canada, May 2000.

67. **New insights into the molecular basis of 3β–HSD dificiency**. *IXth Adrenal Cortex conference*, Toronto, ON, Canada, June 17-20, 2000.

68. **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire chez les Canadiennes françaises**. *De l'ADN à la communauté, Colloque sur la génétique communautaire*, Jonquière, QC, Canada, June 20-22, 2000.

69. **Multiple Signaling Pathways Mediate Interleukin-4-Induced Formation of Active Sex Steroids in Normal and Tumoral Target Tissues**. *14th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology*, Quebec, QC, Canada, June 24-27, 2000.

70. **Crucial role of cytokines in sex steroid formation in normal and tumoral tissues**. *Conférence: Loeb Health Research Institute*, Ottawa, ON, Canada, September 18, 2000.

71. **Prédispositions génétiques: Quoi de neuf?** *Colloque Santé du Sein: Réseau Québécois pour la santé du sein*, Montreal, QC, Canada, October 7, 2000.

72. **La DHEA agit-elle comme un œstrogène**. *Cinquième journées européennes de la société française de gynécologie*, Paris, France, October 2000.

73. **A strong candidate prostate cancer predisposition gene at chromosome 17p**. *6th International symposium on GnRH analogues in cancer and human reproduction*, Geneva, Switzerland, February 8-11, 2001.

74. **Mécanismes d'action des cytokines dans la formation des stéroïdes sexuels dans les cellules de cancer du sein**. *Réunion scientifique de l'équipe de Physiopathologie Endocrinienne du centre de recherche clinique de Sherbrooke*, Lac-Brome, QC, Canada, March 26, 2001.

75. **Mise à jour sur les gènes de prédisposition aux cancers du sein, de l'ovaire et de la prostate**. *Hôpital Maisonneuve-Rosemont*, Montreal, QC, Canada, April 10, 2001.

76. **Épidémiologie moléculaire de mutation dans *BRCA1* et *BRCA2* chez les familles Canadiennes françaises à hauts risques pour le cancer du sein et de l'ovaire**. *Reasons for Hope,* Quebec, QC, Canada, May 3-5, 2001.

77. **Séance de travail sur l'interdisciplinarité et l'évaluation par les pairs**. *La fédération canadienne des sciences humaines et sociales et les instituts canadiens de recherche en santé*, Quebec, QC, Canada, May 29, 2001.

78. **Novel prostate cancer susceptibility gene on 17p**. *Endo 2001*, Denver, Colorado, USA, June 20-23, 2001.

79. **Advances and pitfalls in genetic screening for breast and prostate cancer susceptibilities**. *Biofuture 2001*, Toronto, ON, Canada, September 5-7, 2001.

80. **Hereditary Susceptibility to Breast and Prostate Cancer**. *Partnership Group for Science & Engineering Symposium*, Ottawa, ON, Canada, October 17, 2001.

81. **The French Canadian families**. *First Annual Meeting of the Interdisciplinary Health Research International Team on Breast Cancer Susceptibility*, Quebec, QC, Canada, October 29-30, 2001.

82. **Genes responsible for sex steroid formation and inactivation a key candidates**. *First Annual Meeting of the Interdisciplinary Health Research International Team on Breast Cancer Susceptibility*, Quebec, QC, Canada, October 29-30, 2001.

83. **Establishment of a close collaboration between Canada and European countries**. *First Annual Meeting of the Interdisciplinary Health Research International Team on Breast Cancer Susceptibility*, Quebec, QC, Canada, October 29-30, 2001.

84. **Les enjeux éthiques de l'identification d'une prédisposition génétique au cancer du sein dans un contexte de recherche clinique intégrée**. *Séminaire d'experts de l'IREB*, Paris, France, December 12-13, 2001.

85. **La généalogie appliquée à l'étude des prédispositions génétiques aux cancers du sein et de l'ovaire**. *Société de généalogie de Québec*, Quebec, QC, Canada, January 16, 2002.

86. **Enjeux éthiques de la recherche clinique: historique et avenir appliqué à la génétique des cancers de l'ovaire et du sein**. *Journée de la recherche du Département d'obstétrique-gynécologie de la Faculté de Médecine de l'Université de Sherbrooke*, Sherbrooke, QC, Canada, February 1, 2002.

87. **The impact of Patents in Genomics Research: The view from the laboratory floor**. *Genetics Patents, Insight Conference*, Ottawa, ON, Canada, February 19, 2002.

88. **La génomique: impact sur la formation des futurs médecins**. *Journée de la Faculté de médecine*, Manoir Montmorency, Quebec, QC, Canada, February 28, 2002.

89. **Fonction et régulation de l'expression des gènes de prédisposition au cancer du sein et de l'ovaire *BRCA1* et *BRCA2.*** *10^e^ Réunion annuelle des biologistes de la reproduction*, Quebec, QC, Canada, March 11, 2002.

90. **L'impact de la génomique dans l'étude des gènes de susceptibilité aux cancers du sein, de l'ovaire et de la prostate**. *Réunion scientifique du département de médecine*, CHUL, Quebec, QC, Canada, April 3,2002.

91. **The INterdisciplinary HEalth Research International Team on BReast CAncer susceptibility**. *Ontario Cancer Genetics Network*, Niagara-on-the-Lake, ON, Canada, April 16-17, 2002.

92. **INHERIT BRCAs**. *Réunion des ACRS et EIRS,* Ottawa, ON, Canada, April 30-May 1, 2002.

93. **Hérédité et cancer du sein: rôles et fonctions des gènes *BRCA1* et *BRCA2***. *2^e^ Réunion scientifique annuelle de l'AMGQ*, Quebec, QC, Canada, May 3, 2002.

94. **Males with 17β-HSD Deficiency**. *First World Congress on Hormonal and Genetic Basis of Sexual Differentiation*, Tempe, Arizona, USA, May 18-19, 2002.

95. **Table-ronde du RMGA et de l'IREB: Brevetabilité des gènes humains: recherche, droit, systèmes de santé et éthique**. *Quatrièmes journées génétiques 2002 du RMGA*, Montreal, QC, Canada, May 23-24, 2002.

96. **L'impact de la génomique dans l'étude des gènes de susceptibilité aux cancers du sein, de l'ovaire et de la prostate**. *Journée de la recherche du Centre de recherche Guy-Bernier de l'hôpital Maisonneuve-Rosemont*, Montreal, QC, Canada, June 14, 2002.

97. **Translating breast cancer research into policies and improved clinical services**. *Twenty-second annual meeting Association for Politics and the Life Sciences*, Montreal, QC, Canada, August 11-14, 2002.

98. **Et la génétique dans tout cela?** *Colloque sur le cancer du sein, Réseau québécois pour la santé du sein*, Montmartre Canadien, Quebec, QC, Canada, October 52002.

99. **Hormone Dependent Cancers**. *International Congress on Hormonal Steroids*, Fukuoka City, Japan, October 21-25, 2002.

100. **The Cancer Genomics Laboratory's Information Management System: An Essential Bioinformatic Tool for the INHERIT BRCAs Program**. *Joint Conference on Inherited Susceptibiltiy to Breast and Ovarian Cancers. Second Annual INHERIT BRCAs Meeting & First National Hereditary Cancer Task Force*. Quebec, QC, Canada, November 24-26, 2002.

101. **Génétique du cancer du sein et du colon**. *Journées chirurgicales de l'Université Laval*, Quebec, QC, Canada, November 1-2, 2002.

102. **Breast and Prostate Cancer Susceptibility Genes: Lessons Learned and Challenges Posed.** *Oncology Grand Rounds*, London, ON, Canada, December 10, 2002.

103. **The Impact of Patents in Genomics Research: The View From the Laboratory Floor**. *Genetics, Intellectual Property, Innovation and Health Care Workshop*, Ottawa, ON, Canada, January 14-15, 2003.

104. **Génomique: enjeux cliniques, psychosociaux et éthique**. C*ongrès 2003 Médicament, Pharmacie & Société*, Centre des congrès de Québec, Quebec, QC, Canada, January 23-25, 2003.

105. **La recherche communautaire sur la génétique du cancer du sein**. *Assemblée annuelle 2003 de L'Association des facultés de médecine du Canada*, Quebec, QC, Canada, April 26-29, 2003.

106. **Épidémiologie moléculaire des mutations *BRCA1* et *BRCA2* chez plus de 200 familles canadiennes-françaises à risque élevé**. *Journée de la recherche de la faculté de médecine de l'Université Laval*, Quebec, QC, Canada, May 8, 2003.

107. **Hérédité et cancer du sein: Réalisations et défis**. *Symposium en mammographie*, Centre hospitalier régional de Rimouski, Rimouski, QC, Canada, September 27-28, 2003.

108. **Interdisciplinarity in gender and health research**. *2nd Annual National Workshop for Graduate Students, Postdoctoral Fellows & New Investigators in Gender & Health Research*, University of Alberta, Edmonton, AB, Canada, October 21-22, 2003.

109. **Projet INHERIT BRCAs, Interdisciplinary in Genetic Research**. *Federal, provincial and territorial planning committee on genetics*, Quebec, QC, Canada, March 5, 2004.

110. **Génomique, protéomique et bioinformatique: Stratégies pour accélérer les applications cliniques**. *Retraite scientifique du Centre de Recherche du CHU Mère-Enfant,* Centre de Recherche de l'Hôpital Ste-Justine, Montreal, QC, Canada, April 17, 2004.

111. **The State of the Science in cancer genomics**. *Population Genomics: Science and Policy*. *Canada-European Union Thematic Workshop on Genomics for Health Applications*. Ottawa, ON, Canada, June 22-23, 2004.

112. **Hérédité et cancer du sein: Réalisations et défis**. *6e Colloque du RQSS – Réseau québécois pour la santé du sein*, Montreal, QC, Canada, October 2, 2004.

113. **Familial Breast/Ovarian Cancer in the French-Canadian Founder Population**. *Oncogenetics: Achievements and Challenges. 17ièmes Entretiens du Centre Jacques-Cartier,* Montreal, QC, Canada, October 7-8, 2004.

114. **Genetic and Hormonal Risk Factors of Breast and Prostate Cancers: Issues and Challenges**. *2004 CDA/CSEM Professional Conference and Annual Meetings*, Quebec, QC, Canada, October 27-30, 2004.

115. **Le retour des résultats**. *Colloque Éthique et génétique: nouveaux défis de L'institut International de Recherche en Éthique Biomédicale IIREB*, Quebec, QC, Canada, November 18, 2004.

116. **INHERIT BRCAs: Réalisations et défis**. *6ième Conférence Claude Fortier,* Département d'anatomie et de physiologie, Université Laval, Quebec, QC, Canada, November 22, 2004.

117. **Les enjeux du partage des résultats de recherche: L'expérience d'INHERIT BRCAs**. *Symposium GE3Ds: La recherche en génétique et en génomique: droits et responsabilités,* Montreal, QC, Canada, December 2-3, 2004.

118. **L'accès à l'information. Conférence citoyenne sur le génome: Et l'homme créa la génomique**. *Forum citoyen sur le génome, Centre des sciences de Montréal*, Montreal, QC, Canada, February 5-6, 2005.

119. **Genetic Susceptibility to Breast and Prostate Cancer: Lessons Learned and Challenges Posed**. *Reproductive Biology Seminar Series*, Dallas, USA, March 1, 2005.

120. **Susceptibilité aux cancers du sein et de l'ovaire: Interactions des facteurs de risque génétiques, hormonaux et environnementaux**. *Journées CREMO 2005, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval*, Lac-Beauport, QC, Canada, April 11-12, 2005.

121. **Interdisciplinary Health Research Team on Breast Cancer susceptibility: INHERIT BRCAs pour les professionnels(elles) de la santé**. *Courtage en ligne: échange des données de recherche en santé sur l'Internet*, *Faculté de droit, Université de Montréal*, Montreal, QC, Canada, April 13, 2005.

122. **Familial Breast Cancer Risk: Assessment, Communication and Management**. *Breast and Colon Cancer Family Registry Biannual Meeting*, Washington, Montreal, December 2-7, 2005.

123. **Les enjeux des tests de prédisposition génétique au cancer du sein et de l'ovaire: L'expérience de l'équipe interdisciplinaire INHERIT BRCAs**. *Activité de formation continue du Comité d'éthique de la recherche, Hôtel-Dieu de Lévis, Centre Hospitalier affilié universitaire*, Lévis, QC, Canada, February 22, 2006.

124. **L'expérience de l'équipe interdisciplinaire INHERIT BRCAs en oncogénétique**. *La génétique humaine au Québec – Qui fait quoi? 6ièmes Journées Génétiques, RMGA*, Montreal, QC, Canada, May 1-2, 2006.

125. **Evaluation of *BRCA1* and *BRCA2* mutation prevalence, risk prediction models and multi-step testing approach in French-Canadian high-risk breast and/or ovarian cancer families**. *Five Year Celebration, Institute of Gender and Health, CIHR-Canadian Institutes of Health Research*, Alberta, ON, Canada, May 11, 2006.

126. **Interdisciplinary Health Research International Team on Breast Cancer Susceptibility INHERIT II – Breast**, *Ontario Cancer Genetics Network, 2006 Scientific Workshop*, Toronto, ON, Canada, June 19-20, 2006.

127. **Pertinence de l'histoire familiale : Le cancer du sein familial comme un prototype**. *Les défis de l'intégration du savoir en génomique. Symposium Génome Québec*, Montreal, QC, Canada, November 7-8, 2006.

128. **Le « réseau » des CÉR. Avons-nous dépassé la virtualité?** *3e Édition, Journées d'étude des comités d'éthique de la recherche et de leurs partenaires. Unité de l'éthique, Ministère de la Santé et des Services sociaux.* Montreal, QC, Canada, November 22-23, 2006.

129. **Identification, évaluation et prise en charge clinique d'une prédisposition génétique au cancer du sein et de l'ovaire: L'expérience d'INHERIT BRCAs**. *Ministère de la santé et des services sociaux*, Quebec, QC, Canada, January 25, 2007.

130. **Identification, évaluation et prise en charge clinique d'une prédisposition génétique au cancer du sein et de l'ovaire : l'expérience d'INHERIT BRCAs**. *75e Congrès de l'ACFAS*. Université du Québec à Trois-Rivières, QC, Canada, May 7-11, 2007.

131. **Evaluation of *BRCA1* and *BRCA2* mutation prevalence, risk prediction models and a multi-step testing approach in French-Canadian families with high risk of breast and ovarian cancer**. *BRCA: New Frontiers in research and Practice, 2nd International Symposium on Hereditary Breast and Ovarian Cancer,* Montreal, QC, Canada, October 17-19, 2007.

132. **Le cancer du sein héréditaire au Québec-Les avancées en clinique et recherche**. *Association des Médecins Généticiens du Québec : 7e réunion scientifique annuelle*, Montreal, QC, Canada, December 5-6, 2007.

133. **Identification, évaluation et prise en charge clinique d'une prédisposition génétique au cancer du sein et de l'ovaire: L'expérience d'INHERIT BRCAs**. *Clinique des maladies du sein*, Hôpital St-Sacrement, Quebec, QC, Canada, May 7, 2008.
134. **Axe Oncogénétique : Prédiction, communication et prise en charge clinique du risque de cancer**. *7ième Journée Génétique, Réseau de Médecine Génétique Appliquée (RMGA)*, Quebec, QC, Canada, May 14-16, 2008.
135. **Hérédité et cancer du sein : l'expérience de l'équipe INHERIT BRCAs**. *10ième Journée Annuelle de Recherche de la Faculté de Médecine de l'Université Laval*, Quebec, QC, Canada, May 27, 2008.
136. **Canada : Your global partner in cancer research innovation**. *BIO International Convention (BIO 2008)*, San Diego, CA, Montreal, June 15-19, 2008.
137. **Role of Heredity in Breast Cancer**. *International Congress on Hormonal Steroids and Hormones & Cancer*, Quebec, QC, Canada, September 27-30, 2008.
138. **Genomic risk profiles: A tool for cancer prevention? The INHERIT BRCAs experience**. *Forum scientifique 2008 de Santé Canada*, Ottawa, ON, Canada, October 9-10, 2008.
139. **Genomic risk profiles: A tool for breast cancer prevention**. *Génome Québec multidisciplinary mini-symposium*, Montreal, QC, Canada, November 7, 2008.
140. **Réflexions de chercheurs sur l'éthique comme dimension intégrante d'une recherche de qualité**. *L'éthique de la recherche est-elle dans une impasse? Centre de recherche en droit public*, Université de Montréal, Montreal, QC, Canada, March 12, 2009.
141. **CIHR Team in familial risks of breast cancer**. *ApogéeNet-CanGèneTest Scientific Meeting*, Montreal, QC, Canada, March 16, 2009.
142. **Breast cancer risk in *BRCA1* mutation carriers is influenced by *BRCA1* wild-type allele variants: Genetic and functional analyses.** *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*, Amsterdam, The Netherlands, May 15-16, 2009.
143. **INHERIT Cohort.** *International BRCA1/2 Carrier Cohort Study (IBCCS)*, Amsterdam, The Netherlands, May 16, 2009.
144. ***BRCA1* and *BRCA2*: Past, Present and Future**. *3e International Symposium on Hereditary Breast and Ovarian Cancer*, Montreal, QC, Canada, October 14-16, 2009.
145. **Breast cancer risk in *BRCA1* mutation carriers is influenced by *BRCA1* wild-type allele variants: Gentic and functional analyses. Presentations on the status of previous studies and publication plans (session 2).** *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA),* New York, USA, October 26, 2009.
146. **17ß-Hydroxysteroid Dehydrogenases. Results of analysis of Phase VII CIMBA SNPs** (session 4). *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA),* New York, USA, October 26, 2009.
147. **L'expérience de notre équipe inter-disciplinaire sur la susceptibilité au cancer du sein.** *Café scientifique des IRSC : les bio-banques et leur rôle dans l'avancement de la recherche sur le cancer*, Quebec, QC, Canada, November 2, 2009.
148. **Status of CIMBA genotyping centralization in Québec City**. *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*, Cambridge, United Kingdom, April 30, 2010.
149. ***BRCA1* wild-type allele variants and Cancer Risk in *BRCA1* mutation carriers: Genetic and functional analyses.** *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*, Cambridge, United Kingdom, April 30, 2010.
150. **17ß-Hydroxysteroid Dehydrogenases Types 1 and 2. Results of analysis of Phase VII CIMBA SNPs.** *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*, Cambridge, United Kingdom, April 30, 2010.

151. **Utilisation secondaire: le point de vue d'un chercheur membre du RMGA**. *78e Congrès de l'Association francophone pour le savoir (Acfas)*, Montreal, QC, Canada, May 10, 2010.
152. **Identification, évaluation, et communication des facteurs de risque du cancer du sein.** *"CIHR Team in Familial Risks of Breast Cancer"*, Centre hospitalier affilié universitaire de Québec (CHA), Quebec, QC, Canada, June 4, 2010.
153. **Analysis of 17BHSD type I and II – Validation of previous study**, *Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA),* Riva del Garda, Italy, September 23-24, 2010.
154. **Gene-Environment Interactions in Postmenopausal Breast Cancer: A Case-control Study**, *Breast Cancer Association Consortium (BCAC)*, 11th Meeting, Riva del Garda, Italy, September 20-21, 2010.
155. **Identification, prédiction et communication du risque du cancer du sein**. *Séminaire thématique "Cancers, mutations et pharmacogénétique"*, CHUQ/HDQ, Quebec, QC, Canada, October 14, 2010.
156. **Identification, Prediction and Communication of Familial Risks of Breast Cancer**. *Hereditary Breast and Ovarian Cancer Society of Alberta - Hereditary Breast and Ovarian Cancer Society of Alberta Fall Conference*, Edmonton, AB, Canada, November 6, 2010.
157. **Instaurer un dialogue entre CÉR et chercheurs : comment mieux intégrer l'éthique dans la recherche?** *5è Édition journées d'étude des Comité d'Éthique de la recherche et de leurs partenaires*, Ministère de la Santé et des Services Sociaux, Montreal, QC, Canada, November 18-19, 2010.
158. **Characterization of Functional Regulatory SNPs in Multiple Pathways: DNA repair, Sex steroid synthesis and action, *BRCA1/2* Interactors**. *2011 Annual Meeting - CIHR Team in Familial Risks of Breast Cancer*, Quebec, QC, Canada, March 21-22, 2011.
159. **Le risque familial de cancer du sein: Qu'en savons-nous?** *Colloque annuel du Centre de recherche Biomédicales (BioMed)*, Université du Québec à Montréal (UQAM), Montreal, QC, Canada, April 27, 2011.
160. **Identification, prédiction et communication du risque du cancer du sein : un prototype de recherche interdisciplinaire pour des soins de santé personnalisés**. *79e Congrès de l'ACFAS – Transdisciplinarité et Génétique Humaine, Passer du défi à l'objectif*, Université de Sherbrooke, Sherbrooke, QC, Canada, May 11, 2011.
161. ***Governance of CIMBA. Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*** *10th Meeting, Karolinksa Institute*, Stockholm, Sweden, June 18-19, 2011.
162. **Café Scientifique des IRSC "Vivre avec le cancer, survivre aux traitements et à la maladie" /** *CIHR Café Scientifique "Cancer: Living with it, through it, and beyond it*". Librairie Indigo, Montreal, QC, Canada, October 27, 2011.
163. **Can knowing your familial risks save your life? Deciphering inherited susceptibility to breast cancer using genomics risk profiling**. *Institut du cancer des IRSC/CIHR Institute of Cancer Research Journalist Workshop*, Montreal, QC, Canada, October 28, 2011.
164. **Identification, prédiction et communication du risque de cancer du sein : un prototype de recherche interdisciplinaire pour des soins de santé personnalisés**. *15è Congrès annuel de l'AQIIRC (Association québécoise des infirmières et infirmiers en recherche clinique)*, Quebec, QC, Canada, April 19-20, 2012.
165. **Génomique du cancer du sein: de la découverte à la clinique** *Cinquième colloque annuel de biotechnologie - Les sciences omiques - Santé, environnement et société*, Centre de recherche en biovalorisation, Institut des sciences de la santé et de la vie, La Cité Collégiale, Ottawa, ON, Canada, March 21, 2013.
166. **Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer**. *GAME-ON (Genetic Associations and Mechanisms in Oncology): Seventh Plenary Meeting*, Bethesda, Md., USA, July 25-26, 2013.

167. **Personalised Risk Stratification: Towards the Integration of Genetic Modifiers.** *Hereditary Breast and Ovarian Cancer Society (HBOC) 2013 Conference – Our Genes Conference & Annual General Meeting*, Edmonton, AB, Canada, September 21, 2013.
168. **Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer / Stratification du risque pour la prévention et la détection précoce du cancer du sein.** *Colloque sur la médecine personnalisée: Parce que les solutions sont dans nos gènes*, Quebec, QC, Canada, October 1, 2013.
169. **Café scientifique des IRSC – Science en vrac. On y prend goût! Cancer du sein: Quel rôle joue l'âge de la patiente?** Le Cercle, Quebec, QC, Canada, October 8, 2013.
170. **Bar des sciences de l'UQAM/IRSC – Débat public sur la médecine personnalisée**. *Coeur des sciences de l'UQAM*, animé par la journaliste scientifique Valérie Borde, Montreal, QC, Canada, October 9, 2013.
171. **Towards a Comprehensive Understanding of the Inherited Genetic Susceptibility to Breast Cancer.** *2013 Canadian Cancer Research Conference (CCRC) Symposium: Hereditary Cancers: New Ways to Prevent Cancer Deaths*, Toronto, ON, Canada, November 5, 2013.
172. **Cancer Genomics: Access to Genetic Information by Life Insurers.** *2013 Canadian Cancer Research Conference (CCRC)*, Toronto, ON, Canada, November 6, 2013.
173. **Risk Factors and Risk Stratification.** *Canadian Breast Cancer Research Collaborative Satellite Meeting – The CBCRC: Going After the Grand Challenges in Breast Cancer*, Toronto, ON, Canada, November 6, 2013.
174. **Towards a Comprehensive Understanding of the Inherited Genetic Susceptibility to Breast Cancer**. *Rendez-Vous Génome Québec 2013 / Montreal NGS Symposium*. Montreal, QC, Canada, November 14, 2013.
175. **Hérédité et cancer du sein 1996-2016 : une approche interdisciplinaire** - *Centre R.O.S.E.*, Quebec, QC, Canada, November 18, 2013.
176. **Les Rencontres science et société de Québec de l'Université Laval, en collaboration avec le Musée de la Civilisation de Québec. Débat public : La médecine du futur sera-t-elle génomique?** *Café scientifique*, Musée de la civilisation. Quebec, QC, Canada, November 28, 2013.
177. **SNPs in genes involved in steroid hormone biosynthesis/metabolism and breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *Réunion du consortium CIMBA*, Sorrento, Italy, December 13, 2013.
178. **Functional regulatory SNPs in candidate genes and modification of breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *Réunion du consortium CIMBA*, Sorrento, Italy, December 13, 2013.
179. **Functional regulatory SNPs in candidate genes and breast cancer risk**. *Réunion du consortium BCAC* - Sorrento, Italy, December 10, 2013.
180. **Panel : Opportunités et défis : points de vue des chercheurs québécois ayant intégré des réseaux européens** de la journée d'information **Passeport pour le partenariat – Lier le Québec et l'Europe en recherche et innovation**, *Direction des collaborations internationales du Ministère de l'Enseignement supérieur, de la Recherche, de la Science et de la Technologie (MESRST), en collaboration avec ERA-CAN +*, Montreal, QC, Canada, January 31, 2014.
181. **Hérédité et cancer du sein : de la découverte à la clinique**. *Congrès biomédical Université du Québec à Trois-Rivières (UQTR) 2014*. Trois-Rivières, QC, Canada, March 27, 2014.
182. **Stratification personnalisée des risques pour la prévention et la détection précoce du cancer du sein.** *Sommet du Regroupement en soins de santé personnalisés au Québec*, Montreal, QC, Canada, June 5, 2014.
183. **Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer**. *Illumina User Group Meeting*, Montreal, QC, Canada, September 9, 2014.

184. **Towards a Comprehensive Understanding of the Inherited Genetic Susceptibility to Breast Cancer**. *Hereditary Cancer Science Day*, University of Alberta, Edmonton, AB, Canada, October 3, 2014.

185. **La formation des chercheurs et du personnel de recherche : comment améliorer la qualité de leur formation en éthique?** *5e Colloque sur l'éthique de la recherche et l'intégrité scientifique*, Montreal, QC, Canada, November 6-7, 2014.

186. **Stratification personnalisée des risques pour la prévention et la détection précoce du cancer du sein : PERSPECTIVE / Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer: PERSPECTIVE**. *"Développement et mise en pratique de solutions novatrices en médecine personnalisée en cancérologie : leçons apprises sur le terrain,* Montreal, QC, Canada, March 27, 2015.

187. **Risk stratification for prevention and early detection of breast cancer**. In Predictive Modelling and Applied Personalized Medicine Session (April 21, 2015), in the *4th Annual Canadian Human and Statistical Genetics Meeting*, Vancouver, BC, Canada, April 18-21, 2015.

188. **Accessibilité aux biobanques internationales et gestion du partage des données dans le cadre du projet PERSPECTIVE.** *Journée d'échange et d'information - La recherche avec les êtres humains : pérenniser les données et le matériel*, Université Laval, Quebec, QC, Canada, April 23, 2015.

189. **Mieux se soigner à partir de notre génome.** *La recherche d'aujourd'hui, le Québec de demain*. Présentation scientifique devant les deputés de l'Assemblée nationale du Québec, Assemblée nationale du Québec, Quebec, QC, Canada, April 30, 2015.

190. **Bar des sciences sur les soins de santé personnalisés - 24 heures de sciences 2015.** Activité organisée par la *Commission de l'éthique en science et en technologie Québec*, Quebec, QC, Canada, May 8, 2015.

191. **Deciphering Inherited Susceptibility to Breast Cancer: Personalized Risk Stratification for Prevention and Early Detection**. *Rethink Breast Cancer High Risk Forum,* Toronto, ON, Canada, May 19, 2015.

192. **Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE).** *18th meeting of the Breast Cancer Association Consortium (BCAC)*, Porto, Portugal, June 3-6, 2015.

193. **Functional regulatory SNPs in candidate genes and modification of breast and ovarian cancer risk in *BRCA1/2* mutation carriers.** *16th meeting of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*, Porto, Portugal, June 8-9, 2015.

194. **Towards a comprehensive understanding of the inherited genetic susceptibility to breast cancer for personalized risk stratification / Vers une compréhension globale de la susceptibilité génétique au cancer du sein pour la stratification du risque personnalisé**. *6th International Congress of the International and Interdisciplinary Association on the Pharmaceutical Life Cycle (IIAPC) "Médecine personnalisée et enjeux interdisciplinaires"*, Montreal, QC, Canada, August 19-21, 2015.

195. **Stratification du risque pour améliorer la prévention et la détection précoce du cancer du sein (PERSPECTIVE)**. *Ministère de la Santé et des Services sociaux, Direction québécoise de cancérologie*, Quebec, QC, Canada, October 14, 2015.

196. **Personalized Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE) project**. *CBCSN (Canadian Breast Cancer Screening Network) meeting*, by Webinar, Calgary, AB, Canada, October 22, 2015.

197. **Prévention et santé des femmes : Optimiser le dépistage précoce du cancer du sein pour plus d'efficience dans le système de santé**. *Genomics on the Hill 2016, Colline parlementaire, (organisé par Génome Canada)*, Ottawa, ON, Canada, February 22, 2016.

198. **Stratification du risque pour la prévention et le diagnostic précoce en cancer.** Dans la section "L'intégration des "-omiques" en médecine : vers une médecine de précision". *7e Journée des professeurs du Département de médecine*, Québec, QC, Canada, March 31, 2016.

199. **Cancer du sein et médecine personnalisée : je m'informe!** *Carrefour santé personnalisée (conférence publique). Panel sur le cancer du sein du Forum grand public sur la médecine personnalisée, (organisé par Génome Québec), dans le cadre du CISSP/ICPHC (Congrès International sur la Santé Personnalisée/International Congress on Personalized Health Care)*, Montréal, QC, Canada, June 13, 2016.
200. **Personalized Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE)**. *1st International Congress on Personalized Health Care (ICPHC),* Montréal, QC, Canada, June 15, 2016.
201. **The potential for Risk Stratification to Tailor Recommendations for Breast Cancer Screening**. *Canadian Partnership Against Cancer (CPAC)* "Trends in Cancer Screening in Canada: Future Opportunities!", Toronto, ON, Canada, June 23, 2016.
202. **L'ADN à l'Assemblée Nationale**. Scientific presentation by Dre Jocelyne Chiquette and Ms Joanne Castonguay, on behalf of Dr Jacques Simard, of the poster "*Le cancer du sein au Canada*" organized by Génome Québec at the "*Assemblée Nationale du Québec*", October 19, 2016.
203. **Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE).** *HEBON Meeting*, Utrecht, The Netherlands, November 10, 2016.
204. **Évaluation personalisée des risques pour améliorer la prévention et la détection précoce du cancer du sein.** *1er Symposium – Risque de Cancer Héréditaire*, conference to the lay public, Québec, QC, Canada, November 24, 2017.
205. **Évaluation personalisée des risques pour améliorer la prévention et la détection précoce du cancer du sein.** *1er Symposium – Risque de Cancer Héréditaire*, conference to health professionals, Québec, QC, Canada, November 24, 2017.
206. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer.** *Scientific meeting with the Scientific Advisory Board of Q-CROC,* Québec, QC, Canada, December 18, 2017.
207. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation.** *Genome Canada Science Symposium for the Science and Industry Advisory Committee,* Montreal, QC, Canada, February 7, 2018.
208. **La génomique : un dépistage personnalisé du cancer du sein.** *12ième édition - Souper Bénéfice de la Jonquille. Société Canadienne du Cancer,* Québec, QC, Canada, April 17, 2018.
209. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer.** *Rendez-Vous Génome Québec,* Québec, QC, Canada, April 22, 2018.
210. **Regroupement stratégique 3. Génomique intégrée de nouvelle génération: Vision et renouvellement.** *12ième Journées génétiques du RMGA,* Montréal, QC, Canada, April 30-May 1, 2018.
211. **Oncogénétique, avancée scientifique et médecine personnalisée.** *Le Forum 2018 – Fondation du Cancer du Sein du Québec,* Montréal, QC, Canada, May 5, 2018.
212. **Un Dépistage Personnalisé du Cancer du Sein***:* **La Génomique à votre Service.** *Pint of Science 2018,* Québec, QC, Canada, May 15, 2018.
213. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Lessons Learned and Challenges Posed.** *Illumina User Group Meeting,* Montréal, QC, Canada, May 22, 2018.
214. **Plans for exome sequencing (PERSPECTIVE/BRIDGES).** *Breast Cancer Association Consortium (BCAC),* Edinburgh, Scotland, June 12, 2018.
215. **Implementation in PERSPECTIVE.** *Inaugural Joint BCAC / ENIGMA / CIMBA Meeting,* Edinburgh, Scotland, June 14, 2018.
216. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation**. *2nd International Congress on Personalized Health Care (ICPHC) 2018.* Montréal, QC, Canada, September 23 – 26, 2018.

217. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation**. *Canadian Science Policy Conference (CSPC). "Mitigating disruption: integrating social, ethical and policy research into the development of disruptive genomic technologies."* Ottawa, Ontario, Canada, November 8, 2018.

218. **Personalized Risk Stratification for Prevention and Early Detection of Breast Cancer: Integration and Implementation**. *European Alliance for Personalized Medicine (EAPM) Congress. "Forward as One: Integrating Innovation into Europe's Healthcare Systems."* Milan, Italy, November 26-28, 2018.

219. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration & Implementation.** *Canadian Partnership Against Cancer (CPAC) Board Member and Stakeholder Reception.* Montreal, Quebec, February 27, 2019.

220. **Évaluation personnalisée des risques pour la prévention et le dépistage précoce du cancer du sein : Integration et Implementation**. *10e conférence annuelle pour vaincre le cancer : Coalition Priorité Cancer au Québec*, Longueuil-Montréal, Québec, February 28, 2019.

221. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer**: **Integration & Implementation.** *Future of Individualized Medicine Conference*. La Jolla, California, USA, March 14 & 15, 2019.

222. **Évaluation personnalisée des risques pour la prévention et le dépistage précoce du cancer du sein : Integration et Implementation.** *Journée Érudition Recherche.* Department of Family Medicine and Emergency Medicine. Faculty of Medicine, Université Laval, Québec City, QC, May 17, 2019.

223. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer**. *City of Hope Comprehensive Cancer Center Seminar*. Duarte, California, USA, May 22, 2019.

224. **Where are we with our ability to predict risk for mutation carriers and ER-disease?** *Athena/WISDOM Spring Retreat*. San Francisco, California, USA, May 23, 2019.

225. **Hérédité et cancer du sein : 25 ans d'Histoire.** *Journées de la recherche 2019 du CHU de Québec – Université Laval*, Québec City, QC, May 30 & 31, 2019.

226. **Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration & Implementation.** *ENVISION Network: European Conference on Risk-Stratified Prevention and Early Detection of Breast Cancer,* Hall in Tirol, Austria, June 26-28, 2019.

227. **Un score de risque polygénique pour la prédiction précoce des personnes à risque élevé de cancer du sein.** *Le score de risque polygénique : Une percée de la médecine personnalisée pour améliorer la prévention et le traitement des maladies chroniques. Innove-Action 2019*. Centre Hospitalier Universitaire de Montréal (CHUM), Montréal, Québec, Canada, November 19-21, 2019.

228. **Un test de salive peut-il prédire le risque de cancer du sein?** *Congrès annuel de l'Association québécoise des infirmières et intervenants en recherche clinique (AQIIRC).* Virtual format. Québec, QC, Canada, October 1-2, 2020.

ARTICLES IN PEER REVIEWED JOURNALS
[Google Scholar citations as at November 1, 2020]

MECHANISMS UNDERLYING THE ACTION, SYNTHESIS AND INACTIVATION OF STEROID HORMONES

1. Simard J, Labrie F (1985) **Keoxifene shows pure antiestrogenic activity in pituitary gonadotrophs**. *Molecular and Cellular Endocrinology,* 39: 141-144. [51]
2. Heisler, S, Simard J, Assayag E, Mehri Y, Labrie F (1986) **Atrial natriuretic factor does not affect basal, forskolin- and CRF-stimulated adenylate cyclase activity, cAMP formation or ACTH secretion, but does stimulate cGMP synthesis in anterior pituitary**. *Molecular and Cellular Endocrinology,* 44: 125-131. [62]
3. Simard J, Hubert JF, Hosseinzadeh T, Labrie F (1986) **Stimulation of growth hormone release and synthesis by estrogens in rat anterior pituitary cells in culture**. *Endocrinology* 119: 2004-2011. [104]
4. Simard J, Hubert JF, Labrie F, Israel-Assayag E, Heisler S (1986) **Atrial natriuretic factor-induced cGMP accumulation in rat anterior pituitary cells in culture is not coupled to hormonal secretion**. *Regulatory Peptides,* 15: 269-278. [36]
5. Simard J, Labrie F (1986) **Characteristics of the desensitization of growth hormone and cyclic AMP responses to growth hormone-releasing factor and prostaglandin E2 in rat anterior pituitary cells in culture**. *Molecular and Cellular Endocrinology* 46: 79-89. [11]
6. Simard J, Labrie F, Gossard F (1986) **Regulation of growth hormone mRNA and pro-opiomelanocortin mRNA levels by cyclic AMP in rat anterior pituitary cells in culture**. *DNA,* 5: 263-270. [41]
7. Simard J, Luthy I, Guay J, Bélanger A, Labrie F (1986) **Characteristics of interaction of the antiandrogen flutamide with the androgen receptor in various target tissues**. *Molecular and Cellular Endocrinology,* 44: 261-270. [248]
8. Labrie F, Dupont A, Bélanger A, Emond J, Monfette G, Luthy I, Simard J, Lachance R (1987) **Flutamide in combination with castration (surgical or medical) is the standard treatment in advanced prostate cancer**. *Journal of Drug Development,* 1: 34-51.
9. Simard J, Labrie F (1987) **Adrenal C19-5-ene steroids induce full estrogenic responses in rat pituitary gonadotrophs**. *Journal of Steroid Biochemistry,* 26: 539-546. [36]
10. Simard J, Lefèvre G, Labrie F (1987) **Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release**. *Peptides,* 8: 199-205. [21]
11. Hubert JF, Simard J, Gagné B, Barden N, Labrie F (1988) **Effect of luteinizing hormone-releasing hormone (LHRH) and [D-Trp^{6}, des-Gly-NH$_2^{10}$] LHRH ethylamide on α-subunit and LHβ messenger ribonucleic acid levels in rat anterior pituitary cells in culture**. *Molecular Endocrinology,* 2: 521-527. [27]
12. Pelletier G, Labrie C, Simard J, Duval M, Martinoli MG, Zhao HF, Labrie F (1988) **Effects of sex steroids on regulation of the levels of C1 peptide of rat prostatic steroid-binding protein mRNA evaluated by insitu hybridization**. *Journal of Molecular Endocrinology,* 1: 213-223. [43]
13. Simard J, Labrie C, Hubert JF, Labrie F (1988) **Modulation by sex steroids and [D-Trp^{6}, des-Gly-NH$_2^{10}$] LHRH ethylamide of α-subunit and LHβ mRNA levels in the rat anterior pituitary gland**. *Molecular Endocrinology,* 2: 775-784. [33]
14. Simard J, Vincent A, Duchesne R, Labrie F (1988) **Full estrogenic activity of C19-Δ5 adrenal steroids in rat pituitary lactotrophs and somatotrophs**. *Molecular and Cellular Endocrinology,* 55: 233-242. [53]
15. Dumont M, Dauvois S, Simard J, Garcia T, Schachter B, Labrie F (1989) **Antagonism between estrogens and androgens on GCDFP-15 gene expression in ZR-75-1 cells and correlation between GCDFP-15 and estrogen as well as progesterone receptor expression in human breast cancer**. *Journal of Steroid Biochemistry,* 34: 397-402. [24]

16. Labrie F, Luu-The V, Labrie C, Bérubé D, Couët J, Zhao HF, Gagné, R, Simard J (1989) **Characterization of two mRNA species encoding human estradiol 17β-dehydrogenase and assignment of the gene to chromosome 17**. *Journal of Steroid Biochemistry,* 34: 189-197. [18]
17. Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G, Labrie F (1989) **Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate**. *Endocrinology,* 124: 2745-2754. [101]
18. Luu-The V, Labrie C, Zhao HF, Couët J, Lachance Y, Simard J, Leblanc, G, Côté J, Bérubé D, Gagné R, Labrie F (1989) **Characterization of cDNAs for human estradiol 17β-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5' termini in human placenta**. *Molecular Endocrinology,* 3: 1301-1309. [193]
19. Poulin R, Simard J, Labrie C, Petitclerc L, Dumont M, Lagacé L, Labrie F (1989) **Down-regulation of estrogen receptors by androgens in the ZR-75-1 human breast cancer cell line**. *Endocrinology,* 125: 392-399. [115]
20. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, Haagensen DE, Labrie F (1989) **Inhibitory effect of estrogens on GCDFP-15 mRNA levels and secretion in ZR-75-1 human breast cancer cells**. *Molecular Endocrinology,* 3: 694-702. [63]
21. Tong Y, Simard J, Labrie C, Zhao HF, Labrie F, Pelletier G. (1989) **Inhibitory effect of androgen on estrogen-induced prolactin messenger ribonucleic acid accumulation in the male rat anterior pituitary gland**. *Endocrinology,* 125: 1821-1828. [51]
22. Tong Y, Zhao HF, Simard J, Labrie F, Pelletier G (1989) **Electron microscopic autoradiographic localization of prolactin mRNA in rat pituitary**. *Journal of Histochemistry and Cytochemistry,* 37: 567-571. [44]
23. Toranzo D, Dupont E, Simard J, Labrie C, Couët J, Labrie F, Pelletier G (1989) **Regulation of pro-gonadotropin-releasing hormone gene expression by sex steroids in the brain of male and female rats**. *Molecular Endocrinology,* 3: 1748-1756. [103]
24. Zhao HF, Simard J, Labrie C, Breton N, Rhéaume R, Luu-The V, Labrie F (1989) **Molecular cloning, cDNA structure and predicted amino acid sequence of bovine 3β-hydroxy-5-ene-steroid dehydrogenase/Δ5-Δ4 isomerase**. *FEBS Letters,* 259: 153-157. [65]
25. Baker ME, Luu-The V, Simard J, Labrie F (1990) **A common ancestor for mammalian 3*β*-hydroxysteroid dehydrogenase and plant dihydroflavonol reductase**. *Biochemical Journal,* 269: 558-559. [29]
26. Dauvois S, Simard J, Dumont M, Haagensen DE, Labrie F (1990) **Opposite effects of estrogen and the progestin R5020 on cell proliferation and GCDFP-15 expression in ZR-75-1 human breast cancer cells**. *Molecular and Cellular Endocrinology,* 73:171-178. [15]
27. Dupont E, Zhao HF, Rhéaume E, Simard J, Luu-The V, Labrie F, Pelletier G (1990) **Localization of 3β -hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in the rat gonads and adrenal glands by immunocytochemistry and in situ hybridization**. *Endocrinology,* 127: 1394-1403. [39]
28. Labrie F, Bélanger A, Dupont A, Pelletier G, Luu-The V, Simard J, Cusan L. Labrie C, Lachance Y, Poulin R, Dupont E, Zhao HF, Martel C (1990) **Synthèse périphérique des androgènes chez l'homme. Génétique moléculaire du système et sa prise en compte dans le traitement du cancer de la prostate**. *Médecine-Sciences,* 6: 261-267.
29. Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F (1990) **Synthetic progestins stimulate prostatic binding protein messenger RNAs in the rat ventral prostate**. *Molecular and Cellular Endocrinology,* 68: 169-179. [37]
30. Lachance Y, Luu-The V, Labrie C. Simard J, Dumont M, de Launoit Y, Guérin S, Leblanc G, Labrie F (1990) **Characterization of human 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene and its expression in mammalian cells**. *Journal of Biological Chemistry,* 265: 20469-20475. [174]

31. Luu-The V, Labrie C, Simard J, Lachance Y, Zhao HF, Couët J, Leblanc G, Labrie F (1990) **Structure of two in tandem human 17β-hydroxysteroid dehydrogenase genes**. *Molecular Endocrinology,* 4: 268-275. [131]
32. Martel C, Labrie C, Dupont E, Couët J, Trudel C, Rhéaume E, Simard J, Luu-The V, Pelletier G, Labrie F (1990) **Regulation of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase expression and activity in the hypophysectomized rat ovary: interactions between the stimulatory effect of human chorionic gonadotropin and the luteolytic effect of prolactin**. *Endocrinology,* 127: 2726-2737. [36]
33. Rhéaume E, Tonon MC, Smih F, Simard J, Désy L, Vaudry H, Pelletier G (1990) **Localization of the endogenous benzodiazepine ligand octadecaneuropeptide (ODN) in the rat testis**. *Endocrinology,* 127: 1986-1994. [43]
34. Simard J, Dauvois S, Haagensen DE, Lévesque C, Mérand Y, Labrie F (1990) **Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action in breast cancer**. *Endocrinology,* 126: 3223-3231. [121]
35. Tong Y, Couët J, Simard J, Pelletier G (1990) **Glucocorticoid regulation of proopiomelanocortin mRNA levels in rat arcuate nucleus**. *Molecular and Cellular Neurosciences,* 1: 78-83. [31]
36. Zhao HF, Rhéaume E, Trudel C, Couët J, Labrie F, Simard J (1990) **Structure and sexual dimorphic expression of a liver-specific rat 3β-hydroxysteroid dehydrogenase/isomerase**. *Endocrinology,* 127: 3237-3239. [96]
37. Zorilla R, Simard J, Rhéaume E, Labrie F, Pelletier G (1990) **Multihormonal control of pre-pro-somatostatin mRNA levels in the periventricular nucleus of the male and female rat hypothalamus**. *Neuroendocrinology,* 52: 527-536. [45]
38. de Launoit Y, Dauvois S, Dufour M, Simard J, Labrie F (1991) **Inhibition of cell cycle kinetics and proliferation by the androgen 5α-dihydrotestosterone and antiestrogen N, n-butyl-N-methyl-11-[16'α-chloro-3',17β-dihydroxy-estra-1',3',5'-(10')triene-7'α-yl] undeca-namide in human breast cancer ZR-75-1 cells**. *Cancer Research,* 51: 2797-2802. [85]
39. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F (1991) **Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells**. *Cancer Research,* 51: 5165-5170. [101]
40. Dupont E, Rhéaume E, Simard J, Luu-The V, Labrie, F, Pelletier G (1991) **Ontogenesis of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in the rat adrenal as revealed by immunocytochemistry and in situ hybridization**. *Endocrinology,* 129: 2687-2692. [21]
41. Labrie F, Simard J, Luu-The V, Trudel C, Martel C, Labrie C, Zhao HF, Rhéaume E, Couët J, Breton N (1991) **Expression of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) and 17β–hydroxysteroid dehydrogenase (17β-HSD) in adipose tissue**. *International Journal of Obesity,* 15 Suppl. 2: 91-99. [30]
42. Pelletier G, Simard J (1991) **Dopaminergic regulation of pre-proNPY mRNA levels in the rat arcuate nucleus**. *Neuroscience Letters,* 127: 96-98. [34]
43. Pelletier G, Tong Y, Rhéaume E, Simard J, Tonon MC, Vaudry H (1991) **Localization of endogenous benzodiazepine ligand octadecaneuropeptide (ODN) and peripheral benzodiazepine receptors in the rat prostate**. *Molecular Andrology,* 3: 95-108. [43]
44. Rhéaume E, Lachance Y, Zhao HF, Breton N, Dumont M, de Launoit Y, Trudel C, Luu-The V, Simard J, Labrie F (1991) **Structure and expression of a new cDNA encoding the almost exclusive 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in human adrenals and gonads**. *Molecular Endocrinology,* 5: 1147-1157. [267]
45. Rhéaume E, Leblanc JF, Lachance Y, Labrie F, Simard J (1991) **Detection of a frequent Bgl II polymorphism by PCR and Taq I RFLP for 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase at the human HSDB3 locus (1p11-p13)**. *Human Genetics,* 87: 753-754. [10]

46. Rhéaume E, Sirois I, Labrie F, Simard J (1991) **Codon 367 polymorphism of the human type I 3β-hydroxysteroid dehydrogenase/isomerase gene (HS5 DB3)**. *Nucleic Acids Research,* 19: 6060. [20]

47. Simard J, de Launoit Y, Labrie F (1991) **Characterization of the structure-activity relationships of rat types I and II 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase by site-directed mutagenesis and expression in HeLa cells**. *Journal of Biological Chemistry,* 266: 14842-14845. [59]

48. Simard J, Melner MH, Breton N, Low KG, Zhao HF, Periman LM, Labrie F (1991) **Characterization of macaque 3β-hydroxy-5-ene steroid dehydrogenase/Δ5-Δ4 isomerase: structure and expression in steroidogenic and peripheral tissues in primate**. *Molecular and Cellular Endocrinology,* 75: 101-110. [69]

49. Simard J, Veilleux R, de Launoit Y, Haagensen DE, Labrie F (1991) **Stimulation of apoliprotein D secretion by steroids coincides with inhibition of cell proliferation in human LNCaP prostate cancer cells**. *Cancer Research,* 51: 4336-4341. [87]

50. Tong Y, Rhéaume E, Simard J, Pelletier G (1991) **Localization of peripheral benzodiazepine binding sites and diazepam-binding inhibitor (DBI) mRNA in mammary glands and dimethylbenz(α)anthrene(DMBA)-induced mammary tumors in the rat**. *Regulatory Peptides,* 33: 263-273. [23]

51. Zhao HF, Labrie C, Simard J, de Launoit Y, Trudel C, Martel C, Rhéaume E, Dupont E, Luu-The V, Pelletier G, Labrie F (1991) **Characterization of rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase cDNAs and differential tissue-specific expression of corresponding mRNAs in steroidogenic and peripheral tissues**. *Journal of Biological Chemistry,* 266: 583-593. [143]

52. Zorilla R, Simard J, Labrie F, Pelletier G (1991) **Variations of pre-somatostatin mRNA levels in the hypothalamic periventricular nucleus during the rat estrous cycle**. *Molecular and Cellular Neurosciences,* 2: 294-298. [8]

53. Couët J, Simard J, Martel C, Trudel C, Labrie Y, Labrie F (1992) **Regulation of 3-ketosteroid reductase messenger ribonucleic acid levels and 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase activity in rat liver by sex steroids and pituitary hormones**. *Endocrinology,* 131: 3034-3044. [23]

54. de Launoit Y, Simard J, Durocher F, Labrie F (1992) **Androgenic 17β-hydroxysteroid dehydrogenase activity of expressed rat type I 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase**. *Endocrinology,* 130: 553-555. [32]

55. de Launoit Y, Zhao HF, Bélanger A, Labrie F, Simard J (1992) **Expression of liver-specific member of the 3β-hydroxysteroid dehydrogenase family, an isoform possessing an almost exclusive 3-ketosteroid reductase activity**. *Journal of Biological Chemistry,* 267: 4513-4517. [52]

56. Foss KB, Simard J, Bérubé D, Beebe SJ, Sandberg M, Grzeschik KH, Gagné R, Hansson V, Jahnsen T (1992) **Localization of the catalytic subunit Cγ of cAMP-dependent protein kinase on human chromosome 9 q13**. *Cytogenetics and Cell Genetics,* 60: 22-25. [21]

57. Kaynard AH, Periman LM, Simard J, Melner MH (1992) **Ovarian 3β-hydroxysteroid dehydrogenase and sulfated glycoprotein-2 gene expression are differentially regulated by the induction of ovulation, pseudopregnancy, and luteolysis in the immature rat**. *Endocrinology,* 130: 2192-2200. [51]

58. Labrie F, Simard J, de Launoit Y, Poulin, R, Thériault C, Dumont M, Dauvois S, Martel C, Li, SM (1992) **Androgens and breast cancer**. *Cancer Detection and Prevention,* 16: 31-38. [56]

59. Labrie F, Simard J, Luu-The V, Bélanger A, Pelletier G (1992) **Structure, function and tissue-specific gene expression of multiple 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase isoenzymes in classical and peripheral intracrine steroidogenic tissues**. *Journal of Steroid Biochemistry and Molecular Biology,* 43: 805-826. [171]

60. Labrie F, Simard J, Luu-The V, Pelletier G, Bélanger A, Lachance Y, Zhao HF, Labrie C, Breton N, de Launoit Y, Dumont M, Dupont E, Rhéaume E, Martel C, Couët J, Trudel C (1992) **Structure and tissue-specific expression of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat classical and peripheral steroidogenic tissues**. *Journal of Steroid Biochemistry and Molecular Biology,* 41: 421-435. [79]

61. Labrie F, Sugimoto Y, Luu-The V, Simard J, Lachance Y, Bachvarov D, Leblanc G, Durocher F, Paquet N (1992) **Structure of human type II 5α-reductase gene**. *Endocrinology,* 131: 1571-1573. [223]

62. Martel C, Rhéaume E, Takahashi M, Trudel C, Couët J, Luu-The V, Simard J, Labrie F (1992) **Distribution of 17β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues**. *Journal of Steroid Biochemistry and Molecular Biology,* 41: 597-603. [240]

63. Orstavik S, Sandberg M, Bérubé D, Natarajan V, Simard J, Walter U, Gagné R, Hansson V, Jahnsen T. (1992) **Localization of the human gene for the type I cyclic GMP-dependent protein kinase to chromosome 10**. *Cytogenetics and Cell Genetics,* 59: 270-273. [14]

64. Pelletier G, Dupont E, Simard J, Luu-The V, Bélanger A, Labrie F (1992) **Ontogeny and subcellular localization of 3β-hydroxysteroid dehydrogenase (3β-HSD) in the human and rat adrenal, ovary and testis**. *Journal of Steroid Biochemistry and Molecular Biology,* 43: 451-467. [46]

65. Pelletier G, Rhéaume E, Simard J (1992) **Variations of pre-proNPY mRNA in the arcuate nucleus during the rat estrous cycle**. *NeuroReport,* 3: 253-255. [10]

66. Rhéaume E, Simard J, Morel Y, Mébarki F, Zachmann M, Forest MG, New MI, Labrie F (1992) **Congenital adrenal hyperplasia due to point mutations in the type II 3β-hydroxysteroid dehydrogenase gene**. *Nature Genetics,* 1: 239-245. [259]

67. Simard J, Bérubé D, Sandberg M, Grzeschik KH, Gagné R, Hansson V, Jahnsen T (1992) **Assignment of the gene encoding the catalytic subunit Cβ or cAMP-dependent protein kinase to the p36 band on chromosome 1**. *Human Genetics,* 88: 653-657. [11]

68. Simard J, de Launoit Y, Haagensen DE, Labrie F (1992) **Additive stimulatory action of glucocorticoids and androgens on basal and estrogen-repressed apolipoprotein D messenger RNA levels and secretion in human breast cancer cells**. *Endocrinology,* 130: 1115-1121. [84]

69. Simard J, Luu-The V, Labrie F (1992) **Structure and expression of the genes encoding the enzymes for ovarian and peripheral steroidogenesis**. *J. Gynecol. Obstet. Biol. Reprod., (Paris)* 21: 292-295.

70. Solberg R, Sistonen P, Träskelin AL, Bérubé D, Simard J, Krajci P, Jahnsen T, de la Chapelle A (1992) **Mapping of the regulatory subunits RIβ- and RIIβ of cAMP-dependent protein kinase genes on human chromosome 7**. *Genomics,* 14: 63-69. [20]

71. Couture P, Thériault C, Simard J, Labrie F (1993) **Androgen receptor-mediated stimulation of 17β-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxy-progesterone acetate in ZR-75-1 human breast cancer cells**. *Endocrinology*, 132: 179-185. [68]

72. Labrie F, Bélanger A, Dupont A, Luu-The V, Simard J, Labrie C (1993) **Science behind total androgen blockade: from gene to combination therapy**. *Clinical and Investigative Medicine,* 16: 475-492. [124]

73. Labrie F, Bélanger A, Simard J, Labrie C, Dupont A (1993) **Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first-line therapy**. *Cancer,* 71: 1059-1067. [142]

74. Labrie F, Dupont A, Simard J, Luu-The V, Bélanger A (1993) **Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer**. *European Urology,* 24: 94-105.

75. Normand T, Narod SA, Labrie F, Simard J (1993) **Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the EDH17B2 Locus on 17q11-q21**. *Human Molecular Genetics,* 2: 479-483. [40]

76. Simard J, Couët J, Durocher F, Labrie Y, Sanchez R, Breton N, Turgeon C, Labrie F (1993) **Structure and tissue-specific expression of a novel member of the rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) family. The exclusive 3β-HSD gene expressed in the skin**. *Journal of Biological Chemistry,* 268: 19659-19668. [94]

77. Simard J, Rhéaume E, Sanchez R, Laflamme N, de Launoit Y, Luu-The V, van Seters AP, Gordon RD, Bettendorf M, Heinrich U, Moshang T New MI, Labrie F (1993) **Molecular basis of congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency**. *Molecular Endocrinology,* 7: 716-728. [132]

78. Blais Y, Sugimoto K, Carrière MC, Haagensen DE, Labrie F, Simard J (1994) **Potent stimulatory effect of interleukin-1α on apolipoprotein D and gross cystic disease fluid protein-15 expression in human breast cancer cells**. *International Journal of Cancer,* 59: 400-407. [40]

79. Couët J, Martel C, Labrie Y, Luo S, Simard J, Labrie F (1994) **Opposite effects of prolactin and corticosterone on the expression and activity of 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase in rat skin**. *Journal of Investigative Dermatology,* 103: 60-64. [9]

80. Dupont E, Simard J, Luu-The V, Labrie F, Pelletier G (1994) **Localization of 3β-hydroxysteroid dehydrogenase in rat brain as studied by in situ hybridization**. *Molecular and Cellular Neurosciences*, 5 : 119-123. [83]

81. Eskild W, Robidoux S, Simard J, Hansson V, Guérin SL (1994) **Binding of a member of the NF1 family of transcription factors to two distinct cis-acting elements in the promoter and 5'-flanking region of the human cellular retinol binding protein 1 gene**. *Molecular Endocrinology,* 8: 732-745. [30]

82. Labrie Y, Couët J, Simard J, Labrie F (1994) **Multihormonal regulation of dehydroepiandrosterone sulfotransferase messenger ribonucleic acid levels in adult rat liver**. *Endocrinology,* 134: 1693-1699. [25]

83. Labrie F, Simard J, Luu-The V, Pelletier G, Belghmi K, Bélanger A (1994) **Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in formation of sex steroids in classical and peripheral intracrine tissues**. *Baillieres Clin Endocrinol Metab,* 8: 451-474. [68]

84. Martel C, Gagné D, Couët J, Labrie Y, Simard J, Labrie F (1994) **Rapid modulation of ovarian 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat**. *Molecular and Cellular Endocrinology,* 99: 63-71. [33]

85. Martel C, Melner MH, Gagné D, Simard J, Labrie F (1994) **Widespread tissue distribution of steroid sulfatase, 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase (3β-HSD), 17β-HSD 5α-reductase and aromatase activities in the rhesus monkey**. *Molecular and Cellular Endocrinology,* 104: 103-111. [235]

86. Poirier D, Auger S, Mérand Y, Simard J, Labrie F (1994) **Synthesis and antiestrogenic activity of diaryl thioether derivatives**. *Journal of Medicinal Chemistry,* 37: 1115-1125. [37]

87. Rhéaume E, Sanchez R, Simard J, Chang YT, Wang J, Pang S, Labrie F (1994) **Molecular basis of congenital adrenal hyperplasia in two siblings with classical nonsalt-losing 3β-hydroxysteroid dehydrogenase deficiency**. *Journal of Clinical Endocrinology and Metabolism,* 79: 1012-1018. [57]

88. Sanchez R, de Launoit Y, Durocher F, Bélanger A, Labrie F, Simard J (1994) **Formation and degradation of dihydrotestosterone by recombinant members of the rat 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase family**. *Molecular and Cellular Endocrinology,* 103: 29-38. [14]

89. Sanchez R, Mébarki F, Rhéaume E, Laflamme N, Forest MG, Bey-Omard F, David M, Morel Y, Labrie F, Simard J (1994) **Functional characterization of the novel L108W and P186L mutations detected in the type II 3β-hydroxysteroid dehydrogenase gene of a male pseudohermaphrodite with congenital adrenal hyperplasia**. *Human Molecular Genetics,* 3: 1639-1645. [32]

90. Sanchez R, Rhéaume E, Laflamme N, Rosenfield RL, Labrie F, Simard J (1994) **Detection and functional characterization of the novel missense mutation Y254D in type II 3β-hydroxysteroid dehydrogenase (3β-HSD) gene of a female patient with nonsalt-losing 3β-HSD deficiency**. *Journal of Clinical Endocrinology and Metabolism,* 78: 561-567. [59]

91. Simard J, Moorjani S, Vohl MC, Couture P, Torres AL, Gagné C, Després JP, Labrie F, Lupien PJ (1994) **Detection of the novel mutation (stop 468) in exon 10 of the low-density lipoprotein (LDL) receptor gene causing familial hypercholesterolemia among French Canadians**. *Human Molecular Genetics,* 3: 1689-1691. [37]

92. Simard J, Rhéaume E, Leblanc JF, Wallis SC, Joplin GF, Gilbey S, Allanson J, Mettler G, Bettendorf M, Heinrich U, Labrie F (1994) **Congenital adrenal hyperplasia caused by a novel homozygous frameshift mutation 273ΔAA in type II 3β-hydroxysteroid dehydrogenase gene (HSD3B2) in three male patients of Afghan/Pakistani origin**. *Human Molecular Genetics,* 3: 327-330. [41]

93. Sugimoto K, Simard J, Haagensen DE, Labrie F (1994) **Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells**. *Journal of Steroid Biochemistry and Molecular Biology,* 51: 167-174. [51]

94. Verreault H, Dufort I, Simard J, Labrie F, Luu-The V (1994) **Dinucleotide repeat polymorphisms in the HSD3B2 gene**. *Human Molecular Genetics,* 3: 384. [25]

95. Zerah M, Rhéaume E, Mani P, Schram P, Simard J, Labrie F, New MI (1994) **No evidence of mutations in the genes for Type I and Type II 3b-hydroxysteroid dehydrogenase (3bHSD) in nonclassical 3bHSD deficiency**. *Journal of Clinical Endocrinology and Metabolism,* 79: 1811-1817. [73]

96. Blais Y, Sugimoto K, Carrière MC, Haagensen DE, Labrie F, Simard J (1995) **Interleukin-6 inhibits the potent stimulatory action of androgens, glucocorticoids and interleukin-1α on apolipoprotein D and GCDFP-15 expression in human breast cancer cells**. *International Journal of Cancer,* 62: 732-737. [46]

97. Chen C, Puy LA, Simard J, Li X, Singh SM, Labrie F (1995) **Local and systemic reduction by topical finasteride or flutamide on hamster flank organ size and enzyme activity**. *Journal of Investigative Dermatology,* 105: 678-682. [44]

98. Dalla Valle L, Couët J, Labrie Y, Simard J, Belvedere P, Simontacchi C, Labrie, F, Colombo L (1995) **Occurrence of cytochrome P450c17 mRNA and dehydro-epiandrosterone biosynthesis in the rat gastrointestinal tract**. *Molecular and Cellular Endocrinology,* 111: 83-92. [39]

99. Durocher F, Morissette J, Dufort I, Simard J, Luu-The V (1995) **Genetic linkage mapping of the dehydroepiandrosterone sulfotransferase (STD) gene on the chromosome 19q13.3 region**. *Genomics,* 29: 781-783. [12]

100. Durocher F, Morissette J, Labrie Y, Labrie F, Simard J (1995) **Mapping of the HSD17B2 gene encoding type II 17β-hydroxysteroid dehydrogenase close to D16S422 on chromosome 16q 24.1-q24.2**. *Genomics,* 25: 724-726. [38]

101. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C (1995) **Intracrinology. Autonomy and freedom of peripheral tissues**. *Ann. Endocrinol.,* 56: 23-29. [22]

102. Labrie Y, Durocher F, Lachance Y, Turgeon C, Simard J, Labrie C, Labrie F (1995) **The human type II 17β-hydroxysteroid dehydrogenase gene encodes two alternatively spliced messenger RNA species**. *DNA and Cell Biology,* 14: 849-861. [89]

103. Mébarki F, Sanchez R, Rhéaume E, Laflamme N, Simard J, Forest MG, Bey-Omard F, David M, Labrie F, Morel Y (1995) **Nonsalt-losing male pseudohermaphroditism due to the novel homozygous N100S mutation in the type II 3β-hydroxysteroid dehydrogenase gene**. *Journal of Clinical Endocrinology and Metabolism,* 80: 2127-2134. [44]

104. Morissette J, Rhéaume E, Leblanc JF, Luu-The V, Labrie F, Simard J (1995) **Genetic linkage mapping of HSD3B1 and HSD3B2 encoding human types I and II 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4-isomerase close to D1S514 and the centromeric D1Z5 locus**. *Cytogenetics and Cell Genetics,* 69: 59-62. [27]

105. Rhéaume E, Sanchez R, Mébarki F, Gagnon E, Carel JC, Chaussain JL. Morel Y, Labrie F, Simard J (1995) **Identification and characterization of the G15D mutation found in a male patient with 3β-hydroxysteroid dehydrogenase (3β-HSD) deficiency: alteration of the putative NAD-binding domaine of type II 3β-HSD**. *Biochemistry,* 34: 2893-2900. [38]

106. Simard J, Rhéaume E, Mébarki F, Sanchez R, New MI, Morel Y, Labrie F (1995) **Molecular basis of human 3β-hydroxysteroid dehydrogenase deficiency**. *Journal of Steroid Biochemistry and Molecular Biology,* 53: 127-138. [75]

107. Simard J, Sanchez R, Durocher F, Rhéaume E, Turgeon C, Labrie Y, Luu-The V, Mebarki F, Morel Y, de Launoit Y, Labrie F (1995) **Structure-function relationship and molecular genetics of the 3β-hydroxysteroid dehydrogenase gene family**. *Journal of Steroid Biochemistry and Molecular Biology,* 55: 489-505. [32]

108. Vohl MC, Couture P, Moorjani S, Torres AL, Gagné C, Després JP, Lupien PJ, Labrie F, Simard J (1995) **Rapid restriction fragment analysis for screening of four point mutations of the low-density lipoprotein receptor gene in French Canadians**. *Human Mutation,* 6: 243-246. [27]

109. Blais Y, Gingras S, Haagensen DE, Labrie F, Simard J (1996) **Interleukin-4 and interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and stimulate GCDFP-15 expression in human breast cancer cells**. *Molecular and Cellular Endocrinology,* 121: 11-18. [69]

110. Labrie F, Bélanger A, Cusan L, Labrie C, Simard J, Luu-The V, Diamond P, Gomez JL, Candas B (1996) **History of LHRH agonist and combination therapy in prostate cancer**. *Endocrine-Related Cancer,* 3: 243-278. [70]

111. Laflamme N, Leblanc JF, Mailloux J, Faure N, Labrie F, Simard J (1996) **Mutation R96W in cytochrome P450c17 gene causes combined 17α-hydroxylase/17-20 lyase deficiency in two French Canadian patients**. *Journal of Clinical Endocrinology and Metabolism,* 81: 264-268. [57]

112. Luo S, Martel C, Leblanc G, Candas B, Singh SM, Labrie C, Simard J, Bélanger A, Labrie F (1996) **Relative potencies of flutamide and casodex: preclinical studies**. *Endocrine-Related Cancer,* 3: 229-241. [25]

113. Morissette J, Durocher F, Leblanc JF, Normand T, Labrie F, Simard J (1996) **Genetic linkage mapping of the human steroid 5α-reductase type 2 gene (SRD5A2) close to D2S352 on chromosome region 2p23 → p22**. *Cytogenetics and Cell Genetics,* 73: 304-307. [29]

114. Puy LA, Turgeon C, Gagné D, Labrie Y, Chen C, Pelletier G, Simard J, Labrie F (1996) **Localization and regulation of expression of the FAR-17A gene in the hamster flank organs**. *Journal of Investigative Dermatology,* 107: 44-50. [15]

115. Simard J, Durocher F, Mébarki F, Turgeon C, Sanchez R, Labrie Y, Couët J, Trudel C, Rhéaume E, Morel Y, Luu-The V, Labrie F (1996) **Molecular biology and genetics of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family**. *Journal of Endocrinology,* 150: S189-S207. [152]

116. Foss KB, Solberg R, Simard J, Myklebust F, Hansson V, Jahnsen T, Taskén K (1997) **Molecular cloning, upstream sequence and promoter studies of the human gene for the regulatory subunit RII a of cAMP-dependent protein kinase**. *BBA - Biochimica & Biophysica Acta,* 1350: 98-108. [22]

117. Gauthier S, Caron B, Cloutier J, Dory YL, Favre A, Larouche D, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, Mérand Y, Bélanger A, Labrie C, Labrie F (1997) **(*S*)-(+)-[4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl) ethoxy]phenyl]-2*H*-1-benzopyran-3-yl]phenyl]-2,2-dimethylpropanoate (EM-800): a highly potent, specific and orally active non-steroidal antiestrogen**. *Journal of Medicinal Chemistry,* 40: 2117-2122. [177]

118. Labrie F, Luu-The V, Lin SX, Labrie C, Simard J, Breton R, Bélanger A (1997) **The key role of 17β-HSDs in sex steroid biology**. *Steroids,* 62: 148-158. [441]

119. Labrie F, Simard J, Candas B (1997) **Reply to the authors (PF Schellhammer)**. *Urology,* 49: 586-589.

120. Labrie F, Simard J, Singh SM, Candas B (1997) **Estimated potency of Casodex: a problematic design (letter, comment)**. *Urology,* 50: 309-313. [9]

121. Morel Y, Mébarki F, Rhéaume E, Sanchez R, Forest MG, Simard J (1997) **Structure-function relationships of 3β-hydroxysteroid dehydrogenase: contribution made by the molecular genetics of 3β-hydroxysteroid dehydrogenase defiency**. *Steroids,* 62: 176-184. [75]

122. Poulin MJ, Simard J, Catford JG, Labrie F, Piché Y (1997) **Response of symbiotic endomycorrhizal fungi to estrogens and antiestrogens.** *Molecular Plant-Microbe Interactions,* 10: 481-487. [59]

123. Simard J, Labrie C, Bélanger A, Gauthier S, Singh SM, Mérand Y, Labrie F (1997) **Characterization of the effects of the novel non-steroidal antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breasts cancer cells in vitro**. *International Journal of Cancer,* 73: 104-112. [80]

124. Simard J, Sanchez R, Poirier D, Gauthier S, Singh SM, Mérand Y, Bélanger A, Labrie C, Labrie F (1997) **Blockade of the stimulatory effect of estrogens, OH-Tamoxifen, OH-Toremifene, Droloxifene, and Raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells**. *Cancer Research,* 57: 3494-3497. [88]

125. Simard J, Singh SM, Labrie F (1997) **Comparison of in vitro effects of the pure antiandrogens OH-Flutamide, Casodex, and Nilutamide on androgen-sensitive parameters**. *Urology,* 49: 580-589. [45]

126. Couture P, Brun LD, Szots F, Lelièvre M, Gaudet D, Després JP, Simard J, Lupien PJ, Gagné C (1998) **Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia**. *Arteriosclerosis, Thrombosis, and Vascular Biology,* 1007-1012. [87]

127. Couture P, Demers C, Morissette J, Delage R, Jomphe M, Couture L, Simard J (1998) **Type I protein C defiency in French Canadians: evidence of a founder effect and association of specific protein C gene mutations with plasma protein C levels**. *Journal of Trombosis Haemostasis,* 80: 551-556. [10]

128. Couture P, Vohl MC, Gagné C, Gaudet D, Torres AL, Lupien PJ, Després JP, Labrie F, Simard J, Moorjani S (1998) **Identification of three mutations in the low-density lipoprotein receptor gene causing familial hypercholesterolemia among French Canadians**. *Human Mutation,* Supplement: S226-S231. [39]

129. Durocher F, Morissette J, Simard J (1998) **Genetic linkage mapping of the CYP11A1 gene encoding the cholesterol side-chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region**. *Pharmacogenetics,* 8: 49-53. [14]

130. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez JL, Candas B (1998) **DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging**. *Steroids,* 63: 322-328. [310]

131. Turgeon C, Gingras S, Carrière MC, Blais Y, Labrie F, Simard J (1998) **Regulation of sex steroid formation by interleukin-4 and interleukin-6 in breast cancer cells**. *Journal of Steroid Biochemistry and Molecular Biology,* 65: 151-162. [36]

132. Couture P, Morissette J, Gaudet D, Vohl MC, Gagné C, Bergeron J, Després JP, Simard J (1999) **Fine mapping of low-density lipoprotein receptor gene by genetic linkage on chromosome 19p13.1-p13.3 and study of the founder effect of four French Canadian low-density lipoprotein receptor gene mutations**. *Atherosclerosis,* 143: 145-151. [29]

133. Gingras S, Moriggl R, Groner B, Simard J (1999) **Induction of 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase type I gene transcription in human breast cancer cell lines and in normal mammary epithelial cells by interleukin-4 and interleukin-13**. *Molecular Endocrinology,* 13: 66-81. [86]

134. Gingras S, Simard J (1999) **Induction of 3β-hydroxysteroid dehydrogenase/isomerase type 1 expression by interleukin-4 in human normal prostate epithelial cells, immortalized keratinocytes, colon and cervix cancer cell lines**. *Endocrinology,* 140: 4573-4584. [70]

135. Gingras S, Simard J, Groner B, Pfitzner E (1999) **p300/CBP is required for transcriptional induction by interleukin-4 and interacts with Stat6**. *Nucleic Acids Research,* 27: 2722-2729. [134]

136. Labrie F, Labrie C, Bélanger A, Simard J, Gauthier S, Luu-The V, Mérand Y, Giguère, V, Candas B, Luo S, Martel C, Singh SM, Fournier M, Coquet A, Richard V, Charbonneau R, Charpenet G, Tremblay A, Tremblay G, Cusan L, Veilleux R (1999) **EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium**. *J. Steroid Biochem. Molec. Biol.,* 69: 51-84. [165]

137. Labrie F, Simard J, Coquet A, Leblanc G, Candas B (1999) **Relative Potency of Bicalutamide (Casodex) and Flutamide (Eulexin)**. *Urology,* 54: 194-196.

138. Moisan AM, Ricketts ML, Tardy V, Desrochers M, Mébarki F, Chaussain JL, Cabrol S, Raux-Demay MC, Forest MG, Sippell WG, Peter M, Morel Y, Simard J (1999) **New Insight into the Molecular Basis of 3β-Hydroxysteriod Dehydrogenese Deficiency: Identification of Eight Mutations in the HSD3B2 Gene in Eleven Patients from Seven New Families and Comparison of the Functional Properties of Twenty-Five Mutant Enzymes**. *Journal of Clinical Endocrinology and Metabolism,* 84: 4410-4425. [116]

139. Peltoketo H, Luu-The V, Simard J, Adamski J (1999) **17β-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes**. *J. Mol. Endocrinol.,* 23: 1-11. [305]

140. Tremblay MR, Simard J, Poirier D (1999) **Parallel Solid-Phase Synthesis of a Model Library of 7α-Alkylamide Estradiol Derivatives as Potential Estrogen Receptor Antagonists**. *Bioorganic & Medicinal Chemistry Letters,* 9: 2827-2832. [26]

141. Alos N, Moisan AM, Ward L, Desroschers M, Legault L, Leboeuf G, Van Vliet G, Simard J (2000) **A novel A10E homozygous mutation in the HSD3B2 gene causing severe salt-wasting 3β–hydroxysteroid dehydrogenase deficiency in 46,XX and 46,XY French-Canadians: evaluation of gonadal function after puberty**. *Journal of Clinical Endocrinology and Metabolism,* 85: 1968-1974. [44]

142. Gingras S, Côté S, Simard J (2000) **Multiple signaling pathways mediate interleukin-4-induced 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4 isomerase type 1 gene expression in human breast cancer cells**. *Molecular Endocrinology,* 14: 229-240. [25]

143. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C (2000) **Role of 17β–hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues**. *Trends in Endocrinology and metabolism*, 11(10): 421-427. [149]

144. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G, Bélanger A (2000) **Intracrinology: role of the family of 17β-hydroxysteroid dehydrogenases in human physiology and disease**. *J. Molecular Endocrinology*, 25: 1-16.

145. Simard J, Ricketts ML, Moisan AM, Tardy V, Peter M, Morel Y (2000) **A new insight into the molecular basis of 3β–hydroxysteroid dehydrogenase deficiency**. *Endocrine Research*, 26: 761-770. [22]

146. Couture P, Bovill EG, Demers C, Simard J, Delage R, Scott BT, Valliere JE, Callas PW, Jomphe M, Rosendaal FR, Aiach M, Long GL (2001) **Evidence of a founder effect for the protein C gene 3363 inserted C mutation in thrombophilic pedigrees of French origin**. *Thrombosis and Homeostasis,* 86: 1000-6. [16]

147. Gingras S, Côté S, Simard J (2001) **Multiple Signal transduction Pathways Mediate Interleukin-4-Induced 3β–hydroxysteroid dehydrogenase/Δ^5–Δ^4 isomerase in normal and tumoral target tissues**. *J. Steroid Biochem. Molec. Biol.,* 76: 213-25. [27]

148. Labrie F, Labrie C, Bélanger A, Giguère V, Simard J, Mérand Y, Gauthier S, Luu-The V, Candas B, Martel C, Luo S (2001) **Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities**. *Advances in Protein Chemistry,* Vol. 56: 293-368. [18]

149. Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Tremblay A, Tremblay G (2001) **EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium**. *J. Steroid Biochem. Mol. Biol.,* 79: 213-225. [57]

150. Labrie F, Luu-The V, Labrie C, Simard J (2001) **DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology**. *Frontiers in Neuroendocrinology,* 22: 185-212. [357]

151. Simard J, Gingras S (2001) **Crucial role of cytokines in sex steroid formation in normal and tumoral tissues**. *Mol. Cell. Endocrinology,* 171: 25-40. [53]

152. Carsol JL, Gingras S, Simard J (2002) **Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: A unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor**. *Molecular Endocrinology,* 16: 1696-1710. [36]

153. Feltus A, Côté S, Simard J, Gingras S, Kovacs W, Nicholson W, Clark B, Melner M (2002) **Glucocorticoids enhance activation of the human type II 3β-hydroxysteroid dehydrogenase/Δ5-Δ4ene isomerase gene**. *Journal of Steroid Biochemistry and Molecular Biology,* 82: 55-63. [40]

154. Simard J, Moisan AM, Morel Y (2002) **Congenital Adrenal Hyperplasia due to 3β-hydroxysteroid Dehydrogenase/Δ5-Δ4 Isomerase Deficiency**. *Semin Reprod Med.,* 20: 255-276. [72]

155. Gingras S, Turgeon N, Brochu N, Soucy P, Labrie F and Simard J (2003) **Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells**. *Journal of Steroid Biochemistry and Molecular Biology,* 87: 167-179. [30]

156. Labrie F, Cusan L, Gomez JL, Candas B, Bélanger A, Luu-the V, Labrie C, Simard J (2003) **De la biologie à la clinique: le décès dû au cancer de la prostate peut-il maintenant être une exception?** *Medicine/Sciences,* Vol. 19: 910-919. [5]

157. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX and Pelletier G (2003) **Endocrine and intracrine sources of androgens in women – inhibition of breast cancer and other roles of andogens and their precursor DHEA**. *Endocrine Reviews,* 24: 152-182. [476]

158. Ruel IL, Couture P, Gagné C, Deshaies Y, Simard J, Hegele RA and Lamarche B (2003) **Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians**. *Journal of Lipid Research,* 44: 1508-1514. [27]

159. Simard J, Moisan AM, Calemard ML and Morel Y (2003) **Males with 17β-hydroxysteroid dehydrogenase deficiency**. *The Endocrinologist* Vol 13: 195-200. [3]

160. Durocher F, Sanchez R, Ricketts ML, Labrie Y, Laudet V, Simard J (2005) **Characterization of the guinea pig 3β-hydroxysteroid dehydrogenase/Δ^5-Δ^4-isomerase expressed in the adrenal gland and gonads**. *Journal of Steroid Biochemistry and Molecular Bioloy,* 97: 289-298. [4]

161. Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C, Schwerdtfeger A, Merand Y, Martel C, Simard J, Labrie F (2005) **Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution**. *Journal of Enzyme Inhibition and Medicinal Chemistry,* 20: 165-177. [23]

162. Labrie F, Bélanger A, Candas B, Cusan L, Gomez J, Labrie C, Luu-The V, Simard J. (2005) **Gonadotropin-Releasing Hormone Agonists in the Treatment of Prostate Cancer**. *Endocrine Reviews,* 26: 361-379. [168]

163. Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G (2005) **Is dehydro-epiandrosterone a hormone?** *Journal of Endocrinology,* 187: 169-196. [421]

164. Martin LJ, Taniguchi H, Robert NM, Simard J, Tremblay JJ, Viger RS (2005) **GATA Factors and the Nuclear Receptors, Steroidogenic Factor 1/Liver Receptor Homolog 1, Are Key Mutual Partners in the Regulation of the Human 3b-Hydroxysteroid Dehydrogenase Type 2 Promoter**. *Molecular Endrocrinology,* 19: 2358-2370. [81]

165. Schwab KO, Moisan AM, Homoki J, Peter M, Simard J (2005) **17α-hydroxylase/17,20-lyase deficiency due to novel compound heterozygote mutations: treatment for tall stature in a female with male pseudohermaphroditism and spontaneous puberty in her affected sister**. *Journal of Pediatric Endocrinology and Metabolism,* 18: 403-411. [13]

166. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus A, Melner MH (2005) **Molecular biology of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family**, *Endocrine Reviews,* 26: 525-582. [481]

GENETIC SUSCEPTIBILITY TO HORMONE-DEPENDENT CANCERS

Section A : Significant contributions

167. Simard J, Feunteun J, Lenoir G, Tonin P, Normand T, Luu-The V, Vivier A, Lasko D, Morgan K, Rouleau GA, Lynch H, Labrie F, Narod SA (1993) **Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA**. *Human Molecular Genetics,* 2: 1193-1199. [70]

168. Simard J, Tonin P, Durocher F, Morgan K, Rommens J, Gingras S, Samson C, Leblanc JF, Bélanger C, Dion F, Liu Q, Skolnick M, Shattuck-Bidens D, Goldgar D, Labrie F, Narod SA (1994) **Common origins of *BRCA1* mutations in Canadian breast and ovarian cancer families**. *Nature Genetics,* 8: 392-398. [382]

169. Tonin P, Serova O, Simard J, Lenoir G, Feunteun J, Morgan K, Lynch H, Narod SA (1994) **The gene for hereditary breast-ovarian cancer, *BRCA1*, maps distal to EDH17B2 in chromosome region 17q12-q21**. *Human Molecular Genetics,* 3: 1679-1682. [22]

170. Rommens JM, Durocher F, McArthur J, Tonin P, Leblanc JF, Allen T, Samson C, Ferri L, Narod SA, Morgan K, Simard J (1995) **Generation of a transcription map at the HSD17B locus centromeric to *BRCA1* at 17q21**. *Genomics,* 28: 530-542. [54]

171. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod SA, Weber B, Collins F, Friedman L, Ostermeyer E, Szabo C, King MC, Jhanwar S, Offit K, Norton L, Gilewski T, Lubin M, Osborne M, Black D, Boyd M, Steel M, Ingles S, Haile R, Borg A, Lindblom A, Gayther S, Ponder B, Warren B, Stratton M, Liu Q, Kamb A, Fujimura F, Skolnick M, Goldgar DE (1995) **A collaborative survey of 80 mutations in the *BRCA1* breast and ovarian cancer susceptibility gene. Implications of presymptomatic testing and screening**. *Journal of the American Medical Association,* 273: 535-541. [558]

172. Tonin P, Moslehi R, Normand T, Vivier A, Miller S, Ginsburg O, Cutler C, Margolese R, McGillivray B, Labrie F, Simard J, Narod SA (1995) **Linkage analysis of 26 canadian breast and breast-ovarian cancer families**. *Human Genetics,* 5: 545-550. [45]

173. Tonin P, Serova O, Lenoir G, Lynch H, Durocher F, Simard J, Morgan K, Narod SA (1995) ***BRCA1* mutations in Ashkenazi Jewish women**. *American Journal of Human Genetics,* 57: 189. [135]

174. Couch FJ, Farid LM, DeShano ML, Tavtigian SV, Calzone K, Campeau L, Peng Y, Bogden B, Chen Q, Neuhausen S, Shattuck-Eidens D, Godwin AK, Daly M, Radford DM, Sedlacek S, Rommens J, Simard J, Garber J, Merajver S, Weber BL (1996) ***BRCA2* germline mutations in male breast cancer cases and breast cancer families**. *Nature Genetics,* 13: 123-125. [400]

175. Couch FJ, Rommens JM, Neuhausen SL, Bélanger C, Dumont M, Abel K, Bell R, Berry S, Bogden R, Cannon-Albright L, Farid L, Frye C, Hattier T, Janecki T, Jiang P, Kehrer R, Leblanc JF, McArthur-Morrison J, Meney D, Miki Y, Peng Y, Samson C, Schroeder M, Snyder SC, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thakur S, Tran T, Tranchant M, Welver-Feldhaus J, Wong AKC, Labrie F, Skolnick MH, Goldgar DE, Kamb A, Weber BL, Tavtigian SV, Simard J (1996) **Generation of an integrated transcription map of the *BRCA2* region on chromosome 13q12-q13**. *Genomics,* 36: 86-99. [48]

176. Durocher F, Shattuck-Eidens D, McClure M, Labrie F, Skolnick MH, Goldgar DE, Simard J (1996) **Comparison of *BRCA1* polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations**. *Human Molecular Genetics,* 5: 835-842. [155]

177. Durocher F, Tonin P, Shattuck-Eidens D, Skolnick M, Narod SA, Simard J (1996) **Mutation analysis of the *BRCA1* gene in 23 families with cases of cancer of the breast, ovary and multiple other sites**. *Journal of Medical Genetics,* 33: 814-819. [53]

178. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Bélanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Mitchell JT, Peng Y, Samson C, Schroeder M, Snyder S, Stringfellow M, Stroup C, Swedlund B, Swensen J, Teng D, Thomas A, Tran T, Tranchant M, Weaver-Feldhaus J, Wong AKC, Shizuya H, Eyfjord JE, Cannon-Albright L, Labrie F, Skolnick M, Weber B, Kamb A, Goldgar DE (1996) **The complete *BRCA2* gene and mutations in chromosome 13q-linked kindreds**. *Nature Genetics,* 12: 333-337. [1022]

179. Durocher F, Simard J, Ouellette J, Richard V, Labrie F, Pelletier G (1997) **Localization of *BRCA1* gene expresion in adult cynomolgus monkey tissues**. *Journal of Histochemistry and Cytochemistry,* 45: 1173-1188. [9]

180. Durocher F, Simard J, Ouellette J, Richard V, Pelletier G (1998) ***BRCA1* gene expression in reproductive and endocrine tissues in adult cynomolgus monkey**. *Annals of the New York Academy of Sciences*, Volume 839: 444-446.

181. Eeles RA, Durocher F, Edwards S, Teare D, Badzioch M, Hamoudi R, Gill S, Biggs P, Dearnaley D, Ardern-Jones A, Dowe A, Shearer R, McLennan DL, Norman RL, Ghadirian P, Aprikian A, Ford D, Amos C, King TM, Labrie F, Simard J, Narod SA, Easton D, Foulkes WD (1998) **Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators**. *American Journal of Human Genetics,* 62: 653-658. [158]

182. Badzioch M, Eeles R, Leblanc G, Foulkes WD, Giles G, Edwards S, Goldgar D, Hopper J, Bishop DT, Moller P, Heimdal K, Easton D, the CRC/BPG UK Familial Prostate Cancer Study Coordinators & Collaborators, the EU Biomed Collaborators, Simard J (2000) **Suggestive evidence for a site-specific prostate cancer gene on chromosome 1p36**. *Journal of Medical Genetics,* 37: 947-948. [43]

183. Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch M, Teare D, Ford D, Dearnaley D, Ardern-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, Labrie F, The CRC/BPG UK Familial Prostate Cancer Study Collaborators, Easton D, Narod SA, Tonin PN, Foulkes W (2000) **High risk genes predisposing to prostate cancer development-do they exist?** *Prostate Cancer and Prostatic Diseases,* 3: 241-247. [30]

184. Dorval M, Maunsell E, Dugas M and Simard J (2001) **Support groups for people carrying a BRCA mutation**. *Canadian Medical Association Journal,* 165: 740-741. [10]

185. Tavtigian SV, Simard J, Teng D, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desroschers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright L (2001) **A candidate prostate cancer susceptibility gene at chromosome 17p**. *Nature Genetics,* 27: 172-180. [663]

186. Callens N, Dumont M, Begue A, Lint C, Baert JL, Simard J, Launoit Y (2002) **Genomic organization and identification of the promoter region of the mouse *BRCA2* gene**. *Mammalian Genome,* 13: 352-358. [3]

187. Simard J, Dumont M, Soucy P, Labrie F (2002) **Perspective: Prostate Cancer Susceptibility Genes**. *Endocrinology,* 143: 2029-2040. [97]

188. Ginolhac S, Gad S, Corbex M, Bressac-de-Paraillets B, Chompret A, Bignon YJ, Peyrat JP, Fournier J, Lasset C, Giraud S, Muller D, Fricker JP, Hardouin A, Berthet P, Maugard C, Nogues C, Lidereau R, Longy M, Olschwang S, Toulas C, Guimbaud R, Yannoukakos D, Szabo C, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch H, Goldgar D, Stoppa-Lyonnet D, Lenoir G and Sinilnikova O (2003) ***BRCA1* wild-type allele modifies risk of ovarian cancer in carriers of *BRCA1* germ-line mutations**. *Cancer Epidemiology Biomarkers and Prevention,* 12:90-95. [28]

189. Simard J, Dumont M, Labuda D, Sinnett, D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F and Tavtigian SV (2003) **Prostate Cancer Susceptibility Genes: Lessons Learned and Challenges Posed**. *Endocrine-Related Cancer,* 10: 225-259. [118]

190. Dumont M, Frank D, Moisan AM, Tranchant M, Soucy P, Breton R, Labrie F, Tavtigian SV, Simard J (2004) **Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2**. *BBA – Gene Structure and Expression,* 1679: 230-247. [16]

191. Knoppers BM, Joly Y, Lemmens T, Godard B, Avard D, Clark T, Hamet P, Hoy M, Lanctôt S, Lowden S, Martin H, Maugard C, Millette Y, Simard J, Vachon MH, Zinatelli F (2004) **Physiciancs, genetics and life insurance**. *Canadian Medical Association Journal,* 170:1421-1423. [33]

192. Rouleau I, Chiquette J, Plante M, Simard J, Dorval M (2004) **Changes in health-related behaviours following *BRCA1/2* genetic testing: the case of hormone replacement therapy**. *Journal of Obstetrics and Gynaecology Canada,* 26: 1059-1066. [13]

193. Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JGM, van den Ouweland AMW, the BRCA-X Consortium, Cooperative Family Registry Breast Cancer Study, INterdisciplinary HEalth Research INternational Team on BReast CAncer susceptibility INHERIT BRCAs, Wagner TMU, Devillee P, Simard J, van't Veer LJ, Goldgar DE, Meijers-Heijboer H (2004) **Are *ATM* mutations 7271T→G and IVS10-6T→G really high-risk breast cancer-susceptibility alleles?** *Cancer Research,* 64: 840-843. [58]

194. Dorval M, Gauthier G, Maunsell E, Dugas MJ Rouleau I, Chiquette J, Plante M, Laframboise R, Gaudet M, Bridge PJ, INHERIT BRCAs, Simard J (2005) **No Evidence of False Reassurance Among Women with an Inconclusive *BRCA1/2* Genetic Test Result**. *Cancer Epidemiology Biomarkers and Prevention,* 14: 2862-2867. [57]

195. Fortin J, Moisan AM, Dumont M, Leblanc G, Labrie Y, Durocher F, Bessette P, Bridge P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Provencher L, Voyer P, Simard J (2005) **A new alternative splice variant of *BRCA1* containing an additional in-frame exon**. *BBA - Gene Structure and Expression,* 1731: 57-65. [26]

196. Hughes DJ, Ginolhac SM, Coupier I, Corbex M, Bressac-de-Paillerets B, Chompret A, Bignon, YJ, Uhrhammer N, Lasset C, Giraud S, Hardouin A, Berthet P, Peyrat JP, Fournier J, Nogues C, Lidereau R, Muller D, Fricker JP, Longy M, Toulas C, Guimbaud R, Maugrad C, Olschwang S, Yannoukakos D, Durocher F, Moisan AM, Simard J, Mazoyer S, Lynch HT, Szabo C, Lenoir GM, Goldgar DE, Stoppa-Lyonnet D, Sinilnikova OM (2005) **Common *BRCA2* variants and modification of breast and ovarian cancer risk in *BRCA1* mutation carriers**. *Cancer Epidemiology Biomarkers and Prevention,* 14: 265-267. [22]

197. Little J, Simard J (2005) ***CYP17* and breast cancer: no overall effect, but what about interactions?** *Breast Cancer Research,* 7: 238-242. [12]

198. Vallée MH, Rouleau I, Chiquette J, Plante M, Simard J and Dorval M (2005) **HRT use among women tested for *BRCA1/2* mutations following the publication of the women's health initiative study results**. *Journal of Obstetrics Gynecology Can,* 27:321. [2]

199. Vézina H, Durocher F, Dumont M, Houde L, Szabo C, Tranchant M, Chiquette J, Plante M, Laframboise R, Lépine J, BCLC Haplotype Group, Nevanlinna H, Stoppa-Lyonnet D, Goldgar D, Bridge P, INHERIT BRCAs and Simard J (2005) **Molecular and Genealogical Characterization of the R1443X-*BRCA1* Mutation in High-risk French-Canadian Breast/Ovarian Cancer Families**. *Human Genetics,* 117: 119-132. [65]

200. Alamian A, Rouleau I, Simard J, Dorval M for INHERIT BRCAs (2006) **Use of Dietary Supplements Among Women at High Risk of Hereditary Breast and Ovarian Cancer (HBOC) tested for Cancer Susceptibility**. *Nutrition and Cancer,* 54: 157-165. [19]

201. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, Van't Veer L, Van Leeuwen FE, Goldgar DE (2006) **Effect of chest X-rays on the risk of breast cancer among *BRCA1/2* mutation carriers in the International *BRCA1/2* Carrier Cohort Study: A Report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group**. *Journal of Clinical Oncology*, 24: 3361-3366. [228]

202. Antoniou AC, Durocher F, Smith P, Simard J, INHERIT BRCAs program members, Easton DF (2006) ***BRCA1* and *BRCA2* mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high risk French-Canadian families**. *Breast Cancer Research,* 8:R3. [83]

203. Avard D, Bridge P, Bucci LM, Chiquette J, Dorval M, Durocher F, Easton D, Godard B, Goldgar D, Knoppers BM, Laframboise R, Lespérance B, Plante M, Tavtigian SV, Vézina H, Wilson B, INHERIT BRCAs, Simard J (2006) **Partnering in Oncogenetic Research – The INHERIT BRCAs Experience: Opportunities and Challenges**. *Familial Cancer,* 5: 3-13. [19]

204. Dorval M, Drolet M, LeBlanc M, Maunsell E, Dugas MJ, Simard J (2006) **Using the impact of events scale to evaluate distress in the context of genetic testing for breast cancer susceptibility**. *Psychological Reports*, 98: 873-881. [4]

205. Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Tavtigian SV, Simard J (2006) **Mutation analysis and characterization of *ATR* sequence variants in breast cancer cases from high risk French Canadian breast/ovarian cancer families**. *BMC Cancer*, 6: 230. [52]

206. Godard B, Hurlimann T, Letendre M, Egalite N, INHERIT BRCAs. (2006) **Guidelines for disclosing genetic information to family members: from development to use**. *Familial Cancer*, 5 :103-116. [89]

207. Knoppers BM, Joly Y, Simard J, Durocher F (2006) **The emergence of an ethical duty to disclose genetic research results: International perspectives**. *European Journal of Human Genetics*, 14: 1170-1178. [278]

208. Moisan AM, Fortin J, Dumont M, Samson C, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Provencher L, Voyer P, Goldgar D, Bridge P, Simard J (2006) **No evidence of *BRCA1/2* genomic rearrangements in high risk French-Canadian breast/ovarian cancer families**. *Genetic Testing*, 10: 104-115. [57]

209. Spurdle AB, Antoniou AC, Kelemen L, Holland H, Peock S, Cook MR, Smith PL, Greene MH, Simard J, Plourde M, Southey MC, Godwin AK, Beck J, Miron A, Daly MB, Santella RM, Hopper JL, John EM, Andrulis IL, Durocher F, Struewing JP, Easton DF, Chenevix-Trench G, Australian Breast Cancer Family Study, Australian Jewish Breast Cancer Study, Breast Cancer Family Registry, Interdisciplinary Health Research International Team on Breast Cancer Susceptibility, The Kathleen Cunningham Foundation Consortium for Research into Familial Breast Cancer, and Epidemiological Study of Familial Breast Cancer Study Collaborators (2006) **The *AIB1* polyglutamine repeat does not modify breast cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *Cancer Epidemiology Biomarkers and Prevention,* 15: 76-79. [30]

210. Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, GEMO, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Gray J, Daly PA, Dorkins H, EMBRACE, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, kConFab, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Wreeswijk MPG, Greene MH, Prindiville SA, Osorio A, Benítez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlina H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2* (2007) ***RAD51* 135G>C modifies breast cancer risk among *BRCA2* mutation carriers: results from a combined analysis of 19 studies**. *American Journal of Human Genetics*, 81:1186-1200. [271]

211. Avard D, Simard J, Horsman D, Wilson B, Meschino W, Kim Sing C, Plante M, Eisen A, Howley H (2007) **Variations in rates: Why we need clinical management recommendations**. **(***Rapid Response to: Metcalfe K et al., p. e92-8*). *Open Medicine*, August 31st, 1: http://www.openmedicine.ca/cms/view/rapidresponsemetcalfe. [1]

212. Dorval M, Vallée MH, Plante M, Chiquette J, Gaudet M, INHERIT BRCAs, Simard J (2007) **Effect of the women's health initiative study publication on hormone replacement therapy use among women wo have undergone *BRCA1/2* testing**. *Cancer Epidemiology, Biomarkers and Prevention,* 16: 157-160. [8]

213. Durocher F, Labrie Y, Ouellette G, INHERIT BRCAs, Simard J (2007) **Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer**. *Journal of Human Genetics,* 52: 963-977. [11]

214. Godard B, Pratte A, Dumont M, Simard-Lebrun A, Simard J (2007) **Factors associated with an individual's decision to withdraw from genetic testing for breast and ovarian cancer susceptibility: Implications for counselling**. *Genetic Testing,* 11: 45-54. [49]

215. Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, Eisen A, Howley HE, Simard J, on behalf of the National Hereditary Cancer Task Force (2007) **Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious *BRCA1* or *BRCA2* mutation**. *Journal of Obstetrics and Gynaecology Canada*, 29: 45-60. [46]

216. Plourde M, Samson C, Durocher F, INHERIT BRCAs, Simard J (2007) **Characterization of *HSD17B1* Sequence Variants in Breast Cancer Cases from French Canadian Families with High Risk of Breast and Ovarian Cancer**. *Journal of Steroid Biochemistry and Molecular Biology*, 109: 115-128. [8]

217. Simard J, Dumont M, Moisan AM, Gaborieau V, Vézina H, Durocher F, Chiquette J, Plante M, Avard D, Bessette P, Brousseau C, Dorval M, Godard B, Houde L, Joly Y, Lajoie MA, Leblanc G, Lépine J, Lespérance B, Malouin H, Parboosingh J, Pichette R, Provencher L, Rhéaume J, Sinnett D, Samson C, Simard JC, Tranchant M, Voyer P, INHERIT BRCAs, Easton D, Tavtigian SV, Knoppers BM, Laframboise R, Bridge P, Goldgar D (2007) **Evaluation of *BRCA1* and *BRCA2* mutation prevalence, risk prediction**

models and a multi-step testing approach in French-Canadian high-risk breast and/or ovarian cancer families. *Journal of Medical Genetics*, 44: 107-121. [92]

218. Desjardins S, Ouellette G, Labrie Y, Simard J, INHERIT BRCAs, Durocher F (2008) **Analysis of *GADD45A* sequence variations in French Canadian families with high risk of breast cancer**. *Journal of Human Genetics,* 53: 490-498. [7]

219. Dorval M, Bouchard K, Maunsell E, Plante M, Chiquette J, Camden S, Dugas M, Simard J, INHERIT BRCAs (2008) **Health behaviors and psychological distress in women initiating *BRCA1/2* genetic testing: comparison with control population**. *Journal of Genetic Counseling*, 17: 314-326. [49]

220. Guénard F, Labrie Y, Ouellette G, Joly Beauparlant, Simard J, INHERIT BRCAs, Durocher F (2008) **Mutational analysis of the breast cancer susceptibility gene BRIP1/BACH1/FANCJ in high-risk non-*BRCA1/BRCA2* breast cancer families**. *Journal of Human Genetics,* 53: 579-591. [45]

221. Plourde M, Manhes C, Leblanc G, Durocher F, Dumont M, INHERIT BRCAs, Simard J (2008) **Mutation analysis and characterization of *HSD17B2* sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer**. *Journal of Endocrinology*, 40: 161-172. [13]

222. Antoniou AC, Rookus M, Andrieu N, Brohet R, Chang-Claude J, Peock S, Cook M, Evans DG, Eeles R, EMBRACE, Nogues C, Faivre L, Gesta P, GENEPSO, van Leeuwen FE, Ausems MGEM, GEO-HEBON, Osorio A, Caldes T, Simard J, Lubinski J, Gerdes A-M, Olah E, Fürhauser C, Olsson H, Arver B, Radice P, Easton DF and Goldgar DE (2009) **Reproductive and hormonal factors, and ovarian cancer risk among *BRCA1* and *BRCA2* mutation carriers: results from the International *BRCA1/2* Carrier Cohort Study**. *Cancer Epidemiology, Biomarkers & Prevention,* (Feb) 18: 601-610. PMID: 19190154. [153]

223. Antoniou AC, Sinilnikova OM, McGuffog L, Healey S, Nevanlinna H, Heikkinen T, Simard J, Spurdle AB, Beesley J, Chen X; The Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Neuhausen SL, Ding YC, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Peissel B, Bonanni B, Viel A, Bernard L, Radice P, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai PL, Rennert G, Lejbkowicz F, Andrulis IL, Ozcelik H, Glendon G; OCGN, Gerdes AM, Thomassen M, Sunde L, Caligo MA, Laitman Y, Kontorovich T, Cohen S, Kaufman B, Dagan E, Baruch RG, Friedman E, Harbst K, Barbany-Bustinza G, Rantala J, Ehrencrona H, Karlsson P, Domchek SM, Nathanson KL, Osorio A, Blanco I, Lasa A, Benítez J, Hamann U, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, van der Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, van Roozendaal CE; HEBON, Peock S, Cook M, Frost D, Oliver C, Platte R, Evans DG, Lalloo F, Eeles R, Izatt L, Davidson R, Chu C, Eccles D, Cole T, Hodgson S; EMBRACE, Godwin AK, Stoppa-Lyonnet D, Buecher B, Léoné M, Bressac-de Paillerets B, Remenieras A, Caron O, Lenoir GM, Sevenet N, Longy M, Ferrer SF, Prieur F; GEMO, Goldgar D, Miron A, John EM, Buys SS, Daly MB, Hopper JL, Terry MB, Yassin Y; Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Staudigl C, Hansen TV, Barkardottir RB, Kirchhoff T, Pal P, Kosarin K, Offit K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deißler H, Fiebig B, Suttner C, Schönbuchner I, Gadzicki D, Caldes T, de la Hoya M, Pooley KA, Easton DF; Georgia Chenevix-Trench; on behalf of CIMBA (2009) **Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for *BRCA1* and *BRCA2* mutation carriers**. *Human Molecular Genetics*, (Nov) 18: 4442-4456. PMID : 19656774. [127]

224. Osorio A, Milne RL, Pita G, Peterlongo P, Heikkinen T, Simard J, Chenevix-Trench G, Spurdle AB, Beesley J, Chen X, Healey S; KConFab, Neuhausen SL, Ding YC, Couch FJ, Wang X, Lindor N, Manoukian S, Barile M, Viel A, Tizzoni L, Szabo CI, Foretova L, Zikan M, Claes K, Greene MH, Mai P, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Weerasooriya N; OCGN, Gerdes AM, Thomassen M, Cruger DG, Caligo MA, Friedman E, Kaufman B, Laitman Y, Cohen S, Kontorovich T, Gershoni-Baruch R, Dagan E, Jernström H, Askmalm MS, Arver B, Malmer B; SWE-BRCA, Domchek SM, Nathanson KL, Brunet J, Ramón Y Cajal T, Yannoukakos D, Hamann U; HEBON, Hogervorst FB, Verhoef S, Gómez García EB, Wijnen JT, van den Ouweland A; EMBRACE, Easton DF, Peock S, Cook M, Oliver CT, Frost D, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Cook J, Hodgson S, Morrison PJ, Douglas F, Godwin AK; GEMO, Sinilnikova OM, Barjhoux L, Stoppa-Lyonnet D, Moncoutier V, Giraud S, Cassini C, Olivier-Faivre L, Révillion F, Peyrat JP, Muller D, Fricker JP, Lynch HT, John EM,

Buys S, Daly M, Hopper JL, Terry MB, Miron A, Yassin Y, Goldgar D; Breast Cancer Family Registry, Singer CF, Gschwantler-Kaulich D, Pfeiler G, Spiess AC, Hansen TV, Johannsson OT, Kirchhoff T, Offit K, Kosarin K, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Schwartz PE, Blank SV, Toland AE, Montagna M, Casella C, Imyanitov EN, Allavena A, Schmutzler RK, Versmold B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Deissler H, Fiebig B, Varon-Mateeva R, Schaefer D, Froster UG, Caldes T, de la Hoya M, McGuffog L, Antoniou AC, Nevanlinna H, Radice P, Benítez J; CIMBA. (2009) **Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in *BRCA1* and *BRCA2* mutation carriers. Results from the Consortium of Investigators of Modifiers of *BRCA1/BRCA2* (CIMBA)**. *British Journal of Cancer,* (Dec) 101: 2048-2054. PMID : 19920816. [24]

225. Plourde M, Ferland A, Soucy P, Hamdi Y, Tranchant M, Durocher F, Sinilnikova O, The VL, Simard J (2009) **Analysis of 17β-Hydroxysteroid Dehydrogenase Types 5, 7, and 12 Genetic Sequence Variants in Breast Cancer Cases from French Canadian Families with High Risk of Breast and Ovarian Cancer**. *The Journal of Steroid Biochemistry and Molecular Biology,* (Sept) 116: 134-153. PMID : 19460435. [16]

226. Rebbeck TR, Antoniou AC, Llopis TC, Nevanlinna H, Aittomäki K, Simard J, Spurdle AB, KConFab, Couch FJ, Pereira LH, Greene MH, Andrulis IL, Ontario Cancer Genetics Network, Pasche B, Kaklamani V, Breast Cancer Family Registries, Hamann U, Szabo C, Peock S, Cook M, Harrington PA, Donaldson A, Male AM, Gardiner CA, Gregory H, Side LE, Robinson AC, Emmerson L, Ellis I, EMBRACE, Peyrat J-P, Fournier J, Vennin P, Adenis C, Muller D, Fricker J-P, Longy M, Sinilnikova OM, Stoppa-Lyonnet D, GEMO, Schmutzler RK, Versmold B, Engel C, Meindl A, Kast K, Schaefer D, Froster UG, Chenevix-Trench G, and Easton DF (2009) **No association of TGFB1 L10P genotypes and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers: a multi-center cohort study**. *Breast Cancer Research and Treatment,* (May) 115: 185-92. PMID : 18523885. [12]

227. Sinilnikova OM, Antoniou AC, Simard J, Healey S, Léoné M, Sinnett D, Spurdle AB, Beesley J, Chen X; kConFab, Greene MH, Loud JT, Lejbkowicz F, Rennert G, Dishon S, Andrulis IL; OCGN, Domchek SM, Nathanson KL, Manoukian S, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez J, Hamann U, Hogervorst FB, van Os TA, Gille HJ; HEBON, Peock S, Cook M, Luccarini C, Evans DG, Lalloo F, Eeles R, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Brewer C; EMBRACE, Hughes DJ, Coupier I, Giraud S, Coulet F, Colas C, Soubrier F, Rouleau E, Bièche I, Lidereau R, Demange L, Nogues C, Lynch HT; GEMO, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Sutter C, Deissler H, Schaefer D, Froster UG; GC-HBOC, Aittomäki K, Nevanlinna H, McGuffog L, Easton DF, Chenevix-Trench G, Stoppa-Lyonnet D; Consortium of Investigators of Modifiers of *BRCA1/2* (2009) **The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *British Journal of Cancer*, (Oct) 101: 1456-1460. PMID : 19707196. [24]

228. Antoniou AC, Beesley J, McGuffog L, Sinilnikova OM, Healey S, Neuhausen SL, Ding YC, Rebbeck TR, Weitzel JN, Lynch HT, Isaacs C, Ganz PA, Tomlinson G, Olopade OI, Couch FJ, Wang X, Lindor NM, Pankratz VS, Radice P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Viel A, Allavena A, Dall'Olio V, Peterlongo P, Szabo CI, Zikan M, Claes K, Poppe B, Foretova L, Mai PL, Greene MH, Rennert G, Lejbkowicz F, Andrulis IL, Ozcelik H, Glendon G, Ontario Cancer Genetics Network, Thomassen M, Gerdes AM, Sunde L, Cruger D, Jensen UB, Caligo M, Friedman E, Kaufman B, Laitman Y, Milgrom R, Dubrovsky M, Cohen S, Borg A, Jernström H, Lindblom A, Rantala J, Stenmark-Askmalm M, Melin B, SWE-BRCA, Nathanson K, Domchek S, Jakubowska A, Lubinski J, Huzarski T, Osorio A, Lasa A, Durán M, Tejada MI, Godino J, Benitez J, Hamann U, Kriege M, Hoogerbrugge N, van der Luijt RB, van Asperen CJ, Devilee P, Meijers-Heijboer EJ, Blok MJ, Aalfs CM, Hogervorst F, Rookus M, HEBON, Peock S, Cook M, Oliver C, Frost D, Conroy D, Evans DG, Lalloo F, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Hodgson S, Morrison PJ, Porteous ME, Walker L, Kennedy MJ, Dorkins H, EMBRACE, Godwin AK, Stoppa-Lyonnet D, de Pauw A, Mazoyer S, Bonadona V, Lasset C, Dreyfus H, Leroux D, Hardouin A, Berthet P, Faivre L, Loustalot C, Noguchi T, Sobol H, Rouleau E, Nogues C, Frénay M, Vénat-Bouvet L, GEMO Study Collaborators, Goldgar D, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Breast Cancer Family Registry, Singer CF, Dressler AC, Gschwantler-Kaulich D, Pfeiler G, Hanser TVO, Jønson L, Agnarsson BA, Kirchhoff T, Offit K, Devlin V, Dutra-Clarke A, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Schwartz JBPE, Blank SV, Ewart Toland A,

Montagna M, Casella C, Imyanitov E, Tihomirova L, Blanco I, Lazaro C, Ramus SJ, Sucheston L, Karlan BY, Gross J, Schmutzler R, Wappenschmidt B, Engel C, Meindl A, Lochmann M, Arnold N, Heidemann S, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Kast K, Schönbuchner I, Caldes T, de la Hoya M, Aittomäki K, Nevanlinna H, Simard J, Spurdle AB, Holland H, Chen X, kConFab, Platte R, Chenevix-Trench G and Easton DF on behalf of CIMBA. (2010) **Common breast cancer susceptibility alleles and the risk of breast cancer for *BRCA1* and *BRCA2* mutation carriers: implications for risk prediction**. *Cancer Research,* (Dec) 70:9742-54. PMID : 21118973. [210]

229. Black L, Simard J, Knoppers B.M (2010) **Genetic testing, physicians and the law : will the tortoise ever catch up with the hare?** Annal Health Law 2010, (Jan) 19 :115-120. PMID : 21495558. [7]

230. Engel C, Versmold B, Wappenschmidt B, Simard J, EMBRACE, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes R, Evans DG, Eeles R, Paterson J, Brewer C, McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C, Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon Y-J, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench Georgia, Spurdle AB, Chen X, Beesley J, kConFab, Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A, SWE-BRCA, van der Luijt RB, van Os TA, van Leeuwen FE, HEBON, Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón y Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK, on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) (2010) **Association of the Variants *CASP8* D302H and *CASP10* V410l with Breast and Ovarian Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers**. *Cancer Epidemiology Biomarkers Prevention,* (Nov) 19:2859-2868. PMID : 20978178. [49]

231. Guénard F, Pedneault CS, Ouellette G, Labrie Y, Simard J; INHERIT, Durocher F (2010) **Evaluation of the contribution of the three breast cancer susceptibility genes *CHEK2*, *STK11*, and *PALB2* in non-*BRCA1/2* French Canadian families with high risk of breast cancer**. *Genetic Testing and Molecular Biomarkers,* (Aug) 14:515-26. PMID : 20722467. [31]

232. Spurdle AB, Fahey P, Chen X, McGuffog L, kConFab, Easton D, Peock S, Cook M, EMBRACE, Simard J, INHERIT, Rebbeck T, MAGIC, Antoniou AC, Chenevix-Trench G (2010) **Pooled analysis indicates that the *GSTT1* deletion, *GSTM1* deletion and *GSTP1* Ile105Val polymorphisms do not modify breast cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *Breast Cancer Research Treatment,* (July) 122:281-5. PMID : 19921428. [13]

233. Antoniou AC, Kartsonaki C, Sinilnikova OM, Soucy P, McGuffog L, Healey S, Lee A, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Barile M, Pensotti V, Pasini B, Dolcetti R, Giannini G, Putignano AL, Varesco L, Radice P, Mai PL, Greene MH, Andrulis IL, Glendon G, Ozcelik H, Ontario Cancer Genetics Network, Thomassen M, Gerdes A-M, Kruse TA, Jensen UB, Crüger DG, Caligo MA, Laitman Y, Milgrom R, Kaufman B, Paluch-Shimon S, Freedman E, Loman N, Harbst K, Lindblom A, Arver B, Ehrencrona H, Melin B, SWE-BRCA, Nathanson KL, Domchek SM, Rebbeck T, Jakubowska A, Lubinski J, Gronwald J, Huzarski T, Byrski T, Cybulski C, Gorski B, Osorio A, Ramón y Cajal T, Fostira F, Andrés R, Benitez J, Hamann U, Hogervorst FB, Rookus MA, Hooning MJ, Nelen MR, van der Luijt RB, van O TA, van Asperen CJ, Devilee P, Meijers-Heijboer HEJ, Gómez Garcia EB, HEBON, Peock S, Cook M, Frost D, Platte R, Leyland J, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Eccles D, Ong K, Cook J, Douglas F, Paterson J, Kennedy MJ, Miedzybrodzka Z, EMBRACE, Godwin A, Stoppa-Lyonnet D, Buecher B, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Lasset C, Leroux D, Faivre L, Bronner M, Prieur F, Nogues C, Rouleau E, Pujol P, Coupier I, Frénay M, GEMO Study Collaborators, Hopper JL, Daly MB, Terry MB, John EM, Buys SS, Yassin Y, Miron A, Goldgar D, Breast Cancer Family Registry, Singer CF, Tea M-K, Pfeiler G, Dressler BE, Hansen TVO, Jønson L, Ejlertsen B, Barkardottir RB, Kirchhoff T, Offit K, Piedmonte M, Rodriguez G, Small L, Boggess J, Blank S, Basil J, Azodi M, Ewart Toland A, Montagna M, Tognazzo S, Agata S, Imyanitov E, Janavicius R, Lazaro C, Blanco I, Pharoah PDP, Sucheston L, Karlan BY, Walsh CS, Olah E, Bozsik A, Teo SH, Seldon JL, Beattie MS, van Rensburg LJ, Sluiter MD, Diez O, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ruehl I, Varon-Mateeva R, Kast K, Deissler H, Niederacher D, Arnold N, Gadzicki D, Schönbuchner I, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Dumont M, Chiquette J, Tischkowitz M, Chen X, Beesley J, Spurdle AB, kConFab, Neuhausen SL, Ding YC, Fredericksen Z, Wang X, Pankratz VS, Couch F, Simard J, Easton DF

and Chenevix-Trench G on behalf of CIMBA (2011) **Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for *BRCA1* and *BRCA2* mutation carriers**. *Human Molecular Genetics*, (Aug) 20:3304-3321. PMID : 21593217. [91]

234. Bouchard K, Dubuisson W, Simard J, Dorval M (2011) **Systematic mixed-methods reviews are not ready to be assessed with the available tools**. *Journal of Clinical Epidemiology,* (Aug) 64:926-928. PMID : 21474281. [7]

235. Cox DG, Simard J, Sinnett D, Hamdi Y, Soucy P, Ouimet M, Barjhoux L, Verny-Pierre C, McGuffog L, Healey S, Szabo C, Greene MH, Mai PL, Andrulis IL, Ontario Cancer Genetics Network, Thomassen M, Gerdes A-M, Caligo MA, Friedman E, Laitman Y, Kaufman B, Paluch SS, Borg Å, Karlsson P, Askmalm MS, Bustinza GB, SWE-BRCA collaborators, Nathanson K, Domchek SM, Rebbeck TR, Benítez J, Hamann U, Rookus MA, van den Ouweland AMW, Ausems MGEM, Aalfs CM, van Asperen CJ, Devilee P, Gille HJJP, HEBON, EMBRACE, Peock S, Frost D, Evans DG, Eeles R, Izatt L, Adlard J, Paterson J, Eason J, Godwin AK, Remon M-A, Moncoutier V, Gauthier-Villars M, Lasset C, Giraud S, Hardouin A, Berthet P, Sobol H, Eisinger F, Bressac-de Paillerets B, Caron O, Delnatte C, GEMO Study Collaborators, Goldgar D, Miron A, Ozcelik H, Buys S, Southey MC, Terry MB, Breast Cancer Family Registry, Singer CF, Dressler A-C, Tea M-K, van Overeem Hansen T, Johannsson O, Piedmonte M, Rodriguez GC, Basil JB, Blank S, Toland AE, Montagna M, Isaacs C, Blanco I, Gayther SA, Moysich KB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Niederacher D, Sutter C, Gadzicki D, Fiebig B, Caldes T, Laframboise R, Nevanlinna H, Chen X, Beesley J, Spurdle AB, Neuhausen SL, Ding YC, Couch FJ, Wang X, Peterlongo P, Manoukian S, Bernard L, Radice P, Easton DF, Chenevix-Trench G, Antoniou AC, Stoppa-Lyonnet D, Mazoyer S, Sinilnikova OM, on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2* (2011) **Common variants of the *BRCA1* wild-type allele modify the risk of breast cancer in *BRCA1* mutations carriers**. *Human Molecular Genetics*, (Dec) 20:4732-4747. PMID : 21890493. [50]

236. Dorval M, Noguès C, Berthet P, Chiquette J, Gauthier-Villars M, Lasset C, Picard C, Plante M, INHERIT BRCAs, GENEPSO Cohort, Simard J, Reynier JC. (2011) **Breast and ovarian cancer screening of non-carriers from *BRCA1/2* mutation-positive families: 2-year follow-up of cohorts from France and Quebec**. *European Journal of Human Genetics*, (May) 19:494-499. PMID : 21248744. [15]

237. Kaufman B, Laitman Y, Ziv E, Hamann U, Torres D, Lahad EL, Beeri R, Renbaum P, Jakubowska A, Lubinski J, Huzarski T, Toloczko-Grabarek A, Jaworska K, Durda K, Sprudle AB, Chenevix-Trench G, Simard J, Easton DF, Antonis A, Szabo C, Friedman E (2011) **The CYP17A1 -34T > C polymorphism and breast cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *Breast Cancer Research and Treatment*, (April) 126:521-527. PMID : 20798986. [5]

238. Levesque E, Joly Y, Simard J (2011) **Return of Research Results: General Principles and International Perspectives**. *The Journal of Law, Medicine & Ethics*, (Dec) 583-592. PMID : 22084844. [33]

239. Ramus SJ, Kartsonaki C, Gayther SA, Pharoah PDP, Sinilnikova OM, Beesley J, Chen X, McGuffog L, Healey S, Couch FJ, Wang X, Fredericksen Z, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Roversi G, Barile M, Viel A, Allavena A, Ottini L, Papi L, Gismondi V, Capra F, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN, Thomassen M, Gerdes AM, Kruse TA, Cruger D, Jensen UB, Caligo MA, Olsson H, Kristoffersson U, Lindblom A, Arver B, Karlsson P, Stenmark Askmalm M, Borg A, Neuhausen S, Ding YC, Nathanson KL, Domchek SM, Jakubowska A, Lubiński J, Huzarski T, Byrski T, Gronwald J, Górski B, Cybulski C, Dębniak T, Osorio A, Durán M, Tejada MI, Benítez J, Hamann U, Rookus MA, Verhoef S, Tilanus-Linthorst MA, Vreeswijk MP, Bodmer D, Ausems M G.E.M., van Os TA, Asperen CJ, Blok MJ, Meijers-Heijboer HEJ, HEBON, EMBRACE, Peock S, Cook M, Oliver C, Frost D, Dunning AM, Evans DG, Eeles R, Pichert G, Cole T, Hodgson S, Brewer C, Morrison PJ, Porteous M, Kennedy MJ, Rogers MT, Side LE, Donaldson A, Gregory H, Godwin A, Stoppa-Lyonnet D, Moncoutier V, Castera L, Mazoyer S, Barjhoux L, Bonadona V, Leroux D, Faivre L, Lidereau R, Nogues C, Bignon YJ, Prieur F, Collonge-Rame MA, Venat-Bouvet L, Fert Ferrer S, GEMO Study Collaborators, Miron A, Buys SS, Hopper JL, Daly MB, John E, Terry MB, Goldgar D, BCFR, Hansen TVO, Jønson L, Ejlertsen B, Agnarsson BA, Offit K, Kirchhoff T, Vijai J, Dutra-Clarke AVC, Przybylo JA, Montagna M, Casella C, Imyanitov EN, Janavicius R, Blanco I, Lázaro C, Moysich KB, Karlan BY, Gross J, Beattie MS, Schmutzler R, Wappenschmidt B, Meindl A, Ruehl I, Fiebig B, Sutter C, Arnold N, Deissler H, Varon-Mateeva R, Kast

K, Niederacher D, Gadzicki D, Caldes T, de la Hoya M, Nevanlinna H, Aittomäki K, Simard J, Soucy P, kConFab Investigators, Spurdle AB, Holland H, Chenevix-Trench G, Easton DF, Antoniou AC on behalf of Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) (2011) **Genetic Variation at 9p22.2 and Ovarian Cancer Risk for *BRCA1* and *BRCA2* Mutation Carriers**. *Journal of the National Cancer Institute,* (Jan) 103:105-116. PMID : 21169536. [54]

240. Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Lee A, Barrowdale D, Healey S, Sinilnikova OM, Caligo MA, SWE-BRCA, Loman N, Harbst K, Lindblom A, Arver B, Rosenquist R, Karlsson P, Nathanson K, Domchek S, Rebbeck T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka E, Osorio A, Durán M, Andrés R, Benítez J, Hamann U, Hogervorst FB, van O TA, Verhoef S, Meijers-Heijboer HEJ, Wijnen J, Gómez Garcia EB, Ligtenberg MJ, Kriege M, Collée JM, Ausems MGEM, Oosterwijk JC, HEBON, EMBRACE, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Jacobs C, Eeles R, Adlard J, Davidson R, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Rogers MT, Donaldson A, Dorkins H, Godwin AK, Bove B, Stoppa-Lyonnet D, Houdayer C, Buecher B, de Pauw A, Mazoyer S, Verny-Pierre C, Léoné M, Bressac de Paillerets B, Caron O, Sobol H, Frenay M, Prieur F, Fert Ferrer S, Mortemousque I, GEMO Study Collaborators, Buys S, Daly M, Miron A, Terry MB, Hopper JL, John EM, Southey M, Goldgar D, Singer CF, Fink-Retter A, Tea M-K, Geschwantler Kaulich D, v. O. Hansen T, Nielsen FC, Barkardottir RB, Gaudet M, Kirchhoff T, Joseph V, Dutra-Clarke A, Offit K, Piedmonte M, Kirk J, Cohn D, Hurteau J, Byron J, Fiorica J, Toland AE, Montagna M, Oliani C, Imyanitov E, Isaacs C, Tihomirova L, Blanco I, Lazaro C, Teulé A, Del Valle J, Gayther SA, Odunsi K, Gross J, Karlan BY, Olah E, Teo S-H, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes T, de la Hoya M, Nevanlinna H, Muranen TA, Lespérance B, Spurdle AB, kConFab Investigators, Neuhausen SL, Ding YC, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Radice P, Greene MH, Loud JT, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Thomassen M, Gerdes A-M, Jensen UB, Skytte A-B, Kruse TA, Chenevix-Trench G, Couch FJ, Simard J, Easton DF on behalf of CIMBA (2012) **Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for *BRCA1* and/or *BRCA2* mutation carriers**. *Breast Cancer Research.* (Jan) 20:14:R33. PMID : 22348646. [90]

241. Bacha O, Plante M, Gregoire J, Grondin K, Laframboise R, Simard J (2012) **Effectiveness of Risk Reducing Salpingo-Oophorectomy in preventing Ovarian Cancer in French Canadian BRCA mutation Carriers**. *International Journal Gynecologic Cancer,* (July) 22:974-978. PMID : 22740003. [8]

242. Black L, Simard J, Knoppers BM (2012) **Legal Liability and the Uncertain Nature of Prediction: The Case of Breast Cancer Risk Prediction Models.** *Public Health Genomics,* (Jan) 15:335-40. PMID : 22987123. [3]

243. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Lee A, Healey S, Sinilnikova OM, Andrulis IL, Ozcelik H, Mulligan AM, OCGN, Thomassen M, Gerdes AM, Jensen UB, Skytte A-B, Kruse TA, Caligo MA, SWE-BRCA, von Wachenfeldt A, Barbany-Bustinzan G, Loman N, Soller M, Ehrencrona H, Karlsson P, Nathanson K, Rebbeck T, Domchek S, Jakubowska A, Lubinski J, Jaworska K, Durda K, Złowocka E, Huzarski T, Byrski T, Gronwald J, Cybulski C, Górski B, Osorio A, Durán M, Tejada MI, Benitez J, Hamann U, Hogervorst FBL, van Os TA, van Leeuwen FE, Meijers-Heijboer HEJ, Wijnen J, Blok MJ, Kets M, Hooning MJ, Oldenburg RA, Ausems MGEM, HEBON, EMBRACE, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Side LE, Bove B, Godwin AK, GEMO Study Collaborators, Stoppa-Lyonnet D, Fassy-Colcombet M, Castera L, Cornelis F, Mazoyer S, Léoné M, Boutry-Kryza N, Bressac de Paillerets B, Caron O, Pujol P, Coupier I, Delnatte C, Akloul L, Lynch HT, Snyder CL, Buys SS, Daly MB, Terry MB, Chung W, John EM, Miron A, Southey MC, Hopper JL, Goldgar D, Singer CF, Rappaport C, Tea M M-K, Fink-Retter A, Hansen TVO, Nielsen FC, Arason A, Vijai J, Shah S, Sarrel K, Robson M, Piedmonte M, Phillips K, Basil J, Rubinstein W, Boggess J, Wakeley K, Ewart Toland A, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Feliubadalo L, Brunet J, Gayther SA, Pharoah PPD, Odunsi K, Karlan BY, Walsh CS, Olah E, Teo SH, Ganz PA, Beattie MS, van Rensburg EJ, Dorfling CM, Diez O, Kwong A, Schmutzler RK,

Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Heinritz W, Caldes T, de la Hoya M, Muranen TA, Nevanlinna H, Tischkowitz M, Spurdle AB, kConFab investigators, Neuhausen SL, Ding YC, Lindor N, Fredericksen X, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Barile M, Bernard L, Viel A, Giannini G, Varesco L, Radice P, Greene MH, Mai PL, Easton DF, Chenevix-Trench G, Offit K, Simard J (2012) **Common variants at the 19p13.1 and *ZNF365* loci are associated with ER subtypes of breast cancer and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers.** *Cancer, Epidemiology, Biomarkers & Prevention,* (April) 21:645-657. PMID : 22351618. [65]

244. Lapointe J, Abdous B, Camden S, Bouchard K, Goldgar D, Simard J, Dorval M (2012) **Influence of the family cluster effect on psychosocial variables in families undergoing *BRCA1/2* genetic testing for cancer susceptibility**. *Psychooncology*, (May) 21:515-23. PMID : 21370312. [9]

245. Lapointe J, Bouchard K, Patenaude AF, Maunsell E, INHERIT, Simard J, Dorval M (2012) **Incidence and predictors of positive and negative effects of *BRCA1/2* genetic testing on familial relationships: A 3-year follow-up study**. *Genetics in Medicine*, (Jan) 14:60-68. PMID : 22237432. [12]

246. Larouche G, Bouchard K, Chiquette J, Desbiens C, Simard J, Dorval M (2012) **Self-reported mammography use following *BRCA1/2* genetic testing may be overestimated**. *Familial Cancer,* (Mar) 11:27-32. PMID : 22080962. [15]

247. Ouimet M, Cassart P, Larivière M, Kritikou EA, Simard J, Sinnett D (2012) **Functional analysis of promoter variants in *KU70* and their role in cancer susceptibility**. *Genes Chromosomes Cancer*, (Nov) 51:1007-13. PMID : 22833453. [5]

248. Ramus SJ, Antoniou AC, Kuchenbaecker KB, Soucy P, Beesley J, Chen X, McGuffog L, Sinilnikova OM, Healey S, Barrowdale D, Lee A, Thomassen M, Gerdes AM, Kruse TA, Jensen UB, Skytte A-B, Caligo MA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, SWE-BRCA, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Zlowocka E, Gronwald J, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Osorio A, Benitez J, Duran M, Tejada MI, Hamann U, Rookus M, van Leeuwen FE, Aalfs CM, Meijers-Heijboer HEJ, vans Asperen CJ, van Roozendaal KEP, Hoogerbrugge N, Collée JM, Kriege M, van der Luijt RB, HEBON, EMBRACE, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lallo F, Jacobs C, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Paterson J, Douglas F, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy J, Pathak H, Godwin AK, Stoppa-Lyonnet D, Caux-Moncoutier V, de Pauw A, Gauthier-Villars M, Mazoyer S, Léoné M, Calender A, Lasset C, Bonadona V, Hardouin A, Berthet P, Bignon Y-J, Uhrhammer N, Faivre L, Loustalot C, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea Maria M-K, Pfeiler G, Fink-Retter Anneliese, v. O. Hansen T, Ejlertsen B, Johannsson OT, Offit K, Kirchhoff T, Gaudet MM, Vijai J, Robson M, Piedmonte M, Phillips K-A, Van Le L, Hoffman JS, Toland AE, Montagna M, Tognazzo S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Tornero E, Navarro M, Moysich KB, Karlan BY, Gross J, Olah E, Teo S-H, Ganz PA, Beattie MS, Dorfling CM, van Rensburg EJ, Diez O, Kwong A, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Ditsch N, Arnold N, Heidemann S, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Fiebig B, Schäfer D, Caldes T, de la Hoya M, Nevanlinna H, Aittonäki K, Plante M, Spurdle AB, kConFab, Neuhausen SL, Ding YC, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Bonanni B, Bernard L, Dolcetti R, Papi L, Ottini L, Radice P, Greene MH, Mai PL, Andrulis IL, Glendon G, Ozcelik H, OCGN, Pharoah PDP, Gayther SA, Simard J, Easton DF, Cough FJ, Chenevix-Trench G on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) (CIMBA) (2012) **Ovarian cancer susceptibility alleles and risk of ovarian cancer in *BRCA1* and *BRCA2* Mutation carriers**. *Human Mutation,* (April) 33:690-702. PMID : 22253144. [52]

249. Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker K, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova O, Lee A, Bacot F, Vincent D, Hogervorst FBL, Peock S, Stoppa-Lyonnet D, Jakubowska A, KConFab Investigators, Radice P, Schmutzler RK, SWE-BRCA, Domchek SM, Piedmonte M, Singer CF, Friedman E, Thomassen M, OCGN, v. O. Hansen T, Neuhausen SL, Szabo CI, Blanco I, Greene MH, Karlan BY, Garber J, Phelan CM, Weitzel JN, Montagna M, Olah E, Andrulis IL, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Nevanlinna

H, Osorio A, Terry MB, Daly MB, van Rensburg EJ, Hamann U, Ramus SJ, Ewart Toland A, Caligo MA, Olopade OI, Tung N, Claes K, Beattie MS, Southey M, Imyanitov EN, Tischkowitz M, Janavicius R, John EM, Kwong A, Diez O, Balmaña J, Barkardottir RB, Arun BK, Rennert G, Teo S-H, Ganz PA, Campbell I, van der Hout AH, van Deurzen CHM, Seynaeve C, Gómez Garcia EB, van Leeuwen FE, Meijers-Heijboer HEJ, Gille JJP, Ausems MGEM, Blok MJ, Ligtenberg MJL, Rookus MA, Devilee P, Verhoef S, van Os TAM, Wijnen JT, HEBON, EMBRACE, Frost D, Ellis, Fineberg E, Platte P, Evans DG, Izatt L, Eeles RA, Adlard JA, Eccles D, Cook J, Brewer C, Douglas F, Hodgson S, Morrison PJ, Side LE, Donaldson A, Houghton C, Rogers MT, Dorkins H, Eason J, Gregory H, McCann E, Murray A, Calender A, Hardouin A, Berthet P, Delnatte C, Nogues C, Lasset C, Houdayer C, Leroux D, Rouleau E, Prieur F, Damiola F, Sobol H, Coupier I, Venat-Bouvet L, Castera L, Gauthier-Villars M, Léoné M, Pujol P, Mazoyer S, BignonY-J, GEMO Study Collaborators, Złowocka-Perłowska E, Gronwald J, Lubinski J, Durda K, Jaworska K, Huzarski T, Spurdle AB, Viel A, Peissel B, Bonanni B, Melloni G, Ottini L, Papi L, Varesco L, Tibiletti MG, Peterlongo P, Volorio S, Manoukian S, Pensotti V, Arnold N, Engel C, Deissler H, Gadzicki D, Gehrig A, Kast K, Rhiem K, Meindl A, Niederacher D, Ditsch N, Plendl H, Preisler-Adams S, Engert S, Sutter C, Varon-Mateeva R, Wappenschmidt B, Weber BHF, Arver B, Stenmark-Askmalm M, Loman N, Rosenquist R, Einbeigi Z, Nathanson KL, Rebbeck TR, Blank SV, Cohn DE, Rodriguez GC, Small L, Friedlander M, Bae-Jump VL, Fink-Retter A, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea M-K, Lindor N, Kaufman B, Paluch SS, Laitman Y, Skytte A-B, Gerdes A-M, Sokilde Pedersen I, Traasdahl Moeller S, Kruse TA, Birk Jensen U, Vijai J, Sarrel K, Robson M, Kauff N, Mulligan AM, Glendon G, Ozcelik H, Ejlertsen B, Nielsen FC, Jønson L, Andersen MK, Ding YC, Steele L, Foretova L, Teulé A, Lazaro C, Brunet J, Pujana MA, Mai PL, Loud JT, Walsh C, Lester J, Orsulic S, Narod SA, Herzog J, Sand SR, Tognazzo S, Agata S, Vaszko T, Weaver J, Stavropoulou AV, Buys SS, Romero A, de la Hoya M, Aittomäki K, Muranen TA, Duran M, Chung WK, Lasa A, Dorfling CM, Miron A, BCFR, Benitez J, Senter L, Huo D, Chan SB, Sokolenko AP, Chiquette J, Tihomirova L, Friebel TM, Agnarsson BA, Lu KH, Lejbkowicz F, Balmaña J, James PA, Hall P, Dunning AM, Tessier D, Cunningham J, Slager SL, Wang C, Hart S, Stevens K, Simard J, Pastinen T, Pankratz VS, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC on behalf of CIMBA (2013) **Genome-wide association study in *BRCA1* mutation carriers identifies novel loci associated with breast and ovarian cancer risk.** *PLoS Genetics,* (Jan) 9(3):e1003212. PMID : 23544013. [267]

250. Dorval M, Bouchard K, Chiquette J, Glendon G, Maugard CM, Dubuisson W, Panchal S, Simard J (2013) **A focus group study on breast cancer risk presentation: One format does not fit all.** *European Journal of Human Genetics,* (July) 21:719-724. PMID : 23169493. [15]

251. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook M, Orr N, Kyong Rhie E, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, Chang-Claude J, Carpenter J, Godwin A, Nevanlinna H, Giles GG, Cox A, Hopper JL, Humphreys MK, Wang Q, Dennis J, Dicks E, Howat WJ, Schoof N, Bojesen SE, Lambrechts D, Broeks A, Andrulis IL, Guénel P, Burwinkel B, Sawyer EJ, Hollestelle A, Fletcher O, Winqvist R, Brenner H, Mannermaa A, Hamann U, Meindl A, Lindblom A, Zheng W, Devillee P, Goldberg MS, Lubinski J, Kristensen V, Swerdlow A, Anton-Culver H, Dörk T, Muir K, Matsuo K, Wu AH, Radice P, Teo SH, Shu X-O, Blot W, Kang D, Hartman M, Sangrajrang S, Shen C-Y, Southey MC, Park DJ, Hammet F, Stone J, Van't Veer LJ, Rutgers EJ, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Peto J, Schrauder MG, Ekic SB, Beckmann MW, dos Santos Silva I, Johnson N, Warren H, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Truong T, Laurent-Puig P, Kerbrat P, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Arias Perez JI, Menéndez P, Müller H, Arndt V, Stegmaier C, Lichtner P, Lochmann M, Justenhoven C, Ko Y-D, The GENICA Network, Muranen TA, Aittomäki K, Blomqvist C, Greco D, Heikkinen T, Ito H, Iwata H, Yatabe Y, Antonenkova NN, Margolin S, Kataja V, Kosma V-M, Hartikainen JM, Balleine R, , Tseng C-C, Van Den Berg D, Stram DO, Neven P, Dieudonné A-S, Leunen K, Rudolph A, Nickels S, Flesch-Janys D, Peterlongo P, Peissel B, Bernard L, Olson JE, Wang X, Stevens K, Severi G, Baglietto L, McLean C, Coetzee GA, Feng Y, Henderson BE, Schumacher F, Bogdanova NV, Labrèche F, Dumont M, Har Yip C, Aishah Mohd Taib N, Cheng C-Y, Shrubsole M, Long J, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Knight JA, Glendon G, Mulligan AM, Tollenaar RAEM, Seynaeve CM, Kriege M, Hooning MJ, van den Ouweland AMW, van Deurzen CHM, Lu W, Gao Y-T, Cai H, Balasubramanian SP, Cross SS, Reed MWR, Signorello L, Cai Q, Shah M, Miao H, Chan CW, Chia KS, Jakubowska A, Jaworska K, Durda K, Hsiung C-N, Wu P-E, Yu J-C, Ashworth A, Jones M, Tessier DC, González-Neira A, Pita G, Alonso MR, Vincent D, Bacot F,

Ambrosone CB, Bandera EV, John EM, Chen GK, Hu JJ, Rodriquez-Gil JL, Bernstein L, Press MF, Ziegler RG, Millikan RM, Deming-Halverson SL, Nyante S, Ingles SA, Waisfisz Q, Tsimiklis H, Makalic E, Schmidt D, Bui M, Gibson L, Müller-Myhsok B, Hein R, Dahmen N, Beckmann L, Aaltonen K, Czene K, Irwanto A, Liu J, Turnbull C, Rahman N, Meijers-Heijboer H, Uitterlinden AG, Rivadeneira F, Olswold C, Slager S, Pilarski R, Ademuyiwa F, Konstantopoulou I, Martin NG, Montgomery GW, Slamon DJ, Rauh C, Lux MP, Jud SM, Bruning T, Weaver J, Sharma P, Pathak H, Tapper W, Gerty S, Durcan L, Trichopoulos D, Tumino R, Peeters PH, Kaaks R, Campa D, Canzian F, Weiderpass E, Johansson M, Khaw K-T, Travis R, Clavel-Chapelon F, Kolonel LN, Chen C, Beck A, Hankinson SE, Berg C, Hoover RN, Lissowska J, Figueroa J, Chasman DI, Gaudet MM, Diver WR, Willett WC, Hunter DJ, Simard J, Benitez J, Dunning AM, Sherman ME, Chenevix-Trench G, Chanock SJ, Hall P, Pharoah P, Vachon C, Easton DF, Haiman CA, Kraft P (2013) **Genome-wide association studies identify four ER-negative specific breast cancer risk loci.** *Nature Genetics*, (April) 45:392-398. PMID : 23535733. [388]

252. Gaudet MM, Kuchenbaecker KB, Vijai J, Klein RJ, Kirchhoff T, McGuffog L, Barrowdale D, Dunning AM, Lee A, Dennis J, Healey S, Dicks E, Soucy P, Sinilnikova OM, Pankratz VS, Wang X, Eldridge RC, Tessier DC, Vincent DC, Bacot F, Hogervorst FBL, Peock S, Stoppa-Lyonnet D, KConFab Investigators, Peterlongo P, Schmutzler RK, Nathanson KL, Piedmonte M, Singer CF, Thomassen M, OCGN, v. O. Hansen T, Neuhausen SL, Blanco I, Greene MH, Garber J, Weitzel JN, Andrulis IL, Goldgar DE, D'Andrea E, Caldes T, Nevanlinna H, Osorio A, van Rensburg EJ, Arason A, Rennert G, van den Ouweland AMW, van der Hout AH, Kets CM, Aalfs CM, Wijnen JT, Ausems MGEM, HEBON, EMBRACE, Frost D, Ellis S, Fineberg E, Platte R, Evans DG, Jacobs C, Adlard J, Tischkowitz M, Porteous ME, Damiola F, GEMO Study Collaborators, Golmard L, Barjhoux L, Longy M, Belotti M, Fert Ferrer S, Mazoyer S, Spurdle AB, Manoukian S, Barile M, Genuardi M, Arnold N, Meindl A, Sutter C, Wappenschmidt B, Domchek SM, Pfeiler G, Friedman E, Birk Jensen U, Robson M, Shah S, Lazaro C, Mai PL, Benitez J, Southey MC, Schmidt MK, Fasching PA, Peto J, Humphreys MK, Wang Q, Michailidou K, Sawyer EJ, Burwinkel B, Guénel P, Bojesen SE, Milne RL, Brenner H, Lochmann M, The GENICA Network, Aittomäki K, Dörk T, Margolin S, Mannermaa A, Lambrechts D, Chang-Claude J, Radice P, Giles GG, Haiman CA, Winqvist R, Devillee P, García-Closas M, Schoof N, Hooning MJ, Cox A, Pharoah PDP, Jakubowska A, Orr N, González-Neira A, Pita G, Alonso MR, Hall P, Couch FJ, Simard J, Altshuler D, Easton DF, Chenevix-Trench G, Antoniou AC, Offit K (2013) **Identification of a *BRCA2*-specific Modifier Locus at 6p24 Related to Breast Cancer Risk**. *PLoS Genetics*, (Jan) 9(3):e1003173. PMID : 23544012. [131]

253. Joly Y, Ngueng Feze I, Simard J (2013) **Genetic Discrimination and Life Insurance: A Systematic Review of the Evidence**. *BMC Medicine*, (Jan) 31;11:25. PMID : 23369270. [122]

254. Lafrenière D, Bouchard K, Godard B, Simard J, Dorval M (2013) **Family communication following *BRCA1/2* genetic testing: A close look at the process.** *Journal of Genetic Counseling*, (June) 22:323-235. PMID : 23242930. [22]

255. Lapointe J, Côté C, Bouchard K, Godard B, Simard J, Dorval M (2013) **Life events may contribute to family communication about cancer risk following *BRCA1/2* testing**. *Journal of Genetic Counseling,* (April) 22:249-257. PMID : 22892900. [15]

256. McClellan KA, Avard D, Simard J, Knoppers BM (2013) **Personalized medicine and access to health care: potential for inequitable access?** *European Journal of Human Genetics,* (Feb) 21:143-147. PMID : 22781088. [52]

257. McClellan KA, Kleiderman E, Black L, Bouchard K, Dorval M, Simard J, Knoppers BM, Avard D (2013) **Exploring Resources for Intrafamilial Communication of Cancer Genetic Risk: We still need to talk**. *European Journal of Human Genetics*, (Jan) 21:903-910. PMID : 23340514. [16]

258. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Humphreys MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Fletcher O, Peto J, Gibson L, dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, van der Luijt RB, Hein R, Dahmen N, Beckman L, Meindl A, Schmutzler RK, Müller-Myhsok B, Lichtner P, Hopper JL, Southey MC, Makalic E, Schmidt DF, Uitterlinden AG, Hofman A, Hunter DJ, Chanock SJ, Vincent D, Bacot F, Tessier DC, Canisius S, Wessels LFA, Haiman CA, Shah M, Luben R, Brown J, Luccarini C, Schoof N, Humphreys K, Li J, Nordestgaard BG, Nielsen SF, Flyger F, Couch FJ, Wang X, Vachon C, Stevens KN, Lambrechts D, Moisse M, Paridaens

R, Christiaens M-R, Rudolph A, Nickels S, Flesch-Janys D, Johnson N, Aitken Z, Aaltonen K, Heikkinen T, Broeks A, Van 't Veer LJ, van der Schoot CE, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Zamora MP, Arias Perez JI, Pita G, Alonso MR, Cox A, Brock IW, Cross SS, Reed MWR, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Henderson BE, Schumacher F, Le Marchand L, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, van den Ouweland AMW, Jager A, Bui QM, Stone J, Dite GS, Apicella C, Tsimiklis H, Giles GG, Severi G, Baglietto L, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Müller H, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Figueroa J, Lissowska J, Brinton L, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Brüning T, Radice P, Peterlongo P, Manoukian S, Bonanni B, Devilee P, Tollenaar RAEM, Seynaeve C, van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Durda K, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, Bogdanova NV, Antonenkova NV, Dörk T, Kristensen VN, Anton-Culver H, Slager S, Toland AE, Edge S, Fostira F, Kang D, Yoo K-Y, Noh D-Y, Matsuo K, Ito H, Iwata H, Sueta A, Wu AH, Tseng C-C, Van Den Berg D, Stram DO, Shu X-O, Lu W, Gao Y-T, Cai H, Teo SH, Yip CH, Phuah SY, Cornes BK, Hartman M, Miao H, Lim WY, Sng J-H, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Shen C-Y, Hsiung C-N, Wu P-E, Ding S-L, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Blot WJ, Signorello LB, Cai Q, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Simard J, Garcia-Closas M, Pharoah P DP, Chenevix-Trench G, Dunning AM, Benitez J, Easton DF (2013) **Large-scale genotyping identifies 41 new loci associated with breast cancer risk.** *Nature Genetics*, (April) 45:353-361. PMID : 23535729. [1010]

259. Phillips K-A, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, Frost D, Easton DF, Ellis S, Friedlander ML, Buys SS, Andrieu N, Noguès C, Stoppa-Lyonnet D, Bonadona V, Pujol P, McLachlan SA, John EM, Hooning M, Seynaeve C, Tollenaar RAEM, Goldgar D, Terry MB, Caldes T, Weideman PC, Andrulis IL, Singer CF, Birch K, Simard J, Southey MC, Olsson H, Jakubowska A, Olah E, Gerdes A-M, Foretova L, Hopper JL (2013) **Tamoxifen and Risk of Contralateral Breast Cancer for *BRCA1* and *BRCA2* Mutation Carriers.** *Journal of Clinical Oncology,* (Sept) 31:3091-3099. PMID : 23918944. [180]

260. Simard J and Hall P (2013) **Lessons Learned and Challenges Posed in Cancer Genetics**. *Journal of Internal Medicine,* (Nov) 274:396-398. PMID : 24127937.

261. Jbilou J, Halilem N, Blouin-Bougie J, Amara N, Landry R, Simard J (2014) **Medical genetic counseling for breast cancer in primary care: a synthesis of major determinants of physicians' practices in primary care settings.** *Public Health Genomics,* (July) 17:190-208. PMID : 24993835. [19]

262. Joly Y, Burton H, Knoppers BM, Ngueng Feze I, Dent T, Pashayan N, Chowdhury S, Foulkes W, Hall A, Hamet P, Kirwan N, Macdonald A, Simard J, Van Hoyweghen I (2014) **Life insurance: genomic stratification and risk classification.** *European Journal of Human Genetics,* (May) 22:575-579. PMID : 24129434. [37]

263. Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH,

van der Luijt RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC, CIMBA (2014) **Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in *BRCA1* and *BRCA2* mutation carriers**. *Breast Cancer Research,* (Dec) 16:3416. doi: 10.1186/s13058-014-0492-9. PMID: 25919761. [38]

264. Osorio A, Milne RL, Kuchenbaecker K, Vaclová T, Pita G, Alonso R, Peterlongo P, Blanco I, de la Hoya M, Duran M, Díez O, Ramón y Cajal T, Konstantopoulou I, Martínez-Bouzas C, Andrés Conejero R, Soucy P, McGuffog L, Barrowdale D, Lee A, SWE-BRCA, Arver B, Rantala J, Loman N, Ehrencrona H, Olopade OI, Beattie MS, Domchek SM, Nathanson K, Rebbeck TR, Arun BK, Karlan BY, Walsh C, Lester J, John EM, Whittemore AS, Daly MB, Southey M, Hopper J, Terry MB, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, v. O. Hansen T, Jønson L, Ejlertsen B, Gerdes A-M, Infante M, Herráez B, Thais Moreno L, Weitzel JN, Herzog J, Weeman K, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Bonanni B, Mariette F, Volorio S, Viel A, Varesco L, Papi L, Ottini L, Grazia Tibiletti M, Radice P, Yannoukakos D, Garber J, Ellis S, Frost D, Platte R, Fineberg E, Evans G, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Cole T, Eccles D, Cook J, Hodgson S, Brewer C, Tischkowitz M, Douglas F, Porteous M, Side L, Walker L, Morrison P, Donaldson A, Kennedy J, Foo C, Godwin AK, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Damiola F, Poppe B, Claes K, Piedmonte M, Tucker K, Backes F, Rodríguez G, Brewster W, Wakeley K, Rutherford T, Caldés T, Nevanlinna H, Aittomäki K, Rookus MA, van Os TAM, van der Kolk L, de Lange JL, Meijers-Heijboer HEJ, van der Hout AH, van Asperen CJ, Gómez Garcia EB, Hoogerbrugge N, Collée JM, van Deurzen CHM, van der Luijt RB, Devilee P, HEBON, Olah E, Lázaro C, Teulé A, Menéndez M, Jakubowska A, Cybulski C, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Johannsson OT, Maugard C, Montagna M, Tognazzo S, Teixeira MR, Healey S, kConFab Investigators, Olswold C, Guidugli L, Lindor N, Slager S, Szabo CI, Vijai J, Robson M, Kauff N, Zhang L, Rau-Murthy R, Fink-Retter A-L, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea M-K, Berger A, Phelan CM, Greene MH, Mai PL, Lejbkowicz F, Andrulis I, Mulligan AM, Glendon G, Ewart Toland A, Bojesen A, Pedersen S, Sunde L, Thomassen M, Kruse TA, Birk Jensen U, Friedman E, Laitman Y, Paluch Shimon S, Simard J, Easton DF, Offit K, Couch F, Chenevix-Trench G, Antoniou AC, Benitez J (2014) **DNA glycosylases involved in Base Excision Repair may be associated with cancer risk in BRCA1 and *BRCA2* mutation carriers.** *PLos Genetics,* (April) 10:e1004256. PMID : 24698998. [40]

265. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, BCFR, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Gerdes A-M, Ejlertsen B, Nielsen FC, v. O. Hansen T, Osorio A, Benitez J, Andrés-Conejero R, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, EMBRACE, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De Leeneer K, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler S, Markov NB, Wang-Gohrke S, de Pauw A, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F, GEMO Study Collaborators, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon Y-J, Carter J, Van Le L, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomäki K, Jager A, van den Ouweland AMW, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FBL, Meijers-Heijboer HEJ, HEBON, Oosterwijk JC, van Roozendaal KEP, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teulé A, Lazaro C, Blanco I, Del Valle J, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K,

Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor N, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea M-K, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Ewart Toland A, Sokilde Pedersen I, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DG, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG (2015) **An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in *BRCA2* mutation carriers**. *Breast Cancer Research*, (April) 17:61. PMID: 25925750. [18]

266. Guo X, Long J, Zeng C, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Milne RL, Shu X-O, Cai Q, Beesley J, Kar SP, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadie A, Benitez J, Blot W, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A, Brüning T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi J-Y, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dörk T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guénel P, Haiman CA, Hamann U, Hartman M, Hollestelle A, Hopper JL, Hsiung C-N, kConFab Investigators, Ito H, Jakubowska A, Johnson N, Kabisch M, Kang D, Khan S, Knight JA, Kosma V-M, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McLean CA, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Olson JE, Orr N, Peterlongo P, Choudary Putti T, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen C-Y, Shi J, Shrubsole MJ, Southey MC, Swerdlow A, Teo SH, Thienpont B, Ewart Toland A, Tollenaar RAEM, Tomlinson IPM, Truong T, Tseng C-C, van den Ouweland A, Wen W, Winqvist R, Wu A, Yip CH, Zamora MP, Zheng Y, Hall P, Pharoah PDP, Simard J, Chenevix-Trench G, Dunning AM, Easton DF, Zheng W (2015) **Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk.** *Cancer Epidemiology, Biomarkers & Prevention*, (Nov) 24(11):1680-1691. PMID : 26354892. [22]

267. Jamshidi M, Fagerholm R, Khan S, Aittomäki K, Czene K, Darabi H, Li J, Andrulis IL, Chang-Claude J, Devilee P, Fasching PA, Michailidou K, Bolla MK, Dennis J, Wang Q, Guo Q, Rhenius V, Cornelissen S, Rudolph A, Knight JA, Loehberg CR, Burwinkel B, Marme F, Hopper JL, Southey MC, Bojesen SE, Flyger H, Brenner H, Holleczek B, Margolin S, Mannermaa A, Kosma V-M, kConFab Investigators, Van Dyck L, Nevelsteen I, Couch FJ, Olson JE, Giles GG, McLean C, Haiman CA, Henderson BE, Winqvist R, Pylkäs K, Tollenaar RAEM, García-Closas M, Figueroa J, Hooning MJ, Martens JWM, Cox A, Cross SS, Simard J, Dunning AM, Easton DF, Pharoah PDP, Hall P, Blomqvist C, Schmidt MK and Nevanlinna H **(2015) SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival**. *Oncotarget*, (Nov) 6(35):37979-37994. PMID: 26317411. [24]

268. Kabisch M, Lorenzo Bermejo J, Dünnebier T, Ying S, Michailidou K, Bolla MK, Wang Q, Dennis J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Peeters S, Weltens C, Couch FJ, Olson JE, Wang X, Purrington K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Johnson N, Fletcher O, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Schmidt MK, Broeks A, Cornelissen S, Hogervorst FB, Li J, Brand JS, Humphreys K, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marmé F, Yang R, Bugert P, González-Neira A, Benitez J, Pilar Zamora M, Arias Perez JI, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N; kConFab Investigators; Australian Ovarian Cancer Study Group, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindblom A, Margolin S, Hooning MJ, Hollestelle A, Kriege M, Koppert LB, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Slettedahl S, Toland AE, Vachon C, Yannoukakos D, Giles GG, Milne RL, McLean C, Fasching PA, Ruebner M, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Ashworth A, Orr N, Schoemaker MJ, Swerdlow A, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Brüning T, Ko YD; GENICA Network, Radice P, Peterlongo P, Scuvera G, Fortuzzi S, Bogdanova N, Dörk T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RA, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Zheng W,

Shrubsole MJ, Cai Q, Torres D, Anton-Culver H, Kristensen V, Bacot F, Tessier DC, Vincent D, Luccarini C, Baynes C, Ahmed S, Maranian M, Simard J, Chenevix-Trench G, Hall P, Pharoah PD, Dunning AM, Easton DF, Hamann U (2015) **Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer**. *Carcinogenesis*, (Feb) 36:256-271. PMID : 25586992. [14]

269. Leclerc M, EMBRACE Investigators, GEMO Study Collaborators, INHERIT Investigators, Antoniou AC, Simard J, Lakhal-Chaieb L (2015) **Analysis of multivariate failure times in the presence of selection bias with application to breast cancer.** *Journal of the Royal Statistical Society, Series C-Applied Statistics,* (April) 64(3): 525-541. DOI: 10.1111/rssc.12091. [3]

270. Leclerc M, Consortium of Investigators of Modifiers of BRCA1/2, Simard J, Lakhal-Chaieb L (2015) **SNP Set Association Testing for Survival Outcomes in the Presence of Intrafamilial Correlation**. *Genetic Epidemiology*, (Sept) 39 (6):406-414. PMID : 26282997. [10]

271. Lévesque E, Knoppers BM, Simard J (2015) **Ethical challenges and innovations in the dissemination of genomic data: the experience of the PERSPECTIVE project.** *Advances in Genomics and Genetics*, (Aug) 5:283-292. [1]

272. Mavaddat N, Pharoah PD, Michailidou K, Tyrer J, Brook MN, Bolla MK, Wang Q, Dennis J, Dunning AM, Shah M, Luben R, Brown J, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Czene K, Darabi H, Eriksson M, Peto J, Dos-Santos-Silva I, Dudbridge F, Johnson N, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Figueroa J, Chanock SJ, Brinton L, Lissowska J, Couch FJ, Olson JE, Vachon C, Pankratz VS, Lambrechts D, Wildiers H, Van Ongeval C, van Limbergen E, Kristensen V, Grenaker Alnæs G, Nord S, Borresen-Dale AL, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Trentham-Dietz A, Newcomb P, Titus L, Egan KM, Hunter DJ, Lindstrom S, Tamimi RM, Kraft P, Rahman N, Turnbull C, Renwick A, Seal S, Li J, Liu J, Humphreys K, Benitez J, Pilar Zamora M, Arias Perez JI, Menéndez P, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Bogdanova NV, Antonenkova NN, Dörk T, Anton-Culver H, Neuhausen SL, Ziogas A, Bernstein L, Devilee P, Tollenaar RA, Seynaeve C, van Asperen CJ, Cox A, Cross SS, Reed MW, Khusnutdinova E, Bermisheva M, Prokofyeva D, Takhirova Z, Meindl A, Schmutzler RK, Sutter C, Yang R, Schürmann P, Bremer M, Christiansen H, Park-Simon TW, Hillemanns P, Guénel P, Truong T, Menegaux F, Sanchez M, Radice P, Peterlongo P, Manoukian S, Pensotti V, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Brauch H, Brüning T, Ko YD, Sigurdson AJ, Doody MM, Hamann U, Torres D, Ulmer HU, Försti A, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Andrulis IL, Knight JA, Glendon G, Marie Mulligan A, Chenevix-Trench G, Balleine R, Giles GG, Milne RL, McLean C, Lindblom A, Margolin S, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Eilber U, Wang-Gohrke S, Hooning MJ, Hollestelle A, van den Ouweland AM, Koppert LB, Carpenter J, Clarke C, Scott R, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Brenner H, Arndt V, Stegmaier C, Karina Dieffenbach A, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Offit K, Vijai J, Robson M, Rau-Murthy R, Dwek M, Swann R, Annie Perkins K, Goldberg MS, Labrèche F, Dumont M, Eccles DM, Tapper WJ, Rafiq S, John EM, Whittemore AS, Slager S, Yannoukakos D, Toland AE, Yao S, Zheng W, Halverson SL, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, Simard J, Hall P, Easton DF, Garcia-Closas M (2015) **Prediction of breast cancer risk based on profiling with common genetic variants.** *JNCI-Journal of the National Cancer Institute*, (April) 107(5):djv036. PMID : 25855707. [406]

273. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush M, Maranian M, Bolla MK, Wang Q, Sha M, Perkins B, Czene K, Eriksson M, Darabi H, Brand J, Bojesen SE, Nordestgaard BG, Wesicher M, Nielsen SF, Rahman N, Turnbull C, FBCS, Fletcher O, Peto J, Gibson L, dos-Santos-Silva I, Chang-Claude J, Flesch-Janys D, Rudolph A, Eilber U, Behrens S, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Khan S, Aaltonen K, Ahsan, H Kibriya MG, Whittemore AS, John EM, Malone K, Gammon MD, Santella RM, Ursin G, Makalic E, Schmidt DF, Casey G, Hunter DJ, Gapstur SM, Gaudet MM, Diver WR, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Berg C, Chanock S, Figueroa J, Hoover RN, Lambrechts D, Neven P, Wildiers H, van Limbergen E, ABCS, TNBCC, Couch FJ, Olson JE, Hallberg E, Wang X, Waisfisz Q, Meijers-Heijboer H, Adank MA, van der Luijt RB, Li J, Liu J, Humphreys K, Kang D, Choi J-Y, Park SK, Yoo K-Y, Matsuo K, Ito H, Iwata H, Tajima K, Guénel P, Truong T, Mulot C,

Sanchez M, Burwinkel B, Marme F, Surowy H, Sohn C, Wu AH, Tseng C-C, Van Den Berg D, Stram DO, González-Neira A, Benitez J, Zamora MP, Perez JIA, Shu X-O, Lu W, Gao Y-T, Cai H, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, kConFab investigators, AOCS Group, Lindblom A, Margolin S, Teo SH, Yip CH, Mohd Taib NA, Teh, Y-C Hooning MJ, Hollestelle A, Martens JWM, Collée JM, Blot W, Signorello LB, Cai Q, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Shen C-Y, Hsiung C-N, Wu P-E, Ding S-L, Kristensen VN, Nord S, Grenaker Alnaes GI, NBCS, Giles GG, Milne RL, McLean C, Meindl A, Schmutzler RK, Sutter C, Yang R, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Chia KS, Chan CW, Fasching PA, Loehberg CR, Schrauder MG, Haeberle L, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Ashworth A, Orr N, Schoemaker MJ, Swerdlow A, Brinton L, Garcia-Closas M, Zheng W, Halverson SL, Shrubsole M, Long J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Hamann U, Brüning T, The GENICA Network, MBCSG, Bogdanova NV, Dörk T, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, Devilee P, Tollenaar R, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska K, Huzarski T, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Edge S, Fostira F, Kabisch M, Torres D, Neuhausen SL, Anton-Culver H, Luccarini C, Baynes C, Ahmed S, Healey CS, Tessier DC, Vincent D, Bacot F, Pita G, Alonso RM, Álvarez N, Herrero D, Simard J, Pharoah PDP, Kraft P, Dunning AM, Chenevix-Trench G, Hall P, Easton DF (2015) **Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.** *Nature Genetics,* (April) 47:373-380. PMID: 25751625. [449]

274. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez-Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlertsen B, Jønson L, Osorio A, Martinez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T, Godwin AK, Claes K, Van Maerken T, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de Paillerets B, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Perez Segura P, Nevanlinna H, Aittomäki K, van Os TA, Meijers-Heijboer HE, Van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, Van Doorn HC, Collée JM, Olah E, Díez O, Blanco I, Lazaro C, Brunet J, Feliubadaló L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson M, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Geschwantler Kaulich D, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von Wachenfeldt A, Ehrencrona H, Stenmark Askmalm M, Borg A, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G On Behalf Of Aocs Management Group, Antoniou AC, Friedman E (2015**) Candidate genetic modifiers for breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers.** *Cancer Epidemiology Biomarkers & Prevention,* (Jan) 24:308-316. PMID : 25336561. [23]

275. Zhang B, Shu XO, Delahanty RJ, Zeng C, Michailidou K, Bolla MK, Wang Q, Dennis J, Wen W, Long J, Li C, Dunning AM, Chang-Claude J, Shah M, Perkins BJ, Czene K, Darabi H, Eriksson M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Neven P, Wildiers H, Floris G, Schmidt MK, Rookus MA, van den Hurk K, de Kort WL, Couch FJ, Olson JE, Hallberg E, Vachon C, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Li J, Humphreys K, Brand J, Guénel P, Truong T, Cordina-Duverger E, Menegaux F, Burwinkel B, Marme F, Yang R, Surowy H, Benitez J, Zamora MP, Perez JI, Cox A, Cross SS, Reed MW, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller

N, Chenevix-Trench G; kConFab Investigators, Australian Ovarian Study Group, Haiman CA, Henderson BE, Schumacher F, Marchand LL, Lindblom A, Margolin S, Hooning MJ, Martens JW, Tilanus-Linthorst MM, Collée JM, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Giles GG, Milne RL, McLean C, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow AJ, Ashworth A, Orr N, Jones M, Figueroa J, Garcia-Closas M, Brinton L, Lissowska J, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Brauch H, Brüning T, Ko YD, Peterlongo P, Manoukian S, Bonanni B, Radice P, Bogdanova N, Antonenkova N, Dörk T, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubiński J, Jaworska-Bieniek K, Durda K, Hamann U, Torres D, Schmutzler RK, Neuhausen SL, Anton-Culver H, Kristensen VN, Grenaker Alnæs GI; DRIVE Project, Pierce BL, Kraft P, Peters U, Lindstrom S, Seminara D, Burgess S, Ahsan H, Whittemore AS, John EM, Gammon MD, Malone KE, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Pharoah PD, Simard J, Hall P, Hunter DJ, Easton DF, Zheng W (2015) **Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization**. *JNCI-Journal of the National Cancer Institute*. (Nov) 107(11):djv219. PMID : 26296642. [94]

276. Amara N, Blouin-Bougie J, Jbilou J, Halilem N, Simard J, Landry R (2016) **The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes.** *Familial Cancer*. (Jan) 15(1):1-17. PMID : 26334522. [6]

277. Darabi H, Beesley J, Droit A, Kar S, Nord S, Moradi Marjaneh M, Soucy P, Michailidou K, Ghoussaini M, Fues Wahl H, Bolla MK, Wang Q, Dennis J, Alonso MR, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Benitez J, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Broeks A, Brüning T, Burwinkel B, Chang-Claude J, Choi JY, Conroy DM, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Easton DF, Fasching PA, Figueroa J, Fletcher O, Flyger H, Galle E, García-Closas M, Giles GG, Goldberg MS, González-Neira A, Guénel P, Haiman CA, Hallberg E, Hamann U, Hartman M, Hollestelle A, Hopper JL, Ito H, Jakubowska A, Johnson N, Kang D, Khan S, Kosma VM, Kriege M, Kristensen V, Lambrechts D, Le Marchand L, Lee SC, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Matsuo K, Mayes R, McKay J, Meindl A, Milne RL, Muir K, Neuhausen SL, Nevanlinna H, Olswold C, Orr N, Peterlongo P, Pita G, Pylkäs K, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Seynaeve C, Shah M, Shen CY, Shu XO, Southey MC, Stram DO, Surowy H, Swerdlow A, Teo SH, Tessier DC, Tomlinson I, Torres D, Truong T, Vachon CM, Vincent D, Winqvist R, Wu AH, Wu PE, Yip CH, Zheng W, Pharoah PD, Hall P, Edwards SL, Simard J, French JD, Chenevix-Trench G, Dunning AM (2016) **Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs)**. *Scientific Reports*. (Sept) 6:32512. PMID: 27600471. [18]

278. Dunning AM, Michailidou K, Kuchenbaecker KB, Thompson D, French JD, Beesley J, Healey CS, Kar S, Pooley KA, Lopez-Knowles E, Dicks E, Barrowdale D, Sinnott-Armstrong NA, Sallari R, Hillman KM, Kaufmann S, Sivakumaran H, Marjaneh MM, Lee JS, Hills M, Jarosz M, Drury S, Canisius S, Bolla MK, Dennis J, Wang Q, Hopper JL, Southey MC, Broeks A, Schmidt MK, Lophatananon A, Muir K, Beckmann MW, Fasching PA, dos-Santos-Silva I, Peto J, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, González-Neira A, Perez JIA, Anton-Culver H, Eunjung L, Arndt V, Brenner H, Meindl A, Schmutzler RK, Brauch H, Hamann U, Aittomäki K, Blomqvist C, Ito H, Matsuo K, Bogdanova N, Dörk T, Lindblom A, Margolin S, Kosma V-M, Mannermaa A, Tseng C-C, Wu AH, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Peterlongo P, Radice P, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Goldberg MS, Teo SH, Yip CH, Nord S, Borresen-Dale A-L, Kristensen V, Long J, Zheng W, Pylkäs K, Winqvist R, Andrulis IL, Knight JA, Devilee P, Seynaeve C, Figueroa J, Sherman ME, Czene K, Darabi H, Hollestelle A, van den Ouweland AMW, Humphreys K, Gao Y-T, Shu X-O, Cox A, Cross SS, Blot W, Cai Q, Ghoussaini M, Perkins BJ, Shah M, Choi J-Y, Kang D, Lee SC, Hartman M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Brennan P, Sangrajrang S, Ambrosone CB, Toland AE, Shen C-Y, Wu P-E, Orr N, Swerdlow A, McGuffog L, Healey S, Lee A, Kapuscinski M, John EM, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ejlertsen B, Hansen TVO, Osorio A, Benitez J, Rando R, Weitzel JN, Bonanni B, Peissel B, Manoukian S, Papi L, Ottini L, Konstantopoulou I, Apostolou P,

Garber J, Rashid MU, Frost D, EMBRACE, Izatt L, Ellis S, Godwin AK, Arnold N, Niederacher D, Riem K, Bogdanova-Markov N, Sagne C, Stoppa-Lyonnet D, Damiola F, GEMO Study Collaborators, Sinilnikova OM, Mazoyer S, Isaacs C, Claes KBM, De Leeneer K, de la Hoya M, Caldes T, Nevanlinna H, Khan S, Mensenkamp AR, HEBON, Hooning MJ, Rookus MA, Kwong A, Olah E, Diez O, Brunet J, Pujana MA, Gronwald J, Huzarski T, Barkardottir RB, Laframboise R, Soucy P, Montagna M, Agata S, Teixeira MR, kConFab Investigators, Park SK, Lindor N, Couch FJ, Tischkowitz M, Foretova L, Vijai J, Offit K, Singer CF, Rappaport C, Phelan CM, Greene MH, Mai PL, Rennert G, Imyanitov EN, Hulick PJ, Phillips K-A, Piedmonte M, Mulligan AM, Glendon G, Bojesen A, Thomassen M, Caligo MA, Yoon S-Y, Friedman E, Laitman Y, Borg A, von Wachenfeldt A, Ehrencrona H, Rantala J, Olopade OI, Ganz PA, Nussbaum RL, Gayther SA, Nathanson KL, Domchek SM, Arun BK, Mitchell G, Karlan BY, Lester J, Maskarinec G, Woolcott C, Scott C, Stone J, Apicella C, Tamimi R, Luben R, Khaw K-T, Helland Å, Haakensen V, Dowsett M, Pharoah PDP, Simard J, Hall P, García-Closas M, Vachon C, Chenevix-Trench G, Antoniou AC, Easton DF, Edwards SL (2016) **Breast cancer risk variants at 6q25 display different phenotype associations and regulate *ESR1, RMND1* and *CCDC170.*** *Nature Genetics,* (April) 48(4):374-386. PMID : 26928228. [89]

279. Gagnon J, Lévesque E, Borduas F, Chiquette J, Diorio C, Duchesne N, Dumais M, Eloy L. Foulkes W, Gervais N, Lalonde L, L'Espérance B, Meterissian S, Provencher L, Richard J, Savard C, Trop I, Wong N, Knoppers MB, Simard J (2016) **Recommendations on Breast Cancer Screening and Prevention in the Context of Risk Stratification Implementation: Impending Changes to Current Policies**. *Current Oncology, in Practice guidelines section*. (Dec) 23(6):e615-e625. [21]

280. Guo Y, Warren Andersen S, Shu XO, Michailidou K, Bolla MK, Wang Q, Garcia-Closas M, Milne RL, Schmidt MK, Chang-Claude J, Dunning A, Bojesen SE, Ahsan H, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bogdanova NV, Bonanni B, Børresen-Dale AL, Brand J, Brauch H, Brenner H, Brüning T, Burwinkel B, Casey G, Chenevix-Trench G, Couch FJ, Cox A, Cross SS, Czene K, Devilee P, Dörk T, Dumont M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fostira F, Gammon M, Giles GG, Guénel P, Haiman CA, Hamann U, Hooning MJ, Hopper JL, Jakubowska A, Jasmine F, Jenkins M, John EM, Johnson N, Jones ME, Kabisch M, Kibriya M, Knight JA, Koppert LB, Kosma VM, Kristensen V, Le Marchand L, Lee E, Li J, Lindblom A, Luben R, Lubinski J, Malone KE, Mannermaa A, Margolin S, Marme F, McLean C, Meijers-Heijboer H, Meindl A, Neuhausen SL, Nevanlinna H, Neven P, Olson JE, Perez JI, Perkins B, Peterlongo P, Phillips KA, Pylkäs K, Rudolph A, Santella R, Sawyer EJ, Schmutzler RK, Seynaeve C, Shah M, Shrubsole MJ, Southey MC, Swerdlow AJ, Toland AE, Tomlinson I, Torres D, Truong T, Ursin G, Van Der Luijt RB, Verhoef S, Whittemore AS, Winqvist R, Zhao H, Zhao S, Hall P, Simard J, Kraft P, Pharoah P, Hunter D, Easton DF, Zheng W (2016) **Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent**. *PLoS Medicine,* (Aug) 13(8):e1002105. doi: 10.1371/journal.pmed.1002105. eCollection. [89]

281. Hamdi Y, Soucy P, Adoue V, Michailidou K, Canisius S, Lemaçon A, Droit A, Andrulis IL, Anton-Culver H, Arndt V, Baynes C, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borresen-Dale A-L, Brand JS, Brauch H, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, NBCS Collaborators, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Dennis J, Devilee P, Dörk T, Dos-Santos-Silva I, Eriksson M, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Goldberg MS, González-Neira A, Grenaker-Alnæs G, Guénel P, Haeberle L, Haiman CA, Hamann U, Hallberg E, Hooning MJ, Hopper JL, Jakubowska A, Jones M, Kabisch M, Kataja V, Lambrechts D, Le Marchand L, Lindblom A, Lubinski J, Mannermaa A, Maranian M, Margolin S, Marme F, Milne RL, Neuhausen SL, Nevanlinna H, Neven P, Olswold C, Peto J, Plaseska-Karanfilska D, Pylkäs K, Radice P, Rudolph A, Sawyer EJ, Schmidt MK, Shu X-O, Southey MC, Swerdlow A, Tollenaar R.A.E.M., Tomlinson I, Torres D, Truong T, Vachon C, Van Den Ouweland A.M.W., Wang Q, Winqvist R, kConFab/AOCS Investigators, Zheng W, Benitez J, Chenevix-Trench G, Dunning AM, Pharoah PDP, Kristensen V, Hall P, Easton DF, Pastinen T, Nord S, Simard J (2016) **Association of breast cancer risk with genetic variants showing differential allelic expression: identification of a novel breast cancer susceptibility locus at 4q21.** *Oncotarget*, (Dec) 7(49):80140-80163. PMID : 27792995. [28]

282. Larouche G, Chiquette J, Plante M, Pelletier S, Simard J, Dorval M (2016) **Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging**

Technologies for *BRCA1/2* Mutation Carriers. *Canadian Association of Radiologists Journal,* (Oct) 67:308-312. PMID : 27318890. [4]

283. Lawrenson K, Kar S, McCue K, Kuchenbaeker K, Michailidou K, Tyrer J, Beesley J, Ramus SJ, Li Q, Delgado MK, Lee JM, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Bandera EV, Barile M, Barkardottir RB, Barrowdale D, Beckmann MW, Benitez J, Berchuck A, Bisogna M, Bjorge L, Blomqvist C, Blot W, Bogdanova N, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Børresen-Dale AL, Brauch H, Brennan P, Brenner H, Bruinsma F, Brunet J, Buhari SA, Burwinkel B, Butzow R, Buys SS, Cai Q, Caldes T, Campbell I, Canniotto R, Chang-Claude J, Chiquette J, Choi JY, Claes KB; GEMO Study Collaborators, Cook LS, Cox A, Cramer DW, Cross SS, Cybulski C, Czene K, Daly MB, Damiola F, Dansonka-Mieszkowska A, Darabi H, Dennis J, Devilee P, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dumont M, Ehrencrona H, Ejlertsen B, Ellis S; EMBRACE, Engel C, Lee E, Evans DG, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foretova L, Fostira F, Foulkes WD, Fridley BL, Friedman E, Frost D, Gambino G, Ganz PA, Garber J, García-Closas M, Gentry-Maharaj A, Ghoussaini M, Giles GG, Glasspool R, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goode EL, Goodman MT, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hallberg E, Hamann U, Hansen TV, Harrington PA, Hartman M, Hassan N, Healey S; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON), Heitz F, Herzog J, Høgdall E, Høgdall CK, Hogervorst FB, Hollestelle A, Hopper JL, Hulick PJ, Huzarski T, Imyanitov EN; KConFab Investigators; Australian Ovarian Cancer Study Group, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jensen A, John EM, Johnson N, Kabisch M, Kang D, Kapuscinski M, Karlan BY, Khan S, Kiemeney LA, Kjaer SK, Knight JA, Konstantopoulou I, Kosma VM, Kristensen V, Kupryjanczyk J, Kwong A, de la Hoya M, Laitman Y, Lambrechts D, Le N, De Leeneer K, Lester J, Levine DA, Li J, Lindblom A, Long J, Lophatananon A, Loud JT, Lu K, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Massuger LF, Matsuo K, Mazoyer S, McGuffog L, McLean C, McNeish I, Meindl A, Menon U, Mensenkamp AR, Milne RL, Montagna M, Moysich KB, Muir K, Mulligan AM, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Nord S, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olswold C, O'Malley D, Orlow I, Orr N, Osorio A, Park SK, Pearce CL, Pejovic T, Peterlongo P, Pfeiler G, Phelan CM, Poole EM, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Rhenius V, Rhiem K, Risch HA, Rodriguez G, Rossing MA, Rudolph A, Salvesen HB, Sangrajrang S, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Sellers TA, Seynaeve C, Shah M, Shen CY, Shu XO, Sieh W, Singer CF, Sinilnikova OM, Slager S, Song H, Soucy P, Southey MC, Stenmark-Askmalm M, Stoppa-Lyonnet D, Sutter C, Swerdlow A, Tchatchou S, Teixeira MR, Teo SH, Terry KL, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, Toland AE, Tomlinson I, Torres D, Truong T, Tseng CC, Tung N, Tworoger SS, Vachon C, van den Ouweland AM, van Doorn HC, van Rensburg EJ, Van't Veer LJ, Vanderstichele A, Vergote I, Vijai J, Wang Q, Wang-Gohrke S, Weitzel JN, Wentzensen N, Whittemore AS, Wildiers H, Winqvist R, Wu AH, Yannoukakos D, Yoon SY, Yu JC, Zheng W, Zheng Y, Khanna KK, Simard J, Monteiro AN, French JD, Couch FJ, Freedman ML, Easton DF, Dunning AM, Pharoah PD, Edwards SL, Chenevix-Trench G, Antoniou AC, Gayther SA (2016) **Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus**. *Nature Communications*, (Sept) 7:12675. PMID: 27601076. [48]

284. Lee AJ, Cunningham AP, Tischkowitz M, Simard J, Pharoah PD, Easton DF, Antoniou AC (2016) **Incorporating truncating variants in *PALB2*, *CHEK2*, and *ATM* into the BOADICEA breast cancer risk model**. *Genetics in Medicine*, (Dec) 18(12):1190-1198. PMID : 27464310. [50]

285. Pelletier S, Wong N, El-Haffaf Z, Foulkes WD, Chiquette J, Hamet P, Simard J, Dorval M (2016) **Clinical follow-up and breast and ovarian cancer screening of true *BRCA1/2* non-carriers: a qualitative investigation.** *Genetics in Medicine,* (June) 18(6):627-634. PMID : 26540155. [3]

286. Renault AL, Lesueur F, Coulombe Y, Gobeil S, Soucy P, Hamdi Y, Desjardins S, Le Calvez-Kelm F, Vallée M, Voegele C; Breast Cancer Family Registry, Hopper JL, Andrulis IL, Southey MC, John EM, Masson JY, Tavtigian SV, Simard J (2016) **Abraxas (FAM175A) and Breast Cancer Susceptibility: No Evidence of Association in the Breast Cancer Family Registry**. *PLoS One*, (June) 11(6):e0156820. doi : 10.1371/journal.pone.0156820. eCollection 2016. PMID: 27270457. [7]

287. Shi J, Zhang Y, Zheng W, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Dennis J, Lush M, Milne RL, Shu XO, Beesley J, Kar S, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Zhao Z, Guo X,

Benitez J, Beeghly-Fadiel A, Blot W, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A, Brüning T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dork T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guenel P, Haiman CA, Hamann U, Hartman M, Miao H, Hollestelle A, Hopper JL, Hsiung CN; kConFab Investigators, Ito H, Jakubowska A, Johnson N, Torres D, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Li J, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Le Marchand L, Margolin S, Marme F, Matsuo K, McLean C, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Børresen-Dale AL, Olson JE, Orr N, van den Ouweland AM, Peterlongo P, Choudary Putti T, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Hou MF, Shrubsole MJ, Southey MC, Swerdlow A, Hwang Teo S, Thienpont B, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tseng CC, Wen W, Winqvist R, Wu AH, Har Yip C, Zamora PM, Zheng Y, Floris G, Cheng CY, Hooning MJ, Martens JW, Seynaeve C, Kristensen VN, Hall P, Pharoah PD, Simard J, Chenevix-Trench G, Dunning AM, Antoniou AC, Easton DF, Cai Q, Long J (2016) **Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer**. *International Journal of Cancer*, (Sept) 139(6):1303-1317. PMID : 27087578. [24]

288. Wen W, Shu X-O, Guo X, Cai Q, Long J, Bolla MK, Michailidou K, DennisJ, Wang Q, Gao Y-T, Zheng Y, Dunning AM, García-Closas M, Brennan P, Chen S-T, Choi J-Y, Hartman M, Ito H, Lophatananon A, Matsuo K, Miao H, Muir K, Sangrajrang S, Shen C-Y, Teo SH, Tseng C-C, Wu AH, Yip CH, Simard J, Pharoah PDP, Hall P, Kang D, Xiang Y, Easton DF, Zheng W (2016) **Prediction of breast cancer risk based on common genetic variants in women of East Asian ancestry**. *Breast Cancer Research,* (Dec) 18(1):124. [27]

289. Zeng C, Guo X, Long J, Kuchenbaecker KB, Droit A, Michailidou K, Ghoussaini M, Kar S, Freeman A, Hopper JL, Milne RL, Bolla MK, Wang Q, Dennis J, Agata S, Ahmed S, Aittomäki K, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Arun BK, Arver B, Bacot F, Barrowdale D, Baynes C, Beeghly-Fadiel A, Benitez J, Bermisheva M, Blomqvist C, Blot WJ, Bogdanova NV, Bojesen SE, Bonanni B, Borresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Broeks A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldes T, Campbell I, Carpenter J, Chang-Claude J, Choi JY, Claes KB, Clarke C, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, De Leeneer K, Devilee P, Diez O, Domchek SM, Doody M, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dumont M, Dwek M, Dworniczak B, Egan K, Eilber U, Einbeigi Z, Ejlertsen B, Ellis S, Frost D, Lalloo F; EMBRACE, Fasching PA, Figueroa J, Flyger H, Friedlander M, Friedman E, Gambino G, Gao YT, Garber J, García-Closas M, Gehrig A, Damiola F, Lesueur F, Mazoyer S, Stoppa-Lyonnet D; behalf of GEMO Study Collaborators, Giles GG, Godwin AK, Goldgar DE, González-Neira A, Greene MH, Guénel P, Haeberle L, Haiman CA, Hallberg E, Hamann U, Hansen TV, Hart S, Hartikainen JM, Hartman M, Hassan N, Healey S, Hogervorst FB, Verhoef S; HEBON, Hendricks CB, Hillemanns P, Hollestelle A, Hulick PJ, Hunter DJ, Imyanitov EN, Isaacs C, Ito H, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Joly Beauparlant C, Jones M, Kabisch M, Kang D, Karlan BY, Kauppila S, Kerin MJ, Khan S, Khusnutdinova E, Knight JA, Konstantopoulou I, Kraft P, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Le Marchand L, Lee CN, Lee MH, Lester J, Li J, Liljegren A, Lindblom A, Lophatananon A, Lubinski J, Mai PL, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McGuffog L, Meindl A, Menegaux F, Montagna M, Muir K, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Newcomb PA, Nord S, Nussbaum RL, Offit K, Olah E, Olopade OI, Olswold C, Osorio A, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Peeters S, Peissel B, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Presneau N, Radice P, Rahman N, Ramus SJ, Rashid MU, Rennert G, Rhiem K, Rudolph A, Salani R, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Schoemaker MJ, Schürmann P, Seynaeve C, Shen CY, Shrubsole MJ, Shu XO, Sigurdson A, Singer CF, Slager S, Soucy P, Southey M, Steinemann D, Swerdlow A, Szabo CI, Tchatchou S, Teixeira MR, Teo SH, Terry MB, Tessier DC, Teulé A, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Tung N, Turnbull C, van den Ouweland AM, van Rensburg EJ, Ven den Berg D, Vijai J, Wang-Gohrke S, Weitzel JN, Whittemore AS, Winqvist R, Wong TY, Wu AH, Yannoukakos D, Yu JC, Pharoah PD, Hall P, Chenevix-Trench G; KConFab; AOCS Investigators, Dunning AM, Simard J, Couch FJ, Antoniou AC, Easton DF, Zheng W (2016) **Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus**. *Breast Cancer Research,* (June) 18(1):64. PMID : 27459855. [20]

290. Zhao Z, Wen W, Michailidou K, Bolla MK, Wang Q, Zhang B, Long J, Shu XO, Schmidt MK, Milne RL, García-Closas M, Chang-Claude J, Lindstrom S, Bojesen SE, Ahsan H, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Blomqvist C, Bogdanova NV, Børresen-Dale AL, Brand J, Brauch H, Brenner H, Burwinkel B, Cai Q, Casey G, Chenevix-Trench G, Couch FJ, Cox A, Cross SS, Czene K, Dörk T, Dumont M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fostira F, Gammon M, Giles GG, Guénel P, Haiman CA, Hamann U, Harrington P, Hartman M, Hooning MJ, Hopper JL, Jakubowska A, Jasmine F, John EM, Johnson N, Kabisch M, Khan S, Kibriya M, Knight JA, Kosma VM, Kriege M, Kristensen V, Le Marchand L, Lee E, Li J, Lindblom A, Lophatananon A, Luben R, Lubinski J, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, McLean C, Meijers-Heijboer H, Meindl A, Miao H, Muir K, Neuhausen SL, Nevanlinna H, Neven P, Olson JE, Perkins B, Peterlongo P, Phillips KA, Pylkäs K, Rudolph A, Santella R, Sawyer EJ, Schmutzler RK, Schoemaker M, Shah M, Shrubsole M, Southey MC, Swerdlow AJ, Toland AE, Tomlinson I, Torres D, Truong T, Ursin G, Van Der Luijt RB, Verhoef S, Wang-Gohrke S, Whittemore AS, Winqvist R, Pilar Zamora M, Zhao H, Dunning AM, Simard J, Hall P, Kraft P, Pharoah P, Hunter D, Easton DF, Zheng W (2016) **Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry**. *Cancer Causes & Control*, (May) 27(5):679-693. PMID : 27053251. [16]

291. Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, Casey G, Hunter DJ, Sellers TA, Gruber SB, Dunning AM, Michailidou K, Fachal L, Doheny K, Spurdle AB, Li Y, Xiao X, Romm J, Pugh E, Coetzee GA, Hazelett DJ, Bojesen SE, Caga-Anan C, Haiman CA, Kamal A, Luccarini C, Tessier D, Vincent D, Bacot F, Van Den Berg DJ, Nelson S, Demetriades S, Goldgar DE, Couch FJ, Forman JL, Giles GG, Conti DV, Bickeböller H, Risch A, Waldenberger M, Brüske-Hohlfeld I, Hicks BD, Ling H, McGuffog L, Lee A, Kuchenbaecker K, Soucy P, Manz J, Cunningham JM, Butterbach K, Kote-Jarai Z, Kraft P, FitzGerald L, Lindström S, Adams M, McKay JD, Phelan CM, Benlloch S, Kelemen LE, Brennan P, Riggan M, O'Mara TA, Shen H, Shi Y, Thompson DJ, Goodman MT, Nielsen SF, Berchuck A, Laboissière S, Schmit SL, Shelford T, Edlund CK, Taylor JA, Field JK, Park SK, Offit K, Thomassen M, Schmutzler R, Ottini L, Hung RJ, Marchini J, Al Olama AA, Peters U, Eeles RA, Seldin MF, Gillanders E, Seminara D, Antoniou AC, Pharoah PDP, Chenevix-Trench G, Chanock SJ, Simard J, Easton DF (2017) **The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers**. *Cancer Epidemiology, Biomarkers & Prevention*. (Jan) 26(1):126-135. PubMed PMID: 27697780. [180]

292. Dalpé G, Ngueng Feze I, Salman S, Joly Y, Hagan J, Lévesque E, Dorval V, Blouin-Bougie J, Amara N, Dorval M, Simard J (2017) **Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers.** *Frontiers in Genetics* (Sept) 8:128. doi: 10.3389/fgene.2017.00128. eCollection 2017. [7]

293. Gravel A, Dubuc I, Brooks-Wilson A, Aronson KJ, Simard J, Velasquez-Garcia H, Spinelli JJ, Flamand L (2017) **Inherited chromosomally-integrated human herpesvirus 6 and breast cancer**. *Cancer Epidemiology Biomarkers & Prevention*, (Mar) 26(3):425-427. doi: 10.1158/1055-9965.EPI-16-0735. PMID: 27777240. [4]

294. Guedaoura S, Pelletier S, Foulkes WD, Hamet P, Simard J, Wong N, El Haffaf Z, Chiquette J, Dorval M. (2017) **No evidence of excessive cancer screening in female non-carriers from *BRCA1/2* mutation-positive families.** *Current Oncology*, (Dec) 24: 352–359. doi: 10.3747/co.24.3759. PMID: 29270046. [1]

295. Hamdi Y, Soucy P, Kuchenbacker KB, Pastinen T, Droit A, Lemaçon A, Adlard J, Aittomäki K, Andrulis IL, Arason A, Arnold N, Arun BK, Azzollini J, Bane A, Barjhoux L, Barrowdale D, Benitez J, Berthet P, Blok MJ, Bobolis K, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caligo MA, Chiquette J, Chung WK, Claes KBM, Daly MB, Damiola F, Davidson R, De la Hoya M, De Leeneer K, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Eccles D, Eeles R, Einbeigi Z, Ejlertsen B, EMBRACE, Engel C, Evans DG, Feliubadalo L, Foretova L, Fostira F, Foulkes WD, Fountzilas G, Friedman E, Frost D, Ganschow P, Ganz PA, Garber J, Gayther SA, GEMO Study Collaborators, Gerdes A-M, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gronwald J, Hahnen E, Hamann U, Hansen TVO, Hart S, Hays JL, HEBON, Hogervorst FBL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, James P, Janavicius R, Birk Jensen U, John EM, Joseph V, Just W, Kaczmarek K, Karlan BY, KConFab Investigators, Kets CM, Kirk J, Kriege M, Laitman Y, Laurent M, Lazaro C, Leslie G, Lester J, Lesueur F, Liljegren A, Loman N, Loud JT, Manoukian S, Mariani M, Mazoyer S, McGuffog L, Meijers-Heijboer HEJ,

Meindl A, Miller A, Montagna M, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nussbaum RL, Olah E, Olopade OI, Ong K-R, Oosterwijk JC, Osorio A, Papi L, Park SK, Sokilde Pedersen I, Peissel B, Perez Segura P, Peterlongo P, Phelan CM, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Richardson A, Robson M, Rodriguez GC, Rookus MA, Schmutzler RK, Sevenet N, Shah PD, Singer CF, Slavin TP, Snape K, Sokolowska J, Heeholm Sønderstrup IM, Southey M, Spurdle AB, Stadler Z, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Tan Y, Tea M-K, Teixeira MR, Teulé A, Teo S-H, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Tognazzo S, Ewart Toland A, Tung N, van den Ouweland AMW, van der Luijt RB, van Engelen K, van Rensburg EJ, Varon-Mateeva R, Wappenschmidt B, Wijnen JT, Rebbeck T, Chenevix-Trench G, Offit K, Couch FJ, Nord S, Easton DF, Antoniou AC, Simard J (2017) **Association of breast cancer risk in *BRCA1* and *BRCA2* mutation carriers with genetic variants showing differential allelic expression: Identification of a modifier of breast cancer risk at locus 11q22.3.** *Breast Cancer Research and Treatment*, (Jan) 161(1):117-134. PMID : 27796716. [14]

296. Kuchenbaecker K, McGuffog L, Barrowdale D, Lee A, Soucy P, Healy S, Dennis J, Lush M, Robson M, Spurdle AB, Ramus SJ, Mavaddat N, Terry MB, Neuhausen SL, Hamann U, Southey M, John, EM, Chung WK, Daly MB, Buys SS, Goldgar DE, Dorfling CM, van Rensburg EJ, Ding YC, Ejlertsen B, Gerdes A-M, V. O. Hansen T, Slager S, Hallberg E, Benitez J, Osorio A, Cohen N, Lawler W, Weitzel JN, Peterlongo P, Pensotti V, Dolcetti R, Barile M, Bonanni B, Azzollini J, Manoukian S, Peissel B, Radice P, Savarese A, Papi L, Giannini G, Fostira F, Konstantopoulou I, Adlard J, Brewer C, Cook J, Davidson R, Eccles D, Eeles R, Ellis S, EMBRACE, Frost D, Hodgson S, Izatt L, Lalloo F, Ong K, Godwin AK, Arnold N, Dworniczak B, Engel C, Gehrig A, Hahnen E, Hauke J, Kast K, Meindl A, Niederacher D, Schmutzler RK, Varon-Mateeva R, Wang-Gohrke S, Wappenschmidt B, Barjhoux L, Collonge-Rame M-A, Elan C, GEMO Study Collaborators, Golmard L, Barouk-Simonet E, Lesueur F, Mazoyer S, Sokolowska J, Stoppa-Lyonnet D, Isaacs C, Claes K.B.M., Poppe B, de la Hoya M, Garcia-Barberan V, Aittomäki K, Nevanlinna H, Ausems M.G.E.M., de Lange JL., Gómez Garcia EB, HEBON, Hogervorst FBL., Kets C.M., Meijers- Heijboer HEJ, Oosterwijk JC, Rookus MA, van Asperen CJ, van den Ouweland AMW, van Doorn HC, van Os TAM, Kwong A, Olah E, Diez O, Brunet J, Lazaro C, Teulé A, Gronwald J, Jakubowska A, Kaczmarek K, Lubinski J, Sukiennicki G, Barkardottir RB, Chiquette J, Agata S, Montagna M, Teixeira MR, KConFab Investigators, Park SK, Olswold C, Tischkowitz M, Foretova L, Gaddam P, Vijai J, Pfeiler G, Rappaport-Fuerhauser C, Singer CF, Tea MKM, Greene MH, Loud JT, Rennert G, Imyanitov EN, Hulick PJ, Hays JL, Piedmonte M, Rodriguez GC, Martyn J, Glendon G, Mulligan AM, Andrulis IL, Toland AE, Jensen UB, Kruse TA, Pedersen IS, Thomassen M, Caligo MA, Teo S-H, Berger R, Friedman E, Laitman Y, Arver B, Borg A, Ehrencrona H, Rantala J, Olopade OI, Ganz PA, Nussbaum RL, Bradbury AR, Domchek SM, Nathanson KL, Arun BK, James P, Karlan BY, Lester J, Simard J, Pharoah PDP, Offit K, Couch FJ, Chenevix-Trench G, Easton DF, Antoniou AC (2017) **Evaluation of polygenic risk scores for breast and ovarian cancer risk prediction in *BRCA1* and *BRCA2* mutation carriers**. *Journal of the National Cancer Institute* 109(7): djw302. doi:10.1093/jnci/djw302. PMID: 28376175. [124]

297. Larouche G, Chiquette J, Pelletier S, Simard J, Dorval M (2017) **Do women change their breast cancer mammogram screening behaviour after *BRCA1/2* testing?** *Familial Cancer*, (Jan) 16(1):35-40. PMID: 27554086. [4]

298. Lecarpentier J, Silvestri V, Kuchenbaecker KB, Barrowdale D, Dennis J, McGuffog L, Soucy P, Leslie G, Rizzolo P, Navazio AS, Valentini V, Zelli V, Lee A, Amin Al Olama A, Tyrer JP, Southey M, John EM, Conner TA, Goldgar DE, Buys SS, Janavicius R, Steele L, Ding YC, Neuhausen SL, Hansen TVO, Osorio A, Weitzel JN, Toss A, Medici V, Cortesi L, Zanna I, Palli D, Radice P, Manoukian S, Peissel B, Azzollini J, Viel A, Cini G, Damante G, Tommasi S, Peterlongo P, Fostira F, Hamann U, Evans DG, Henderson A, Brewer C, Eccles D, Cook J, Ong KR, Walker L, Side LE, Porteous ME, Davidson R, Hodgson S, Frost D, Adlard J, Izatt L, Eeles R, Ellis S, Tischkowitz M; EMBRACE., Godwin AK, Meindl A, Gehrig A, Dworniczak B, Sutter C, Engel C, Niederacher D, Steinemann D, Hahnen E, Hauke J, Rhiem K, Kast K, Arnold N, Ditsch N, Wang-Gohrke S, Wappenschmidt B, Wand D, Lasset C, Stoppa-Lyonnet D, Belotti M, Damiola F, Barjhoux L, Mazoyer S; GEMO Study Collaborators, Van Heetvelde M, Poppe B, De Leeneer K, Claes KBM, de la Hoya M, Garcia-Barberan V, Caldes T, Perez Segura P, Kiiski JI, Aittomäki K, Khan S, Nevanlinna H, van Asperen CJ; HEBON., Vaszko T, Kasler M, Olah E, Balmaña J, Gutiérrez-Enríquez S, Diez O, Teulé A, Izquierdo A, Darder E, Brunet J, Del Valle J, Feliubadalo L, Pujana MA, Lazaro C, Arason A, Agnarsson BA, Johannsson OT, Barkardottir RB, Alducci E, Tognazzo S, Montagna M, Teixeira

MR, Pinto P, Spurdle AB, Holland H; KConFab Investigators., Lee JW, Lee MH, Lee J, Kim SW, Kang E, Kim Z, Sharma P, Rebbeck TR, Vijai J, Robson M, Lincoln A, Musinsky J, Gaddam P, Tan YY, Berger A, Singer CF, Loud JT, Greene MH, Mulligan AM, Glendon G, Andrulis IL, Toland AE, Senter L, Bojesen A, Nielsen HR, Skytte AB, Sunde L, Jensen UB, Pedersen IS, Krogh L, Kruse TA, Caligo MA, Yoon SY, Teo SH, von Wachenfeldt A, Huo D, Nielsen SM, Olopade OI, Nathanson KL, Domchek SM, Lorenchick C, Jankowitz RC, Campbell I, James P, Mitchell G, Orr N, Park SK, Thomassen M, Offit K, Couch FJ, Simard J, Easton DF, Chenevix-Trench G, Schmutzler RK, Antoniou AC, Ottini L (2017) **Prediction of Breast and Prostate Cancer Risks in Male *BRCA1* and *BRCA2* Mutation Carriers Using Polygenic Risk Scores.** *Journal of Clinical Oncology* 35(20):2240-2250. doi: 10.1200/JCO.2016.69.4935. [83]

299. Lemaçon A, Joly-Beauparlant C, Soucy P, Allen J, Douglas E, Kraft P, Simard J, Droit A (2017) **VEXOR: an integrative environment for prioritization of functional variants in fine-mapping analysis**. *Bioinformatics* (May) 33(9):1389-1391. Doi : 10.1093 / bioinformatics / btw826. PMID: 28172431. [2]

300. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, Lemaçon A, Soucy P, Glubb D, Rostamianfar A, Bolla MK, Wang Q, Tyrer J, Dicks E, Lee A, Wang Z, Allen J, Keeman R, Eilber U, French JD, Qing Chen X, Fachal L, McCue K, McCart Reed AE, Ghoussaini M, Carroll JS, Jiang X, Finucane H, Adams M, Adank MA, Ahsan H, Aittomäki K, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Arun B, Auer PL, Bacot F, Barrdahl M, Baynes C, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børresen-Dale AL, Brand JS, Brauch H, Brennan P, Brenner H, Brinton L, Broberg P, Brock IW, Broeks A, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Butterbach K, Cai Q, Cai H, Caldés T, Canzian F, Carracedo A, Carter BD, Castelao JE, Chan TL, David Cheng TY, Seng Chia K, Choi JY, Christiansen H, Clarke CL; NBCS Collaborators, Collée M, Conroy DM, Cordina-Duverger E, Cornelissen S, Cox DG, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, Dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Elvira M, Engel C, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gaborieau V, Gabrielson M, Gago-Dominguez M, Gao YT, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnæs GI, Grip M, Gronwald J, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hamel N, Hankinson S, Harrington P, Hart SN, Hartikainen JM, Hartman M, Hein A, Heyworth J, Hicks B, Hillemanns P, Ho DN, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Hou MF, Hsiung CN, Huang G, Humphreys K, Ishiguro J, Ito H, Iwasaki M, Iwata H, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kasuga Y, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Kosma VM, Kristensen VN, Krüger U, Kwong A, Lambrechts D, Le Marchand L, Lee E, Lee MH, Lee JW, Neng Lee C, Lejbkowicz F, Li J, Lilyquist J, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Lophatananon A, Lubinski J, Luccarini C, Lux MP, Ma ESK, MacInnis RJ, Maishman T, Makalic E, Malone KE, Kostovska IM, Mannermaa A, Manoukian S, Manson JE, Margolin S, Mariapun S, Martinez ME, Matsuo K, Mavroudis D, McKay J, McLean C, Meijers-Heijboer H, Meindl A, Menéndez P, Menon U, Meyer J, Miao H, Miller N, Taib NAM, Muir K, Mulligan AM, Mulot C, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Noh DY, Nordestgaard BG, Norman A, Olopade OI, Olson JE, Olsson H, Olswold C, Orr N, Pankratz VS, Park SK, Park-Simon TW, Lloyd R, Perez JIA, Peterlongo P, Peto J, Phillips KA, Pinchev M, Plaseska-Karanfilska D, Prentice R, Presneau N, Prokofyeva D, Pugh E, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Ruddy KJ, Rüdiger T, Rudolph A, Ruebner M, Rutgers EJT, Saloustros E, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Scott RJ, Scott C, Seal S, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng G, Sherman ME, Shrubsole MJ, Shu XO, Smeets A, Sohn C, Southey MC, Spinelli JJ, Stegmaier C, Stewart-Brown S, Stone J, Stram DO, Surowy H, Swerdlow A, Tamimi R, Taylor JA, Tengström M, Teo SH, Beth Terry M, Tessier DC, Thanasitthichai S, Thöne K, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Truong T, Tseng CC, Tsugane S, Ulmer HU, Ursin G, Untch M, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van der Kolk L, van der Luijt RB, Vincent D, Vollenweider J, Waisfisz Q, Wang-Gohrke S, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yamaji T, Yang XR, Har Yip C, Yoo KY, Yu JC, Zheng W, Zheng Y, Zhu B, Ziogas A, Ziv E; ABCTB Investigators; ConFab/AOCS Investigators, Lakhani SR, Antoniou AC, Droit A, Andrulis IL, Amos CI,

Couch FJ, Pharoah PDP, Chang-Claude J, Hall P, Hunter DJ, Milne RL, García-Closas M, Schmidt MK, Chanock SJ, Dunning AM, Edwards SL, Bader GD, Chenevix-Trench G, Simard J*, Kraft P*, Easton DF* (2017) **Association analysis identifies 65 new breast cancer risk loci.** *Nature* (Nov) 551(7678): 92-94. doi: 10.1038/nature24284. PMID: 29059683. *jointly supervised this work . [572]

301. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Dennis J, Jiang X, Rostamianfar A, Finucane H, Bolla MK, McGuffog L, Wang Q, Aalfs CM; ABCTB Investigators, Adams M, Adlard J, Agata S, Ahmed S, Ahsan H, Aittomäki K, Al-Ejeh F, Allen J, Ambrosone CB, Amos CI, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Auber B, Auer PL, Ausems MGEM, Azzollini J, Bacot F, Balmaña J, Barile M, Barjhoux L, Barkardottir RB, Barrdahl M, Barnes D, Barrowdale D, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Bernstein L, Bignon YJ, Blazer KR, Blok MJ, Blomqvist C, Blot W, Bobolis K, Boeckx B, Bogdanova NV, Bojesen A, Bojesen SE, Bonanni B, Børresen-Dale AL, Bozsik A, Bradbury AR, Brand JS, Brauch H, Brenner H, Bressac-de Paillerets B, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Brunet J, Brüning T, Burwinkel B, Buys SS, Byun J, Cai Q, Caldés T, Caligo MA, Campbell I, Canzian F, Caron O, Carracedo A, Carter BD, Castelao JE, Castera L, Caux-Moncoutier V, Chan SB, Chang-Claude J, Chanock SJ, Chen X, Cheng TD, Chiquette J, Christiansen H, Claes KBM, Clarke CL, Conner T, Conroy DM, Cook J, Cordina-Duverger E, Cornelissen S, Coupier I, Cox A, Cox DG, Cross SS, Cuk K, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, Davidson R, De Leeneer K, Devilee P, Dicks E, Diez O, Ding YC, Ditsch N, Doheny KF, Domchek SM, Dorfling CM, Dörk T, Dos-Santos-Silva I, Dubois S, Dugué PA, Dumont M, Dunning AM, Durcan L, Dwek M, Dworniczak B, Eccles D, Eeles R, Ehrencrona H, Eilber U, Ejlertsen B, Ekici AB, Eliassen AH; EMBRACE, Engel C, Eriksson M, Fachal L, Faivre L, Fasching PA, Faust U, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gaddam P, Gammon MD, Ganz PA, Gapstur SM, Garber J, Garcia-Barberan V, García-Sáenz JA, Gaudet MM, Gauthier-Villars M, Gehrig A; GEMO Study Collaborators, Georgoulias V, Gerdes AM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Goodfellow P, Greene MH, Alnæs GIG, Grip M, Gronwald J, Grundy A, Gschwantler-Kaulich D, Guénel P, Guo Q, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hallberg E, Hamann U, Hamel N, Hankinson S, Hansen TVO, Harrington P, Hart SN, Hartikainen JM, Healey CS; HEBON, Hein A, Helbig S, Henderson A, Heyworth J, Hicks B, Hillemanns P, Hodgson S, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover B, Hopper JL, Hu C, Huang G, Hulick PJ, Humphreys K, Hunter DJ, Imyanitov EN, Isaacs C, Iwasaki M, Izatt L, Jakubowska A, James P, Janavicius R, Janni W, Jensen UB, John EM, Johnson N, Jones K, Jones M, Jukkola-Vuorinen A, Kaaks R, Kabisch M, Kaczmarek K, Kang D, Kast K; kConFab/AOCS Investigators, Keeman R, Kerin MJ, Kets CM, Keupers M, Khan S, Khusnutdinova E, Kiiski JI, Kim SW, Knight JA, Konstantopoulou I, Kosma VM, Kristensen VN, Kruse TA, Kwong A, Lænkholm AV, Laitman Y, Lalloo F, Lambrechts D, Landsman K, Lasset C, Lazaro C, Le Marchand L, Lecarpentier J, Lee A, Lee E, Lee JW, Lee MH, Lejbkowicz F, Lesueur F, Li J, Lilyquist J, Lincoln A, Lindblom A, Lissowska J, Lo WY, Loibl S, Long J, Loud JT, Lubinski J, Luccarini C, Lush M, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Malone KE, Manoukian S, Manson JE, Margolin S, Martens JWM, Martinez ME, Matsuo K, Mavroudis D, Mazoyer S, McLean C, Meijers-Heijboer H, Menéndez P, Meyer J, Miao H, Miller A, Miller N, Mitchell G, Montagna M, Muir K, Mulligan AM, Mulot C, Nadesan S, Nathanson KL; NBSC Collaborators, Neuhausen SL, Nevanlinna H, Nevelsteen I, Niederacher D, Nielsen SF, Nordestgaard BG, Norman A, Nussbaum RL, Olah E, Olopade OI, Olson JE, Olswold C, Ong KR, Oosterwijk JC, Orr N, Osorio A, Pankratz VS, Papi L, Park-Simon TW, Paulsson-Karlsson Y, Lloyd R, Pedersen IS, Peissel B, Peixoto A, Perez JIA, Peterlongo P, Peto J, Pfeiler G, Phelan CM, Pinchev M, Plaseska-Karanfilska D, Poppe B, Porteous ME, Prentice R, Presneau N, Prokofieva D, Pugh E, Pujana MA, Pylkäs K, Rack B, Radice P, Rahman N, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rennert HS, Rhenius V, Rhiem K, Richardson A, Rodriguez GC, Romero A, Romm J, Rookus MA, Rudolph A, Ruediger T, Saloustros E, Sanders J, Sandler DP, Sangrajrang S, Sawyer EJ, Schmidt DF, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seal S, Senter L, Seynaeve C, Shah M, Sharma P, Shen CY, Sheng X, Shimelis H, Shrubsole MJ, Shu XO, Side LE, Singer CF, Sohn C, Southey MC, Spinelli JJ, Spurdle AB, Stegmaier C, Stoppa-Lyonnet D, Sukiennicki G, Surowy H, Sutter C, Swerdlow A, Szabo CI, Tamimi RM, Tan YY, Taylor JA, Tejada MI, Tengström M, Teo SH, Terry MB, Tessier DC, Teulé A, Thöne K, Thull DL, Tibiletti MG, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Tong L, Torres D, Tranchant M, Truong T, Tucker K, Tung N, Tyrer J, Ulmer HU, Vachon C, van Asperen CJ, Van Den Berg D, van den Ouweland AMW, van

Rensburg EJ, Varesco L, Varon-Mateeva R, Vega A, Viel A, Vijai J, Vincent D, Vollenweider J, Walker L, Wang Z, Wang-Gohrke S, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wesseling J, Whittemore AS, Wijnen JT, Willett W, Winqvist R, Wolk A, Wu AH, Xia L, Yang XR, Yannoukakos D, Zaffaroni D, Zheng W, Zhu B, Ziogas A, Ziv E, Zorn KK, Gago-Dominguez M, Mannermaa A, Olsson H, Teixeira MR, Stone J, Offit K, Ottini L, Park SK, Thomassen M, Hall P, Meindl A, Schmutzler RK, Droit A, Bader GD*, Pharoah PDP*, Couch FJ*, Easton DF*, Kraft P*, Chenevix-Trench G*, García-Closas M*, Schmidt MK*, Antoniou AC*, Simard J* (2017) **Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer.** *Nature Genetics* (Dec.); 49(12):1767-1778. doi: 10.1038/ng.3785. *jointly supervised this work. [160]

302. Nabi H, Dorval M, Chiquette J, Simard J (2017) **Increased use of BRCA mutation test in unaffected women over the period 2004-2014 in the US: Further evidence of the "Angelina Jolie Effect?** *American Journal of Preventive Medicine* (Nov); 53(5): e195–e196. Doi: 10.1016/j.amepre.2017.05.016. [4]

303. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, Dennis J, Pirie A, Riggan MJ, Chornokur G, Earp MA, Lyra PC Jr, Lee JM, Coetzee S, Beesley J, McGuffog L, Soucy P, Dicks E, Lee A, Barrowdale D, Lecarpentier J, Leslie G, Aalfs CM, Aben KK, Adams M, Adlard J, Andrulis IL, Anton-Culver H, Antonenkova N, AOCS study group, Aravantinos G, Arnold N, Arun BK, Arver B, Azzollini J, Balmaña J, Banerjee SN, Barjhoux L, Barkardottir RB, Bean Y, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bermisheva M, Bernardini MQ, Birrer MJ, Bjorge L, Black A, Blankstein K, Blok MJ, Bodelon C, Bogdanova N, Bojesen A, Bonanni B, Borg Å, Bradbury AR, Brenton JD, Brewer C, Brinton L, Broberg P, Brooks-Wilson A, Bruinsma F, Brunet J, Buecher B, Butzow R, Buys SS, Caldes T, Caligo MA, Campbell I, Cannioto R, Carney ME, Cescon T, Chan SB, Chang-Claude J, Chanock S, Chen XQ, Chiew YE, Chiquette J, Chung WK, Claes KB, Conner T, Cook LS, Cook J, Cramer DW, Cunningham JM, D'Aloisio AA, Daly MB, Damiola F, Damirovna SD, Dansonka-Mieszkowska A, Dao F, Davidson R, DeFazio A, Delnatte C, Doheny KF, Diez O, Ding YC, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dossus L, Duran M, Dürst M, Dworniczak B, Eccles D, Edwards T, Eeles R, Eilber U, Ejlertsen B, Ekici AB, Ellis S, Elvira M, EMBRACE Study, Eng KH, Engel C, Evans DG, Fasching PA, Ferguson S, Ferrer SF, Flanagan JM, Fogarty ZC, Fortner RT, Fostira F, Foulkes WD, Fountzilas G, Fridley BL, Friebel TM, Friedman E, Frost D, Ganz PA, Garber J, García MJ, Garcia-Barberan V, Gehrig A, GEMO Study Collaborators, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goldgar DE, Goranova T, Gore M, Greene MH, Gronwald J, Gruber S, Hahnen E, Haiman CA, Håkansson N, Hamann U, Hansen TV, Harrington PA, Harris HR, Hauke J; HEBON Study., Hein A, Henderson A, Hildebrandt MA, Hillemanns P, Hodgson S, Høgdall CK, Høgdall E, Hogervorst FB, Holland H, Hooning MJ, Hosking K, Huang RY, Hulick PJ, Hung J, Hunter DJ, Huntsman DG, Huzarski T, Imyanitov EN, Isaacs C, Iversen ES, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jernetz M, Jensen A, Jensen UB, John EM, Johnatty S, Jones ME, Kannisto P, Karlan BY, Karnezis A, Kast K; KConFab Investigators., Kennedy CJ, Khusnutdinova E, Kiemeney LA, Kiiski JI, Kim SW, Kjaer SK, Köbel M, Kopperud RK, Kruse TA, Kupryjanczyk J, Kwong A, Laitman Y, Lambrechts D, Larrañaga N, Larson MC, Lazaro C, Le ND, Le Marchand L, Lee JW, Lele SB, Leminen A, Leroux D, Lester J, Lesueur F, Levine DA, Liang D, Liebrich C, Lilyquist J, Lipworth L, Lissowska J, Lu KH, Lubiński J, Luccarini C, Lundvall L, Mai PL, Mendoza-Fandiño G, Manoukian S, Massuger LF, May T, Mazoyer S, McAlpine JN, McGuire V, McLaughlin JR, McNeish I, Meijers-Heijboer H, Meindl A, Menon U, Mensenkamp AR, Merritt MA, Milne RL, Mitchell G, Modugno F, Moes-Sosnowska J, Moffitt M, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Nathanson KL, Nedergaard L, Ness RB, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Odunsi K, Olah E, Olopade OI, Olsson H, Olswold C, O'Malley DM, Ong KR, Onland-Moret NC; OPAL study group., Orr N, Orsulic S, Osorio A, Palli D, Papi L, Park-Simon TW, Paul J, Pearce CL, Pedersen IS, Peeters PH, Peissel B, Peixoto A, Pejovic T, Pelttari LM, Permuth JB, Peterlongo P, Pezzani L, Pfeiler G, Phillips KA, Piedmonte M, Pike MC, Piskorz AM, Poblete SR, Pocza T, Poole EM, Poppe B, Porteous ME, Prieur F, Prokofyeva D, Pugh E, Pujana MA, Pujol P, Radice P, Rantala J, Rappaport-Fuerhauser C, Rennert G, Rhiem K, Rice P, Richardson A, Robson M, Rodriguez GC, Rodríguez-Antona C, Romm J, Rookus MA, Rossing MA, Rothstein JH, Rudolph A, Runnebaum IB, Salvesen HB, Sandler DP, Schoemaker MJ, Senter L, Setiawan VW, Severi G, Sharma P, Shelford T, Siddiqui N, Side LE, Sieh W, Singer CF, Sobol H, Song H, Southey MC, Spurdle AB, Stadler Z, Steinemann D, Stoppa-Lyonnet D, Sucheston-Campbell LE, Sukiennicki G, Sutphen R, Sutter C, Swerdlow AJ, Szabo CI, Szafron L, Tan YY, Taylor JA, Tea MK, Teixeira MR, Teo SH, Terry KL, Thompson PJ, Thomsen LC,

Thull DL, Tihomirova L, Tinker AV, Tischkowitz M, Tognazzo S, Toland AE, Tone A, Trabert B, Travis RC, Trichopoulou A, Tung N, Tworoger SS, van Altena AM, Van Den Berg D, van der Hout AH, van der Luijt RB, Van Heetvelde M, Van Nieuwenhuysen E, van Rensburg EJ, Vanderstichele A, Varon-Mateeva R, Vega A, Edwards DV, Vergote I, Vierkant RA, Vijai J, Vratimos A, Walker L, Walsh C, Wand D, Wang-Gohrke S, Wappenschmidt B, Webb PM, Weinberg CR, Weitzel JN, Wentzensen N, Whittemore AS, Wijnen JT, Wilkens LR, Wolk A, Woo M, Wu X, Wu AH, Yang H, Yannoukakos D, Ziogas A, Zorn KK, Narod SA, Easton DF, Amos CI, Schildkraut JM, Ramus SJ, Ottini L, Goodman MT, Park SK, Kelemen LE, Risch HA, Thomassen M, Offit K, Simard J, Schmutzler RK, Hazelett D, Monteiro AN, Couch FJ, Berchuck A, Chenevix-Trench G, Goode EL, Sellers TA, Gayther SA, Antoniou AC, Pharoah PD. (2017) **Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.** *Nature Genetics,* (May) 49(5):680-691. doi: 10.1038/ng.3826. PMID: 28346442. [157]

304. Pouliot M-C, Kothari C, Joly-Beauparlant C, Labrie Y, Ouellette G, Simard J, Droit A, Durocher F (2017) **Transcriptional Signature of lymphoblastoid cell lines of *BRCA1, BRCA2* and non-*BRCA1/2* High Risk Breast Cancer Families.** *Oncotarget,* (Aug) 12;8 (45) : 78691-78712. doi : 10.18632/oncotarget.20219. [6]

305. Amara N, Blouin-Bougie J, Bouthillier D, Simard J (2018) **On the readiness of physicians for pharmacogenomics testing: an empirical assessment**. *The Pharmacogenomics Journal.* 2018 April;18(2):308-318. doi:10.1038/tpj.2017.22. [15]

306. Blouin-Bougie J, Amara N, Bouchard K, Simard J, Dorval M (2018) **Disentangling the determinants of interest and willingness to pay for breast cancer susceptibility testing in the general population: A cross-sectional Web-based survey among women of Québec (Canada)**. *BMJ Open*. (Feb) 27;8(2):e016662. doi: 10.1136/bmjopen-2017-016662.

307. Li J, Ugalde Morales E, Xiong Wen W, Decker B, Eriksson M, Torstensson A, Nordahl Christensen H, Dunning AM, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo S-H, Hall P, Czene K (2018) **Differential burden of rare and common variants on breast cancer tumor characteristics, survival and mode of detection.** *Cancer Research*, (Nov)1;78(21):6329-6338. doi: 10,1158/008-5472.CAN-18-1018. [9]

308. Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, Lee DS, Lee SY, Yoon SY, Lim J, Lau SY, Decker B, Pooley K, Dorling L, Luccarini C, Baynes C, Conroy DM, Harrington P, Simard J, Yip CH, Mohd Taib NA, Ho WK, Antoniou AC, Dunning AM, Easton DF, Teo SH. (2018) **Inherited mutations in *BRCA1* and *BRCA2* in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia.** *Journal of Medical Genetics* (Feb) 55 (2):97-103. doi: 10.1136/jmedgenet-2017-104947. [13]

309. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, Bolla MK, Shu X-O, Lu Y, Cai Q, Al-Ejeh F, Rozali E, Wang Q, Dennis J, Li B, Zeng C, Feng H, Gusev A, Barfield RT, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Auer PL, Barrdahl M, Baynes C, Beckmann MW, Benitez J, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Brinton L, Broberg P, Brucker SY, Burwinkel B, Caldés T, Canzian F, Carter BD, Castelao JE, Chang-Claude J, Chen X, Cheng T-YD, Christiansen H, Clarke CL, NBCS Collaborators, Collée M, Cornelissen S, Couch FJ, Cox D, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Devilee P, Doheny KF, Dörk T, dos-Santos-Silva I, Dumont M, Dwek M, Eccles DM, Eilber U, Eliassen AH, Engel C, Eriksson M, Fachal L, Fasching PA, Figueroa J, Flesch-Janys D, Fletcher O, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Closas M, Gaudet MM, Ghoussaini M, Giles G, Goldberg MS, Goldgar DE, González-Neira A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hallberg E, Hamann U, Harrington P, Hein A, Hicks B, Hillemanns P, Hollestelle A, Hoover RN, Hopper JL, Huang G, Humphreys K, Hunter DJ, Jakubowska A, Janni W, John EM, Johnson N, Jones K, Jones ME, Jung A, Kaaks R, Kerin MJ, Khusnutdinova E, Kosma V-M, Kristensen VN, Lambrechts D, Le Marchand L, Li J, Lindström S, Lissowska J, Lo W-Y, Loibl S, Lubinski J, Luccarini C, Lux MP, MacInnis RJ, Maishman T, Kostovska IM, Mannermaa A, Manson JE, Margolin S, Mavroudis D, Meijers-Heijboer H, Meindl A, Menon U, Meyer J, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Nielsen SF, Nordestgaard BG, Olopade OI, Olson JE, Olsson H, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prentice R, Presneau N, Pylkäs K, Rack B, Radice P, Rahman N, Rennert G, Rennert HS, Rhenius V, Romero A, Romm J, Rudolph A, Saloustros E, Sandler DP, Sawyer EJ, Schmidt

MK, Schmutzler RK, Schneeweiss A, Scott RJ, Scott C, Seal S, Shah M, Shrubsole MJ, Smeets A, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper W, Taylor JA, Terry MB, Tessier DC, Thomas A, Thöne K, Tollenaar REAM, Torres D, Truong T, Untch M, Vachon C, Van Den Berg D, Vincent D, Waisfisz Q, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett WC, Winqvist R, Wolk A, Xia L, Yang XR, Ziogas A, Ziv E, kConFab/AOCS Investigators, Dunning AM, Pharoah PDP, Simard J, Milne RL, Edwards SL, Kraft P, Easton DF, Chenevix-Trench G, Zheng W (2018) **A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer.** *Nature Genetics* (July); 50 (7) : 968-978. doi: 10.1038/s41588-018-0132-x. [64]

310. Antoniou A, Anton-Culver H, Borowsky A, Broeders M, Brooks J, Chiarelli A, Chiquette J, Cuzick J, Delaloge S, Devilee P, Dorval M, Easton D, Eisen A, Eklund M, Eloy L, Esserman L, Garcia-Closas M, Goldgar D, Hall P, Knoppers BM, Kraft P, La Croix A, Madalensky L, Mavaddat N, Mittman N, Nabi H, Olopade O, Pashayan N, Schmidt M, Shieh Y, Simard J, Stover-Fiscallini A, Tice JA, Van't Veer L, Wenger N, Wolfson M, Yau C, Ziv (2019) **A response to** "**Personalised medicine and population health: breast and ovarian cancer."** *Human Genetics*. Mar;138(3):287-289. doi: 10.1007/s00439-019-01984-z. [7]

311. Boonen RACM, Rodrigue A, Stoepker C, Wiegant WW, Vroling B, Sharma M, Rother MB, Celosse N, Vreeswijk MPG, Couch F, Simard J, Devilee P, Masson JY, van Attikum H (2019) **Functional Analysis of genetic variants in the high-risk breast cancer susceptibility gene *PALB2*.** *Nature Communications.* (22 nov.) 10(1):5296. doi:10.1038/s41467-019-13194-2. [11]

312. Ducy M, Sesma-Sanz L, Guitton-Sert L, Lashgari A, Gao Y, Brahiti N, Rodrigue A, Margaillan G, Caron M-C, Côté J, Simard J, Masson J-Y (2019) **The tumor suppressor *PALB2*: Inside Out.** *Trends in Biochemical Sciences.* Mar;44(3):226-240. doi: 10.1016/j.tibs.2018.10.008. [31]

313. Esquivel-Sada D, Lévesque E, Hagan J, Knoppers BM, Simard J (2019) **Envisioning implementation of personalized approach in breast cancer screening programs: Stakeholder Perspectives.** *Healthcare Policy.* 15 (2) November 2019: 39-54. doi: 10.12927/hcpol.2019.26072.

314. Granados Moreno P, Ali-Khan SE, Capps B, Caulfield T, Chalaud D, Edwards A, Gold ER, Rahimzadeh V, Thorogood A, Auld D, Bertier G, Breden F, Caron R, César PMDG, Cook-Deegan R, Doerr M, Duncan R, Issa AM, Reichman J, Simard J, So D, Vanamala S, Joly Y (2019) **Open-Science Precision Medicine in Canada: Points to Consider.** *FACETS.* 4:1-19. doi:10.1139/facets-2018-0034.

315. Hamdi Y, Leclerc M, Dumont M, Dubois S, Tranchant M, Reimnitz G, Soucy P, Cassart P, Ouimet M, Sinnett D, Lakhal Chaieb ML, Simard J (2019) **Functional analysis of promoter variants in genes involved in sex steroid action, DNA repair and cell cycle control**. *Genes*. Feb 28;10.186; doi:10.3390/genes10030186. [1]

316. Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien AS, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Cruz Correa M, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong Y-C, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus

P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubiński J, Maehle L, Maier C, Mannermaa A, Le Marchand L, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, de Ruyck KD, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S (2019) **Shared heritability and functional enrichment across six solid cancers**. *Nature Communications*. 25 Jan;10(1):4386. doi: 10.1038/s41467-019-12095-8. [28]

317. Kar SP, Andrulis IL, Brenner H, Burgess S, Chang-Claude J, Considine D, Dörk T, Evans GR, Gago-Domínguez M, Giles GG, Hartman, M, Huo D, Kaaks R, Li J, Lophatananon A, Margolin S, Milne RL, Muir KR, Olsson H, Punie K, Radice P, Simard J, Tamimi RM, Van Nieuwenhuysen E, Wendt C, Zheng W, Pharoah PDP (2019) **The Association between weight at birth and breast cancer risk revisited using Mendelian randomisation.** *European Journal of Epidemiology.* June;34 (6); 591-600. doi: 10.1007/s10654-019-00485-7. [9]

318. Kar SP, Brenner H, Giles GG, Huo D, Milne RL, Rennert G, Simard J, Zheng W, Burgess S, Pharoah PDP (2019) **Body mass index and the association between low-density lipoprotein cholesterol as predicted by *HMGCR* genetic variants and breast cancer.** *International Journal of Epidemiology.* 1 Oct.;48(5):1727-1730. doi: 10.1093/ije/dyz047.

319. Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S, Babb de Villiers C, Izquierdo A, Simard J, Schmidt MK, Walter FM, Chatterjee N, Garcia-Closas M, Tischkowitz M, Pharoah P, Easton DF, Antoniou AC (2019) **BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and non-genetic risk factors**. *Genetics in Medicine*. 2019 Aug;21(8):1708-1718. doi : 10.1038/s41436-018-0406-9. [96]

320. Lévesque E, Hagan J, Knoppers BM, Simard J (2019) **Organizational challenges to equity in the delivery of services within a new personalized risk-based approach to breast cancer screening.** *New Genetics and Society.* Vol. 38: No. 1, 38-59, doi: 10.1080/14636778.2018.1549477. [4]

321. Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, Torstensson A, Bajalica-Lagercrantz S, Dunning AM, Decker B, Allen J, Luccarini C, Pooley K, Simard J, Dorling L, Easton DF, Teo S-H, Hall P, Borg A, Grönberg H, Czene K (2019) **Prevalence of *BRCA1* and *BRCA2* pathogenic variants in a large, unselected breast cancer cohort**. *International Journal of Cancer*. 1 March;144(5):1195-1204. doi: 10.1002/ijc.31841. [16]

322. Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, Chen TH, Wang Q, Bolla MK, Yang X, Adank MA, Ahearn T, Aittomäki K, Allen J, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Auer PL, Auvinen P, Barrdahl M, Beane Freeman LE, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Børrensen-Dale AL, Brauch H, Bremer M, Brenner H, Brentnall A, Brock IW, Brooks-Wilson A, Brucker SY, Brüning T, Burwinkel B, Campa D, Carter BD, Castelao JE, Chanock SJ, Chlebowski R, Christiansen H, Clarke CL, Collée M, Cordina-Duverger E, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P,

Dörk T, dos-Santos-Silva I, Dumont M, Durcan L, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Engel C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Fletcher O, Flyger H, Försti A, Fritschi L, Gabrielson M, Gago-Dominguez M, Gapstur SM, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Gilyazova IR, Glendon G, Goldberg MS, Goldgar DE, González-Neira A, Grenaker Alnaes GI, Grip M, Grundy A, Guénel P, Haeberle L, Hahnen E, Haiman CA, Häkansson N, Hamann U, Hankinson SE, Harkness EF, Hart SN, He W, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huang G, Humphreys K, Hunter DJ, Jakimovska M, Jakubowska A, Janni W, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kaczmarek K, Kataja V, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Knight JA, Ko Y-D, Kosma V-M, Koutros S, Kristensen VN, Krüger U, Kühl T, Lambrechts K, Le Marchard L, Lee E, Lejbkowicz F, Lilyquist J, Lindblom A, Lindström S, Lissowska J, Lo W-Y, Loibl S, Long J, Lubinski J, Lux MP, MacInnis RJ, Maishman T, Makalic E, Kostovska IM, Mannermaa A, Manoukian S, Margolin S, Martens JWM, Martinez ME, Mavroudis D, McLean C, Meindl A, Menon U, Middha P, Miller N, Moreno F, Mulligan AM, Mulot C, Muñoz-Garzon VM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen SF, Nordestgaard BG, Norman A, Offit K, Olson JE, Olsson H, Orr N, Pankratz VS, Park-Simon T-W, Perez JIA, Pérez-Barrios C, Peterlongo P, Peto J, Pinchev M, Plaseska-Karanfilska D, Polley EC, Prentice R, Presneau N, Prokofyeva D, Purrington K, Pylkäs K, Rack B, Radice P, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Robson M, Romero A, Ruddy KJ, Ruebner M, Saloustros E, Sandler DP, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schürmann P, Schwentner L, Scott C, Scott RJ, Seynaeve C, Shah M, Sherman ME, Shrubsole MJ, Shu X-O, Slager S, Smeets A, Sohn C, Soucy P, Southey MC, Spinelli JJ, Stegmaier C, Stone J, Swerdlow AJ, Tamimi RM, Tapper WJ, Taylor JA, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Truong T, Tzardi M, Ulmer H-U, Untch M, Vachon CM, van Veen EM, Vijai J, Weinberg CR, Wendt C, Whittemore AS, Wildiers H, Willett W, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zhang Y, Zheng W, Ziogas A, ABCTB Investigators, kConFab/AOCS Investigators, NBCS Collaborators, Dunning AM, Thompson DJ, Chenevix-Trench G, Chang-Claude J, Schmidt MK, Hall P, Milne RL, Pharoah PDP, Antoniou AC, Chatterjee N, Kraft P, García-Closas M, Simard J, Easton DF (2019) **Polygenic risk scores for prediction of breast cancer subtypes.** *The American Journal of Human Genetics.* 3 Jan. 104, 21-34. doi: 10.1016/j.ajhg. [218]

323. Puzhko S, Gagnon J, Simard J, Knoppers BM, Siedlikowski SS, Bartlett G (2019) **Health professionals' perspectives on breast cancer risk stratification: understanding evaluation of risk versus screening for disease.** *Public Health Reviews Journal*. 28 February;40:2. doi: 10.1186/s40985-019-0111-5. [4]

324. Rodrigue A, Margaillan G, Torres Gomes T, Coulombe Y, Montalban G, de Costa E Silva Carvalho S, Milano L, Ducy M, De-Gregoriis G, Dellaire G, Araújo da Silva W Jr, Monteiro AN, Carvalho MA*, Simard J*, Masson J-Y* (2019) **A global functional analysis of missense mutations reveals two major hotspots in the *PALB2* tumor suppressor.** *Nucleic Acids Research.* 2019 Nov 18; 47(20):10662-10677. doi: 10.1093/nar/gkz780. *jointly supervised this work. [13]

325. Shu X, Wu L, Khankari NK, Shu X-O, Wang TJ, Michailidou K, Bolla MK, Wang Q, Dennis J, Milne RL, Schmidt MK, Pharoah PDP, Andrulis IL, Hunter DJ, Simard J, Easton DF, Zheng W, Breast Cancer Association Consortium (2019) **Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis**. *International Journal of Epidemiology.* 1 June; 48(3):795-806. doi: 10.1093/ije/dyy201. [30]

326. Yang Y, Shu X, Shu XO, Bolla M, Kweon S-S, Cai Q, Michailidou K, Wang Q, Dennis J, Park B-Y, Matsuo K, Kwong A, Park SK, Wu A, Teo SH, Iwasaki M, Choi J-Y, Li J, Hartman M, Shen C-Y, Muir K, Lophatananon A, Li B, Gao Y-T, Xiang Y-B, Aronson K, Spinell J, Gago-Dominguez M, John E, Kurian A, Chang-Claude J, Chen S-T, Dörk T, Evans GD, Schmidt M, Shin M-H, Giles G, Milne R, Simard J, Kubo M, Kraft P, Kang D, Easton D, Zheng W, Long J. (2019) **Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European Ancestry.** *EBio Medicine.* 2019 Oct; 48:203-211. doi: 10.1016/j.ebiom.2019.09.006. [2]

327. Barnes DR, Rookus MA, McGuffog L, Leslie G, Mooij TM, Dennis J, Adlard J, Ahmed M, Aittomäki K, Andrieu N, Andrulis IL, Arnold N, Arun BK, Azzollini J, Balmaña J, Barkordottir RB, Barrowdale D, Benitez J, Berthet P, Białkowska K, Blanco AM, Blok MJ, Bonanni B, Boonen SE, Borg A, Bozsik A, Bradbury AR, Brennan P, Brewer C, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Christensen LL, Chung WK, Claes KBM, Colas C, GEMO Study Collaborators, EMBRACE Collaborators, Collonge-Rame

M-A, Cook J, Daly MBD, Davidson R, de la Hoya M, de Putter R, Delnatte C, Devilee P, Diez O, Ding YC, Domchek SM, Dorfling CM, Dumont M, Eeles R, Ejlertsen B, Engel C, Evans DG, Faivre L, Foretova L, Fostira F, Friedlander M, Friedman E, Frost D, Ganz PA, Garber J, Gehrig A, Gerdes A-M, Gesta P, Giraud S, Glendon G, Godwin AK, Goldgar DE, González-Neira A, Greene MH, Gschwantler-Kaulich D, Hahnen E, Hamann U, Hanson H, Hentschel J, Hogervorst FBL, Hooning MJ, Horvath J, Hu C, Hulick PJ, Imyanitov EN, KConFab Investigators, HEBON Investigators, GENEPSO Investigators, Isaacs C, Izatt L, Izaquierdo A, Jakubowska A, James PA, Janavicius R, John EM, Joseph V, Karlan BY, Kast K, Koudijs M, Kruse TA, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Lesueur F, Liljegren A, Loud JT, CRNP, Lubiński J, Mai PL, Manoukian S, Mari V, Mavaddat N, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller A, Montagna M, Mouret-Fourme E, Mukherjee SS, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nikitina-Zake L, Noguès C, Olah E, Olopade OI, Ong K-R, O'Shaughnessy-Kirwan A, Osorio A, Ott CE, Papi L, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Peterlongo P, Pfeiler G, Phillips K-A, Prajzendanc K, Pujana MA, Radice P, Ramser J, Ramus SJ, Rantala J, Rennert G, Risch HA, Robson M, Rønlund KR, Salani R, Schuster H, Senter L, Shah PD, Sharma P, Side LE, Singer CF, Slavin TP, Soucy P, Southey MC, Spurdle AB, Steinemann D, Steinsnyder ZZ, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Thull DL, Tischkowitz M, Tognazzo S, Toland AE, Trainer AH, Tung N, van Engelen K, van Rensburg EJ, Vega A, Vierstraete J, Wagner G, Walker L, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yadav S, Yang X, Yannoukakos D, Zimbalatti D, Offit K, Thomassen M, Couch FJ, Schmutzler RK, Simard J, Easton DF, Chenevix-Trench G, Antoniou AC, and on behalf of the Consortium of Investigators of Modifiers of BRCA and *BRCA2* (2020) **Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of *BRCA1* and *BRCA2* pathogenic variants**. *Genetics in Medicine*. 2020; 22(10): 1653-1666. doi: 10.1038/s41436-020-0862-x. [2]

328. Fachal L, Aschard H, Beesley J, Barnes DR, Allen J, Kar S, Pooley KA, Dennis J, Michailidou K, Turman C, Soucy P, Lemaçon A, Lush M, Tyrer JP, Ghoussaini M, Moradi Marjaneh M, Jiang X, Agata S, Aittomäki K, Alonso MR, Andrulis IL, Anton-Culver H, Antonenkova NN, Arason A, Arndt V, Aronson KJ, Arun BK, Auber B, Auer PL, Azzollini J, Balmaña J, Barkardottir RB, Barrowdale D, Beeghly-Fadiel A, Benitez J, Bermisheva M Bialkowska K, Blanco AM, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Bosse K, Brauch H, Brenner H, Briceno I, Brock IW, Brooks-Wilson A, Brüning T, Burwinkel B, Buys SS, Cai Q, Caldés T, Caligo MA, Camp NJ, Campbell I, Canzian F, Carroll JS, Carter BD, Castelao JE, Chiquette J, Christiansen H, Chung WK, Claes KBM, Clarke CL, GEMO Study Collaborators, EMBRACE Collaborators, Collée JM, Cornelissen S, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Domchek SM, Dörk T, dos-Santos-Silva I, Droit A, Dubois S, Dumont M, Duran M, Durcan L, Dwek M, Eccles DM, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Floris G, Flyger H, Foretova L, Foulkes WD, Friedman E, Fritschi L, Frost D, Gabrielson M, Gago-Dominguez M, Gambino G, Ganz PA, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Georgoulias V, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Grip M, Gronwald J, Grundy A, Guénel P, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hartikainen JM, Hartman M, He W, Healey CS, Heemskerk-Gerritsen BAM, Heyworth J, Hillemanns P, Hogervorst FBL, Hollestelle A, Hooning MJ, Hopper JL, Howell A, Huang G, Hulick PJ, Imyanitov EN, ABCTB Investigators, KConFab Investigators, HEBON Investigators, Isaacs C, Iwasaki M, Jager A, Jakimovska M, Jakubowska A, James P, Janavicius R, Rachel C. Jankowitz, John EM, Johnson N, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kang D, Karlan BY, Keeman R, Kerin MJ, Khusnutdinova E, Kiiski JI, Kirk J, Kitahara CM, Ko Y-D, Konstantopoulou I, Kosma V-M, Koutros S, Kubelka-Sabit K, Kwong A, Kyriacou K, Laitman Y, Lambrechts D, Lee E, Leslie G, Lester J, Lesueur F, Lindblom A, Lo W-Y, Long J, Lophatananon A, Loud JT, Lubiński J, MacInnis RJ, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matsuo K, Maurer T, Mavroudis D, Mayes R, McGuffog L, McLean C, Mebirouk N, Meindl A, Middha P, Miller N, Miller A, Montagna M, Moreno F, Mulligan AM, Muñoz-Garzon VM, Muranen TA, Narod SA, Nassir R, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nikitina-Zake L, Norman A, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Osorio A, Pankratz VS, Papp J, Park SK, Park-Simon T-W, Parsons MT, Paul J, Pedersen IS, Peissel B, Peshkin B, Peterlongo P, Peto J, Plaseska-Karanfilska D, Prajzendanz K, Prentice R, Presneau N, Prokofyeva D, Pujana MA, Pylkäs K, Radice P, Ramus SJ, Rantala J, Rau-Murthy R, Rennert G, Risch HA, Robson M, Romero A, Rossing CM, Saloustros E, Sánchez-Herrero E,

Sandler DP, Santamariña M, Saunders C, Sawyer EJ, Scheuner MT, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Scott C, Scott RJ, Senter L, Seynaeve CMD, Shah M, Sharma P, Shen C-Y, Shu X-O, Singer CF, Slavin TP, Smichkoska S, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Stoppa-Lyonnet D, Sutter C, Swerdlow AJ, Tamimi RM, Tan YY, Tapper WJ, Taylor JA, Teixeira MR, Tengström M, Teo SH, Terry MB, Teulé A, Thomassen M, Thull DL, Tibiletti MG, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Torres-Mejía G, Troester MA, Tung N, Tzardi M, Ulmer H-U, Vachon CM, van Asperen CJ, van der Kolk LE, van Rensburg EJ, Vega A, Viel A, Vijai J, Vogel MJ, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Wildiers H, Winqvist R, Wolk A, Wu AH, Yannoukakos D, Zhang Y, Zheng W, Pharoah PDP, Chang-Claude J, García-Closas M, Schmidt MK, Milne RL, Kristensen VN, French JD, Edwards SL, Antoniou AC, Chenevix-Trench G*, Simard J*, Easton DF*, Kraft P*, Dunning AM* (2020) **Fine-Mapping of 150 breast cancer risk regions identifies 191 high confidence target genes**. *Nature Genetics*. 7 Jan; 52(1):56-73. doi: 10.1038/s41588-019-0537-1. * authors jointly supervised this work. [24]

329. Ho W-K, Tan M-M, Mavaddat N, Tai M-C, Mariapun S, Li J, Ho P-J, Dennis J, Tyrer JP, Bolla MK, Michailidou K, Wang Q, Kang D, Choi J-Y, Jamaris S, Shu X-O, Yoon S-Y, Park SK, Kim S-W, Shen C-Y, Yu J-C, Tan EY, Chan PMY, Muir K, Lophatananon A, Wu AH, Stram DO, Matsuo K, Ito H, Chan CW, Ngeow J, Yong WS, Lim SH, Lim GH, Kwong A, Chan TL, Tan SM, Seah J, John EM, Kurian AW, Koh W-P, Khor CC, Iwasaki M, Yamaji T, Tan KMV, Tan KTB, Spinelli JJ, Aronson KJ, Norhidayu HS, Rahmat K, Vijayananthan A, Sim X, Pharoah PDP, Zheng W, Dunning AM, Simard J, van Dam RM, Yip C-H, Taib NAM, Hartman M, Easton DF, Teo S-H, Antoniou AC (2020) **European polygenic risk score for prediction of breast cancer shows similar performance in Asian Women**. *Nature communications*. 2020 july; 11:3833. doi: 10.1038/s41467-020-17680-w. [1]

330. Lakhal-Chaieb L, Simard J, Bull S. (2020) **Sequence kernel association test for survival outcomes in the presence of a non-susceptible fraction.** *Biostatistics*. Jul 1;21(3):518-530. doi: 10.1093/biostatistics/kxy075. [1]

331. Lemaçon A, Scott-Boyer M-P, Ongaro-Carcy R, Soucy P, Simard J, Droit A (2020) **DSNetwork: An Integrative Approach to Visualize Predictions of Variants' Deleteriousness**. *Frontiers in Genetics*, 17 Jan. https://doi.org/10.3389/fgene.2019.01349.

332. Muranen TA, Khan S, Fagerholm R, Aittomäki K, Cunningham JM, Dennis J, Leslie G, McGuffog L, Parsons MT, Simard J., Slager S, Soucy P, Easton DF, Tischkowitz M, Spurdle AB, kConFab Investigators, Schmutzler RK, Wappenschmidt B, Hahnen E, Hooning MJ; HEBON Investigators, Singer CF, Wagner G, Thomassen M, Pedersen IS, Domchek SM, Nathanson KL, Lazaro C, Rossing CM, Andrulis IL, Teixeira MR, James P, Garber J, Weitzel JN; SWE-BRCA Investigators, Jakubowska A, Yannoukakos D, John EM, Southey MC, Schmidt MK, Antoniou AC, Chenevix-Trench G, Blomqvist C, Nevanlinna H (2020) **Association of germline variation with the survival of women with *BRCA1/2* pathogenic variants and breast cancer.** *NPJ Breast Cancer*. 2020 Sep 10;6:44. doi: 10.1038/s41523-020-00185-6. eCollection 2020.

333. Pashayan N, Antoniou AC, Ivanus U, Esserman L, Easton DF, French D, Sroczynski G, Hall P, Cuzick J, Evans DG, Simard J, Garcia-Closas M, Schmutzler R, Wegwarth O, Pharoah P, Moorthie S, de Montgolfier S, Baron C, Herceg Z, Turnbull C, Balleyguier C, Rossi PG, Wesseling J, Ritchie D, Tischkowitz M, Broeders M, Reisel D, Metspalu A, Callender T, de Koning H, Devilee P, Delaloge S, Schmidt MK, Widschwendter M (2020) **Personalized early detection and prevention of breast cancer: ENVISION consensus statement.** *Nature Reviews Clinical Oncology*. 2020 Nov;17(11):687-705. doi: 10.1038/s41571-020-0388-9. [4]

334. Pelletier S, Larouche G, Chiquette J, El Haffaf Z, Foulkes W, Hamet P, Simard J, Dorval M, (2020) **Survey of primary care physicians' views about breast and ovarian cancer screening for true *BRCA1/2* non-carriers**. *Journal of Community Genetics*. April; 11(2):205-213. doi: 10.1007/s12687-019-00438-3.

335. Shu X, Long J, Cai Q, Kweon S-S, Choi J-Y, Kubo M, Park SK, Bolla MK, Dennis J, Wang Q, Yang Y, Shi J, Guo X, Li B, Tao R, Aronson KJ, Chan KYK, Chan TL, Gao Y-T, Hartman M, Ho WK, Ito H, Iwasaki M, Iwata H, John EM, Kasuga Y, Khoo US, Kim M-K, Kong S-Y, Kurian AW, Kwong A, Lee E-S, Li J, Lophatananon A, Low S-K, Mariapun S, Matsuda K, Matsuo K, Muir K, Noh D-Y, Park B, Park M-H, Shen C-Y, Shin M-H, Spinelli JJ, Takahashi A, Tseng C, Tsugane S, Wu AH, Xiang Y-B, Yamaji T, Zheng Y, Milne RL, Dunning AM, Pharoah PDP, Garcia-Closas M, Teo S-H, Shu X-O, Kang D, Easton DF, Simard J, Zheng W (2020) **Identification of novel breast cancer susceptibility loci in meta-analyses**

conducted among Asian and European descendants. *Nature Communications*. Mar 5;11(1):1217. doi: 10.1038/s41467-020-15046-w. [4]

336. Shu X, Bao J, Wu L, Long J, Shu XO, Guo X, Yang Y, Michailidou K, Bolla MK, Wang Q, Dennis J, Andrulis IL, Castelao JE, Dörk T, Gago-Dominguez M, García-Closas M, Giles GG, Lophatananon A, Muir K, Olsson H, Rennert G, Saloustros E, Scott RJ, Southey MC, Pharoah PDP, Milne RL, Kraft P, Simard J, Easton DF, Zheng W (2020) **Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk.** *International Journal of Cancer*. 15 April. doi : 10.1002/ijc.32542. [5]

337. van den Broek J, Schechter CB, van Ravesteyn NT, Janssens CJW, Wolfson MC, Trentham-Dietz A, Simard J, Easton DF, Mandelblatt JS, Kraft P, de Koning HJ. (2020) **Personalizing Breast Cancer Screening Based on Polygenic Risk and Family History**. *Journal of the National Cancer Institute*. 2020 Aug 27;djaa127. doi: 10.1093/jnci/djaa127. Online ahead of print.

338. Wiltshire T, Ducy M, Foo TK, Hu C, Lee KY, Belur Nagaraj A, Rodrigue A, Gomes TT, Simard J, Monteiro ANA, Xia B, Carvalho MA, Masson J-Y, Couch FJ (2020) **Functional characterization of 84 *PALB2* variants of uncertain significance**. *Genetics in Medicine.* 2020 March;22(3):622-632. doi: 10.1038/s41436-019-0682-z. [9]

339. Yang Y, Wu L, Shu XO, Cai Q, Shu X, Li B, Guo X, Ye F, Michailidou K, Bolla MK, Wang Q, Dennis J, Andrulis IL, Brenner H, Chenevix-Trench G, Campa D, Castelao JE, Gago-Dominguez M, Dörk T, Hollestelle A, Lophatananon A, Muir K, Neuhausen SL, Olsson H, Sandler DP, Simard J, Kraft P, Pharoah PDP, Easton DF, Zheng W, Long J (2020) **Genetically predicted levels of DNA methylation biomarkers and breast cancer risk: data from nearly 228,951 women of European descent.** *Journal of the National Cancer Institute.* 1 March; 112(3):295-304. doi: 10.1093/jnci/djz109. [10]

340. Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O'Mara TA, Zhao N, Bolla MK, Dunning AM, Dennis J, Wang Q, Ful ZA, Aittomäki K, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Arun BK, Auer PL, Azzollini J, Barrowdale D, Becher H, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blanco A, Blomqvist C, Bogdanova NV, Bojesen SE, Bonanni B, Bondavalli D, Borg A, Brauch H, Brenner H, Briceno I, Broeks A, Brucker SY, Brüning T, Burwinkel B, Buys SS, Byers H, Caldés T, Caligo MA, Calvello M, Campa D, Castelao JE, Chang-Claude J, Chanock SJ, Christiaens M, Christiansen H, Chung WK, Claes KBM, Clarke CL, Cornelissen S, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Diez O, Domchek SM, Dörk T, Dwek M, Eccles DM, Ekici AB, Evans DG, Fasching PA, Figueroa J, Foretova L, Fostira F, Friedman E, Frost D, Gago-Dominguez M, Gapstur SM, Garber J, García-Sáenz JA, Gaudet MM, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Häberle L, Hahnen E, Haiman CA, Hake CR, Hall P, Hamann U, Harkness EF, Heemskerk-Gerritsen BAM, Hillemanns P, Hogervorst FBL, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Huebner H, Hulick PJ, Imyanitov EN; kConFab Investigators; ABCTB Investigators, Isaacs C, Izatt L, Jager A, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Kapoor PM, Karlan BY, Keeman R, Khan S, Khusnutdinova E, Kitahara CM, Ko YD, Konstantopoulou I, Koppert LB, Koutros S, Kristensen VN, Laenkholm AV, Lambrechts D, Larsson SC, Laurent-Puig P, Lazaro C, Lazarova E, Lejbkowicz F, Leslie G, Lesueur F, Lindblom A, Lissowska J, Lo WY, Loud JT, Lubinski J, Lukomska A, MacInnis RJ, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Matricardi L, McGuffog L, McLean C, Mebirouk N, Meindl A, Menon U, Miller A, Mingazheva E, Montagna M, Mulligan AM, Mulot C, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Nielsen FC, Nikitina-Zake L, Nodora J, Offit K, Olah E, Olopade OI, Olsson H, Orr N, Papi L, Papp J, Park-Simon TW, Parsons MT, Peissel B, Peixoto A, Peshkin B, Peterlongo P, Peto J, Phillips KA, Piedmonte M, Plaseska-Karanfilska D, Prajzendanc K, Prentice R, Prokofyeva D, Rack B, Radice P, Ramus SJ, Rantala J, Rashid MU, Rennert G, Rennert HS, Risch HA, Romero A, Rookus MA, Rübner M, Rüdiger T, Saloustros E, Sampson S, Sandler DP, Sawyer EJ, Scheuner MT, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schöttker B, Schürmann P, Senter L, Sharma P, Sherman ME, Shu XO, Singer CF, Smichkoska S, Soucy P, Southey MC, Spinelli JJ, Stone J, Stoppa-Lyonnet D; EMBRACE Study; GEMO Study Collaborators, Swerdlow AJ, Szabo CI, Tamimi RM, Tapper WJ, Taylor JA, Teixeira MR, Terry M, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Tomlinson I, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van den Ouweland AMW, van der Kolk LE, van Veen EM, vanRensburg EJ,

Vega A, Wappenschmidt B, Weinberg CR, Weitzel JN, Wildiers H, Winqvist R, Wolk A, Yang XR, Yannoukakos D, Zheng W, Zorn KK, Milne RL, Kraft P, Simard J, Pharoah PDP, Michailidou K, Antoniou AC, Schmidt MK, Chenevix-Trench G, Easton DF, Chatterjee N, García-Closas M. (2020) **Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analysis.** *Nature Genetics.* June;52(6):572-581. doi : 10.1038/s41588-020-0609-2. [10]

341. Zhang YD, Hurson AN, Zhang H, Choudhury PP, Easton DF, Milne RL, Simard J, Hall P, Michailidou K, Dennis J, Schmidt MK, Chang-Claude J, Gharahkhani P, Whiteman D, Campbell PT, Hoffmeister M, Jenkins M, Peters U, Hsu L, Gruber SB, Casey G, Schmit SL, O'Mara TA, Spurdle AB, Thompson DJ, Tomlinson I, De Vivo I, Landi MT, Law MH, Iles ML, Demenais F, Kumar R, MacGregor S, Bishop DT, Ward SV, Bondy ML, Houlston R, Wiencke JK, Melin B, Barnholtz-Sloan J, Kinnersley B, Wrensch MR, Amos CI, Hung RJ, Brennan P, McKay J, Caporaso NE, Berndt S, Birmann BM, Camp NJ, Kraft P, Rothman N, Slager SL, Berchuck A, Pharoah PDP, Sellers TA, Gayther SA, Pearce CL, Goode EL, Schildkraut JM, Moysich KB, Amundadottir LT, Jacobs EJ, Klein AP, Petersen GM, Risch HA, Stolzenberg-Solomon RZ, Wolpin BM, Li D, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Olama AA, Purdue MP, Scelo G, Dalgaard MD, Greene MH, Grotmol T, Kanetsky PA, McGlynn KA, Nathanson KL, Turnbull C, Wiklund F, BCAC, BEACON, CCFR, CORECT, ECAC, GECCO, GenoMEL, GICC, ILCCO, INTERGRAL, InterLymph, OCAC, Oral Cancer GWAS, PANC4, PanScan, PRACTICAL, Renal Cancer GWAS, TECAC, Chanock SJ, Chatterjee N*, Garcia-Closas M* (2020) **Assessment of Polygenic Architecture and Risk Prediction based on Common Variants across Fourteen Cancers**. *Nature Communications*. 2020 Jul 3;11(1):3353. doi: 10.1038/s41467-020-16483-3. [7]

GENETIC SUSCEPTIBILITY TO HORMONE-DEPENDENT CANCERS

Section B : Contributions in the context of international consortia: Authorship in agreement with consortia rules.

342. Couch FJ, Weber BL, (BIC) and the BCIC (1996) **Mutations and polymorphisms in the familial early onset breast cancer (*BRCA1*) gene**. *Human Mutations,* 8-18. [325]

343. The *BRCA1* Exon 13 Duplication Screening Group (2000) **The Exon 13 Duplication in the *BRCA1* Gene Is a Founder Mutation Present in Geographically Diverse Populations**. *American Journal of Human Genetics,* 67: 207-212. [96]

344. Xu J, and The International Consortium for Prostate Cancer Genetics (2000) **Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics**. *American Journal of Human Genetics,* 66: 945-957. [172]

345. Edwards S, Meitz J, Eles R, Evans C, Easton D, Hopper J, Giles G, Foulkes WD, Narod S, Simard J, Badzioch M, Mahle L, International AC (2003) **Results of a genome-wide linkage analysis in prostate cancer families ascertained through the ACTANE consortium**. *The Prostate,* 57: 270-279. [48]

346. Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Møller P, Maehle L, Badzioch M, The Cancer Research UK/British Association of Urological Surgeons' Section of Oncology Collaborators, Eeles RA, Easton DF, English DR, Southey M, Hopper JL, Foulkes WD, Giles GG (2005) **Macrophage Scavenger Receptor 1 (*MSR1*) *999C>T* (R293X) mutation and risk of prostate cancer**. *Cancer Epidemiology Biomarkers and Prevention,* 14: 397-402. [28]

347. Schaid DJ, Chang BL, The International Consortium for Prostate Cancer Genetics (2005) **Description of the International Consortium for Prostate Cancer Genetics, and Failure to Replicate Linkage of Hereditary Cancer to 20q13**. *The Prostate* 63: 276-290. [44]

348. Xu J, Dimitrov L, Chang BL, Adams TS, Turner AR, Meyers DA, Eeles RA, Easton DF, Foulkes WD, Simard J, Giles GG, Hopper JL, Mahle L, Moller P, Bishop T, Evans C, Edwards S, Meitz J, Bullock S, Hope Q, The ACTANE Consortium, Hsieh CL, Halpern J, Balise RN, Oakley-Girvan I, Whittemore AS, Ewing CM, Gielzak M, Isaacs SD, Walsh PC, Wiley KE, Isaacs WB, Thibodeau SN, McDonnell SK, Cunningham JM, Zarfas KE, Hebbring S, Schaid, DJ, Friedrichsen DM, Deutsch K, Kolb S, Badzioch M, Jarvik GP, Janer M, Hood L, Ostrander EA, Stanford JL, Lange EM, Beebe-Dimmer JL, Mohai CE, Cooney

KA, Ikonen T, Baffoe-Bonnie A, Fredriksson H, Matikainen MP, Tammela TLJ, Bailey-Wilson J, Schleutker J, Maier C, Herkommer K, Hoegel JJ, Vogel W, Paiss T, Wiklund F, Emanuelsson M, Stenman E, Jonsson BA, Grönberg H, Camp NJ, Farnham J, Cannon-Albright LA, Seminara D (2005) **A Combined Genomewide Linkage Scan of 1,233 Families for Prostate Cancer-Susceptibility Genes Conducted by the International Consortium for Prostate Cancer Genetics**. *American Journal of Human Genetics,* 77: 219-229. [152]

349. Andrieu N, Goldgar DE, Easton DF, Rookus M, Brohet R, Antoniou AC, Peock S, Evans G, Eccles D, Douglas F, EMBRACE, Noguès C, Gauthier-Villars M, Chompret A, GENEPSO, Van Leeuwen FE, Kluijt I, GEO-HEBON, Benitez J, Arver B, Olah E, the IBCCS collaborators Group, Chang-Claude J (2006) **Pregnancies, breast-feeding and breast cancer risk in the International *BRCA1/2* Carrier Cohort Study (IBCCS)**. *Journal of the National Cancer Institute,* 98: 535-544. [251]

350. Schaid DJ, Investigators of the International Consortium for Prostate Cancer Genetics (2006) **Pooled genome linkage scan of aggressive prostate cancer: Results from the International Consortium for Prostate Cancer Genetics**. *Human Genetics*, 120: 471-485. [68]

351. Brohet RM, Goldgar DE, Easton DF, Antoniou AC, Andrieu N, Chang-Claude J, Peock S, Eeles RA, Cook M, Chu C, Noguès C, Lasset Pascaline Berthet C, Meijers-Heijboer H, Gerdes AM, Olsson H, Caldes T, van Leeuwen FE, Rookus MA (2007) **Oral Contraceptives and Breast Cancer Risk in the International *BRCA1/2* Carrier Cohort Study: A Report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group**. *Journal of Clinical Oncology*, 25: 3831-3836. [194]

352. Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou AC, Peock S, Davidson R, Izatt L, Cole T, Noguès C, Luporsi E, Huiart L, Hoogerbrugge N, Van Leeuwen FE, Osorio A, Eyfjord J, Radice P, Goldgar DE, Easton DF, Epidemiological Study of Familial Breast Cancer (EMBRACE), Gene Etude Prospective Sein Ovaire (GENEPSO), Genen Omgeving studie van de werkgroep Hereditiair Borstkanker Onderzoek Nederland (GEO-HEBON), the International *BRCA1/2* Carrier Cohort Study (IBCCS) collaborators group. (2007) **Age at menarche and menopause and breast cancer risk in the International *BRCA1/2* Carrier Cohort Study**. *Cancer Epidemiology Biomarkers and Prevention*, 16: 740-746. [86]

353. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE on behalf of CIMBA (2007) **An international initiative to identify genetic modifiers of cancer risk in *BRCA1* and *BRCA2* mutation carriers: The Consortium of Investigators of Modifiers of *BRCA1* and *BRCA2* (CIMBA)**. *Breast Cancer Research*, 9: 104-107. [164]

354. Couch FJ, Antoniou AC, Sinilnikova O, Vierkant RA, Shane Pankratz V, Fredericksen ZS, Stoppa-Lyonnet D, Coupier I, Hughes D, Hardoin A, Berthet P, GEMO, EMBRACE, Jakubowska A, Lubinski J, Spurdle AB, KConFab, Schmutzler R, Offitt K, Andrulis IL, Ilyushik E, Glennon G, Devilee P, Wreeswijk MPG, Vasen HFA, Borg A, Blackenhorn K, Struewing JP, Greene MH, Neuhausen SL, Rebbeck TR, Nathanson K, Domchek S, Wagner T, Garber JE, Szabo C, Zikan M, Foretova L, Olson JE, Sellers TA, Nevanlinna H, Tommiska J, Aittomaki K, Hamann U, Rashid MU, Torres D, Simard J, Durocher F, Guénard F, INHERIT, Lynch HT, Isaacs C, Weitzel J, Olopade OI, Narod S, Daly MB, Godwin AK, Tomlinson G, Easton DF, Chenevix-Trench G on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2* (2007) ***AURKA* F31I Polymorphism and Breast Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers: A CIMBA study**. *Cancer Epidemiology, Biomarkers and Prevention*, 16 :1416-1421. [44]

355. Guénard F, Labrie Y, Ouellette G, Joly-Beauparlant C, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, INHERIT BRCAs, Durocher F (2007) **Germline mutations in the breast cancer susceptibility gene *PTEN* are rare in high-risk non-*BRCA1/2* French Canadian breast cancer families**. *Familial Cancer*, 6: 483-490. [43]

356. Antoniou AC, Spurdle AB, Sinilnikova OM, Healy S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deisler H, Caldes T, Kämpjärvi K, Nevanlinna H, Simard J, Beesley J, Chen X, The Kathleen Cuningham Consortium for Research into Familial Breast Cancer, Heuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Mateus Pereira LH, Greene MH, Rennert G, Lejbkowicz F, Barnett-Griness O, Andrulis I, Ozcelik H, OCGN, Gerdes AM, Caligo MA, Laitman Y, Kaufmann B, Milgrom R, Friedman E, SWE-BRCA, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benítez J, Hamann U, Hogervorst FBL, Rookus

MA, Manders P, Ligtenberg MJL, van den Ouweland AMW, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F, EMBRACE, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de-Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D, Chenevix-Trench G, Easton DF on behalf of CIMBA (2008) **Common breast cancer predisposition alleles modify breast cancer risk in *BRCA1* and *BRCA2* mutation carriers**. *American Journal of Human Genetics* 82: 937-948. [332]

357. Desjardins S, Belleau P, Labrie Y, Ouellette G, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, INHERIT BRCAs, Durocher F (2008) **Genetic variants and haplotye analyses of the *ZBRK1/ZNF350* gene in high-risk non *BRCA1/2* French Canadian breast and ovarian cancer families**. *International Journal of Cancer*, 122: 108-116. [24]

358. Desjardins S, Beauparlant JC, Labrie Y, Ouellette G, Durocher F; INHERIT BRCAs. (2009) **Variations in the NBN/NBS1 gene and the risk of breast cancer in non-*BRCA1/2* French Canadian families with high risk of breast cancer**. *BMC Cancer*, (Jan) 12;9:181. PMID: 19523210. [41]

359. Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D; EMBRACE, Peock S, Cook M, Oliver C, Frost D, Eccles D, Evans DG, Eeles R, Izatt L, Chu C, Douglas F, Paterson J, Stoppa-Lyonnet D, Houdayer C, Mazoyer S, Giraud S, Lasset C, Remenieras A, Caron O, Hardouin A, Berthet P; GEMO Study Collaborators, Hogervorst FB, Rookus MA, Jager A, van den Ouweland A, Hoogerbrugge N, van der Luijt RB, Meijers-Heijboer H, Gómez García EB; HEBON, Devilee P, Vreeswijk MP, Lubinski J, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Górski B, Cybulski C, Spurdle AB, Holland H; kConFab, Goldgar DE, John EM, Hopper JL, Southey M, Buys SS, Daly MB, Terry MB, Schmutzler RK, Wappenschmidt B, Engel C, Meindl A, Preisler-Adams S, Arnold N, Niederacher D, Sutter C, Domchek SM, Nathanson KL, Rebbeck T, Blum JL, Piedmonte M, Rodriguez GC, Wakeley K, Boggess JF, Basil J, Blank SV, Friedman E, Kaufman B, Laitman Y, Milgrom R, Andrulis IL, Glendon G, Ozcelik H, Kirchhoff T, Vijai J, Gaudet MM, Altshuler D, Guiducci C; SWE-BRCA, Loman N, Harbst K, Rantala J, Ehrencrona H, Gerdes AM, Thomassen M, Sunde L, Peterlongo P, Manoukian S, Bonanni B, Viel A, Radice P, Caldes T, de la Hoya M, Singer CF, Fink-Retter A, Greene MH, Mai PL, Loud JT, Guidugli L, Lindor NM, Hansen TV, Nielsen FC, Blanco I, Lazaro C, Garber J, Ramus SJ, Gayther SA, Phelan C, Narod S, Szabo CI; MOD SQUAD, Benitez J, Osorio A, Nevanlinna H, Heikkinen T, Caligo MA, Beattie MS, Hamann U, Godwin AK, Montagna M, Casella C, Neuhausen SL, Karlan BY, Tung N, Toland AE, Weitzel J, Olopade O, Simard J, Soucy P, Rubinstein WS, Arason A, Rennert G, Martin NG, Montgomery GW, Chang-Claude J, Flesch-Janys D, Brauch H; GENICA, Severi G, Baglietto L, Cox A, Cross SS, Miron P, Gerty SM, Tapper W, Yannoukakos D, Fountzilas G, Fasching PA, Beckmann MW, Dos Santos Silva I, Peto J, Lambrechts D, Paridaens R, Rüdiger T, Försti A, Winqvist R, Pylkäs K, Diasio RB, Lee AM, Eckel-Passow J, Vachon C, Blows F, Driver K, Dunning A, Pharoah PP, Offit K, Pankratz VS, Hakonarson H, Chenevix-Trench G, Easton DF, Couch FJ (2010) **A locus on 19p13 modifies risk of breast cancer in *BRCA1* mutation carriers and is associated with hormone receptor-negative breast cancer in the general population**. *Nature Genetics,* (Oct) 42:885-92. PMID : 20852631. [362]

360. Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, Lee A, McGuffog L, Healey S, Sinilnikova OM, Janavicius R, Hansen TV, Nielsen FC, Ejlertsen B, Osorio A, Munoz-Repeto I, Duran M, Godino J, Pertesi M, Benitez J, Peterlongo P, Manoukian S, Peissel B, Zaffaroni D, Cattaneo E, Bonanni B, Viel A, Pasini B, Papi L, Ottini L, Savarese A, Bernard L, Radice P, Hamann U, Verheus M, Meijers-Heijboer HE, Wijnen J, Gomez Garcia EB, Nelen MR, Kets CM, Seynaeve C, Tilanus-Linthorst MM, van der Luijt RB, van Os T, Rookus M, Frost D, Jones JL, Evans DG, Lalloo F, Eeles R, Izatt L, Adlard J, Davidson R, Cook J, Donaldson A, Dorkins H, Gregory H, Eason J, Houghton C, Barwell J, Side LE, McCann E, Murray A, Peock S, Godwin A, Schmutzler RK, Rhiem K, Engel C,Meindl A, Ruehl I, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Kast K, Preisler-Adams S, Varon-Mateeva R, Schoenbuchner I, Fiebig B, Heinritz W, Schafer D, Gevensleben H, Caux-Moncoutier V, Fassy-Colcombet M, Cornelis F, Mazoyer S, Leone M, Boutry-Kryza N, Hardouin A, Berthet P, Muller D, Fricker JP, Mortemousque I, Pujol P, Coupier I, Lebrun M, Kientz C, Longy M, Sevenet N, Stoppa-Lyonnet D, Isaacs C, Caldes T, de Al Hoya M, Heikkinen T, Aittomaki K, Blanco I, Lazaro C, Barkardottir RB, Soucy P, Dumont M, Simard J, Montagna M, Tognazzo S, D'Andrea E, Fox S, Yan M, Rebbeck

TR, Olopade OI, Weitzel JN, Lynch HT,Ganz PA, Tomlinson GE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet M, Bhatia J, Kauff N, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Mai PL, Greene MH, Imyanitov E, O'Malley FP, Ozcelik H, Glendon G, Toland AE, Gerdes AM, Thomassen M, Kruse TA, Birk Jensen U, Skytte AB, Caligo MA, Soller M, Henriksson K, von Wachenfeldt A, Arver B, Stenmark-Askmalm M, Karlsson P, Ding YC, Neuhausen SL, Beattie M, Pharoah PD, Moysich KB, Nathanson KL, Karlan BY, Gross J, John EM, Daly MB, Buys SM, Southey MC, Hopper JL, Terry MB, Chung W, Miron AF, Goldgar D, Chenevix-Trench G, Easton DF, Andrulis IL, Antoniou AC, Family Registry BC, Embrace, Collaborators GS, Hebon, Network OC, Swe-Brca, CIMBA (2011) **Common breast cancer susceptibility alleles are associated with tumor subtypes in *BRCA1* and *BRCA2* mutation carriers; results from the Consortium of Investigators of Modifiers of *BRCA1/2***. *Breast Cancer Research,* (Jan) 13:R110. PMID : 22053997. [108]

361. Ding YC, McGuffog L, Healey S, Friedman E, Laitman Y, Paluch-Shimon S, Kaufman B; for SWE-BRCA, Liljegren A, Lindblom A, Olsson H, Kristoffersson U, Stenmark-Askmalm M, Melin B, Domchek SM, Nathanson KL, Rebbeck TR, Jakubowska A, Lubinski J, Jaworska K, Durda K, Gronwald J, Huzarski T, Cybulski C, Byrski T, Osorio A, Cajal TR, Stavropoulou AV, Benítez J, Hamann U; for HEBON, Rookus M, Aalfs CM, de Lange JL, Meijers-Heijboer HE, Oosterwijk JC, van Asperen CJ, Gómez García EB, Hoogerbrugge N, Jager A, van der Luijt RB; for EMBRACE, Easton DF, Peock S, Frost D, Ellis SD, Platte R, Fineberg E, Evans DG, Lalloo F, Izatt L, Eeles R, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Tischkowitz M, Godwin AK, Pathak H; for GEMO Study Collaborators, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Barjhoux L, Léoné M, Gauthier-Villars M, Caux-Moncoutier V, de Pauw A, Hardouin A, Berthet P, Dreyfus H, Ferrer SF, Collonge-Rame MA, Sokolowska J, Buys S, Daly M, Miron A, Terry MB, Chung W, John EM, Southey M, Goldgar D, Singer CF, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, Hansen TV, Ejlertsen B, Johannsson OT, Offit K, Sarrel K, Gaudet MM, Vijai J, Robson M, Piedmonte MR, Andrews L, Cohn D, Demars LR, Disilvestro P, Rodriguez G, Toland AE, Montagna M, Agata S, Imyanitov E, Isaacs C, Janavicius R, Lazaro C, Blanco I, Ramus SJ, Sucheston L, Karlan BY, Gross J, Ganz PA, Beattie MS, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Niederacher D, Preisler-Adams S, Gadzicki D, Varon-Mateeva R, Deissler H, Gehrig A, Sutter C, Kast K, Nevanlinna H, Aittomäki K, Simard J; for KConFab Investigators, Spurdle AB, Beesley J, Chen X, Tomlinson GE, Weitzel J, Garber JE, Olopade OI, Rubinstein WS, Tung N, Blum JL, Narod SA, Brummel S, Gillen DL, Lindor N, Fredericksen Z, Pankratz VS, Couch FJ, Radice P, Peterlongo P, Greene MH, Loud JT, Mai PL, Andrulis IL, Glendon G, Ozcelik H; for OCGN, Gerdes AM, Thomassen M, Jensen UB, Skytte AB, Caligo MA, Lee A, Chenevix-Trench G, Antoniou AC, Neuhausen SL; on behalf of Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA) (2012) **A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in *BRCA1* and Ovarian Cancer in *BRCA2* Mutation Carriers.** *Cancer, Epidemiology, Biomarkers & Prevention*, (Août) 21:1362-70. PMID : 22729394. [23]

362. Jakubowska A, Rozkrut D, Antoniou A, Hamann U, Scott RJ, McGuffog L, Healy S, Sinilnikova OM, Rennert G, Lejbkowicz F, Flugelman A, Andrulis IL, Glendon G, Ozcelik H, OCGN, Thomassen M, Paligo M, Aretini P; SWE-BRCA, Kantala J, Aroer B, von Wachenfeldt A, Liljegren A, Loman N, Herbst K, Kristoffersson U, Rosenquist R, Karlsson P, Stenmark-Askmalm M, Melin B, Natanson KL, Domchek SM, Byrski T, Huzarski T, Gronwald J, Menkiszak J, Cybulski C, Serrano P, Osorio A, Ramóny Cajal T, Tsitlaidou M, Benítez J, Gilbert M, HEBON, Rookus M, Aalfs CM, Kluijt I, Boessenkool-Pape JL, Meijers-Heijboer HEJ, Oosterwijk JC, van Asperen CJ, Blok MJ, Nelen MR, van den Ouweland AMW, Seynaeve C, van der Luijt RB, Devilee P, EMBRACE, Easton DF, Peock S, Frost D, Platte R, Eblis SD, Fineberg E, Evans DG, Lalloo F, Eeles R, Jacobs C, Adlard J, Davidson R, Eccles D, Cole T, Cook J, Godwin A, Bove B, GEMO Study Collaborators, Stoppa-Lyonnet D, Caux-Moncoutier V, Belotti M, Tirapo C, Mazoyer S, Barjhoux L, Boutry-Kryza N, Pujol P, Coupier I, Peyrat J-P, Vennin P, Muller D, Fricker J-P, Venat-Bouvet L, Johannsson O Th., Isaacs C, Schmutzler R, Wappenschmidt B, Meindl A, Arnold N, Varon-Mateeva R, Niederacher D, Sutter C, Deissler H, Preisler-Adams S, Simard J, Soucy P, Durocher F, Chenevix-Trench G, Beesley J, Chen X, kConFab, Rebbeck T, Couch F, Wang X, Lindor N, Fredericksen Z, Pankratz VS, Peterlongo P, Bonanni B, Fortuzzi S, Peissel B, Szabo C, Mai PL, Loud JT, Lubinski J on behalf of CIMBA, the Consortium of Investigators of Modifiers of *BRCA1/2*-Related Cancer (2012) **Association of *PHB* 1630 C>T and *MTHFR* 677 C>T polymorphisms with breast and ovarian cancer risk in *BRCA1/2* mutation carriers: results from a multicenter study.** *British Journal of Cancer,* (Juin) 106: 2016-24. PMID : 22669161. [32]

363. Mavaddat N, Barrowdale D, Andrulis IA, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, Mulligan AM, Couch FJ, Engel C, McGuffog L, Healey S, Sinilnikova OM, Southey MC, Terry MB, Goldgar D, O'Malley F, John EM, Ramunas J, Tihomirova L, v O Hansen T, Nielsen FC, Osorio A, Stavropoulou A, Benítez J, Manoukian S, Peissel B, Barile M, Volorio S, Pasini B, Dolcetti R, Putignano AL, Ottini L, Radice P, Hamann U, Rashid MU, Hogervorst FB, Kriege M, van der Luijt RB, HEBON, EMBRACE, Peock S, Frost D, Evans DG, Brewer C, Walker L, Rogers MT, Side LE, Houghton C, Weaver JO, Godwin AK, Schmutzler RK, Wappenschmidt B, Meindl A, Kast K, Arnold N, Niederacher D, Sutter C, Deissler H, Gadzicki D, Preisler-Adams S, Varon-Mateeva R, Schönbuchner I, Gevensleben H, GEMO Study Collaborators, Stoppa-Lyonnet D, Belotti M, Barjhoux L, Isaacs C, Peshkin BN, Caldes T, de al Hoya M, Cañadas C, Heikkinen T, Heikkilä P, Aittomäki K, Blanco I, Lazaro C, Brunet J, Agnarsson BA, Arason A, Barkardottir RB, Dumont M, Simard J, Montagna M, Agata S, D'Andrea E, Yan M, Fox S, kConFab Investigators75, Rebbeck TR, Rubinstein W, Tung N, Garber JE, Wang X, Fredericksen Z, Pankratz VS, Lindor NM, Szabo C, Offit K, Sakr R, Gaudet MM, Singer CF, Tea M-K, Rappaport C, Mai PL, Greene MH, Sokolenko A, Imyanitov E, Toland AE, Senter L, Sweet K, Thomassen M, Gerdes A-M, Kruse T, Caligo M, Aretini P, Rantala J, von Wachenfeld A, Henriksson K, SWE-BRCA Collaborators, Steele L, Neuhausen SL, Nussbaum B, Beattie M, Odunsi K, Sucheston L, Gayther SA, Nathanson K, Gross J, Walsh C, Karlan B, Chenevix-Trench G, Easton DF, Antoniou AC on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2* (2012) **Pathology of breast and ovarian cancers among *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA).** *Cancer, Epidemiology, Biomarkers & Prevention*, (Jan) 21:134-147. PMID : 22144499. [459]

364. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, Radice P, Stoppa-Lyonnet D, Tavtigian S, Wappenschmidt B, Couch FJ, Goldgar DE; ENIGMA collaborators, Couch F, Fackenthal JD, Thomassen M, Teo SH, Hansen TV, Borg Å, Eeles R, Toland A, Rogan P, Hansen TV, Guidugli L, Brody LC, Healey S, Brown M, Kwong A, Lei-po CW, Nevanlinna H, Garber J, Foretova L, Singer CF, Blok MJ, Spurdle AB, Osorio A, Kote-Jarai Z, Wappenschmidt B, Baralle D, Vega A, Blanco A, Santamariña M, Fachal L, Nederlof P, Peock S, Pasini B, Tommasi S, Lafferty A, Ansari A, Konstantopoulou I, Pal T, Simard J, Bonetti A, Varesco L, Peissel B, Evans DG, Foulkes W, Szabo C, van Asperen C, Jonkers J, Walker L, Mitchell G, Gutiérrez-Enríquez S, Diez O, Millot G, Fostira F, Selkirk C, Antoniou A, Monteiro A, Carvalho M, Rubinstein WS, de la Hoya M, Domchek S, Caputo S, Houdayer C, Blanco I, Lázaro C, Whiley P, Becker A, Aretini P, Eccles D, Caldes T, Viel A, Izatt L, Hogervorst F, Radice P, Nathanson K, Pedersen IS, Vreeswijk M, Neuhausen S, Yannoukakos K, Tucker K, Southey M, Leary J, Caligo MA, Garcia EG, Devereau A, Brandao R, Lidereau R, Montagna M, Pertesi M, Cornell M, Rouleau E, Sharan S, Rahman N, Lalloo F, Weitzel J, Campbell J, Cummings, Machakova E, Olopade F, Godwin A, Ozcelik H, Seminara D (2012) **ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in *BRCA1* and *BRCA2* genes**. *Human Mutation*, (Jan) 33:2-7. PMID : 21990146. [217]

365. Stevens KN, Wang X, Fredericksen Z, Pankratz VS, Greene MH, Andrulis IL, Thomassen M, Caligo M, Nathanson KL, Jakubowska A, Osorio A, Hamann U, Godwin AK, Stoppa-Lyonnet D, Southey M, Buys SS, Singer CF, V.O. Hansen T, Arason A, Offit K, Piedmonte M, Montagna M, Imyanitov E, Tihomirova L, Sucheston L, Beattie M, Neuhausen SL, Szabo CI, Simard J, Spurdle AB, Healey S, Chen X, Rebbeck TR, Easton DF, Chenevix-Trench G, Antoniou AC, Couch FJ (2012) **Evaluation of chromosome 6p22 as a breast cancer risk modifier locus in a follow-up study of *BRCA2* mutation carriers.** *Breast Cancer Research and Treatment,* (Nov) 136:295-302. PMID : 23011509. [6]

366. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, Edwards SL, Pickett HA, Shen HC, Smart CE, Hillman KM, Mai PL, Lawrenson K, Stutz MD, Lu Y, Karevan R, Woods N, Johnston RL, French JD, Chen X, Weischer M, Nielsen SF, Maranian MJ, Ghoussaini M, Ahmed S, Baynes C, Bolla MK, Wang Q, Dennis J, McGuffog L, Barrowdale D, Lee A, Healey S, Lush M, Tessier DC, Vincent D, Bacot F, Vergote I, Lambrechts S, Despierre E, Risch HA, González-Neira A, Rossing MA, Pita G, Doherty JA, Álvarez N, Larson MC, Fridley BL, Schoof N, Chang-Claude J, Cicek MS, Peto J, Kalli KR, Broeks A, Armasu SM, Schmidt MK, Braaf LM, Winterhoff B, Nevanlinna H, Konecny GE, Lambrechts D, Rogmann L, Guénel P, Teoman A, Milne RL, Garcia JJ, Cox A, Shridhar V, Burwinkel B, Marme F, Hein R, Sawyer

EJ, Haiman CA, Wang-Gohrke S, Andrulis IL, Moysich KB, Hopper JL, Odunsi K, Lindblom A, Giles GG, Brenner H, Simard J, Lurie G, Fasching PA, Carney ME, Radice P, Wilkens LR, Swerdlow A, Goodman MT, Brauch H, García-Closas M, Hillemanns P, Winqvist R, Dürst M, Devilee P, Runnebaum I, Jakubowska A, Lubinski J, Mannermaa A, Butzow R, Bogdanova NV, Dörk T, Pelttari LM, Zheng W, Leminen A, Anton-Culver H, Bunker CH, Kristensen V, Ness RB, Muir K, Edwards R, Meindl A, Heitz F, Matsuo K, du Bois A, Wu AH, Harter P, Teo S-H, Schwaab I, Shu X-U, Blot W, Hosono S, Kang D, Nakanishi T, Hartman M, Yatabe Y, Hamann U, Karlan BY, Sangrajrang S, Krüger Kjaer S, Gaborieau V, Jensen A, Eccles D, Høgdall E, Shen C-Y, Brown J, Woo YL, Shah M, Adenan Noor Azmi M, Luben R, Zawiah Omar S, Czene K, Vierkant RA, Nordestgaard BG, Flyger H, Vachon C, Olson JE, Wang X, Levine DA, Rudolph A, Palmieri Weber R, Flesch-Janys D, Iversen E, Nickels S, Schildkraut JL, Dos Santos Silva I, Cramer DW, Gibson L, Terry KL, Fletcher O, Vitonis AF, van der Schoot CE, Poole EM, Hogervorst FBL, Tworoger SS, Liu J, Bandera EV, Li J, Olson SH, Humphreys K, Orlow I, Blomqvist C, Rodriguez-Rodriguez L, Aittomäki K, Salvesen HB, Muranen TA, Wik E, Brouwers B, Krakstad B, Wauters E, Halle MK, Wildiers H, Kiemeney LA, Mulot C, Aben KK, Laurent-Puig P, van Altena AM, Truong T, Massuger LFAG, Benitez J, Pejovic T, Arias Perez JI, Hoatlin M, Zamora MP, Cook LS, Balasubramanian SP, Kelemen LE, Schneeweiss A, Le ND, Sohn C, Brooks-Wilson A, Tomlinson I, Kerin MJ, Miller N, Cybulski C, Henderson BE, Menkiszak J, Schumacher F, Wentzensen N, Le Marchand L, Yang HP, Mulligan AM, Glendon G, Aage Engelholm S, Knight JA, Høgdall CK, Apicella C, Gore M, Tsimiklis H, Song H, Southey MC, Jager A, van den Ouweland AMW, Brown R, Martens JWM, Flanagan JM, Kriege M, Paul J, Margolin S, Siddiqui N, Severi G, Whittemore AS, Baglietto L, McGuire V, Stegmaier C, Sieh W, Müller H, Arndt V, Labrèche F, Gao Y-T, Goldberg MS, Yang G, Dumont M, McLaughlin JR, Hartmann A, Ekici AB, Beckmann MW, Phelan CM, Lux MP, Permuth-Wey J, Peissel B, Sellers TA, Ficarazzi F, Barile M, Ziogas A, Ashworth A, Gentry-Maharaj A, Jones M, Ramus SJ, Orr N, Menon U, Pearce CL, Brüning T, Pike MC, Ko Y-D, Lissowska J, Figueroa J, Kupryjanczyk J, Chanock SJ, Dansonka-Mieszkowska A, Jukkola-Vuorinen A, Rzepecka IK, Pylkäs K, Bidzinski M, Kauppila S, Hollestelle A, Seynaeve C, Tollenaar RAEM, Durda K, Jaworska K, Hartikainen JM, Kosma V-M, Kataja V, Antonenkova NN, Long J, Shrubsole M, Deming-Halverson S, Lophatananon A, Siriwanarangsan P, Stewart-Brown S, Ditsch N, Lichtner P, Schmutzler RK, Ito H, Iwata H, Tajima K, Tseng C-C, Stram DO, van den Berg D, Yip CH, Ikram MK, The Y-C, Cai H, Lu W, Signorello LB, Cai W, Noh D-Y, Yoo K-Y, Miao H, Tsau-Choong Iau P, Teo YY, McKay J, Shapiro C, Ademuyiwa F, Fountzilas G, Hsiung C-N, Yu J-C, Hou M-F, Healey CS, Luccarini C, Peock S, Stoppa-Lyonnet D, Peterlongo P, Rebbeck TR, Piedmonte M, Singer CF, Friedman E, Thomassen M, Offit K, van Overeem Hansen T, Neuhausen SL, Szabo CI, Blanco I, Garber J, Narod SA, Weitzel JN, Montagna M, Olah E, Godwin AK, Yannoukakos D, Goldgar DE, Caldes T, Imyanitov EN, Tihomirova L, Arun BK, Campbell I, Mensenkamp AR, van Asperen CJ, van Roozendaal KEP, Meijers-Heijboer HEJ, Collée JM, Oosterwijk JC, Hooning MJ, Rookus MA, van der Luijt RB, van Os TAM, Evans DG, Frost D, Fineberg E, Barwell J, Walker L, Kennedy MJ, Platte R, Davidson R, Ellis SD, Cole T, Bressac-de Paillerets B, Buecher B, Damiola F, Faivre L, Frenay M, Sinilnikova OM, Caron O, Giraud S, Mazoyer S, Bonadona V, Caux-Moncoutier V, Toloczko-Grabarek A, Gronwald J, Byrski T, Spurdle AB, Bonanni B, Zaffaroni D, Giannini G, Bernard L, Dolcetti R, Manoukian S, Arnold N, Engel C, Deissler H, Rhiem K, Niederacher D, Plendl H, Sutter C, Wappenschmidt B, Borg A, Melin B, Rantala J, Soller M, Nathanson KL, Domchek SM, Rodriguez GC, Salani R, Geschwantler Kaulich D, Tea M-K, Paluch SS, Laitman Y, Skytte A-B, Kruse TA, Birk Jensen U, Robson M, Gerdes A-M, Ejlertsen B, Foretova L, Savage SA, Lester J, Soucy P, Kuchenbaecker KB, Olswold C, Cunningham JM, Slager S, Pankratz VS, Dicks E, Lakhani SR, Couch FJ, Hall P, Monteiro ANA, Gayther SA, Pharoah PDP, Reddel RR, Goode EL, Greene MH, Easton DF, Berchuck A, Antoniou AC, Chenevix-Trench G, Dunning AM (2013) **Multiple independent variants at the *TERT* locus are associated with telomere length and risks of breast and ovarian cancer.** *Nature Genetics*, (Avr) 45:371-384. PMID : 23535731. [510]

367. COMPLEXO, Southey M, Park D, Nguyen-Dumont T, Campbell I, Thompson E, Chenevix-Trench G, Simard J, Dumont M, Soucy P, Thomassen M, Jonson L, Pedersen I, Hansen T, Nevanlinna H, Khan S, Sinilnikova O, Mazoyer S, Lesueur F, Damiola F, Schmutler R, Meidl A, Hahnen E, Dufault M, Chan C, Barkardóttir R, Radice P, Peterlongo P, Devilee P, Hilbers F, Benitez J, Kvist A, Törngren TY, Easton D, Hunter D, Lindstrom S, Kraft P, Long J, Ramus S, Feng B-J, Weitzel J, Nathanson K, Offit K, Joseph V, Schrader K, Ming Wang S, Tavtigian S, Neuhausen S, Couch F, Goldgar D, Trainer A, Kwong A, Snyder

C, Lynch H, Zheng W, Gao Y-T and Kim Y (2013) **COMPLEXO: Identifying the missing heritability of breast cancer via next generation collaboration**. *Breast Cancer Research,* (Juin) 21;15:402. PMID: 23809231. [36]

368. French JD, Ghoussaini M, Meyer KB, Edwards S, Michailidou K, Ahmed S, Khan S, Maranian MJ, O'Reilly M, Hillman KM, Betts JA, Carroll T, Bailey PJ, Dicks PJ, Beesley J, Tyrer J, Maia A-T, Barnes D, González-Neira A, Alonso MR, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Conroy D, Dennis J, Humphreys MK, Wang Q, Hopper JL, Southey MC, Schmidt MK, Broeks A, Verhoef S, Cornelissen S, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Loehberg CR, Ekici AB, Beckmann MW, Peto J, dos Santos Silva I, Johnson N, Aitken Z, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Zamora MP, Arias Perez JI, Benitez J, Anton-Culver H, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Engel C, Brauch H, Hamann U, Justenhoven C, The GENICA Network, Aaltonen K, Heikkilä P, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Sueta A, Bogdanova NV, Antonenkova NN, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, kConFab Investigators, Wu AH, Tseng C-C, Van Den Berg D, Stram DO, Lambrechts D, Peeters S, Smeets A, Floris G, Chang-Claude J, Rudolph, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Sardella D, Couch FJ, Wang X, Pankratz VS, Lee A, Giles GG, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, NG C-H, Vithana EN, Kristensen V, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devillee P, Seynaeve C, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Klevebring D, Schoof N, Hooning MJ, Martens JWM, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Liu J, Humphreys K, Shu X-O, Lu W, Gao Y-T, Cai H, Cox A, Balasubramanian SP, Blot W, Signorello LB, Cai Q, Pharoah PDP, Healey CS, Shah M, Pooley KA, Kang D, Yoo K-Y, Noh D-Y, Hartman M, Miao H, Sng J-H, Sim X, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, McKay J, Toland AE, Ambrosone CB, Yannoukakos C, Godwin A, Shen C-Y, Hsiung C-N, Wu P-E, Chen S-T, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Ponder BAJ, Nevanlinna H, Brown MA, Chenevix-Trench G, Easton DF, Dunning AM (2013) **Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers.** *The American Journal of Human Genetics,* (Avr) 92:489-503. PMID : 23540573. [209]

369. Meyer KB, O'Reilly M, Michailidou K, Carlebur S, Edwards SL, French JD, Prathalingham R, Dennis J, Bolla MK, Wang Q, de Santiago I, Hopper JL, Tsimiklis H, Apicella C, Southey MC, Schmidt MK, Broeks A, Van 't Veer LJ, Hogervorst FB, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Lux MP, Ekici AB, Beckmann MW, Peto J, dos Santos Silva I, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Menegaux F, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Zamora MP, Arias JI, Benitez J, Neuhausen S, Anton-Culver H, Ziogas A, Dur CC, Brenner H, Müller H, Arndt V, Stegmaier C, Meindl A, Schmutzler RK, Engel C, Ditsch N, Brauch H, Brüning T, Ko Y-D, The GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Yatabe Y, Dörk T, Helbig S, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, Chenevix-Trench G, kConFab Investigators, Australian Ovarian Cancer Study Group, Wu AH, Tseng C-C, Van Den Berg D, Stram DO, Lambrechts D, Thienpont B, Christiaens M-R, Smeets A, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Bernard L, Couch FJ, Olson JE, Wang X, Purrington K, Giles GG, Severi G, Baglietto L, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo S-H, Yip C-H, Phuah S-Y, Kristensen V, Grenaker Alnæs G, Børresen-Dale AL, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RAEM, Seynaeve CM, García-Closas M, Figueroa J, Chanock AJ, Lissowska J, Czene K, Darabi H, Eriksson K, Hooning MJ, Martens JWM, van den Ouweland AMW, van Deurzen CHM, Hall P, Li J, Liu J, Humphreys K, Shu X-O, Lu W, Gao Y-T, Cai H, Cox A, Reed MWR, Blot W, Signorello LB, Cai Q, Pharoah PDP, Ghoussaini M, Harrington P,Tyrer J, Kang D, Choi J-Y, Park SK, Noh D-Y, Hartman M, Hui M, Lim W-Y, Buhari SA, Hamann U, Försti A, Rüdiger T, Ulmer H-U, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P,

McKay J, Vachon C, Slager S, Fostira F, Pilarski R, Shen C-Y, Hsiung C-N, Wu P-E, Hou M-F, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, Ponder BAJ, Dunning AM, Easton DF (2013) **Fine scale mapping of the FGFR2 breast risk locus: putative functional variants differentially bind FOXA1 and E2F1.** *The American Journal of Human Genetics,* (Déc) 93:1046-1060. PMID: 24290378. [114]

370. Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno LT, Alonso M R, Dennis J, Wang Q, Bolla MK, Meyer K B, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Lindblom A, Margolin S, Swerdlow A, Ashworth A, Orr N, Jones M, Matsuo K, Ito H, Iwata H, Kondo N, kConFab Investigators, Australian Ovarian Cancer Study Group, Hartman M, Hui M, Lim WY, Tsau-Choong Iau P, Sawyer E, Tomlinson I, Kerin, M, Miller N, Kang D, Choi J-Y, Park SK, Noh D-Y, Hopper JL, Schmidt DF, Makalic E, Southey MC, Teo SH, Yip CH, Sivanandan K, Tay W-T, Brauch H, Brüning T, Hamann U, The GENICA Network, Dunning AM, Shah M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Schmidt MK, Broeks A, Rosenberg EH, van't Veer LJ, Fasching PA, Renner SP, Ekici AB, Beckmann MW, Shen C-Y, Hsiung C-N, Yu J-VC, Hou M-F, Blot W, Cai Q, Wu AH, Tseng C-C, Van Den Berg D, Stram DO, Cox A, Brock IW, Reed MWR, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Shu X-O, Lu W, Gao Y-T, Zhang B, Radice P, Peterlongo P, Manoukian S, Mariette F, Sangrajrang S, McKay J, Couch FJ, Toland AE, TNBCC, Yannoukakos D, Fletcher O, Johnson N, Silva IS, Peto J, Marme F, Burwinkel B, Guénel P, Truong T, Sanchez M, Mulot C, Bojesen SE, Nordestgaard BG, Flyer H, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Mannermaa A, Kataja V, Kosma V-M, Hartikainen J, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Giles GG, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Dumont M, Goldberg MS, Labrèche F, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Devilee P, Tollenaar RAEM, Seynaeve C, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Czene K, Eriksson M, Humphreys K, Darabi H, Hooning M, Kriege M, Collée M, Tilanus-Linthorst M, Li J, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova N, Dörk T, Hall P, Chenevix-Trench G, Easton DF, Pharoah PDP, Ignacio Arias-Perez J, Zamora P, Benítez J and R L Milne (2014) **FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium**. *British Journal of Cancer*, (Fév) 110:1088-1100. PMID: 24548884. [23]

371. Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sallari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lamb rechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJ Th, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi J-Y, Park SK, Noh D-Y, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng C-c, Van Den Berg D, Stram DO, Benitez J, Zamora MP, Arias Perez JI, Menéndez P, Shu X-O, Lu W, Gao Y-T, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Australian Ovarian Cancer Management Group, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen C-Y, Wu P-E, Yu J-C, Chen S-T, Grenaker Alnæs G, Borresen-Dale A-L, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Bin Syed Buhar SA, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chan ock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto Y-D, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, Devilee P, Tollenaar R.A.E.M., Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM (2014) **Evidence that breast**

cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications,* (Sept) 4:4999. PMID : 25248036. [108]

372. Johnson N, Dudbridge F, Orr N, Gibson L, Jones ME, Schoemaker MJ, Folkerd EJ, Haynes BP, Hopper JL, Southey MC, Dite GS, Apicella C, Schmidt MK, Broeks A, Van 't Veer LJ, Atsma F, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Ekici AB, Renner SP, Sawyer E, Tomlinson I, Kerin M, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina E, Menegaux F, Bojesen SE, Nordestgaard BG, Flyger H, Milne R, Zamora MP, Arias Perez JI, Benitez J, Bernstein L, Anton-Culver H, Ziogas A, Dur CC, Brenner H, Müller H, Arndt V, Zaineddin K, Meindl A, Heil J, Bartram CR, Schmutzler RK, Brauch H, Justenhoven C, Ko Y-D, The GENICA (Gene Environment Interaction and Breast Cancer in Germany) Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Matsuo K, Dörk T, Bogdanova NV, Antonenkova NN, Lindblom A, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, Chenevix-Trench G, Beesley J, kConFab Investigators, Australian Ovarian Cancer Study Group, Wu AH, Van den Berg D, Tseng C-C, Lambrechts D, Smeets D, Neven P, Wildiers H, Chang-Claude J, Rudolph A, Nickels S, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Pensotti V, Couch FJ, Olson JE, Wang X, Pankratz VS, Giles GG, Severi G, Baglietto L, Haiman C, Simard J, Goldberg MS, Labrèche F, Dumont M, Soucy P, Teo S, Yip CH, Phuah SY, Cornes B, Kristensen VN, Alnæs GG, Børresen-Dale A-L, Zheng W, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devillee P, Figueroa J, Chanock SJ, Lissowska J, Sherman ME, Hall P, Schoof N, Hooning M, Hollestelle A, Oldenburg RA, Tilanus-Linthorst M, Liu J, Cox A, Brock IW, Reed MWR, Cross SS, Blot W, Signorello LB, Pharoah PDP, Dunning AM, Shah M, Kang D, Noh D-Y, Park SK, Choi J-Y, Hartman M, Miao H, Lim WY, Hamann U, Försti A, Rüdiger T, Ulmer HU, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Vachon C, Yannoukakos D, Shen C-Y, Yu J-C, Huang C-S, Hou M-F, González-Neira A, Tessier DC, Vincent D, Bacot F, Luccarini C, Dennis J, Michailidou K, Bolla MK, Wang J, Easton DF, García-Closas M, Dowsett M, Ashworth A, Swerdlow AJ, Peto J, dos Santos Silva I, Fletcher O (2014) **Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.** *Breast Cancer Research,* (Mai) 16:R51. PMID : 24887515. [14]

373. Khan S, Greco D, Michailidou K, Milne RL, Muranen TA, Heikkinen T, Aaltonen K, Dennis J, Bolla MK, Liu J, Hall P, Irwanto A, Humphreys K, Li J, Czene K, Chang-Claude J, Hein R, Rudolph A, Seibold P, Flesch-Janys D, Fletcher O, Peto J, dos Santos Silva I, Johnson N, Gibson L, Aitken Z, Hopper JL, Tsimiklis H, Bui M, Makalic E, Schmidt DF, Southey MC, Apicella C, Stone J, Waisfisz Q, Meijers-Heijboer H, Adank MA, van der Luijt RB, Meindl A, Schmutzler RK, Müller-Myhsok B, Lichtner P, Turnbull C, Rahman N, Chanock SJ, Hunter DJ, Cox A, Cross SS, Reed MWR, Schmidt MK, Broeks A, Van't Veer LJ, Hogervorst FB, Fasching PA, Schrauder MG, Ekici AB, Beckmann MW, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Benitez J, Zamor PM, Perez JIA, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Pharoah PDP, Dunning AM, Shah M, Luben R, Brown J, Couch FJ, Wang X, Vachon C, Olson JE, Lambrechts D, Moisse M, Paridaens R, Christiaens M-R, Guénel P, Truong T, Laurent-Puig P, Mulot C, Marme F, Burwinkel B, Schneeweiss A, Sohn C, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Andrulis IL, Knight JA, Tchatchou S, Mulligan AM, Dörk T, Bogdanova NV, Antonenkova NN, Anton-Culver H, Darabi H, Eriksson M, Garcia-Closas M, Figueroa J, Lissowska J, Brinton L, Devilee P, Tollenaar RAEM, Seynaeve C, van Asperen CJ, Kristensen VN, kConFab Investigators, Australian Ovarian Cancer Study Group, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Lindblom A, Margolin S, Radice P, Peterlongo P, Barile M, Mariani P, Hooning MJ, Martens JWM, Margriet Collée J, Jager A, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Giles GG, McLean C, Brauch H, Brüning T, Ko Y-D, The GENICA Network, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Jones M, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Kataja V, Kosma V-M, Hartikainen JM, Mannermaa A, Hamann U, Chenevix-Trench G, Blomqvist C, Aittomäki C, Easton DF, Nevanlinna H (2014) **MicroRNA related polymorphisms and breast cancer risk.** *PLoS One,* (Nov) 9:e109973. PMID: 25390939. [36]

374. Milne RL, Herranz J, Michailidou K, Dennis J, Tyrer JP, Zamora MP, Arias-Perez JI, González-Neira A, Pita G, Alonso MR, Wang Q, Bolla MK, Czene K, Eriksson M, Humphreys K, Darabi H, Li J, Anton-Culver H, Neuhausen SL, Ziogas A, Clarke CA, Hopper JL, Dite GS, Apicella C, Southey MC, Chenevix-Trench G, kConFab Investigators, Australian Ovarian Cancer Study Group, Anthony Swerdlow, Ashworth A, Orr

N, Schoemaker M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Bojesen SE, Nordestgaard BG, Flyger H, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Dunning AM, Shah M, Guénel P, Truong T, Sanchez M, Mulot C, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Lindblom A, Margolin S, Hooning M, Hollestelle A, Collée M, Jager A, Cox A, Brock IW, Reed MWR, Devilee P, Tollenaar RAEM, Seynaeve C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Dumont M, Soucy P, Dörk T, Bogdanova NV, Hamann U, Försti A, Rüdiger T, Ulmer HU, Fasching PA, Häberle L, Ekici AB, Beckmann MW, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Radice P, Peterlongo P, Peissel B, Mariani P, Giles GG, Severi G, Baglietto L, Sawyer E, Tomlinson I, Kerin M, Miller N, Marme F, Burwinkel B, Mannermaa A, Kataja V, Kosma V-M, Hartikainen J, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Grenaker Alnæs G, Kristensen V, Børresen-Dale A-L, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Schmidt MK, Broeks A, Verhoef S, Rutgers EJ, Brauch H, Brüning T, Ko Y-D, The GENICA Network, Couch FJ, Toland AE, The TNBCC, Yannoukakos D, Pharoah PDP, Hall P, Benítez J, Malats N, Easton DF (2014) **A Large-Scale Assessment of Two-Way SNP Interactions in Breast Cancer Susceptibility Using 46,450 Cases and 42,461 Controls from the Breast Cancer Association Consortium.** *Human Molecular Genetics,* (Nov) 23:1934-1946. PMID: 24242184. [39]

375. Milne RL, Burwinkel B, Michailidou K, Arias-Perez JI, Zamora MP, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Pita G, Alonso MR, Dennis J, Wang Q, Bolla MK, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Ko YD, Brauch H, Hamann U; GENICA Network, Andrulis IL, Knight JA, Glendon G, Tchatchou S; kConFab Investigators; Australian Ovarian Cancer Study Group, Matsuo K, Ito H, Iwata H, Tajima K, Li J, Brand JS, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Lambrechts D, Peuteman G, Christiaens MR, Smeets A, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Hartman M, Hui M, Yen Lim W, Wan Chan C, Marme F, Yang R, Bugert P, Lindblom A, Margolin S, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Bojesen SE, Nordestgaard BG, Flyger H, Hooning MJ, Kriege M, van den Ouweland AM, Koppert LB, Fletcher O, Johnson N, Dos-Santos-Silva I, Peto J, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Cox A, Cross SS, Reed MW, Schmidt MK, Broeks A, Cornelissen S, Braaf L, Kang D, Choi JY, Park SK, Noh DY, Simard J, Dumont M, Goldberg MS, Labrèche F, Fasching PA, Hein A, Ekici AB, Beckmann MW, Radice P, Peterlongo P, Azzollini J, Barile M, Sawyer E, Tomlinson I, Kerin M, Miller N, Hopper JL, Schmidt DF, Makalic E, Southey MC, Hwang Teo S, Har Yip C, Sivanandan K, Tay WT, Shen CY, Hsiung CN, Yu JC, Hou MF, Guénel P, Truong T, Sanchez M, Mulot C, Blot W, Cai Q, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Bogdanova N, Dörk T, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Shu XO, Lu W, Gao YT, Zhang B, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Sangrajrang S, McKay J, Wang X, Olson JE, Vachon C, Purrington K, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Devilee P, Tollenaar RA, Seynaeve C, Czene K, Eriksson M, Humphreys K, Darabi H, Ahmed S, Shah M, Pharoah PD, Hall P, Giles GG, Benítez J, Dunning AM, Chenevix-Trench G, Easton DF; GENICA Network (2014) **Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium.** *Human Molecular Genetics,* (Nov) 23:6096-6111. PMID : 24943594. [88]

376. Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, Bojesen SE, Andrulis IL, Cox A, Hall P, Carpenter J, Yannoukakos D, Haiman CA, Fasching PA, Mannermaa A, Winqvist R, Brenner H, Lindblom A, Chenevix-Trench G, Benitez J, Swerdlow A, Kristensen V, Guénel P, Meindl A, Darabi H, Eriksson M, Fagerholm R, Aittomäki, Blomqvist C, Nordestgaard BG, Nielsen SF, Flyger H, Wang X, Olswold C, Olson JE, Mulligan AM, Knight JA, Tchatchou S, Reed MWR, Cross SS, Liu J, Li J, Humphreys K, Clarke C, Scott R, ABCTB Investigators, Fostira F, Fountzilas G, Konstantopoulou I, Henderson BE, Schumacher F, Le Marchand L, Ekici AB, Hartmann A, Beckmann MW, Hartikainen JM, Kosma V-M, Kataja V, Jukkola-Vuorinen A, Pylkäs K, Kauppila S, Dieffenbach AK, Stegmaier C, Arndt V, Margolin S, Australian Ovarian Cancer Study Group, kConFab Investigators, Balleine R, Arias Perez JI, Zamora MP, Menéndez P, Ashworth A, Jones J, Orr N, Arveux P, Kerbrat P, Truong T, Bugert P, Toland AE, Ambrosone CB, Labrèche F, Goldberg MS, Dumont M, Ziogas A, Lee E, Dite GS, Apicella C, Southey MC, Long J, Shrubsole M, Deming-Halverson S, Ficarazzi F, Barile M, Peterlongo P, Durda K, Jaworska-Bieniek K,

Tollenaar RAEM., Seynaeve C, The GENICA Network, Brüning T, Ko Y-D, Van Deurzen CHM, Martens JWM, Kriege M, Figueroa JD, Chanock SJ, Lissowska J, Tomlinson I, Kerin MJ, Miller N, Schneeweiss A, Tapper WJ, Gerty SM, Durcan L, Mclean C, Milne RL, Baglietto L, dos Santos Silva I, Fletcher O, Johnson N, Van'T Veer LJ, Cornelissen S, Försti A, Torres D, Rüdiger T, Rudolph A, Flesch-Janys D, Nickels S, Weltens C, Floris G, Moisse M, Dennis J, Wang Q, Dunning AM, Shah M, Brown J, Simard J, Anton-Culver H, Neuhausen SL, Hopper JL, Bogdanova N, Dörk T, Zheng W, Radice P, Jakubowska A, Lubinski J, Devillee P, Brauch H, Hooning M, García-Closas M, Sawyer E, Burwinkel B, Marmee F, Eccles DM , Giles GG, Peto J, Schmidt M, Broeks A, Hamann U, Chang-Claude J, Lambrechts D, Pharoah PDP, Easton D, Pankratz VS, Olson JE, Slager S, Vachon CM, Couch FJ (2014) **Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.** *Human Molecular Genetics,* (Nov) 23:6034-6046. PMID : 24927736. [21]

377. Sawyer E, Roylance E, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins K-A, Gillett C, Houlston R, Ross G, De Ieso P, Southey MC, Hopper JL, Provenzano E, Apicella C, Wesseling J, Cornelissen S, Keeman R, Fasching PA, Jud SM, Ekici AB, Beckmann MW, Kerin MJ, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Kerbrat P, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Arias Perez JI, Menéndez P, Benitez J, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Lochmann M, Brauch H, Fischer H-P, Ko Y-D, The GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, Chenevix-Trench G, kConFab Investigators, Lambrechts D, Weltens C, Van Limbergen E, Hatse S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Volorio S, Giles GG, Severi G, Baglietto L, Mclean CA, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Kristensen V, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis I, Knight JA, Glendon G, Mulligan AM, Devillee P, Tollenaar RAEM, Seynaeve CM, Kriege M, Figueroa J, Chanock SJ, Sherman ME, Hooning MJ, Hollestelle A, van den Ouweland AMW, van Deurzen CHM, Li J, Czene K, Humphreys K, Cox A, Cross SS, Reed MWR, Shah M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Couch FJ, Hallberg E, González-Neira A, Pita G, Alonso MR, Tessier DC, Vincent D, Bacot F, Bolla MK, Wang Q, Dennis J, Michailidou K, Dunning AM, Hall P, Easton D, Pharoah P, Schmidt MK, Tomlinson I, Garcia-Closas M (2014) **Genetic predisposition to in situ and invasive lobular carcinoma of the breast.** *PLoS Genetics,* (Avr) 10:e1004285. doi: 10.1371. PMID : 24743323. [50]

378. Schoeps A, Rudolph A, Seibold P, Dunning AM, Milne RL, Bojesen SE, Swerdlow A, Andrulis I, Brenner H, Behrens S, Orr N, Jones M, Ashworth A, Li J, Cramp H, Connley D, Czene K, Darabi H, Chanock SJ, Lissowska J, Figueroa JD, Knight J, Glendon G, Mulligan AM, Dumont M, Severi G, Baglietto L, Olson J, Vachon C, Purrington K, Moisse M, Neven P, Wildiers H, Spurdle A, Kosma V-M, Kataja V, Hartikainen JM, Hamann U, Ko Y-D, Dieffenbach AK, Arndt V, Stegmaier C, Malats N, Arias Perez JI, Benítez J, Flyger H, Nordestgaard BG, Truong T, Cordina-Duverger E, Menegaux F, dos Santos Silva I, Fletcher O, Johnson N, Häberle L, Beckmann MW, Ekici AB, Braaf L, Atsma F, van den Broek AJ, Makalic E, Schmidt DF, Southey MC, Cox A, Simard J, Giles GG, Lambrechts D, Mannermaa A, Brauch H, Guénel P, Peto J, Fasching PA, Hopper J, Flesch-Janys D, Couch F, Chenevix-Trench G, Pharoah PDP, Garcia-Closas M, Schmidt MK, Hall P, Easton DF and Chang-Claude J (2014) **Identification of New Genetic Susceptibility Loci for Breast Cancer Through Consideration of Gene-Environment Interactions.** *Genetic Epidemiology,* (Jan) 38:84-93. PMID : 24248812. [28]

379. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sánchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Català I, Brunet J, Feliubadaló L, Tornero E, Benítez J, Osorio A, Cajal TR, Nevanlinna H, Aittomäki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van Maerken T, Díez O, Hansen TV, Jønson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldés T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR; Teixeira, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE,

Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D, Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G; BCFR, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E; SWE-BRCA, Liljegren A, Rantala J, Stenmark-Askmalm M, Loman N, Imyanitov EN, Hamann U; kConFab Investigators, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gómez A, Sayols S, Vidal E, Heyn H; GEMO, Stoppa-Lyonnet D, Léoné M, Barjhoux L, Fassy-Colcombet M, de Pauw A, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lázaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA (2015) **Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in *BRCA1/2* Mutation Carriers**. *PLoS One*, (Avr), 10(4):e0120020. doi:10.1371/journal.pone.0120020. eCollection 2015. PMID: 25830658. [46]

380. Darabi H, McCue K, Beesley J, Michailidou K, Nord S, Kar S, Humphreys K, Thompson D, Ghoussaini M, Bolla MK, Dennis J, Wang Q, Canisius S, Scott CG, Apicella C, Hopper JL, Southey MC, Stone J, Broeks A, Schmidt MK, Scott RJ, Lophatananon A, Muir K, Beckmann MW, Ekici AB, Fasching PA, Heusinger K, dos-Santos-Silva I, Peto J, Tomlinson I, Sawyer EJ, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, Benitez J, González-Neira A, Anton-Culver H, Neuhausen SL, Arndt V, Brenner H, Engel C, Meindl A, Schmutzler RK, German Consortium of Hereditary Breast and Ovarian Cancer, Arnold N, Brauch H, Hamann U, Chang-Claude J, Khan S, Nevanlinna H, Ito H, Matsuo K, Bogdanova NV, Dörk T, Lindblom A, Margolin S, kConFab/AOCS Investigators, Kosma V-M, Mannermaa A, Tseng C-C, Wu AH, Floris G, Lambrechts D, Rudolph A, Peterlongo P, Radice P, Couch FJ, Vachon C, Giles GG, McLean C, Milne RL, Dugué P-A, Haiman CA, Maskarinec G, Woolcott C, Henderson BE, Goldberg MS, Simard J, Teo SH, Mariapun S, Helland A, Haakensen V, Zheng W, Beeghly-Fadiel A, Tamimi R, Jukkola-Vuorinen A, Winqvist R, Andrulis IL, Knight JA, Devilee P, Tollenaar RAEM, Figueroa J, García-Closas M, Czene K, Hooning MJ, Tilanus-Linthorst M, Li J, Gao Y-T, Shu Y-O, Cox A, Cross SS, Luben R, Khaw K-T, Choi J-Y, Kang D, Hartman M, Lim WY, Kabisch M, Torres D, Jakubowska A, Lubinski J, McKay J, Sangrajrang S, Toland AE, Yannoukakos D, Shen C-Y, Yu J-C, Ziogas A, Schoemaker MJ, Swerdlow A, Borresen-Dale A-L, Kristensen V, French JD, Edwards SL, Dunning AM, Easton DF, Hall P, Chenevix-Trench G (2015) **Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression**. *The American Journal of Human Genetics*, (Juil) 97:22-34. PMID : 26073781. [30]

381. Day FR, Ruth KS, Thompson DJ, Lunetta KL, Pervjakova N, Chasman DI, Stolk L, Finucane HK, Sulem P, Bulik-Sullivan B, Esko T, Johnson AD, Elks CE, Franceschini N, He C, Altmaier E, Brody JA, Franke LL, Huffman JE, Keller MF, McArdle PF, Nutile T, Porcu E, Robino A, Rose LM, Schick UM, Smith JA, Teumer A, Traglia M, Vuckovic D, Yao J, Zhao W, Albrecht E, Amin N, Corre T, Hottenga JJ, Mangino M, Smith AV, Tanaka T, Abecasis GR, Andrulis IL, Anton-Culver H, Antoniou AC, Arndt V, Arnold AM, Barbieri C, Beckmann MW, Beeghly-Fadiel A, Benitez J, Bernstein L, Bielinski SJ, Blomqvist C, Boerwinkle E, Bogdanova NV, Bojesen SE, Bolla MK, Borresen-Dale AL, Boutin TS, Brauch H, Brenner H, Brüning T, Burwinkel B, Campbell A, Campbell H, Chanock SJ, Chapman JR, Chen YI, Chenevix-Trench G, Couch FJ, Coviello AD, Cox A, Czene K, Darabi H, De Vivo I, Demerath EW, Dennis J, Devilee P, Dörk T, Dos-Santos-Silva I, Dunning AM, Eicher JD, Fasching PA, Faul JD, Figueroa J, Flesch-Janys D, Gandin I, Garcia ME, García-Closas M, Giles GG, Girotto GG, Goldberg MS, González-Neira A, Goodarzi MO, Grove ML, Gudbjartsson DF, Guénel P, Guo X, Haiman CA, Hall P, Hamann U, Henderson BE, Hocking LJ, Hofman A, Homuth G, Hooning MJ, Hopper JL, Hu FB, Huang J, Humphreys K, Hunter DJ, Jakubowska A, Jones SE, Kabisch M, Karasik D, Knight JA, Kolcic I, Kooperberg C, Kosma VM, Kriebel J, Kristensen V, Lambrechts D, Langenberg C, Li J, Li X, Lindström S, Liu Y, Luan J, Lubinski J, Mägi R, Mannermaa A, Manz J, Margolin S, Marten J, Martin NG, Masciullo C, Meindl A, Michailidou K, Mihailov E, Milani L, Milne RL, Müller-Nurasyid M, Nalls M, Neale BM, Nevanlinna H, Neven P, Newman AB, Nordestgaard BG, Olson JE, Padmanabhan S, Peterlongo P, Peters U, Petersmann A, Peto J,

Pharoah PD, Pirastu NN, Pirie A, Pistis G, Polasek O, Porteous D, Psaty BM, Pylkäs K, Radice P, Raffel LJ, Rivadeneira F, Rudan I, Rudolph A, Ruggiero D, Sala CF, Sanna S, Sawyer EJ, Schlessinger D, Schmidt MK, Schmidt F, Schmutzler RK, Schoemaker MJ, Scott RA, Seynaeve CM, Simard J, Sorice R, Southey MC, Stöckl D, Strauch K, Swerdlow A, Taylor KD, Thorsteinsdottir U, Toland AE, Tomlinson I, Truong T, Tryggvadottir L, Turner ST, Vozzi D, Wang Q, Wellons M, Willemsen G, Wilson JF, Winqvist R, Wolffenbuttel BB, Wright AF, Yannoukakos D, Zemunik T, Zheng W, Zygmunt M, Bergmann S, Boomsma DI, Buring JE, Ferrucci L, Montgomery GW, Gudnason V, Spector TD, van Duijn CM, Alizadeh BZ, Ciullo M, Crisponi L, Easton DF, Gasparini PP, Gieger C, Harris TB, Hayward C, Kardia SL, Kraft P, McKnight B, Metspalu A, Morrison AC, Reiner AP, Ridker PM, Rotter JI, Toniolo D, Uitterlinden AG, Ulivi S, Völzke H, Wareham NJ, Weir DR, Yerges-Armstrong LM; PRACTICAL Consortium; kConFab Investigators; AOCS Investigators; Generation Scotland; EPIC-InterAct Consortium; LifeLines Cohort Study, Price AL, Stefansson K, Visser JA, Ong KK, Chang-Claude J, Murabito JM, Perry JR, Murray A (2015) **Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and *BRCA1*-mediated DNA repair.** *Nature Genetics*, (Nov) 47(11):1294-1303. PMID: 26414677. [205]

382. Glubb DM, Maranian MJ, Michailidou K, Pooley KA, Meyer KB, Kar S, Carlebur S, O'Reilly M, Betts JA, Hillman KM, Kaufmann S, Beesley J, Hopper JL, Southey MC, Tsimiklis H, Apicella C, Schmidt MK, Broeks A, Hogervorst FB, van der Schoot CE, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Ruebner M, Ekici AB, Beckmann MW, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Pharoah PDP, Bolla MK, Wang Q, Dennis J, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Burwinkel B, Marme F, Yang R, Surowy H, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, González-Neira A, Benitez J, Zamora MP, Perez JIA, Anton-Culver H, Neuhausen SL, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Schmutzler RK, Brauch H, Ko Y-D, Brüning T, The GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Matsuo K, Ito H, Iwata H, Tanaka H, Dörk T, Bogdanova NV, Helbig S, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, kConFab Investigators, Wu AN, Tseng C-C, Van Den Berg D, Stram DO, Lambrechts D, Zhao H, Weltens C, van Limbergen E, Chang-Claude J, Flesch-Janys D, Rudolph A, Seibold P, Radice P, Peterlongo P, Capra MBF, Couch FJ, Olson JE, Hallberg E, Vachon C, Giles GG, Milne RL, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, See M-H, Cornes B, Cheng C-Y, Ikram MK, Kristensen V, NBCS, Zheng W, Halverson SL, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Klevebring D, Darabi H, Eriksson M, Hooning MJ, Hollestelle A, Martens JWM, Collée JM, Hall P, Li J, Humphreys K, Shu X-O, Lu W, Gao Y-T, Cai H, Cox A, Cross SS, Reed MWR, Blot W, Signorello LB, Cai Q, Shah M, Ghoussaini M, Kang D, Choi J-Y, Park SK, Noh D-Y, Hartman M, Miao H, Lim WY, Tang A, Hamann U, Torres D, Jakubowska A, Lubinski J, Jaworska K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Olswold C, Slager S, Toland AE, Yannoukakos D, Shen C-Y, Wu P-E, Yu J-C, Hou M-F, Swerdlow A, Ashworth A, Orr N, Jones M, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Luccarini C, Baynes C, Ahmed S, Healey CS, Brown MA, Ponder BAJ, Chenevix-Trench G, Thompson DJ, Edwards SL, Easton DF, Dunning AM and French JD (2015) **Fine scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.** *American Journal of Human Genetics,* (Jan) 96:5-20. PMID : 25529635. [73]

383. Kuchenbaecker K, Ramus S, Tyrer J, Lee A, Shen H, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen T V. O., Jønson L, Gerdes A-M, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, EMBRACE, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, GEMO Study Collaborators, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De Leeneer K, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomäki K, Nevanlinna H, Collée JM, Rookus MA, Oosterwijk JC, Breast Cancer Family Registry, Tihomirova L, Tung N, Hamann U, Isaccs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell I, Hogervorst FBL, HEBON, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M,

Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, KConFab Investigators, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea M-K, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmalm M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Australian Cancer Study (Ovarian Cancer), Australian Ovarian Cancer Study Group, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Dürst M, Hillemanns P, Dörk T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du Bois S, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kruger Kjaer S, Hogdall E, Nazihah Hasmad H, Noor Azmi MA, Teo S-H, Woo Y-L, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MAT, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Palmieri Weber R, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KKH, Kiemeney LA, Massuger LFAG, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, JI B-T, Zheng W, Shu X-U, Gao Y-T, Rosen B, Risch HA, McLaughlin JR, Narod SA, Monteiro AN, Chen A, Lin H-Y, Permuth-Wey J, Sellers TA, Tsai Y-Y, Chen Z, Ziogas A, Anton-Culver H, Gentry-Maharaj A, Menon U, Harrington P, Lee AW, Wu AH, Pearce CL, Coetzee G, Pike MC, Dansonka-Mieszkowska A, Timorek A, Rzepecka IK, Kupryjanczyk J, Freedman M, Noushmehr H, Easton DF, Offit K, Couch FJ, Gayther S, Pharoah PP, Antoniou AC and Chenevix-Trench G (2015) **Identification of six new susceptibility loci for invasive epithelial ovarian cancer.** *Nature Genetics,* (Fév) 47:164-171. PMID: 25581431. [222]

384. Lin W-Y, Camp NJ, Ghoussaini M, Beesley J, Michailidou K, Hopper JL, Apicella C, Southey MC, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Rutgers EJ Th, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Wang Q, Dennis J, Sawyer EJ, Cheng T, Tomlinson I, Kerin MJ, Miller N, Marmé F, Surowy HM, Burwinkel B, Guénel P, TruongT, Menegaux F, Mulot C, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Benitez J, Zamora MP, Arias Peres JI, Menéndez P, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Anton-Culver H, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Müller-Myhsok B, Brauch H, Brüning T, Ko Y-D, The GENICA Network, Tessier DC, Vincent D, Bacot F, Nevanlinna H, Aittomäki K, Blomqvist C, Khan S, Matsuo K, Ito H, Iwata H, Horio A, Bogdanova NV, Antonenkova NN, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma V-M, Hartikainen JM, KConFab Investigators, Australian Ovarian Cancer Study Group, Wu AH, Tseng C-C, Van Den Berg D, Stram DO, Neven P, Wauters E, Wildiers H, Lambrechts D, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Manoukian S, Bonanni B, Couch FJ, Wang X, Vachon C, Purrington K, Giles GG, Milne R, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Teo SH, Yip CH, Hassan N, Vithana EN, Kristensen V, Zheng W, Deming-Halverson S, Schrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, García-Closas M, Figueroa J, Lissowska J, Brinton L, Czene K, Darabi H, Eriksson M, Brand JS, Hooning MJ, Hollestelle A, van den Ouweland AMW, Jager A, Li J, Liu J, Humphreys K, Shu X-O, Lu W, Gao Y-T, Cai H, Cross SS, Reed MWR, Blot W, Signorello LB, Cai Q, Pharoah PDP, Perkins B, Shah M, Blows FM, Kang D, Yoo K-Y, Noh D-Y, Hartman M, Miao H, Chia KS, Choudary Putti T, Hamann U, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Slager S, Toland AE, Yannoukakos D, Shen C-Y, Hsiung C-N, Wu P-E, Ding S-L, Ashworth A, Jones M, Orr N, Swerdlow AJ, Tsimiklis H, Makalic E, Schmidt DF, Bui QM, Chanock SJ, Hunter DJ, Hein R, Dahmen N, Beckmann L, Aaltonen K, Muranen TA, Heikkinen T, Irwanto A, Rahman N, Turnbull C, The Breast and Ovarian Cancer Susceptibility Study, Waisfisz Q, Meijers-Heijboer HEJ, Adank MA, van der Luijt RB, Hall P, Chenevix-Trench G, Dunning A, Easton DF, Cox A

(2015) **Identification and characterisation of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk.** *Human Molecular Genetics,* (Jan) 24:285-298. PMID : 25168388. [65]

385. Orr N, Dudbridge F, Dryden N, Maguire S, Novo D, Perrakis E, Johnson N, Ghoussaini M, Hopper JL, Southey MC, Apicella C, Stone J, Schmidt MK, Broeks A, Van't Veer LJ, Hogervorst FB, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Gibson L, Aitken Z, Warren H, Sawyer E, Tomlinson I, Kerin MJ, Miller N, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Guénel P, Truong T, Cordina-Duverger E, Sanchez M, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Benitez J, Zamora MP, Arias Perez JI, Menéndez P, Anton-Culver H, Neuhausen SL, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Hamann U, Brauch H, Justenhoven C, Brüning T, Ko YD; The GENICA Network, Nevanlinna H, Aittomäki K, Blomqvist C, Khan S, Bogdanova N, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G, Beesley J; kConFab Investigators; Australian Ovarian Cancer Study Group, Lambrechts D, Moisse M, Floris G, Beuselinck B, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Peissel B, Pensotti V, Couch FJ, Olson JE, Slettedahl S, Vachon C, Giles GG, Milne RL, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Kristensen V, Alnæs GG, Nord S, Borresen-Dale AL, Zheng W, Deming-Halverson S, Shrubsole M, Long J, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Devilee P, Tollenaar RA, Seynaeve CM, Van Asperen CJ, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Klevebring D, Hooning MJ, Hollestelle A, van Deurzen CH, Kriege M, Hall P, Li J, Liu J, Humphreys K, Cox A, Cross SS, Reed MW, Pharoah PD, Dunning AM, Shah M, Perkins BJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Ashworth A, Swerdlow A, Jones M, Schoemaker MJ, Meindl A, Schmutzler RK, Olswold C, Slager S, Toland AE, Yannoukakos D, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Matsuo K, Ito H, Iwata H, Ishiguro J, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Teo SH, Yip CH, Kang P, Ikram MK, Shu XO, Lu W, Gao YT, Cai H, Kang D, Choi JY, Park SK, Noh DY, Hartman M, Miao H, Lim WY, Lee SC, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Wu PE, Hou MF, Yu JC, Shen CY, Blot W, Cai Q, Signorello LB, Luccarini C, Bayes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Hunter DJ, Lindstrom S, Dennis J, Michailidou K, Bolla MK, Easton DF, Dos Santos Silva I, Fletcher O, Peto J; GENICA Network; kConFab Investigors; Australian Ovarian Cancer Study Group. (2015) **Fine-mapping identifies two additional breast cancer susceptibility loci at 9q32.2**. *Human Molecular Genetics*, (Mai) 24:2966-2984. PMID : 25652398. [46]

386. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL; CIMBA Consortium, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmalm M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen TV, Ramón y Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De Paepe A, Poppe B, Claes K, De Leeneer K, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomäki K, van der Hout AH, Hogervorst FB, Verhoef S, Collée JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah

E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Złowocka-Perłowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH, Selkirk CG, Hulick PJ, Andrulis I (2015) **Association of type and location of *BRCA1* and *BRCA2* mutations with risk of breast and ovarian cancer**. *JAMA-Journal of the American Medical Association,* (Avr) 313:1347-1361. PMID: 25849179. [303]

387. Stone J, Thompson DJ, Dos Santos Silva I, Scott C, Tamimi RM, Lindstrom S, Kraft P, Hazra A, Li J, Eriksson L, Czene K, Hall P, Jensen M, Cunningham J, Olson JE, Purrington K, Couch FJ, Brown J, Leyland J, Warren RM, Luben RN, Khaw KT, Smith P, Wareham NJ, Jud SM, Heusinger K, Beckmann MW, Douglas JA, Shah KP, Chan HP, Helvie MA, Le Marchand L, Kolonel LN, Woolcott C, Maskarinec G, Haiman C, Giles GG, Baglietto L, Krishnan K, Southey MC, Apicella C, Andrulis IL, Knight JA, Ursin G, Alnaes GI, Kristensen VN, Borresen-Dale AL, Gram IT, Bolla MK, Wang Q, Michailidou K, Dennis J, Simard J, Pharoah PD, Dunning AM, Easton DF, Fasching PA, Pankratz VS, Hopper JL, Vachon CM (2015) **Novel associations between common breast cancer susceptibility variants and risk-predicting mammographic density measures.** *Cancer Research,* (Juin) 75:2457-2467. PMID: 25862352. [49]

388. Couch FJ, Kuchenbaecker KB, Michailidou K, Mendoza-Fandino GA, Nord S, Lilyquist J, Olswold C, Hallberg E, Agata S, Ahsan H, Aittomäki K, Ambrosone C, Andrulis IL, Anton-Culver H, Arndt V, Arun BK, Arver B, Barile M, Barkardottir RB, Barrowdale D, Beckmann L, Beckmann MW, Benitez J, Blank SV, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Brauch H, Brenner H, Burwinkel B, Buys SS, Caldes T, Caligo MA, Canzian F, Carpenter J, Chang-Claude J, Chanock SJ, Chung WK, Claes KB, Cox A, Cross SS, Cunningham JM, Czene K, Daly MB, Damiola F, Darabi H, de la Hoya M, Devilee P, Diez O, Ding YC, Dolcetti R, Domchek SM, Dorfling CM, Dos-Santos-Silva I, Dumont M, Dunning AM, Eccles DM, Ehrencrona H, Ekici AB, Eliassen H, Ellis S, Fasching PA, Figueroa J, Flesch-Janys D, Försti A, Fostira F, Foulkes WD, Friebel T, Friedman E, Frost D, Gabrielson M, Gammon MD, Ganz PA, Gapstur SM, Garber J, Gaudet MM, Gayther SA, Gerdes AM, Ghoussaini M, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Gunter M, Haeberle L, Haiman CA, Hamann U, Hansen TV, Hart S, Healey S, Heikkinen T, Henderson BE, Herzog J, Hogervorst FB, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Humphreys K, Hunter DJ, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Jones M, Kabisch M, Kar S, Karlan BY, Khan S, Khaw KT, Kibriya MG, Knight JA, Ko YD, Konstantopoulou I, Kosma VM, Kristensen V, Kwong A, Laitman Y, Lambrechts D, Lazaro C, Lee E, Le Marchand L, Lester J, Lindblom A, Lindor N, Lindstrom S, Liu J, Long J, Lubinski J, Mai PL, Makalic E, Malone KE, Mannermaa A, Manoukian S, Margolin S, Marme F, Martens JW, McGuffog L, Meindl A, Miller A, Milne RL, Miron P, Montagna M, Mazoyer S, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson JE, Osorio A, Park SK, Peeters PH, Peissel B, Peterlongo P, Peto J, Phelan CM, Pilarski R, Poppe B, Pylkäs K, Radice P, Rahman N, Rantala J, Rappaport C, Rennert G, Richardson A, Robson M, Romieu I, Rudolph A, Rutgers EJ, Sanchez MJ, Santella RM, Sawyer EJ, Schmidt DF, Schmidt MK, Schmutzler RK, Schumacher F, Scott R, Senter L, Sharma P, Simard J, Singer CF, Sinilnikova OM, Soucy P, Southey M, Steinemann D, Stenmark-Askmalm M, Stoppa-Lyonnet D, Swerdlow A, Szabo CI, Tamimi R, Tapper W, Teixeira MR, Teo SH, Terry MB, Thomassen M, Thompson D, Tihomirova L, Toland AE, Tollenaar RA, Tomlinson I, Truong T, Tsimiklis H, Teulé A, Tumino R, Tung N, Turnbull C, Ursin G, van Deurzen CH, van Rensburg EJ, Varon-Mateeva R, Wang Z, Wang-Gohrke S, Weiderpass E, Weitzel JN, Whittemore A, Wildiers H, Winqvist R, Yang XR, Yannoukakos D, Yao S, Zamora MP, Zheng W, Hall P, Kraft P, Vachon C, Slager S, Chenevix-Trench G, Pharoah PD, Monteiro AA, García-Closas M, Easton DF, Antoniou AC (2016) **Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer.** *Nature Communications*, (Avr) 7:11375. PMID: 27117709. [72]

389. Ghoussaini M, French JD, Michailidou K, Nord S, Beesley J, Canisus S, Hillman KM, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lee JS, Dennis J, Bolla MK, Wang Q, Dicks E, Milne RL, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, Benitez J, González-Neira A, Alonso MR, Pita G, Neuhausen SL, Anton-Culver H, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Hamann U, Tessier DC, Vincent D, Nevanlinna H, Khan S, Matsuo K, Ito H, Dörk T, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kosma VM; kConFab/AOCS Investigators, Wu AH, Van Den Berg D, Lambrechts D, Floris G, Chang-Claude J, Rudolph A, Radice P, Barile M, Couch FJ, Hallberg E, Giles GG, Haiman CA, Le Marchand L, Goldberg MS, Teo SH, Yip CH, Borresen-Dale AL; NBCS Collaborators, Zheng W, Cai Q, Winqvist R, Pylkäs K, Andrulis IL, Devilee P, Tollenaar RA, García-Closas M, Figueroa J, Hall P, Czene K, Brand JS, Darabi H, Eriksson M, Hooning MJ, Koppert LB, Li J, Shu XO, Zheng Y, Cox A, Cross SS, Shah M, Rhenius V, Choi JY, Kang D, Hartman M, Chia KS, Kabisch M, Torres D, Luccarini C, Conroy DM, Jakubowska A, Lubinski J, Sangrajrang S, Brennan P, Olswold C, Slager S, Shen CY, Hou MF, Swerdlow A, Schoemaker MJ, Simard J, Pharoah PD, Kristensen V, Chenevix-Trench G, Easton DF, Dunning AM, Edwards SL (2016) **Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation**. *American Journal of Human Genetics*, (Oct) 99(4):903-911. PMID: 27640304. [41]

390. Horne HN, Chung CC, Zhang H, Yu K, Prokunina-Olsson L, Michailidou K, Bolla MK, Wang Q, Dennis J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Fletcher O, Johnson N, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Flyger H, Benitez J, González-Neira A, Anton-Culver H, Neuhausen SL, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Hamann U, Nevanlinna H, Khan S, Matsuo K, Iwata H, Dörk T, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Chenevix-Trench G; kConFab/AOCS Investigators, Wu AH, Ven den Berg D, Smeets A, Zhao H, Chang-Claude J, Rudolph A, Radice P, Barile M, Couch FJ, Vachon C, Giles GG, Milne RL, Haiman CA, Marchand LL, Goldberg MS, Teo SH, Taib NA, Kristensen V, Borresen-Dale AL, Zheng W, Shrubsole M, Winqvist R, Jukkola-Vuorinen A, Andrulis IL, Knight JA, Devilee P, Seynaeve C, García-Closas M, Czene K, Darabi H, Hollestelle A, Martens JW, Li J, Lu W, Shu XO, Cox A, Cross SS, Blot W, Cai Q, Shah M, Luccarini C, Baynes C, Harrington P, Kang D, Choi JY, Hartman M, Chia KS, Kabisch M, Torres D, Jakubowska A, Lubinski J, Sangrajrang S, Brennan P, Slager S, Yannoukakos D, Shen CY, Hou MF, Swerdlow A, Orr N, Simard J, Hall P, Pharoah PD, Easton DF, Chanock SJ, Dunning AM, Figueroa JD (2016) **Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus**. *PLoS One*, 11(8):e0160316. doi:10.1371/journal.pone.0160316. eCollection 2016. PMID: 27556229. [13]

391. Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ; ABCTB Investigators, Kibel AS, Dansonka-Mieszkowska A, Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A; AOCS Study Group & Australian Cancer Study (Ovarian Cancer); APCB BioResource, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT; kConFab Investigators, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N; NBCS Investigators, Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P,

Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL; GENICA Network; PRACTICAL consortium, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D (2016) **Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types**. *Cancer Discovery,* (Sep) 6(9):1052-1067. PMID: 27432226. [102]

392. Lei J, Rudolph A, Moysich KB, Behrens S, Goode EL, Bolla MK, Dennis J, Dunning AM, Easton DF, Wang Q, Benitez J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Fasching PA, Haeberle L, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Marmé F, Guénel P, Truong T, Bojesen SE, Flyger H, Nielsen SF, Nordestgaard BG, González-Neira A, Menéndez P, Anton-Culver H, Neuhausen SL, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Hamann U, Nevanlinna H, Fagerholm R, Dörk T, Bogdanova NV, Mannermaa A, Hartikainen JM; Australian Ovarian Study Group; kConFab Investigators, Van Dijck L, Smeets A, Flesch-Janys D, Eilber U, Radice P, Peterlongo P, Couch FJ, Hallberg E, Giles GG, Milne RL, Haiman CA, Schumacher F, Simard J, Goldberg MS, Kristensen V, Borresen-Dale AL, Zheng W, Beeghly-Fadiel A, Winqvist R, Grip M, Andrulis IL, Glendon G, García-Closas M, Figueroa J, Czene K, Brand JS, Darabi H, Eriksson M, Hall P, Li J, Cox A, Cross SS, Pharoah PD, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Ademuyiwa F, Ambrosone CB, Swerdlow A, Jones M, Chang-Claude (2016) **Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium**. *Human Genetics*, (Jan) 135(1):137-154. PMID : 26621531. [8]

393. Liu J, Lončar I, Collée JM, Bolla MK, Dennis J, Michailidou K, Wang Q, Andrulis IL, Barile M, Beckmann MW, Behrens S, Benitez J, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Brauch H, Brennan P, Brenner H, Broeks A, Burwinkel B, Chang-Claude J, Chen ST, Chenevix-Trench G, Cheng CY, Choi JY, Couch FJ, Cox A, Cross SS, Cuk K, Czene K, Dörk T, Dos-Santos-Silva I, Fasching PA, Figueroa J, Flyger H, García-Closas M, Giles GG, Glendon G, Goldberg MS, González-Neira A, Guénel P, Haiman CA, Hamann U, Hart SN, Hartman M, Hatse S, Hopper JL, Ito H, Jakubowska A, Kabisch M, Kang D, Kosma VM, Kristensen VN, Le Marchand L, Lee E, Li J, Lophatananon A, Jan Lubinski, Mannermaa A, Matsuo K, Milne RL; NBCS Collaborators, Neuhausen SL, Nevanlinna H, Orr N, Perez JI, Peto J, Putti TC, Pylkäs K, Radice P, Sangrajrang S, Sawyer EJ, Schmidt MK, Schneeweiss A, Shen CY, Shrubsole MJ, Shu XO, Simard J, Southey MC, Swerdlow A, Teo SH, Tessier DC, Thanasitthichai S, Tomlinson I, Torres D, Truong T, Tseng CC, Vachon C, Winqvist R, Wu AH, Yannoukakos D, Zheng W, Hall P, Dunning AM, Easton DF, Hooning MJ, van den Ouweland AM, Martens JW, Hollestelle A (2016) **rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk**. *Scientific Reports* (Nov) 6:36874. PMID: 27845421. [3]

394. Meeks HD, Song H, Michailidou K, Bolla MK, Dennis J, Wang Q, Barrowdale D, Frost D, McGuffog L, Ellis S, Feng B-J, Buys SS, Hopper JL, Southey MC, Tesoriero A, James PA, Bruinsma F, Campbell IG, Broeks A, Schmidt MK, Hogervorst FBL, Beckman MW, Fasching PA, Fletcher O, Johnson N, Sawyer EJ, Riboli E, Banerjee S, Menon U, Tomlinson I, Burwinkel B, Marme F, Hamann U, Rudolph A, Janavicius R, Tihomirova L, Tung N, Garber J, Cramer D, Terry KL, Poole EM, Tworoger SS, Dorfling CM, van Rensburg EJ, Godwin AK, Guénel P, Truong T, Stoppa-Lyonnet, Damiola F, Mazoyer S, Sinilnikova OM, Isaacs C, Maugard C, Bojesen SE, Flyger H, Gerdes A-M, Hansen TVO, Jensen A, Kjaer SK, Hogdall C, Hogdall E, Pedersen IS, Thomassen M, Benitez J, González-Neira A, Osorio A, de la Hoya M, Perez Segura P, Diez O, Lazaro C, Brunet J, Anton-Culver H, Lee E, John EM, Neuhausen SL, Yuan DC, Castillo D, Weitzel JN, Ganz PA, Nussbaum RL, Chan SB, Karlan BY, Lester J, Wu A, Gayther S, Ramus SJ, Sieh W, Whittermore AS, Monteiro ANA, Phelan CM, Terry MB, Piedmonte M, Offit K, Robson M, Levine D, Moysich KB, Cannioto R, Olson SH, Daly MB, Nathanson KL, Domchek SM, Lu KH, Liang D, Hildebrant MAT, Ness R, Modugno F, Pearce L, Goodman MT, Thompson PJ, Brenne H, Butterbach K, Meindl A, Hahnen E, Wappenschmidt B, Brauch H, Brüning T, Blomqvist C, Khan S, Nevanlinna H, Pelttari LM,

Aittomäki K, Butzow R, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Rantala J, Kosma V-M, Mannermaaa A, Lambrechts D, Neven P, Claes KBM, Van Maerken T, Chang-Claude J, Flesch-Janys D, Heitz F, Varon-Mateeva R, Peterlongo P, Radice P, Viel A, Barile M, Peissel B, Manoukian S, Montagna M, Oliani C, Peixoto A, Teixeira MR, Collavoli A, Hallberg E, Olson JE, Cunningham JM, Goode EL, Hart S, Shimelis H, Giles GG, Milne RL, Healey S, Tucker K, Haiman CA, Henderson BE, Goldberg MS, Tischkowitz M, Simard J, Soucy P, Eccles DM, Le N, Borresen-Dale A-L, Kristensen V, Salvesen HB, Bjorge L, Bandera EV, Risch H, Zheng W, Beeghly-Fadiel A, Cai H, Pylkäs K, Tollenaar RAEM, van den Ouweland AMW, Andrulis IL, Knight JA, Narod S, Devilee P, Winqvist R, Figueroa J, Greene MH, Mai PL, Loud JT, García-Closas M, Schoemaker MJ, Czene K, Darabi H, McNeish I, Siddiquil N, Glasspool R, Kwong A, Park SK, Teo SH, Yoon S-Y, Matsuo K, Hosono S, Woo YL, Gao Y-T, Foretova L, Singer CF, Rappaport-Fuerhauser C, Friedman E, Laitman Y, Rennert G, Imyanitov EN, Hulick PJ, Senter L, Olopade OI, Olah E, Doherty JA, Schildkraut J, Hollestelle A, Koppert LB, Kiemeney LA, Massuger LFAG, Cook LS, Pejovic T, Li J, Borg A, Öfverholm A, Rossing MA, Wentzensen N, Henriksson K, Cox A, Cross SS, Perkins BJ, Shah M, Kabisch M, Torres D, Jakubowska A, Lubinski J, Gronwald J, Agnarssn BA, Kupryjanczyk J, Moes-Sosnowska J, Fostira F, Konstantopoulou I, Slager S, Jones M, Antoniou AC, Berchuck A, Swerdlow A, Chenevix-Trench G, Dunning AM, Pharoah PDP, Hall P, Easton DF, Couch PJ, Spurdle AB, Goldgar DA (2016) ***BRCA2* Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate and Ovarian Cancers.** *JNCI-Journal of The National Cancer Institute*, (Feb) 108(2). pii: djv315. PMID : 26586665. [67]

395. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of *BRCA1* and *BRCA2*, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KBM, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, DeFazio A, Dennis J, Devilee P, Dicks EDM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Dos Santos Silva I, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD, EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA, GEMO Study Collaborators, GENICA Network, Gentry-Maharaj A, Gerdes A-M, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TVO, Harter P, Hartikainen JM, Healey S, HEBON, Hein A, Heitz F, Henderson BE, Herzog J, Hildebrandt MAT, Høgdall CK, Høgdall E, Hogervorst FBL, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Birk Jensen U, Johnson N, Jukkola-Vuorinen A, Kabisch M, Karlan BY, Kataja V, Kauff N, KConFab Investigators, Kelemen LE, Kerin MJ, Kiemeney LA, Kjaer SK, Knight JA, Knol-Bout JP, Konstantopoulou I, Kosma V-M, Krakstad C, Kristensen V, Kuchenbaecker KB, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson MC, Lasa A, Laurent-Puig P, Lazaro C, Le ND, Le Marchand L, Leminen A, Lester J, Levine DA, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu KH, Lubinski J, Lundvall L, Lurie G, Mai PL, Mannermaa A, Margolin S, Mariette F, Marme F, Martens JWM, Massuger LFAG, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menéndez P, Menkiszak J, Menon U, Mensenkamp AR, Miller N, Milne RL, Modugno F, Montagna M, Moysich KB, Müller H, Mulligan AM, Muranen TA, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL, Pedersen IS, Peissel B, Pejovic T, Pelttari LM, Perkins J, Permuth-Wey J, Peterlongo P, Peto J, Phelan CM, Phillips K-A, Piedmonte M, Pike MC, Platte R, Plisiecka-Halasa J, Poole EM, Poppe B, Pylkäs K, Radice P, Ramus SJ, Rebbeck TR, Reed MWR, Rennert G, Risch HA, Robson M, Rodriguez GC, Romero A, Rossing MA,

Rothstein JH, Rudolph A, Runnebaum I, Salani R, Salvesen HB, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schrauder MG, Schumacher F, Schwaab I, Scuvera G, Sellers TA, Severi G, Seynaeve CM, Shah M, Shrubsole M, Siddiqui N, Sieh W, Simard J, Singer CF, Sinilnikova OM, Smeets D, Sohn C, Soller M, Song H, Soucy P, Southey MC, Stegmaier C, Stoppa-Lyonnet D, Sucheston L, SWE-BRCA, Swerdlow A, Tangen IL, Tea M-K, Teixeira MR, Terry KL, Terry MB, Thomassen M, Thompson PJ, Tihomirova L, Tischkowitz M, Ewart Toland A, Tollenaar RAEM, Tomlinson I, Torres C, Truong T, Tsimiklis H, Tung N, Tworoger SS, Tyrer JP, Vachon CM, Van 't Veer LJ, van Altena AM, Van Asperen CJ, van den Berg D, van den Ouweland AMW, van Doorn HC, Van Nieuwenhuysen E, van Rensburg EJ, Vergote I, Verhoef S, Vierkant RA, Vijai J, Vitonis AF, von Wachenfeldt A, Walsh C, Wang Q, Wang-Gohrke S, Wappenschmidt B, Weischer M, Weitzel JN, Weltens C, Wentzensen N, Whittemore AD, Wilkens LR, Winqvist R, Wu AH, Wu X, Yang XP, Zaffaroni D, Zamora MP, Zheng W, Ziogas A, Chenevix-Trench G, Pharoah PDP, Rookus MA, Hooning MJ, Goode EL (2016) **No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer**. *Gynecologic Oncology*, (Mai) 141(2):386-401. PMID : 25940428. [11]

396. Pelttari LM, Khan S, Vuorela M, Kiiski JI, Vilske S, Nevanlinna V, Ranta S, Schleutker J, Winqvist R, Kallioniemi A, Dörk T, Bogdanova NV, Figueroa J, Pharoah PD, Schmidt MK, Dunning AM, García-Closas M, Bolla MK, Dennis J, Michailidou K, Wang Q, Hopper JL, Southey MC, Rosenberg EH, Fasching PA, Beckmann MW, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Surowy H, Guénel P, Truong T, Bojesen SE, Nordestgaard BG, Benitez J, González-Neira A, Neuhausen SL, Anton-Culver H, Brenner H, Arndt V, Meindl A, Schmutzler RK, Brauch H, Brüning T, Lindblom A, Margolin S, Mannermaa A, Hartikainen JM, Chenevix-Trench G; kConFab/AOCS Investigators, Van Dyck L, Janssen H, Chang-Claude J, Rudolph A, Radice P, Peterlongo P, Hallberg E, Olson JE, Giles GG, Milne RL, Haiman CA, Schumacher F, Simard J, Dumont M, Kristensen V, Borresen-Dale AL, Zheng W, Beeghly-Fadiel A, Grip M, Andrulis IL, Glendon G, Devilee P, Seynaeve C, Hooning MJ, Collée M, Cox A, Cross SS, Shah M, Luben RN, Hamann U, Torres D, Jakubowska A, Lubinski J, Couch FJ, Yannoukakos D, Orr N, Swerdlow A, Darabi H, Li J, Czene K, Hall P, Easton DF, Mattson J, Blomqvist C, Aittomäki K, Nevanlinna H (2016) **RAD51B in Familial Breast Cancer**. *PLoS One*, (Mai) 11(5):e0153788. doi: 10.1371/journal.pone.0153788. eCollection 2016. PMID: 27149063. [19]

397. Petridis C, Brook MN, Shah V, Kohut K, Gorman P, Caneppele M, Levi D, Papouli E, Orr N, Cox A, Cross SS, Dos-Santos-Silva I, Peto J, Swerdlow A, Schoemaker MJ, Bolla MK, Wang Q, Dennis J, Michailidou K, Benitez J, González-Neira A, Tessier DC, Vincent D, Li J, Figueroa J, Kristensen V, Borresen-Dale AL, Soucy P, Simard J, Milne RL, Giles GG, Margolin S, Lindblom A, Brüning T, Brauch H, Southey MC, Hopper JL, Dörk T, Bogdanova NV, Kabisch M, Hamann U, Schmutzler RK, Meindl A, Brenner H, Arndt V, Winqvist R, Pylkäs K, Fasching PA, Beckmann MW, Lubinski J, Jakubowska A, Mulligan AM, Andrulis IL, Tollenaar RA, Devilee P, Le Marchand L, Haiman CA, Mannermaa A, Kosma VM, Radice P, Peterlongo P, Marme F, Burwinkel B, van Deurzen CH, Hollestelle A, Miller N, Kerin MJ, Lambrechts D, Floris G, Wesseling J, Flyger H, Bojesen SE, Yao S, Ambrosone CB, Chenevix-Trench G, Truong T, Guénel P, Rudolph A, Chang-Claude J, Nevanlinna H, Blomqvist C, Czene K, Brand JS, Olson JE, Couch FJ, Dunning AM, Hall P, Easton DF, Pharoah PD, Pinder SE, Schmidt MK, Tomlinson I, Roylance R, García-Closas M, Sawyer EJ (2016) **Genetic predisposition to ductal carcinoma *in situ* of the breast**. *Breast Cancer Research*. (Feb) 18(1):22. PMID: 26884359. [38]

398. Rebbeck TR, Friebel TM, Mitra N, Wan F, Chen S, Andrulis IL, Apostolou P, Arnold N, Arun BK, Barrowdale D, Benitez J, Berger R, Berthet P, Borg A, Buys SS, Caldes T, Carter J, Chiquette J, Claes KB, Couch FJ, Cybulski C, Daly MB, de la Hoya M, Diez O, Domchek SM, Nathanson KL, Durda K, Ellis S; EMBRACE, Evans DG, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Glendon G, Godwin AK, Greene MH, Gronwald J, Hahnen E, Hallberg E, Hamann U, Hansen TV; HEBON, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska-Bieniek K, John EM, Karlan BY, Kaufman B, Investigators K, Kwong A, Laitman Y, Lasset C, Lazaro C, Lester J, Loman N, Lubinski J, Manoukian S, Mitchell G, Montagna M, Neuhausen SL, Nevanlinna H, Niederacher D, Nussbaum RL, Offit K, Olah E, Olopade OI, Park SK, Piedmonte M, Radice P, Rappaport-Fuerhauser C, Rookus MA, Seynaeve C, Simard J, Singer CF, Soucy P, Southey M, Stoppa-Lyonnet D, Sukiennicki G, Szabo CI, Tancredi M, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tihomirova L, Tischkowitz M, Toland AE, Toloczko-Grabarek A, Tung N, van Rensburg EJ, Villano D, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Zidan J, Zorn KK, McGuffog L,

Easton D, Chenevix-Trench G, Antoniou AC, Ramus SJ (2016) **Inheritance of deleterious mutations at both *BRCA1* and *BRCA2* in an international sample of 32,295 women**. *Breast Cancer Research* (Nov) 18(1):112. PMID: 27836010. [26]

399. Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, Foulkes WD, Dennis J, Michailidou K, van Rensburg EJ, Heikkinen T, Nevanlinna H, Hopper JL, Dörk T, Claes KB, Reis-Filho J, Teo ZL, Radice P, Catucci I, Peterlongo P, Tsimiklis H, Odefrey FA, Dowty JG, Schmidt MK, Broeks A, Hogervorst FB, Verhoef S, Carpenter J, Clarke C, Scott RJ, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Peto J, Dos-Santos-Silva I, Fletcher O, Johnson N, Bolla MK, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Marme F, Burwinkel B, Yang R, Guénel P, Truong T, Menegaux F, Sanchez M, Bojesen S, Nielsen SF, Flyger H, Benitez J, Zamora MP, Perez JI, Menéndez P, Anton-Culver H, Neuhausen S, Ziogas A, Clarke CA, Brenner H, Arndt V, Stegmaier C, Brauch H, Brüning T, Ko YD, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Antonenkova NN, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Spurdle AB, Investigators K; Australian Ovarian Cancer Study Group, Wauters E, Smeets D, Beuselinck B, Floris G, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Olson JE, Vachon C, Pankratz VS, McLean C, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Kristensen V, Alnæs GG, Zheng W, Hunter DJ, Lindstrom S, Hankinson SE, Kraft P, Andrulis I, Knight JA, Glendon G, Mulligan AM, Jukkola-Vuorinen A, Grip M, Kauppila S, Devilee P, Tollenaar RA, Seynaeve C, Hollestelle A, Garcia-Closas M, Figueroa J, Chanock SJ, Lissowska J, Czene K, Darabi H, Eriksson M, Eccles DM, Rafiq S, Tapper WJ, Gerty SM, Hooning MJ, Martens JW, Collée JM, Tilanus-Linthorst M, Hall P, Li J, Brand JS, Humphreys K, Cox A, Reed MW, Luccarini C, Baynes C, Dunning AM, Hamann U, Torres D, Ulmer HU, Rüdiger T, Jakubowska A, Lubinski J, Jaworska K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Swerdlow A, Ashworth A, Orr N, Jones M, González-Neira A, Pita G, Alonso MR, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, Simard J, Dumont M, Soucy P, Eeles R, Muir K, Wiklund F, Gronberg H, Schleutker J, Nordestgaard BG, Weischer M, Travis RC, Neal D, Donovan JL, Hamdy FC, Khaw KT, Stanford JL, Blot WJ, Thibodeau S, Schaid DJ, Kelley JL, Maier C, Kibel AS, Cybulski C, Cannon-Albright L, Butterbach K, Park J, Kaneva R, Batra J, Teixeira MR, Kote-Jarai Z, Olama AA, Benlloch S, Renner SP, Hartmann A, Hein A, Ruebner M, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambretchs S, Doherty JA, Rossing MA, Nickels S, Eilber U, Wang-Gohrke S, Odunsi K, Sucheston-Campbell LE, Friel G, Lurie G, Killeen JL, Wilkens LR, Goodman MT, Runnebaum I, Hillemanns PA, Pelttari LM, Butzow R, Modugno F, Edwards RP, Ness RB, Moysich KB, du Bois A, Heitz F, Harter P, Kommoss S, Karlan BY, Walsh C, Lester J, Jensen A, Kjaer SK, Høgdall E, Peissel B, Bonanni B, Bernard L, Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Larson MC, Fogarty ZC, Kalli KR, Liang D, Lu KH, Hildebrandt MA, Wu X, Levine DA, Dao F, Bisogna M, Berchuck A, Iversen ES, Marks JR, Akushevich L, Cramer DW, Schildkraut J, Terry KL, Poole EM, Stampfer M, Tworoger SS, Bandera EV, Orlow I, Olson SH, Bjorge L, Salvesen HB, van Altena AM, Aben KK, Kiemeney LA, Massuger LF, Pejovic T, Bean Y, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Górski B, Gronwald J, Menkiszak J, Høgdall CK, Lundvall L, Nedergaard L, Engelholm SA, Dicks E, Tyrer J, Campbell I, McNeish I, Paul J, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Cai H, Shu XO, Teten RT, Sutphen R, McLaughlin JR, Narod SA, Phelan CM, Monteiro AN, Fenstermacher D, Lin HY, Permuth JB, Sellers TA, Chen YA, Tsai YY, Chen Z, Gentry-Maharaj A, Gayther SA, Ramus SJ, Menon U, Wu AH, Pearce CL, Van Den Berg D, Pike MC, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Moes-Sosnowska J, Kupryjanczyk J, Pharoah PD, Song H, Winship I, Chenevix-Trench G, Giles GG, Tavtigian SV, Easton DF, Milne RL (2016) ***PALB2*, *CHEK2* and *ATM* rare variants and cancer risk: data from COGS.** *Journal of Medical Genetics*, (Dec) 53(12):800-811. PMID: 27595995. [116]

400. Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw A, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S, Kwong A, Laitman Y, Lester J, Lesueur F,

Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P, Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J, Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J, Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K, Pharoah PD, Chenevix-Trench G, Antoniou AC (2016) **Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers**. *PLoS One*, (July) 11(7):e0158801. doi: 10.1371/journal.pone.0158801. eCollection 2016. PMID : 27463617. [8]

401. Wyszynski A, Hong CC, Lam K, Michailidou K, Lytle C, Yao S, Zhang Y, Bolla MK, Wang Q, Dennis J, Hopper JL, Southey MC, Schmidt MK, Broeks A, Muir K, Lophatananon A, Fasching PA, Beckmann MW, Peto J, Dos-Santos-Silva I, Sawyer EJ, Tomlinson I, Burwinkel B, Marme F, Guénel P, Truong T, Bojesen SE, Nordestgaard BG, González-Neira A, Benitez J, Neuhausen SL, Brenner H, Dieffenbach AK, Meindl A, Schmutzler RK, Brauch H; GENICA Network, Nevanlinna H, Khan S, Matsuo K, Ito H, Dörk T, Bogdanova NV, Lindblom A, Margolin S, Mannermaa A, Kosma VM; kConFab Investigators; Australian Ovarian Cancer Study Group, Wu AH, Van Den Berg D, Lambrechts D, Wildiers H, Chang-Claude J, Rudolph A, Radice P, Peterlongo P, Couch FJ, Olson JE, Giles GG, Milne RL, Haiman CA, Henderson BE, Dumont M, Teo SH, Wong TY, Kristensen V, Zheng W, Long J, Winqvist R, Pylkäs K, Andrulis IL, Knight JA, Devilee P, Seynaeve C, García-Closas M, Figueroa J, Klevebring D, Czene K, Hooning MJ, van den Ouweland AM, Darabi H, Shu XO, Gao YT, Cox A, Blot W, Signorello LB, Shah M, Kang D, Choi JY, Hartman M, Miao H, Hamann U, Jakubowska A, Lubinski J, Sangrajrang S, McKay J, Toland AE, Yannoukakos D, Shen CY, Wu PE, Swerdlow A, Orr N, Simard J, Pharoah PD, Dunning AM, Chenevix-Trench G, Hall P, Bandera E, Amos C, Ambrosone C, Easton DF, Cole MD (2016) **An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression**. *Human Molecular Genetics*, (Sept) 25(17): 3863-3876. PMID: 27402876. [25]

402. Barrdahl M, Rudolph A, Hopper JL, Southey MC, Broeks A, Fasching PA, Beckmann MW, Gago-Dominguez M, Castelao JE, Guénel P, Truong T, Bojesen SE, Gapstur SM, Gaudet MM, Brenner H, Arndt V, Brauch H, Hamann U, Mannermaa A, Lambrechts D, Jongen L, Flesch-Janys D, Thoene K, Couch FJ, Giles GG, Simard J, Goldberg MS, Figueroa J, Michailidou K, Bolla MK, Dennis J, Wang Q, Eilber U, Behrens S, Czene K, Hall P, Cox A, Cross S, Swerdlow A, Schoemaker MJ, Dunning AM, Kaaks R, Pharoah PDP, Schmidt M, Garcia-Closas M, Easton DF, Milne RL, Chang-Claude J (2017) **Gene-environment interactions involving functional variants: results from the Breast Cancer Association Consortium.** *International Journal of Cancer*, Nov 1;141(9):1830-1840. doi: 10.1002/ijc.30859. [14]

403. Jiao X, Aravidis C, Marikkannu R, Rantala R, Picelli S, Adamovic T, Liu T, Maguire P, Kremeier B, Luo L, von Holst S, Kontham V, Thutkawkorapin J, Margolin S, Du Q, Lundin J, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Beckmann MW, Blomqvist C, Blot W, Boeckx B, Bojesen S, Bonanni B, Brand JS, Brauch H, Brenner H, Broeks A, Brüning T, Burwinkel B, Cai Q, Chang-Claude J, NBCS Collaborators, Couch FJ, Cox A, Cross SS, Deming-Halverson SL, Devilee P, dos-Santos-Silva I, Dörk T, Eriksson M, Fasching PA, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, García-Closas M, Giles GG, González-Neira A, Guénel P, Guo Q, Gündert M, Haiman CA, Hallberg E, Hamann U, Harrington P, Hooning MJ, Hopper JL, Guanmengqian H, Jakubowska A, Jones ME, Kerin MJ, Kosma V-M, Kristensen VN, Lambrechts D, Le Marchand L, Lubinski J, Mannermaa A, Martens JWM, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Peto J, Pylkäs K, Radice P, Rhenius V, Sawyer EJ, Schmidt MK, Schmutzler RK, Seynaeve C, Shah M, Simard J, Southey MC, Swerdlow AJ, Truong T, Wendt C, Winqvist R, Zheng W, kConFab/AOCS Investigators, Benitez J, Dunning AM, Pharoah PDP, Easton DF, Czene K, Hall P, Lindblom A (2017) **PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1.** *Oncotarget,* 8(61): 102769-102782. doi: 10.18632/oncotarget.21800. PMID: 29262523. [7]

404. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, Jervis S, van Leeuwen FE, Milne RL, Andrieu N, Goldgar DE, Terry MB, Rookus MA, Easton DF, Antoniou AC, *BRCA1* and *BRCA2* Cohort Consortium, McGuffog L, Evans DG, Barrowdale D, Frost D, Adlard J, Ong KR, Izatt L,

Tischkowitz M, Eeles R, Davidson R, Hodgson S, Ellis S, Nogues C, Lasset C, Stoppa-Lyonnet D, Fricker JP, Faivre L, Berthet P, Hooning MJ, van der Kolk LE, Kets CM, Adank MA, John EM, Chung WK, Andrulis IL, Southey M, Daly MB, Buys SS, Osorio A, Engel C, Kast K, Schmutzler RK, Caldes T, Jakubowska A, Simard J, Friedlander ML, McLachlan SA, Machackova E, Foretova L, Tan YY, Singer CF, Olah E, Gerdes AM, Arver B, Olsson H. (2017) **Risks of Breast, Ovarian, and Contralateral Breast Cancer for *BRCA1* and *BRCA2* Mutation Carriers.** *JAMA* (June) 317(23):2402-2416. doi: 10.1001/jama.2017.7112. PMID : 28632866. [904]

405. Castroviejo-Bermejo M, Cruz C, Llop-Guevara A, Gutiérrez-Enríquez S, Ducy M, Ibrahim YH, Gris-Oliver A, Pellegrino B, Bruna A, Guzmán M, Rodriquez O, Grueso J, Bonache S, Moles-Fernández A, Villacampa G, Viaplana C, Gómez P, Vidal M, Peg V, Serres-Créixams X, Dellaire G, Simard J, Nuciforo P, Rubio IT, Dientsmann R, Barrett CJ, Caldas C, Baselga J, Saura C, Cortés J, Déas O, Jonkers J, Masson JY, Cairo S, Judde JG, O'Connor MJ, Díez O, Balmaña J, Serra V (2018) **A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.** *EMBO Molecular Medicine,* Dec; 10 (12); pii: e9172. doi: 10.15252/emmm.201809172. [53]

406. Lu Y, Beeghly-Fadiel A, Wu L, Guo X, Li B, Schildkraut JM, Im HK, Chen YA, Permuth JB, Reid BM, Teer JK, Moysich KB, Andrulis IL, Anton-Culver H, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Benitez J, Bjørge L, Brenton J, Butzow R, Caldes T, Caligo MA, Campbell IG, Chang-Claude J, Claes KBM, Couch FJ, Cramer DW, Daly MB, DeFazio A, Dennis J, Díez O, Domchek SM, Dork T, Easton DF, Eccles DM, Fasching PA, Fortner RT, Fountzilas G, Friedman E, Ganz PA, Garber J, Giles GG, Godwin AK, Goldgar DE, Goodman MT, Greene MH, Gronwald J, Hamann U, Heitz F, Hildebrandt MAT, Høgdall CK, Hollestelle A, Hulick PJ, Huntsman DG, Imyanitov EN, Isaacs C, Jakubowska A, James P, Karlan BY, Kelemen LE, Kiemeney LA, Kjaer SK, Kwong A, Le ND, Leslie G, Lesueur F, Levine DA, Mattiello A, May T, McGuffog L, McNeish IA, Merritt MA, Modugno F, Montagna M, Neuhausen SL, Nevanlinna H, Cilius Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olson SH, Olsson H, Osorio A, Park SK, Parsons MT, Peeters PHM, Pejovic T, Peterlongo P, Phelan CM, Pujana MA, Ramus SJ, Rennert G, Risch H, Rodriguez GC, Rodríguez-Antona C, Romieu I, Rookus MA, Rossing MA, Rzepecka IK, Sandler DP, Schmutzler RK, Setiawan VW, Sharma P, Sieh W, Simard J, Singer CF, Song H, Southey MC, Spurdle AB, Sutphen R, Swerdlow AJ, Teixeira MR, Teo SH, Thomassen M, Tischkowitz M, Toland AE, Trichopoulou A, Tung N, Tworoger SS, van Rensburg EJ, Vanderstichele A, Vega A, Velez Edwards D, Webb PM, Weitzel JN, Wentzensen N, White E, Wolk A, Wu AH, Yannoukakos D, Zorn KK, Gayther SA, Antoniou AC, Berchuck A, Goode EL, Chenevix-Trench G, Sellers TA, Pharoah PDP, Zheng W, Long J. (2018) **A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk.** *Cancer Research* (sept.) 15; 78(18):5419-5430. Doi: 10.1158/008-5472.CAN-18-0951. [22]

407. Rebbeck TR, Friebel TM, Friedman E, Hamann U, Huo D, Kwong A, Olah E, Olopade OI, Solano AR, Teo S-H, Thomassen M, Weitzel JN, Chan TL, Couch FJ, Goldgar DE, Kruse TA, Palmero EI, Park SK, Torres D, van Rensburg EJ, Aalfs CM, Abugattas J, Adlard J, Agata S, Aittomäki K, Andrews L, Andrulis IL, Antoniou AC, Arason A, Arnold N, Arun BK, Asseryanis E, Auerbach L, Azzollini J, Balmaña J, Barile M, Barkardottir RB, Barrowdale D, Benitez J, Berger A, Berger R, Blanco AM, Blazer KR, Blok MJ, Bonadona V, Bonanni B, Bradbury AR, Brewer C, Buecher B, Buys SS, Caldes T, Caliebe A, Caligo MA, Campbell I, Chenevix-Trench G, Chiquette J, Chung WK, Claes KBM, Collée JM, Cook J, Davidson R, de la Hoya M, De Leeneer K, de Pauw A, Delnatte C, Diez O, Ding YC, Ditsch N, Domchek SM, Dorfling CM, Duran M, Dworniczak B, Eason J, Easton DF, Eeles R, Ehrencrona H, EMBRACE, Engel C, Engert S, D. Evans G, Faivre L, Faust U, Feliubadalo L, Ferrer SF, Foretova L, Fowler J, Frost D, Campos Galvão H, Ganz P, Garber J, Gauthier-Villars M, Gehrig A, GEMO Study Collaborators, Gesta P, Giannini G, Giraud S, Glendon G, Godwin AK, Greene MH, Gronwald J, Gutierrez Barrera A, Hahnen E, V. O. Hansen T, Hauke J, HEBON, Henderson A, Hentschel J, Hogervorst FBL, Honisch E, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James P, Janavicius R, Jensen UB, John EM, Joseph V, Kaczmarek K, Karlan BY, Kast K, KConFab Investigators, Kim S-W, Konstantopoulou I, Korach J, Laitman Y, Lasa A, Lasset C, Lazaro C, Lee A, Lee MH, PhD, Leslie G, Lester J, Lesueur F, Liljegren A, Lindor N, Longy M, Loud JT, Lu KH, Lubinski J, Machackova E, Manoukian S, Mari V, Martínez-Bouzas C, Matrai Z, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Mickys U, Miller A, Montagna M, Moysich KB, Mulligan AM, Musinsky J, Neuhausen SL, Nevanlinna H, Yie JNY, Niederacher D, Roed Nielsen H, Nussbaum RL, Offit K, Öfverholm

A, Ong K-R, Osorio A, Papi L, Papp J, Parsons MT, Pasini B, Sokilde Pedersen I, Peixoto A, Peruga N, Peterlongo P, Pohl E, Pradhan N, Prajzendanc K, Prieur F, Pujol P, Radice P, Ramus SJ, Rantala J, Usman Rashid M, Rhiem K, Robson M, Rodriguez GC, Rogers MT, Rudaitis V, Schmutzler RK, Senter L, Shah PD, Sharma P, Side LE, Simard J, Singer CF, Skytte A-B, Slavin TP, Snape K, Sobol H, Southey M, Spurdle AB, Steele L, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tan YY, Teixeira MR, Terry MB, Teulé A, Thomas A, Thull DL, Tischkowitz M, Tognazzo S, Ewart Toland A, Topka S, Trainer AH, Tung N, van Asperen CJ, van der Hout AH, van der Kolk LE, van der Luijt RB, Van Heetvelde M, Varesco L, Varon-Mateeva R, Vega A, Villarreal-Garza C, von Wachenfeldt A, Walker L, Wang-Gohrke S, Wappenschmidt B, Weber BHF, Yannoukakos D, Yoon S-Y, Zanzottera C, Zidan J, Zorn KK, Hutten Selkirk GG, Hulick PJ, Nathanson KL for the CIMBA Consortium. (2018) **Mutational spectrum in a worldwide study of 29,700 families with *BRCA1* or *BRCA2* mutations.** *Human Mutation* (mai) 39(5):593-620.doi: 10.1002/humu.23406. PMID: 29446198. [103]

408. Schrijver LH, Olsson H, Phillips K-A, Terry MB, Goldgar DE, Kast K, Engel C, Mooij TM, Adlard J, Barrowdale D, Davidson R, Eeles R, Ellis S, Evans DG, Frost D, Izatt L, Porteous ME, Side LE, Walker L, Berthet P, Bonadona V, Leroux D, Mouret-Fourme E, Venat-Bouvet L, Buys SS, Southey MC, John EM, Chung WK, Daly MB, Bane A, van Asperen CJ, Gomez Garcia EB, Mourits MJE, van Os TAM, Roos-Blom M-J, Friedlander ML, McLachlan S-A, Singer CF, Tan YY, Foretova L, Navratilova M, Schmutzler RK, Ellberg C, Gerdes A-M, Caldes T, Simard J, Olah E, Jakubowska A, Arver B, Osorio A, Nogue`s C, Andrieu N, Easton DF, van Leeuwen FE, Hopper JL, Milne RL, Antoniou AC, Rookus MA; on behalf of EMBRACE, GENEPSO, BCFR, HEBON, kConFab, and IBCCS (2018) **Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a *BRCA1* and *BRCA2* Mutation Carrier Cohort Study.** *JNCI Cancer Spectrum* (28 juin); 2(2): pky023. doi: 10.1093/jncics. [9]

409. Terry MB, Liao Y, Kast K, Antoniou AC, McDonald JA, Mooij TM, Engel C, Nogues C, Buecher B, Mari V, Moretta-Serra J, Gladieff L, Luporsi E, Barrowdale D, Frost D, Henderson A, Brewer C, Evans DG, Eccles D, Cook J, Ong K-R, Izatt L, Ahmed M, Morrison PJ, Dommering CJ, Oosterwijk JC, Ausems MGEM, Kriege M, Buys SS, Andrulis IL, John EM, Daly M, Friedlander M, McLachlan SA, Osorio A, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes A-M, Roos-Blom M-J, Arver B, Olsson H, Schmutzler RK, Hopper JL, van Leeuwen F, Goldgar D, Milne RL, Easton DF, Rookus M, Andrieu N; on behalf of EMBRACE, GENEPSO, BCFR, HEBON, kConFab and IBCCS (2018) **The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women with *BRCA1* or *BRCA2* mutations**. *Journal of the National Cancer Institute Cancer Spectrum*. 2018 Dec;2(4); pky078. doi.org/10.1093/jncics. [10]

410. Dörk T, Peterlongo P, Mannermaa A, Bolla MK, Wang Q, Dennis J, Ahearn T, Andrulis IL, Anton-Culver H, Arndt V, Aronson KJ, Augustinsson A, Beane Freeman LE, Beckmann MW, Beeghly A, Behrens S, Bermisheva M, Blomqvist C, Bogdanova NV, Bojesen SE, Brauch H, Brenner H, Burwinkel B, Canzian F, Chan TL, Chang-Claude J, Chanock SJ, Choi J-Y, Christiansen H, Clarke CL, Couch FJ, Czene K, Daly MB, dos-Santos-Silva I, Dwek M, Eccles DM, Ekici AB, Eriksson M, Evans DG, Fasching. PA, Figueroa J, Flyger H, Fritschi L, Gabrielson M, Gago-Dominguez M, Gao C, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Hartman M, Hauke J, Hein A, Hillemanns P, Hogervorst FBL, Hooning MJ, Hopper JL, Howell T, Huo D, Ito H, Iwasaki M, Jakubowska A, Janni W, John EM, Jung A, Kaaks R, Kang D, Kapoor PM, Khusnutdinova E, Kim S-W, Kitahara CM, Koutros S, Kraft P, Kristensen VN, Kwong A, Lambrechts D, Le Marchand L, Li J, Lindström S, Linet M, Lo W-Y, Long J, Lophatananon A, Lubiński J, Manoochehri M, Manoukian S, Margolin S, Martinez E, Matsuo K, Mavroudis D, Meindl A, Menon U, Milne RL, Mohd Taib NA, Muir K, Mulligan AM, Neuhausen SL, Nevanlinna H, Neven P, Newman WG, Offit K, Olopade OI, Olshan AF, Olson JE, Olsson H, Park SK, Park-Simon T-W, Peto J, Plaseska-Karanfilska D, Pohl-Rescigno E, Presneau N, Rack B, Radice P, Rashid MU, Rennert G, Rennert HS, Romero A, Ruebner M, Saloustros E, Schmidt MK, Schmutzler RK, Schneider MO, Schoemaker MJ, Scott C, Shen C-Y, Shu XO, Simard J, Slager S, Smichkoska S, Southey MC, Spinelli JJ, Stone J, Surowy H, Swerdlow AJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Toland AE, Tollenaar RAEM, Torres D, Torres-Mejía G, Troester MA, Truong T, Tsugane S, Untch M, Vachon CM, van den Ouweland AMW, van Veen EM, Vijai J, Wendt C, Wolk A, Yu J-C, Zheng W, Ziogas A, Ziv E, ABCTB Investigators, NBCS Collaborators, Dunning AM, Pharoah PDP, Detlev Schindler D, Devilee P, Easton DF (2019) **Two**

truncating variants in FANCC and breast cancer Risk. Scientific Resports. 2019 Aug 29;9(1):12524. doi: 10.1038/s41598-019-48804-y. [2]

411. Escala-Garcia M, Guo Q, Dörk T, Canisius S, Keeman R, Dennis J, Beesley J, Lecarpentier J, Bolla MK, Wang Q, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Auer PL, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bernstein L, Blomqvist C, Boeckx B, Bojesen SE, Bonanni B, Børresen-Dale A-L, Brauch H, Brenner H, Brentnall A, Brinton L, Broberg P, Brock IW, Brucker SY, Burwinkel B, Caldas C, Caldés T, Campa D, Carracedo A, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Cheng T-YD, Chin S-F, Clarke CL, NBCS Collaborators, Cordina-Duverger E, Couch FJ, Cox DG, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dunn JA, Dunning AM, Durcan L, Dwek M, Earl HM, Ekici AB, Eliassen H, Ellberg C, Engel C, Eriksson M, Evans DG, Figueroa J, Flesch-Janys D, Flyger H, Gabrielson M, Gago-Dominguez M, Galle E, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Georgoulias V, Giles GG, Glendon G, Goldgar DE, González-Niera A, Grenaker Alnaes GI, Grip M, Guénel P, Haeberle L, Hahnen E, Haiman CA, Håkansson N, Hall P, Hamann U, Hankinson S, Harkness EF, Harrington PA, Hart SN, Hartikainen JM, Hein A, Hillemanns P, Hiller L, Holleczek B, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Howell A, Guanmengqian H, Humphreys K, Hunter DJ, Janni W, John EM, Jones ME, Jukkola-Vuorinen A, Jung A, Kaaks R, Kabisch M, Kaczmarek K, Kerin MJ, Khan S, Khusnutdinova E, Kiiski JI, Kitahara CM, Knight JA, Ko Y-D, Koppert LB, Kosma V-M, Kraft P, Kristensen VN, Krüger U, Kühl T, Lambrechts D, Le Marchand L, Lee E, Lejbkowicz F, Li L, Lindblom A, Lindström S, Linet M, Lissowska J, Lo W-Y, Loibl S, Lubinski J, Lux MP, MacInnis RJ, Maierthaler M, Maishman T, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Mavroudis D, McLean C, Meindl A, Middha P, Miller N, Milne RL, Moreno F, Mulligan AM, Mulot C, Nassir R, Neuhausen SL, Newman WT, Nielsen SF, Nordestgaard BG, Norman A, Olsson H, Orr N, Pankratz VS, Park-Simon T-W, Perez JIA, Pérez-Barrios C, Peterlongo P, Petridis C, Pharoah PDP, Pinchev M, Prajzendanc K, Prentice R, Presneau N, Prokofieva D, Pylkäs K, Rack B, Radice P, Ramachandran D, Rennert G, Rennert HS, Rhenius V, Romero A, Roylance R, Saloustros E, Sawyer EJ, Schmidt DF, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schumacher F, Schwentner L, Scott R, Scott C, Seynaeve C, Shah M, Simard J, Smeets A, Sohn C, Southey MC, Swerdlow AJ, Talhouk A, Tamimi RM, Tapper WJ, Teixeira MR, Tengström M, Terry MB, Thöne K, Tollenaar RAEM, Tomlinson I, Torres D, Truong T, Turman C, Turnbull C, Ulmer H-U, Untch M, Vachon C, van Asperen CJ, van den Ouweland AMW, van Veen EM, Wendt C, Whittemore AS, Willet W, Winqvist R, Wolk A, Yang XR, Zhang Y, Easton DF, Fasching PA, Nevanlinna H, Eccles DM, Pharoah PDP, Schmidt MK (2019) **Genome-wide association study of germline variants and breast cancer-specific mortality.** *British Journal of Cancer.* March; 120(6):647-657. doi: 10.1038/s41416-019-0393-x. [10]

412. Ferreira MA, Gamazon ER, Al Ejeh F, Aittomäki K, Andrulis IL, Anton-Culver H, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Azzollini J, Balmaña J, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blomqvist C, Bogdanova NV, Bojesen SE, Bolla MK, Borg A, Brauch H, Brenner H, Broeks A, Burwinkel B, Caldés T, Caligo MA, Campa D, Campbell I, Canzian F, Carter J, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL, GC-HBOC Study Collaborators, GEMO Study Collaborators, EMBRACE Collaborators, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, de la Hoya M, Denis J, Devilee P, Diez O, Dörk T, Dunning AM, Dwek M, Eccles DM, Ejlertsen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Friedman E, Frost D, Gabrielson M, Gago-Dominguez M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hoover RN, Hopper JL, Hulick PJ, Humphreys K, Imyanitov EN, HEBON Investigators, BCFR Investigators, ABCTB Investigators, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Karlan BY, Khusnutdinova E, Kiiski JI, Ko Y-D, Jones ME, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts K, Lazaro C, Leslie G, Lester J, Lesueur F, Lindström S, Long J, Loud JT, Lubinski J, Makalic E, Mannermaa A, Manoocherhri M, Margolin S, Maurer T, Mavroudis D, McGuffog L, Meindl A, Menon U, Michailidou K, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Nussbaum RL, Offit K, Olah E, Olopade OI, Olsson H, Osoria A, Papp J, Park-Simon T-W, Parsons MT, Pedersen SI, Peixoto A, Peterlongo P, Pharoah PDP, Plaseska-Karanfilska D, Poppe B, Presneau N, Radice P, Rantala J, Rennert G, Risch HA, Saloustros

E, Sanden K, Sawyer EJ, Schmidt MK, Schmutzler RK, Sharma P, Shu X-O, Simard J, Singer CF, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Torres D, Truong T, Tung N, Vachon C, van Asperen CJ, van den Ouweland AMW, van Rensburg EJ, Vega A, Viel A, Wang Q, Wappenschmidt B, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Kraft P, Antoniou AC, Zheng W, Easton DF, Milne RL, Beesley J, Chenevix-Trench G (2019) **Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer.** *Nature Communications.* 15 April;10(1):1741. doi:10.1038/s41467-018-08053-5. [17]

413. Figlioli G, Bogliolo M, Catucci I, Caleca L, Lasheras SV, Pujol R, Kiiski J, Muranen T, Barnes DR, Dennis J, Michailidou K, Bolla MK, Leslie G, Aalfs C, ABCTB Investigators, Adank M, Adlard J, Agata S, Cadoo K, Agnarsson B, Ahearn T, Aittomäki K, Ambrosone CB, Andrews L, Anton-Culver H, Antonenkova N, Arndt V, Arnold N, Aronson K, Arun B, Asseryanis E, Auber B, Auvinen P, Azzollini J, Balmaña J, Barkardottir R, Barrowdale D, Barwell J, Beane Freeman L, Beauparlant CJ, Beckmann M, Behrens S, Benitez J, Berger R, Bermisheva M, Blanco A, Blomqvist C, Bogdanova N, Bojesen A, Bojesen SE, Bonanni B, Borg A, Brady A, Brauch H, Brenner H, Brüning T, Burwinkel B, Buys S, Caldés T, Caliebe A, Caligo M, Campa D, Campbell IG, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Claes KBM, Clarke CL, Collavoli A, Conner TA, Cox DG, Cybulski C, Czene K, Daly MB, de la Hoya M, Devilee P, Diez O, Ding YC, Dite GS, Ditsch N, Domchek SM, Dorfling CM, dos-Santos-Silva I, Durda K, Dwek M, Eccles DM, Ekici AB, Eliassen AH, Ellberg C, Eriksson M, Evans DG, Fasching PA, Figueroa J, Flyger H, Foulkes WD, Friebel TM, Friedman E, Gabrielson M, Gaddam P, Gago-Dominguez M, Gao C, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Gayther SA, GEMO Study Collaborators, Giles GG, Glendon G, Godwin AK, Goldberg MS, Godgar DE, Guénel P, Gutierrez-Barrera AM, Haeberle L, Haiman CA, Håkansson N, Hall P, Hamann U, Harrington PA, Hein A, Heyworth J, Hillemanns P, Hollestelle A, Hopper JL, Hosgood HD, Howell A, Hu C, Hulick PJ, Hunter DJ, Imyanitov EN, kConFab Investigators, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Janni W, John EM, Jones ME, Jung A, Kaaks R, Karlan BY, Khusnutdinova E, Kitahara CM, Konstantopoulou I, Koutros S, Kraft P, Lambrechts D, Lazaro C, Le Marchand L, Lester J, Lesueur F, Lilyquist J, Loud JT, Lu KH, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWN, Maurer T, Mavroudis D, Mebirouk N, Meindl A, Menon U, Miller A, Montagna M, Nathanson KL, Neuhausen SL, Newman WG, Nguyen-Dumont T, Nielsen FC, Nielsen S, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olshan AF, Olson JE, Olsson H, Osorio A, Ottini L, Peissel B, Peixoto A, Peto J, Plaseska-Karanfilska D, Pocza T, Presneau N, Pujana MA, Punie K, Rack B, Rantala J, Rashid MU, Rau-Murthy R, Rennet G, Lejbkowicz F, Rhenius V, Romero A, Rookus MA, Ross EA, Rossing M, Rudaitis V, Ruebner M, Saloustros E, Sanden K, Santamariña M, Scheuner MT, Schmutzler RK, Schneider M, Scott C, Senter L, Shah M, Sharma P, Shu X-O, Simard J, Singer CF, Sohn C, Soucy P, Southey MC, Spinelli JJ, Steele L, Stoppa-Lyonnet D, Tapper WJ, Teixeira MR, Terry MB, Thomassen M, Thompson J, Thull DL, Tischkowitz M, Tollenaar RAEM, Torres D, Troester MA, Truong T, Tung N, Untch M, Vachon CM, van Rensburg EJ, van Veen EM, Vega A, Viel A, Wappenschmidt B, Weitzel JN, Wendt C, Wieme G, Wolk A, Yang XR, Zheng W, Ziogas A, Zorn KK, Dunning AM, Lush M, Wang Q, McGuffog L, Parsons MT, Pharoah PDP, Fostira F, Toland AE, Andrulis IL, Ramus SJ, Swerdlow AJ, Greene MH, Chung WK, Milne RL, Chenevix-Trench G, Dörk T, Schmidt MK, Easton DF, Radice P, Hahnen E, Antoniou AC, Couch FJ, Nevanlinna H, Surrallés J, Peterlongo P. (2019) **The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer**. *NPJ Breast Cancer.* 1 nov 2019; 5:38. doi: 10.1038/s41523-019-0127-5. eCollection 2019. [7]

414. Qian F, Wang S, Mitchell J, McGuffog L, Barrowdale D, Leslie G, Oosterwijk JC, Chung WK, Evans DG, Engel C, Kast K, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Arun BK, Ausems MGEM, Azzollini J, Barouk-Simonet E, Barwell J, Belotti M, Benitez J, Berger A, Borg A, Bradbury AR, Brunet J, Buys SS, Caldes T, Caligo MA, Campbell I, Caputo SM, Chiquette J, Claes KBM, Margriet Collée J, Couch FJ, Coupier I, Daly MB, Davidson R, Diez O, Domchek SM, Donaldson A, Dorfling CM, Eeles R, Feliubadaló L, Foretova L, Fowler J, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Glendon G, Godwin AK, Gómez Garcia EB, Gronwald J, Hahnen E, Hamann U, Henderson A, Hendricks CB, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo Á, Jakubowska A, Kaczmarek K, Kang E, Karlan BY, Kets CM, Kim S-W, Kim Z, Kwong A, Laitman Y, Lasset C, Hyuk Lee M, Won Lee J, Lee J, Lester J, Lesueur F, Loud JT, Lubinski J, Mebirouk N, Meijers-

Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Morrison PJ, Mouret-Fourme E, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Nielsen FC, Nussbaum RL, Offit K, Olah E, Ong K-R, Ottini L, Park SK, Peterlongo P, Pfeiler G, Phelan CM, Poppe B, Pradhan N, Radice P, Ramus SJ, Rantala J, Robson M, Rodriquez GC, Schumtzler RK, Hutten Selkirk CG, Shah PD, Simard J, Singer CF, Sokolowska J, Stoppa-Lyonnet D, Sutter C, Yen Tan Y, Teixeira RM, Teo SH, Terry MB, Thomassen M, Tischkowitz M, Toland AE, Tucker KM, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Yannoukakos D; GEMO Study Collaborators, HEBON, EMBRACE, Greene MH, Rookus MA, Easton DF, Chenevix-Trench G, Antoniou AC, Goldgar DE, Olopade OI, Rebbeck TR, Huo D (2019) **Height and Body Mass Index as Modifiers of Breast Cancer Risk in *BRCA1/2* Mutation Carriers: A Mendelian Randomization Study**. *Journal of The National Cancer Institute.* 2019 April 1; 1;111(4):350-364. doi: 10.1093/jnci/djy 132. [8]

415. Qian F, Rookus MA, Leslie G, Risch HA, Greene MH, Aalfs CM, Adank MA, Adlard J, Agnarsson BA, Ahmed M, Aittomäki K, Andrulis IL, Arnold N, Arun BK, Ausems MGEM, Azzollini J, Barrowdale D, Barwell J, Benitez J, Białkowska K, Bonadona V, Borde J, Borg A, Bradbury AR, Brunet J, Buys SS, Caldés T, Caligo MA, Campbell I, Carter J, Chiquette J, Chung WK, Claes KBM, Collée JM, Collonge-Rame MA, Couch FJ, Daly MB, Delnatte C, Diez O, Domchek SM, Dorfling CM, Eason J, Easton DF, Eeles R, Engel C, Evans DG, Faivre L, Feliubadaló L, Foretova L, Friedman E, Frost D, Ganz PA, Garber J, Garcia-Barberan V, Gehrig A, Glendon G, Godwin AK, Gómez Garcia EB, Hamann U, Hauke J, Hopper JL, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Jakubowska A, Janavicius R, John EM, Karlan BY, Kets CM, Laitman Y, Lázaro C, Leroux D, Lester J, Lesueur F, Loud JT, Lubiński J, Lukomska A, McGuffog L, Mebirouk N, Meijers-Heijboer HEJ, Meindl A, Miller A, Montagna M, Mooij TM, Mouret-Fourme E, Nathanson KL, Nehoray B, Neuhausen SL, Nevanlinna H, Nielsen FC, Offit K, Olah E, Ong KR, Oosterwijk JC, Ottini L, Parsons MT, Peterlongo P, Pfeiler G, Pradhan N, Radice P, Ramus SJ, Rantala J, Rennert G, Robson M, Rodriguez GC, Salani R, Scheuner MT, Schmutzler RK, Shah PD, Side LE, Simard J, Singer CF, Steinemann D, Stoppa-Lyonnet D, Tan YY, Teixeira MR, Terry MB, Thomassen M, Tischkowitz M, Tognazzo S, Toland AE, Tung N, van Asperen CJ, van Engelen K, van Rensburg EJ, Venat-Bouvet L, Vierstraete J, Wagner G, Walker L, Weitzel JN, Yannoukakos D; KConFab Investigators; HEBON Investigators; GEMO Study Collaborators; EMBRACE Collaborators, Antoniou AC, Goldgar DE, Olopade OI, Chenevix-Trench G, Rebbeck TR, Huo D; CIMBA (2019) **Mendelian randomization study of height and body mass index as modifiers of ovarian cancer risk in 22,588 *BRCA1* and *BRCA2* mutation carriers**. *British Journal of Cancer.* 2019 Jul;121(2): 180-192. doi: 10.1038/s41416-019-0492-8. [3]

416. Escala-Garcia M, Abraham J, Andrulis IL, Anton-Culver H, Arndt V, Ashworth A, Auer PL, Auvinen P, Beckmann MW, Beesley J, Behrens S, Benitez J, Bermisheva M, Blomqvist C, Blot W, Bogdanova NV, Bojesen SE, Bolla MK, Børresen-Dale A-L, Brauch H, Brenner H, Brucker SY, Burwinkel B, Caldas C, Canzian F, Chang-Claude J, Chanock SJ, Chin S-F, Clarke CL, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Dennis J, Devilee P, Dunn JA, Dunning AM, Dwek M, Earl HM, Eccles DM, Eliassen H, Ellberg C, Evans DG, Fasching PA, Figueroa J, Flyger H, Gago-Dominguez M, Gapstur SM, García-Closas M, García-Sáenz JA, Gaudet MM, George A, Giles GG, Goldgar DE, González-Neira A, Grip M, Guénel P, Guo Q, Haiman CA, Håkansson N, Hamann U, Harrington PA, Hiller L, Hooning MJ, Hopper JL, Howell A, Huang C-S, Huang G, Hunter DJ, Jakubowska A, John EM, Kaaks R, Kapoor PM, Keeman R, Kitahara CM, Koppert LB, Kraft P, Kristensen VN, Lambrechts D, Le Marchand L, Lejbkowicz F, Lindblom A, Lubiński J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martinez ME, Maurer T, Mavroudis D, Meindl A, Milne RL, Mulligan AM, Neuhausen SL, Nevanlinna H, Newman WG, Olshan AF, Olson JE, Olsson H, Orr N, Peterlongo P, Petridis C, Prentice RL, Presneau N, Punie K, Ramachandran D, Rennert G, Romero A, Sachchithananthan M, Saloustros E, Sawyer EJ, Schmutzler RK, Schwentner L, Scott C, Simard J, Sohn C, Southey MC, Swerdlow AJ, Tamimi RM, Tapper WJ, Teixeira MR, Terry MB, Thorne H, Tollenaar RAEM, Tomlinson I, Troester MA, Truong T, Turnbull C, Vachon CM, van der Kolk LE, Wang Q, Winqvist R, Wolk A, Yang XR, Ziogas A, Pharoah PDP, Hall P, Wessels LFA, Chenevix-Trench G, Bader GD, Dörk T, Easton DF, Canisius S* and Schmidt MK* (2020) **A network analysis to identify mediators of germline-driven differences in breast cancer prognosis.** *Nature communications*. Jan 16;11(1):312. doi.org/10.1038/s41467-019-14100-6. * jointly supervised this work.[8]

417. Feng H, Gusev A, Pasaniuc B, Wu L, Long J, Abu-full Z, Aittomäki K, Andrulis IL, Anton-Culver H, Antoniou AC, Arason A, Arndt V, Aronson KJ, Arun BK, Asseryanis E, Auer PL, Azzollini J, Balmaña J,

Barkardottir RB, Barnes DR, Barrowdale D, Beckmann MW, Behrens S, Benitez J, Bermisheva M, Bialkowska K, Blanco A, Blomqvist C, Boeckx B, Bogdanova NV, Bojesen SE, Bolla MK, Bonanni B, Borg A, Brauch H, Brenner H, Briceno I, Broeks A , Brüning T, Burwinkel B, Cai Q, Caldés T, Caligo MA, Campbell I, Canisius S, Campa D, Carter J, Carter BD, Castelao JE, Chang-Claude J, Chanock SJ, Christiansen H, Chung WK, Claes KBM, Clarke CL, GEMO Study Collaborators, EMBRACE Collaborators, GC-HBOC Study Collaborators, Couch FJ, Cox A, Cross SS, Cybulski C, Czene K, Daly MB, de la Hoya M, de Leeneer K, Dennis J, Devilee P, Diez O, Domchek SM, Dörk T, dos-Santos-Silva I, Dunning AM, Dwek M, Eccles DM, Ejlertsen B, Ellberg C, Engel C, Eriksson M, Fasching PA, Fletcher O, Flyger H, Fostira F, Friedman E, Fritschi L, Frost D, Gabrielson M, Ganz PA, Gapstur SM, Garber J, García-Closas M, García-Sáenz JA, Gaudet MM, Giles GG, Glendon G, Godwin AK, Goldberg MS, Goldgar DE, González-Neira A, Greene MH, Gronwald J, Guénel P, Haiman CA, Hall P, Hamann U, Hake C, He W, Heyworth J, Hogervorst FBL, Hollestelle A, Hooning MJ, Hoover RN, Hopper JL, Huang G, Hulick PJ, Humphreys K, Imyanitov EN, ABCTB Investigators, HEBON Investigators, BCFR Investigators, OCGN Investigators, Isaacs C, Jakimovska M, Jakubowska A, James P, Janavicius R, Jankowitz RC, John EM, Johnson N, Joseph V, Jung A, Karlan BY, Khusnutdinova E, Kiiski JI, Konstantopoulou I, Kristensen VN, Laitman Y, Lambrechts D, Lazaro C, Leroux D, Leslie G, Lester J, Lesueur F, Lindor N, Lindström S, Lo W-Y, Loud JT, Lubinski J, Makalic E, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Martens JWM, Martinez ME, Matricardi L, Maurer T, Mavroudis D, McGuffog L, Meindl A, Menon U, Michailidou K, M. Kapoor P, Miller A, Montagna M, Moreno F, Moserle L, Mulligan AM, Muranen TA, Nathanson KL, Neuhausen SL, Nevanlinna H, Nevelsteen I, Nielsen FC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Olsson H, Osorio A, Papp J, Park-Simon T-W, Parsons MT, Pedersen IS, Peixoto A, Peterlongo P, Peto J, Pharoah PDP, Phillips K-A, Plaseska-Karanfilska D, Poppe B, Pradhan N, Prajzendanc K, Presneau N, Punie K, Pylkäs K, Radice P, Rantala J, Rashid MU, Rennert G, Risch HA, Robson M, Romero A, Saloustros E, Sandler DP, Santos C, Sawyer EJ, Schmidt MK, Schmidt DF, Schmutzler RK, Schoemaker MJ, Scott RJ, Sharma P, Shu X-O, Simard J, Singer CF, Skytte A-B, Soucy P, Southey MC, Spinelli JJ, Spurdle AB, Stone J, Swerdlow AJ, Tapper WJ, Taylor JA, Teixeira MR, Terry MB, Teulé A, Thomassen M, Thöne K, Thull DL, Tischkowitz M, Toland AE, Tollenaar RAEM, Torres D, Truong T, Tung N, Vachon CM, van Asperen CJ, van den Ouweland ANW, van Rensburg EJ, Vega A, Viel A, Vieiro-Balo P, Wang Q, Wappenschmidt B, Weinberg CR, Weitzel JN, Wendt C, Winqvist R, Yang XR, Yannoukakos D, Ziogas A, Milne RL, Easton DF, Chenevix-Trench G, Zheng W, Kraft P, Jiang X (2020) **Transcriptome-wide association study of breast cancer risk by estrogen-receptor status.** *Genetic Epidemiology.* July;44(5):442-468. doi: 10.1002/gepi.22288. [3]

418. Li H, Terry MB, Antoniou AC, Phillips K-A, Kast K, Mooij TM, Engel C, Noguès C, Stoppa-Lyonnet D, Lasset C, Berthet P, Mari V, Caron O for the GENEPSO study; Barrowdale D, Frost D, Brewer C, Evans DGR, Izatt L, Side L, Walker L, Tischkowitz M, Rogers MT, Porteous ME, Snape K for the EMBRACE study; Meijers-Heijboer HEJ, Gille JJP, Blok MJ, Hoogerbrugge N for the HEBON Investigators; Daly MB, Andrulis IL, Buys SS, John EM, McLachlan SA, Friedlander M for the kConFab Investigators; Tan YY, Osorio A, Caldes T, Jakubowska A, **Simard J**, Singer CF, Olah E, Navratilova M, Foretova L, Gerdes A-M, Roos-Blom M-J, Arver B, Olsson H, Schmutzler RK, Hopper JL, Milne RL, Easton DF, van Leeuwen FE, Rookus MA, Andrieu N, Goldgar DE (2020) **Alcohol consumption, cigarette smoking, and risk of breast cancer for *BRCA1* and *BRCA2* mutation carriers: results from The *BRCA1* and *BRCA2* Cohort Consortium.** *Cancer Epidemiology, Biomarkers & Prevention.* 2020 Feb;29(2):368-378. doi: 10.1158/1055-9965.EPI-19-0546. [2]

419. Liu J, Prager- van der Smissen WJC, Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Arnold N, Aronson KJ, Augustinsson A, Auvinen P, Becher H, Beckmann MW, Behrens S, Bermisheva M, Bernstein L, Bogdanova NV, Bogdanova-Markov N, Bojesen SE, Brauch H, Brenner H, Briceno I, Brucker SY, Brüning T, Burwinkel B, Cai Q, Cai H, Campa D, Canzian F, Castelao JE, Chang-Claude J, Chanock SJ, Choi J-Y, Chrisiaens M, Clarke CL, NBCS Collaborators, Couch FJ, Czene K, Daly MB, Devilee P, dos-Santos-Silva I, Dwek M, Eccles DM, Eliassen AH, Fasching PA, Figueroa J, Flyger H, Fritschi L, Gago-Dominguez M, Gapstur SM, García-Closa M, García-Sáenz JA, Gaudet MM, Giles GG, Goldberg MS, Goldgar DE, Guénel P, Haiman CA, Håkansson N, Hall P, Harrington PA, Hart SN, Hartman M, Hillemanns P, Hopper JL, Hou M-F, Hunter DJ, Huo D, ABCTB Investigators, Ito H, Iwasaki M, Jakimovska M, Jakubowska A, John EM, Kaaks R, Kang D, Keeman R, Khusnutdivnova E, Kim S-W, Kraft P, Kristensen

VN, Kurian AW, Le Marchand L, Li J, Lindblom A, Lophatananon A, Luben RN, Lubinski J, Mannermaa A, Manoochehri M, Manoukian S, Margolin S, Mariapun S, Matsuo K, Maurer T, Mavroudis D, Meindl A, Menon U, Milne RL, Muir K, Mulligan AM, Neuhausen SL, Nevanlinna H, Offit K, Olopade OI, Olson JE, Olsson H, Orr N, Park SK, Peterlongo P, Peto J, Plaseska-Karanfilska D, Presneau N, Rack B, Rau-Murthy R, Rennert G, Rennert HS, Rhenius V, Romero A, Ruebner M, Saloustros E, Schmutzler RK, Schneeweiss A, Scott C, Shah M, Shen C-Y, Shu X-O, Simard J, Sohn C, Southey MC, Spinelli JJ, Tamimi RM, Tapper WJ, Teo SH, Terry MB, Torres D, Truong T, Untch M, Vachon CM, van Asperen CJ , Wolk A, Yamaji T, Zheng W, Ziogas A, Ziv E, Torres-Mejía G, Dörk T, Swerdlow AJ, Hamann U, Schmidt MK, Dunning AM, Pharoah PDP, Easton DF, Hooning MJ, Martens JWM, Hollestelle A (2020) **Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk**. *Scientific Reports.* Jun 16;10(1):9688. doi:10.1038/s41598-020-65665-y.

420. Mavaddat N, Antoniou AC, Mooij TM, Hooning MJ, Heemskerk-Gerritsen BA, GENEPSO, Noguès C, Gauthier-Villars M, Caron O, Gesta P, Pujol P, Lortholary A, EMBRACE, Barrowdale D, Frost D, Evans DG, Izatt L, Adlard J, Eeles R, Brewer C, Tischkowitz M, Henderson A, Cook J, Eccles D, HEBON, van Engelen K, Mourits MJE, Ausems MGEM, Koppert LB, Hopper JL, John EM, Chung WK, Andrulis IL, Daly MB, Buys SS, kConFab Investigators, Benitez J, Caldes T, Jakubowska A, Simard J, Singer CF, Tan Y, Olah E, Navratilova M, Foretova L, Gerdes A-M, Roos-Blom M-J, van Leeuwen FE, Arver B, Olsson H, Schmutzler RK, Engel C, Kast K, Phillips K-A, Terry MB, Milne RL, Goldgar DE, Rookus MA, Andrieu N*, Easton DF* on behalf of IBCCS, kConFAB and BCFR (2020) **Risk-reducing salpingo-oophorectomy, natural menopause and breast cancer risk: an international prospective cohort of *BRCA1* and *BRCA2* mutation carriers.** *Breast Cancer Research.* 16 Jan; 22(1):8. doi: 10.1186/s13058-020-1247-4. [3]

421. Patel VL, Busch EL, Friebel TM, Cronin A, Leslie G, McGuffog L, Adlard J, Agata S, Agnarsson BA, Ahmed M, Aittomäki K, Alducci E, Andrulis IL, Arason A, Arnold N, Artioli G, Arver B, Auber B, Azzollini J, Balmaña J, Barkardottir RB, Barnes DR, Barroso A, Barrowdale D, Belotti M, Benitez J, Bertelsen B, Blok MJ, Bodrogi I, Bonadona V, Bonanni B, Bondavalli D, Boonen S, Borde J, Borg A, Bradbury AR, Brady A, Brewer C, Brunet J, Buecher B, Buys SS, Cabezas S, Caldés T, Caliebe A, Caligo MA, Calvello M, Campbell I, Carnevali I, Carrasco E, Chan TL, Chu ATW, Chung WK, Claes KBM, GEMO Study Collaborators, EMBRACE Collaborators, Cook J, Cortesi L, Couch FJ, Daly MB, Damante G, Darder E, Davidson R, de la Hoya M, Della Puppa L, Dennis J, Diez O, Ding YC, Ditsch N, Domchek SM, Donaldson A, Dworniczak B, Easton DF, Eccles DM, Eeles R, Ehrencrona H, Ejlertsen B, Engel C, Evans DG, Faivre L, Faust U, Feliubadalo L, Foretova L, Fostira F, Fountzilas G, Frost D, Garcia-Barberan V, Garre P, Gauthier-Villars M, Geczy L, Gehrig A, Gerdes A-M, Gesta P, Giannini G, Glendon G, Godwin AK, Goldgar DE, Greene MH, Gutierrez-Barrera A, Hahnen E, Hamann U, Hauke J, Herold N, Hogervorst FBL, Honisch E, Hopper JL, Hulick PJ, KConFab Investigators, HEBON Investigators, Izatt L, Jager A, James P, Janavicius R, Jensen UB, Jensen TD, Johannsson OT, John EM, Joseph V, Kang E, Kast K, Kiiski JI, Kim S-W, Kim Z, Ko K, Konstantopoulou I, Kramer G, Krogh L, Kruse TA, Kwong A, Larsen M, Lasset C, Lautrup C, Lazaro C, Lee J, Lee JW, Lee MH, Lemke J, Lesueur F, Liljegren A, Lindblom A, Llovet P, Lopez-Fernández A, Lopez-Perolio I, Lorca V, Loud JT, Ma ESK, Mai PL, Manoukian S, Mari V, Martin L, Matricardi L, Mebirouk N, Medici V, Meijers-Heijboer HEJ, Meindl A, Mensenkamp AR, Miller C, Molina Gomes D, Montagna M, Mooij TM, Moserle L, Mouret-Fourme E, Mulligan AM, Nathanson KL, Navratilova M, Nevanlinna H, Niederacher D, Nielsen FC, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Ong K-R, Osorio A, Ott C-E, Palli D, Park SK, Parsons MT, Pedersen IS, Peissel B, Peixoto A, Perez-Segura P, Peterlongo P, Petersen AH, Porteous ME, Pujana MA, Radice P, Ramser J, Rantala J, Rashid MU, Rhiem K, Rizzolo P, Robson M, Rookus MA, Rossing CM, Ruddy KJ, Santos C, Saule C, Scarpitta R, Schmutzler RK, Schuster H, Senter L, Seynaeve CMD, Shah PD, Sharma P, Shin VY, Silvestri V, Simard J, Singer CF, Skytte A-B, Snape K, Solano AR, Soucy P, Southey MC, Spurdle AB, Steele L, Steinemann D, Stoppa-Lyonnet D, Stradella A, Sunde L, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Tibiletti MG, Tischkowitz M, Tognazzo S, Toland AE, Tommasi S, Torres D, Toss A, Trainer AH, Tung N, van Asperen CJ, ven der Baan FH, van der Kolk LE, van der Luijt RB, van Hest LP, Varesco L, Varon-Mateeva R, Viel A, Vierstrate J, Villa R, von Wachenfeldt A, Wagner P, Wang-Gohrke S, Wappenschmidt B, Weitzel JN, Wieme G, Yadav S, Yannoukakos D, Yoon S-Y, Zanzottera C, Zorn KK, D'Amico A, Freedman M, Pomerantz M, Chenevix-Trench G, Antoniou AC, Neuhausen SL, Ottini L, Roed Nielsen H, Rebbeck TR (2020) **Association of Genomic Domains in *BRCA1* and *BRCA2* with Prostate Cancer**

Risk and Aggressiveness. *Cancer Research*. 2020 Feb 1:80(3):624-638. doi: 10.1158/0008-5472.CAN-19-1840. [8]

422. Silvestri V, Leslie G, Barnes DR, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Barkardottir RB, Barroso A, Barrowdale D, Benitez J, Bonanni B, Borg A, Buys SS, Caldés T, Caligo MA, Capalbo C, Campbell I, Chung WK, Claes KBM, Colonna SV, Cortesi L, Couch FJ, de la Hoya M, Diez O, Ding YC, Domchek S, Easton DF, Ejlertsen B, Engel C, Evans DG, Lidia Feliubadalo L, Foretova L, Fostira F, Géczi L, Gerdes A-M, Glendon G, Godwin AK, Goldgar DE, Hahnen E, Hogervorst FBL, Hopper JL, Hulick PJ, Isaacs C, Izquierdo A, James PA, Janavicius R, Jensen UB, John EM, Joseph V, Konstantopoulou I, Kurian AW, Kwong A, Landucci E, Lesueur F, Loud JT, Machackova E, Mai PL, Majidzadeh-A K, Manoukian S, Montagna M, Moserle L, Mulligan AM, Nathanson KL, Nevanlinna H, Ngeow Yuen Ye J, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Papi L, Park SK, Pedersen IS, Perez-Segura P, Petersen AH, Pinto P, Porfirio B, Pujana MA, Radice P, Rantala J, Rashid MU, Rosenzweig B, Rossing M, Santamariña M, Schmutzler RK, Senter L, Simard J, Singer CF, Solano AR, Southey MC, Steele L, Steinsnyder Z, Stoppa-Lyonnet D, Tan Y-Y, Teixeira MR, Teo SH, Terry MB, Thomassen M, Toland AE, Torres-Esquius S, Tung N, van Asperen CJ, Vega A, Viel A, Vierstraete J, Wappenschmidt B, Weitzel JN, Wieme G, Yoon S-Y, Zorn KK, Hamann U, Greene MH, Kirk JA, Neuhausen SL, Rebbeck TR, Tischkowitz M, Chenevix-Trench G, Antoniou AC, Friedman E*, Ottini L* (2020) **Characterization of the Cancer Spectrum in Men with Germline *BRCA*1 and *BRCA2* Pathogenic Variants : Results from the Consortium of Investigators of Modifiers of *BRCA1/2* (CIMBA)**. *JAMA Oncology*. 2020 Aug 1;6(8):1218-1230. doi: 10.1001/jamaoncol.2020.2134. [1]

REFEREED BOOK CHAPTERS

1. Labrie F, Proulx L, Giguère V, Marchetti B, Godbout M, Simard J (1984) **Steroid modulation of LHRH action**. In: *Steroid modulation of neuroendocrine function of steroids. Steroids and bone metabolism* (L Martini, GS Gordon and F Sciarra, eds), Biochemical Press, 23-37.

2. Labrie F, Dupont A, Bélanger A, Cusan L, Giguère M, Lacourcière Y, Luthy I, Bégin D, Labrie C, Simard J, Monfette G, Emond J (1987) **Combination therapy in stage C and D prostatic cancer: rationale and 5-year clinical experience**. In: *Cancer and Metastatic Reviews* (G Poste and IJ Fidler, eds), Martinus Nijhoff Publishing, 6: 615-636.

3. Labrie F, Giguère V, Meunier H, Simard J, Gossard F, Raymond V (1987) **Multiple factors controlling ACTH secretion at the anterior pituitary level**. *Annals of the New York Academy Sciences,* 512: 97-114.

4. Labrie F, Luthy I, Veilleux R, Simard J, Bélanger A, Dupont A (1987) **New concepts on the androgen sensitivity of prostate cancer**. In: *Progress in clinical and biological research*. Prostate cancer Part A: Research. Endocrine treatment and histopathology (GP Murphy, S Khoury, R Kuss, C Chatelain, L Denis, eds), vol. 243A: 145-172.

5. Labrie F, Poulin R, Simard J, Hubert JF, Spinola P, Marchetti B (1987) **Adrenal steroids exert potent estrogen action in both normal and cancer tissue**. In: *Hormonal Manipulation of Cancer: Peptides Growth Factors and New (Anti-)Steroidal Agents*. Monograph Series of the European Organization for Research on Treatment of Cancer (JGM Klijn, R Paridaens and JA Foekens, eds), Raven Press 18: 7-16.

6. Labrie F, Dupont A, Bélanger A, Simard J, Labrie C, Poulin R, Luthy I, Veilleux R, Lacoste D, Marchetti B, Cusan L, Manhès G, Monfette G, Emond J (1988) **Combination therapy with the antiandrogen Flutamide and the LHRH agonist [D-Trp^{6}, des-Gly-NH$_2$^{10}]LHRH ethylamide in prostate cancer: rationale and 5-year clinical experience**. In: *Molecular Biology of Brain and Endocrine Peptidergic Systems* (KW McKerns, ed), Plenum Press 83-101.

7. Labrie F, Simard J, Labrie C, Hubert JF, Barden N, Gagné B (1988) **Modulation of α-subunit and LHβ-mRNA in the rat anterior pituitary gland by sex steroids and an LHRH agonist**. In: *Recent Research on Gynecological Endocrinology* (AR Genazzani, F Petraglia, A Volé and F Facchinetti, eds), 1: 15-22.

8. Vincens M, Simard J, De Lignières B (1988) **Androgènes**. In: *Pharmacologie clinique. Base de la thérapeutique* (JP Giroud, G Mathé and G Meyniel, eds), 2^{e} édition, Expansion Scientifique (Paris), 2139-2158.

9. Labrie C, Simard J, Marchetti B, Pelletier G, Zhao HF, Bélanger A, Labrie F (1989) **Conversion of precursor adrenal steroids into potent androgens in peripheral tissue**. In: *Early Stage Prostate Cancer: Diagnosis and Choice of Therapy* (F Labrie, F Lee, A Dupont, eds), Elsevier, ICS 841: 1-22.

10. Pelletier G, Tong Y, Simard J, Zhao HF, Labrie F (1989) **Localization of peptide gene expression by in situ hybridization at the electron microscopic level**. In: *Methods in Neurosciences* (Conn M, ed), Academic Press 1: 197-208.

11. Labrie C, Simard J, Poulin M, Bélanger A, Pelletier G, Labrie F (1990) **Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione**. In: *Steroid Formation, Degradation and Action in Peripheral Tissues* (H Bradlow, L Castagnetta, S d'Aquino and F Labrie, eds), Annals of the New York Academy Sciences, 595: 392-394.

12. Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G, Labrie F (1990) **Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate**. In*: Steroid Formation, Degradation and Action in Peripheral Tissues* (H Bradlow, L Castagnetta, S d'Aquino and F Labrie, eds), Annals of the New York Academy Sciences, 595: 395-398.

13. Labrie F, Poulin R, Simard J, Zhao HF, Labrie C, Dauvois S, Dumont M, Hatton AC, Poirier D, Mérand Y (1990) **Interactions between estrogens, androgens, progestins and glucocorticoids in ZR-75-1 human breast cancer cells**. Annals of the New York Academy Sciences, 595: 130-148.

14. Labrie F, Simard J, Poulin R, Hatton AC, Labrie C, Dauvois S, Zhao HF, Petitclerc L, Couët J, Dumont M (1990) **Potent antagonism between estrogens and androgens on GCDFP-15 expression and cell growth in the ZR-75-1 human breast cancer cells**. In: *Workshop on Biochemistry of Breast Cyst Fluid and Cancer Risk* (A Angeli, H Bradlow, FI Chasalow and L Dogliotti, eds), Annals of the New York Academy Sciences, 586: 174-187.

15. Luu-The V, Labrie C, Zhao HF, Couët J, Lachance,Y, Simard J, Côté J, Leblanc G, Lagacé L, Bérubé D, Gagné R, Labrie F (1990) **Purification, cloning, complementary DNA structure and predicted amino acid sequence of human estradiol 17β-dehydrogenase**. In: *Steroid Formation, Degradation and Action in Peripheral, Normal and Neoplastic Tissues* (H Bradlow, L Castagnetta, S d'Aquino and F Labrie, eds), Annals of the New York Academy Sciences, 595: 40-52.

16. Simard J, Labrie C, Mérand Y, Dufour JM, Lévesque C, Labrie F (1990) **Pure antagonistic effect of a new steroidal antiestrogen in rat anterior pituitary cells in culture and in mouse uterus**. In: *Steroid Formation, Degradation and Action in Peripheral Tissues* (H Bradlow, L Castagnetta, S d'Aquino and F Labrie, eds), Annals of the New York Academy Sciences, 595: 425-427.

17. Labrie F, Simard J, Luu-The V, Bélanger A, Cusan L, Dupont A, Trudel C, Martel C, Labrie C, Zhao HF, Dupont E, Couët J, Lachance Y, Dumont M, de Launoit Y, Breton N (1991) **Androgens in post-menopause**. In: *Rivista di Ostetricia e Ginecologia Pratica e Medicina Perinatale Palermo*, 1: 15-24.

18. Simard J, Zhao HF, Labrie C, Trudel C, Rhéaume E, Dupont E, Breton N, Luu-The V, Pelletier G, Labrie F (1991) **Molecular cloning of rat 3β-HSD: structure of two types of cDNAs and differential expression of corresponding mRNAs in the ovary**. In: *Signaling Mechanisms and Gene Expression in the Ovary*. Serono Symposia, Springer-Verlag, New York, 274-279.

19. Labrie F, Simard J, Luu-The V, Pelletier G, Bélanger A (1992) **Cloning, expression and regulation of tissue-specific expression of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase**. In: *Cellular and Molecular Biology of the Adrenal Cortex*, John Libbey Eurotext Ltd, 222: 89-109.

20. de Launoit Y, Simard J, Zhao HF, Couture, P, Labrie F (1993) **Structure-function relationships of multiple rat members of the 3β-hydroxysteroid dehydrogenase family**. In: *Molecular Basis of Reproductive Endocrinology* (Leung PCK, Hsueh AJW, Friesen HG, Eds), New York, Springer-Verlag, 201-209.

21. Labrie F, Simard J, Luu-The V, Pelletier G, Labrie C, Dupont E, Martel C, Couët J, Trudel C, Rhéaume E, Breton N, de Launoit Y, Dumont M, Zhao HF, Lachance Y (1993) **Structure and control of expression of the 3β-HSD and 17β-HSD genes in classical steroidogenic and peripheral intracrine tissues**. In: *Molecular Basis of Reproductive Endocrinology* (Leung PS, Hsueh AJW and Friesen HG, eds), Karger, New York, 112-143.

22. Forest MG, Mébarki F, Simard J, Morel Y (1994) **Le déficit en 3β-hydroxystéroide déshydrogénase/Δ5-Δ4 isomérase: hétérogénéité des formes cliniques et apport de la biologie**. *Rev. Fr. Endocrinol. Clin.*, 35: 4-5.

23. Labrie F, Simard J, Bélanger A, Luu-The V, Labrie C (1994) **Molecular biology of the intracrine steroidogenic enzymes in the human prostate**. In: *Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects*. New York, Elsevier, 77-92.

24. Labrie F, Simard J, Luu-The V, Pelletier G (1994) **Molecular genetics, structure-function relationships and tissue-specific expression and tissue-specific expression and regulation of the 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene family**. In: *Function of Somatic Cells in the Testis*. New York, Springer-Verlag, 126-150.

25. Mébarki F, Morel Y, Simard J, Forest MG (1994) **Les déficits en 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4 isomérase: clinique et biologie moléculaire**. *Séminaire d'Endocrinologie Pédiatrique de l'Hôpital des Enfants Malades*. 195-204.

26. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C (1995) **DHEA and peripheral androgen and estrogen formation: intracrinology**. *Annals of the New York Academy Sciences,* 774: 16-28.

27. Labrie F, Bélanger A, Simard J, Luu-The V, Labrie C, Cusan L, Gomez JL, Diamond P, Candas B (1996) **Sources d'androgènes chez l'homme et traitement hormonal du cancer de la prostate**. In: *Endocrinologie Sexuelle de l'Homme* (Belaisch J, Drodowsky MA, Vermeulen A, eds), Doin, 1-15.

28. Labrie F, Cusan L, Dupont A, Gomez JL, Simard J, Luu-The V, Pelletier G, Labrie C, Bélanger A (1996) **Androgen receptor antagonists**. *In*: *Reproductive Endocrinology, Surgery and Technology*, (Adashi EY, Rock JA and Rosenwaks Z, eds.), New York: Raven Press, 559-584.

29. Labrie F, Simard J, Bélanger A, Lin SX, Luu-The V, Labrie F (1996) **Cancer: What are the role and sources of steroid hormones and the possible role of adipose tissue?** In: *Progress in obesity research*. (Angel A, Anderson H, Bouchard C, Lau D, Leiter L and Mendelson R, eds), 7: 559-567.

30. Labrie F, Simard J, Luu-The V, Pelletier G, Morel Y, Mebarki F, Sanchez R, Durocher F, Turgeon C, Labrie Y, Rhéaume E, Labrie C, Lachance Y (1996) **The 3β-hydroxysteroid dehydrogenase/ isomerase gene family: lessons from type II 3β-HSD congenital deficiency**. *In*: *Proc. 9th European Testis Workshop. Signal Transduction in Testicular Cells - Basic and clinical Aspects*, Springer-Verlag, 185-218.

31. Simard J, Rhéaume E, Sanchez R, Mébarki F, Morel Y, Zerah M, New MI, Labrie F (1996) **Relation between molecular defect and phenotypic manifestation of human 3β-hydroxysteroid dehydrogenase deficiency**. In: *Frontiers Endocrinol.*, Serono Symposia Series, pp. 39-68 (New, M., eds.).

32. Durocher F, Simard J (1997) **Hérédité et cancer du sein. Réseau d'échange et d'information du Québec sur le cancer du sein**. 2: 10.

33. Simard J, Labrie F (1997) **Recent advances in androgen receptor research: relative potencies of pure antiandrogens and implications for prostate cancer therapy. New diagnostic and treatment modalities in prostate cancer**. *Projects in knowledge*, 15-23.

34. Durocher F, Simard J, Ouellette J, Richard V, Pelletier G (1998) ***BRCA1* gene expression in reproductive and endocrine tissues in adult cynomolgus monkey**. *Annals of the New York Academy Sciences,* 839: 444-446.

35. Labrie F, Simard J, Luu-The V, Labrie C, Bélanger A (1998) **Adrenal androgens are responsible for 40-50% and not 5-10% of total prostatic androgens in 65-year-old men: intracrinology**. In: *First International Consultation on Prostate Cancer*, Published on CD-ROM. Monaco.

36. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Lin SX (1999) **DHEA, the precursor of androgens and estrogens in peripheral target tissues in the human: intracrinology**. In: *The Biological Role of DHEA* (Kalimi M and Regelson W, eds), (Volume II), pp. in press. Berlin, New York: Walter de Gruyter.

37. Labrie F, Bélanger A, Luu-The V, Simard J, Lin SX, Cusan L, Labrie C (1999) **Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues**. *DHEA Workshop*. New York: Parthenon Publishing, pp.69-103.

38. Labrie F, Bélanger A, Simard J Luu-The V, Labrie C, Lin SX, Candas B, Cusan L (1999) **Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et la ménopause**. *La Revue Française d'Endocrinologie Clinique Nutrition et Métabolisme.* 40: 169-204.

39. Simard J, Durocher F (1999) **Hérédité et cancer du sein: Les gènes de susceptibilité *BRCA1* et *BRCA2***. *L'Actualité Médicale.* 20: 4-10.

40. Labrie C, Labrie F, Bélanger A, Simard J, Luo S, Martel C (2000) **EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium**. *Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction.* Elsevier Science. Pages 381-397.

41. Labrie F, Labrie C, Bélanger A, Simard J, Luu-The V, Candas B (2000) **Mechanisms of action of estrogens and antiestrogens**. *The menopause at the millenium: proceedings of the 9th world congress on the ménopause*, Yokohama, 14-22.

42. Gaudet D, Laberge C, Simard J (2002) **The challenge of connecting genomic knowledge to disease prevention: a canadian integrative expérience**. In: *Community genetics: Past and future,* (Broertjes JJS, Henneman L, Beemer FA, eds.), Utrecht University, Pages 49-59.

43. Labrie F, Bélanger A, Luu-The V, Simard J, Labrie C (2002) **DHEA replacement therapy as source of androgens and estrogens at menopause**. In: *Gynecological Endocrinology,* (Genazzani AR, Petraglia F, Artini PG, eds), London UK, Parthenon Publishing, Pages 249-258.

44. Labrie F, Labrie C, Bélanger A, Simard J (2002) **Third and fourth generation SERMs**. *Selective Estrogen Receptor Modulators: Research and Clinical Applications*. Manni A, Verderame MF, Totowa NJ. Humana Press Inc.: 167-187.

45. Simard J, Moisan AM, Calemard Michel L, Morel Y (2002) **17β–hydroxysteroid dehydrogenase and 5a-reductase deficiencies**. In: *Genetics of Steroid Biosynthesis and Function,* Modern Genetics series (JI Mason, ed) – Harwood Academic Publishers. Vol 6, 297-338.

46. Simard J, Ricketts ML, Moisan AM, Morel Y (2002) **3β–hydroxysteroid dehydrogenase Δ5-Δ4-isomerase deficiency**. In: *Genetics of Steroid Biosynthesis and Function,* Modern Genetics series (JI Mason, ed) – Harwood Academic Publishers. Vol 6, 209-258.

47. Godard B, Simard J, et INHERIT BRCAs (2003) **Les enjeux éthiques de l'identification d'une susceptibilité génétique au cancer du sein dans un contexte de recherche clinique intégrée**. In: Les pratiques de la recherche médicale visitées par la bioéthique. Eds. C Hervé, BM Knoppers, PA Molinari, Dalloz, P ages 113-136.

48. Simard J, Dumont M, Soucy P, Labrie F, Tavtigian SV (2004) **Prostate Cancer Susceptibility Genes**. In: *Prostate Cancer: Understanding the Pathophysiology and Re-Designing a Therapeutic Approach*, (F. Labrie, M. Koutsilieries eds), Paschalidis Medical Publications, Ltd., Pages 1-38.

49. Simard J, Joly Y, Durocher F, Knoppers BM pour INHERIT BRCAs (2005) **Les enjeux éthiques du partage des résultats de recherche: L'expérience d'INHERIT BRCAS**. *"La recherche en génétique et en génomique: droits et responsabilités",* (Philips-Nootens S, Godard B, Knoppers BM et Régnier MH, eds), Les Éditions Thémis. Pages 103-139.

50. Labrie F, Poulin R, Simard J, Luu-The V, Labrie C, Bélanger A (2006) **Androgens, DHEA and Breast Cancer**. In: *Androgens and Reproductive Aging*. Gelfand T, ed., Oxsfordshire, UK, Taylor and Francis, Pages 113-135.

51. Lévesque E, Bédard K, Avard D, Simard J (2009) **Intégrer l'éthique dans la recherche**. In : *La malréglementation : Une éthique de la recherche est-elle possible et à quelles conditions?* Sous la direction de Pierre Trudel et Michèle S. Jean. Les Presses de l'Université de Montréal, Pages 137-154.

52. Morel Y, Roucher F, Plotton I, Simard J, Coll M (2014) **3ß-Hydroxysteroid Dehydrogenase Deficiency**. In : *Genetic Steroid Disorders*. (Maria New, Oksana Lekarev, Alan Parsa, Bert O'Malley, Bert O'Malley and Gary D. Hammer eds). Academic Press. Chapter 3F, Pages 99-110.

SCIENTIFIC ABSTRACTS

1. Simard J, Labrie F (1983) **Désensibilisation de l'action de la GRF sur la libération de GH et l'accumulation d'AMP cyclique dans les cellules adénohypohysaires en culture**. *Union Médicale du Canada*, p. 38, Abst. 2, 1983.
2. Ayoub J, Audet-Lapointe P, Methot Y, Déry JP, Pichet R, Michon B, Chemaly R, Guay JP, Stanimir G, Simard J, Hanley J, Labrie, F (1984) **Randomized trial of the addition of cyclical hormonal therapy to conventional treatment for endometrial cancer**. *Annals Royal College of Physicians and Surgeons*, Vol. 17, p. 345, 1984.
3. Gagnon P, Poyet P, Simard J, Bélanger A, Labrie F (1984) **Stimulatory effect of adrenal steroids on uterine weight and progesterone receptors in the rat**. *Excerpta Medica ICS 652*, p. 564, Abst. 607, 1984.
4. Labrie F, Simard J (1984) **Unoccupied androgen receptors are biologically active in pituitary gonadotrophs**. Vol. 20, p. 1397, Abst. A65, 1984.
5. Labrie F, Simard J (1984) **Unoccupied androgen receptors are biologically active in rat pituitary gonadotrophs**. *Excerpta Medica ICS 652*, p. 973, Abst. 1426, 1984.
6. Simard J, Kreis C, Gossard F, Labrie F (1984) **Interactions between growth hormone releasing factor and thyroid and glucocorticoid hormones on GH secretion, GH synthesis and GHmRNA levels in rat adenohypophyseal cells in culture**. *Physiol. Canada*, Vol. 15, p. 180, 1984.
7. Simard J, Labrie F (1984) **Stimulatory effect of adrenal steroids on LHRH-induced LH release in rat pituitary cells in culture**. *J. Steroid Biochem.* Vol. 20, p. 1404, Abst. A80, 1984.
8. Simard J, Labrie F (1984) **Antiestrogenic activity of LY 156758 in adenohypophysial cells in culture**. *J. Steroid Biochem.* Vol. 20, p.1405, Abst. A81, 1984.
9. Simard J, Labrie F (1984) **Antiestrogenic activity of LY 156758 in rat pituitary gonadotrophs in primary culture**. *Excerpta Medica ICS 652*, p. 1522, Abst. 2523, 1984.
10. Simard J, Lefebvre F, Labrie F (1984) **Interactions de la somatostatine et du GRF dans le contrôle de la sécrétion de GH dans les cellules adénohypophysaires de rat en culture**. *Annales de l'ACFAS*, Vol. 51, p. 103, 1984.
11. Simard J, Lefebvre G, Labrie F (1984) **Desensitization of the cell response to growth hormone-releasing factor in rat adenohypophysial cells in culture**. *Excerpta Medica ICS 652*, 1422, Abst. 2324, 1984.
12. Simard J, Michel D, Kreis C, Labrie F (1984) **Glucocorticoids and triiodothyronine are potent stimulators of growth hormone-releasing factor-induced cyclic AMP accumulation and growth hormone synthesis in adenohypophysial cells in culture**. *Excerpta Medica ICS 652*, p. 1423, Abst. 2325, 1984.
13. Simard J, Ruel F. Labrie F (1984) **Estrogenic activity of adrenal steroids on LH and prolactin release in rat pituitary cells in culture**. *Physiol. Canada*, Vol. 15, p. 181, 1984.
14. Anderson R, Simard J, Labrie F (1985) **Activité oestrogénique des stéroïdes surrénaliens sur la sécrétion de LH et de prolactine par les cellules adénohypophysaires de rat**. *53^{e} Congrès de l'ACFAS*, p. 114, 1985.
15. Labrie F, Bélanger A, Dupont A, Simard J (1985) **Medical or surgical castration in men leaves androgens levels sufficient to stimulate the growth of prostate cancer: the absolute requirement for Flutamide as part of all regimens using antihormonal therapy**. *Proc. 3^{ième} Forum d'Andrologie*, p. 119, 1985.
16. Simard J, Anderson R, Labrie F (1985) **Blockade of the potent estrogenic effects of C19 adrenal steroids by LY-156758, a pure antiestrogen, in rat anterior pituitary cells in culture**. *Can. Soc. Clin. Invest.*, Vancouver, BC, Canada, p. A79, Abst. C-244, September 1985.

17. Simard J, Anderson R, Labrie F (1985) **Estrogenic effects of adrenal steroids on LH, FSH and prolactin release in rat adenohypophyseal cells in culture**. *Fed. Proc.*, Vol. 44, p. 912, 1985.

18. Simard J, Gossard F, Kreis C, Labrie F (1985) **Multiple control of GH mRNA levels and GH synthesis in cultured rat anterior pituitary cells**. *Proc. of the 67th Meeting of the Endocrine Society*, p. 120, Abst. 479, 1985.

19. Simard J, Gossard F, Labrie F (1985) **Multiple control of growth hormone mRNA levels in adenohypophyseal cells in culture**. *Proc. of the Eastern Student Research Forum*, p. 61, 1985.

20. Simard J, Gossard F, Labrie F (1985) **Régulation hormonale du niveau d'ARNm de l'hormone de croissance (GH) dans les cellules adénohypophysaires de rat**. *Proc. of the 53th Meeting of the ACFAS*, p. 114, 1985.

21. Simard J, Gossard F, Labrie F (1985) **Regulation of growth hormone mRNA levels by cyclic AMP in rat anterior pituitary somatotrophs**. *Can. Soc. Clin. Invest.*, Vancouver, BC, Canada, p. A84, Abst. 276, September 1985.

22. Simard J, Hubert JF, Hosseinzadeh T, Labrie F (1985) **Stimulation par les estrogènes de la synthèse et de la sécrétion de l'hormone de croissance (GH) dans les cellules adénohypophysaires en culture**. Vol. 114, p. 701, Abst. 157, 1985.

23. Simard J. Labrie F (1985) **Blockage of the potent estrogenic activity of 5-androstene-3β,l7β-diol (Δ5-diol) and dehydroepiandrosterone (DHEA) by the antiestrogen LY-156758 in rat anterior pituitary cells in culture**. *Can. Soc. Clin. Invest.*, Vancouver, BC, Canada, p. 27S, Abst. 26, September 1985.

24. Hubert JF, Simard J, Assayag E, Heisler S, Labrie F (1986) **Le facteur atrionatriurétique (ANF) induit une accumulation de GMP cyclique dans les cellules adénohypophysaires en culture sans modification de la sécrétion hormonale**. *Annales de l'ACFAS*, Vol. 54, p. 151, 1986.

25. Labrie F, Poulin R, Simard J, Hubert JF, Dupont A, Bélanger A, Spinola P, Marchetti B (1986) **Role of adrenal steroids in breast cancer**. *Proc. Symposium Clinical and Pathological Advances in Breast Tumors*, p. 53-54, 1986.

26. Labrie F, Poulin R, Simard J, Spinola P, Marchetti B, Bélanger A (1986) **Estrogenic importance of adrenal steroids**. *First International Congress on Gynecological Endocrinology*, p. 56, 1986.

27. Labrie F, Simard J, Poulin R, Hubert JF, Spinola P, Marchetti B (1986) **Potent estrogenic activity of adrenal steroids**. *International Symposium on "Hormonal Manipulation of Cancer: Peptides, growth factors and new anti-steroidal agents*, Rotterdam, The Netherlands, Vol. 22, p. 715, 1986.

28. Simard J, Heisler S, Hubert JF, Assayag E, Labrie F (1986) **Effect of atrial natriuretic factor in rat anterior pituitary cells in culture**. *XXXième Congrès de l'Union Internationale des Sciences Physiologiques*, Vancouver, BC, Canada, p. 311, Abst. 320.05, 9-15 March 1986.

29. Simard J, Hubert JF, Hosseinzadeh T (1986) **Stimulatory effects of estrogens on basal and growth hormone (GH)-releasing factor-induced GH release and synthesis in rat anterior pituitary cells in culture**. *Proc. of the 68th Endocrine Society Meeting*, p. 142, Abst. 445, 1986.

30. Simard J, Hubert JF, Hosseinzadeh T, Labrie F (1986) **Effet de l'estradiol-17β sur la synthèse et la sécrétion de l'hormone de croissance dans les cellules adénohypophysaires en culture**. *Annales de l'ACFAS*, Vol. 54, p. 150, 1986.

31. Govindan M V, Simard J, Labrie F (1987) **Cloning of the human androgen receptor cDNA**. *International Symposium on Hormonal Therapy of prostatic diseases: basic and clinical aspects*, Milan, Italy, Vol. 10, p. 63, April 6-8, 1987.

32. Govindan MV, Simard J, Cantin C, Leblanc G, Burelle M (1987) **e. L. F. Isolement et expression de l'ADN complémentaire du récepteur androgénique humain**. *Annales de l'ACFAS*, Université d'Ottawa, ON, Canada, Vol. 55, p. 120, May 19-22, 1987.

33. Govindan MV, Simard J, Cantin C, Leblanc G, Burelle M (1987) **e. L. F. Isolement et expression de l'ADN complémentaire du récepteur androgénique humain**. *70ième Congrès Canadien de Chimie*, Quebec, QC, Canada, p. 128, June 7-11, 1987.

34. Govindan MV, Simard J, Labrie F (1987) **Cloning of the human androgen receptor cDNA**. *3rd Intenational Congress on Hormones and Cancer*, Hamburg, Germany, Vol. 28, p. 139S, September 6-11, 1987.

35. Govindan MV, Burelle M, Cantin C, Devic M, Labrie F, Leblanc G, Lefebvre C, Patel P, Simard J, Stropp U (1987) **Isolation and sequence of the human glucocorticoid receptor gene**. *Cloning of the human androgen receptor cDNA. Meadow Brook Conference on Steroid Receptors*, Oakland University, Rochester, MI, USA, p. 16, September 20-23, 1987.

36. Labrie F, Dupont A, Poulin R, Bélanger A, Simard J (1987) **Role of adrenal sex steroids in prostate and breast cancer**. *8th International Symposium of the Journal of Biochemistry*, Paris, France, May 24-27, 1987.

37. Labrie C, Simard J, Hubert JF. Barden N (1987) **e. L. F. La progestérone amplifie l'effet de l'estradiol sur l'accumulation des ARNms encodant les sous-unités de la LH dans l'adenohypophyse**. *XXIX Réunion Annuelle du Club de Recherches Cliniques du Québec*, Montebello, QC, Canada, Vol. 3, p. 16A, October 30-31, 1987.

38. Labrie F, Giguère V, Meunier H, Raymond V, Simard J (1987) **Mechanism of action for CRF in the pituitary gland**. *Symposium on "The Hypothalamic-Pituitary Adrenal Axis Revisited 1987*.

39. Simard J, Cantin C, Leblanc G, Burelle M, Labrie F (1987) **e. G. M. V. Caractérisation de la structure primaire et de l'expression de l'ADN complémentaire du récepteur humain des androgènes**. *XXIX Réunion Annuelle du Club de Recherches Cliniques du Québec*, Montebello, QC, Canada, Vol. 3, p. 15A, October 30-31, 1987.

40. Simard J. Labrie F (1987) **Inhibition of the potent estrogenic activity of C19-?5 adrenal steroids by the antiestrogen keoxifene (LY-156758) in rat anterior pituitary cells in culture**. *Congrès Canadien de Chimie*, Quebec, QC, Canada, p. 137, June 7-11, 1987.

41. Vincent A, Simard J, Labrie F (1987) **Adrenal C19-D5 steroids induce full estrogenic responses in rat pituitary cells**. *28th Annual National Student Research Forum*, Texas, USA, April 22-24, 1987.

42. Hubert JF, Simard J, Labrie C, Labrie F (1988) **Regulation of α-subunit and LH-β mRNA levels by LHRH and [D-Trp6, des- Gly-NH210]LHRH ethylamide in rat anterior pituitary cells in culture *in vivo***. *International Symposium on GnRH Analogues in Cancer and Human Reproduction*, Genève, Suisse, Vol. 2, p. 99, Abst. 89, February 18-21, 1988.

43. Labrie F, Labrie C, Hubert JF, Simard J (1988) **Control of α-subunit and LH-β mRNA levels by LHRH and sex steroids in pituitary gonadotrophs**. *1st Congress of the International Society of Gynecological Endocrinology*, Crans-Montana, Suisse, Abst. S83, March 6-12, 1988.

44. Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F (1988) **Stimulation of prostatic steroid binding protein gene expression by synthetic "progestins" in the rat**. *Satellite Symposium on Steroids Antagonists*, Kyoto, Japan, July 16, 1988.

45. Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G, Labrie F (1988) **Physiological concentrations of adrenal steroids stimulate prostatic binding protein gene expression in the rat prostate**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Ottawa, ON, Canada, Abst. C-212, September 23-26, 1988.

46. Labrie C, Simard J, Zhao HF, Pelletier G, Labrie F (1988) **Synthetic "progestins" stimulate androgen-dependent prostatic binding protein gene expression in the rat**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Ottawa, ON, Canada, Abst. C-213, September 23-26, 1988.

47. Labrie C, Simard J, Bélanger A, Pelletier G (1988) e. L. F. **La déhydroépiandrostérone et l'androstènedione stimulent l'expression de gènes androgéno-sensibles chez le rat**. *XXX^e Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, Abst. 79, October 1988.

48. Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G, Labrie F (1988) **Regulation of prostatic spermine-binding protein gene expression by dehydroepiandrosterone and androstenedione in the rat**. *Aps/Aspet*, Montreal, QC, Canada, Abst. 452, October 1988.

49. Latulippe JF, Hatton AC, Dauvois S, Labrie C, Simard J, Labrie F (1988) **Modulation de l'expression de l'ARN messager de la "gross cystic disease fluid protein-15" (GCDFP-15) dans la lignée cellulaire ZR-75-1 du cancer du sein humain**. *Colloque annuel des stages d'été en recherche*, Université Laval, Quebec, QC, Canada, p. 14, November 1988.

50. Martinoli MG, Zhao HF, Simard J, Pelletier G (1988) **Thyroid hormone regulation of growth hormone (GH) mRNA levels in rat anterior pituitary as revealed by *in situ* hybridization**. *Fourth International Congress of Cell Biology*, Montreal, QC, Canada, Abst. P10.4.10, June 1988.

51. Martinoli MG, Zhao HF, Simard J, Labrie F (1988) **e. P. G. Effets des hormones thyroïdiennes et des glucocorticoïdes sur les niveaux de RNA messager de l'hormone de croissance dans l'hypophyse de rat tels qu'évalués par hybridation *in situ***. *XXX^e Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, Abst. 100, October 1988.

52. Martinoli MG, Zhao HF, Simard J, Labrie F, Pelletier G (1988) **Effects of thyroid hormones and glucocorticoids on regulation of growth hormone (GH) mRNA levels in rat pituitary as revealed by *in situ* hybridization**. *Italian Congress of Neuroscience*, Bologne, Italy, Abst. S123, November 1988.

53. Pelletier G, Simard J, Duval M, Martinoli MG (1988) **Regulation by sex steroids of C1 prostatic binding protein gene expression measured by *in situ* hybridization**. *Canadian Physiological Society*, Mont-Tremblant, QC, Canada, p. Axxi, January 1988.

54. Pelletier G, Simard J, Duval M, Martinoli MG (1988) **Regulation by sex steroids of C1 peptide of prostatic binding protein mRNA levels measured by *in situ* hybridization**. *70^th Endocrine Society Meeting*, New Orleans, LO, USA, Abst. 497, June 8-11, 1988.

55. Petitclerc L, Labrie C, Simard J, Badr M, Zhao HF, Pelletier G, Barden N, Labrie F (1988) **e. C. D. H. Mécanismes d'action d'un antagoniste de la LHRH et de l'agoniste [D-Trp6, des-Gly-NH210]LHRH éthylamide**. *XXX^e Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, Abst. 101, October 1988.

56. Petitclerc L, Labrie C, Simard J, Badr M, Zhao HF, Pelletier G, Coy DH, Labrie F (1988) **Inhibitory effect of the LHRH angonist [D-Trp6, des-Gly-NH210]-LHRH ethylamide and an LHRH antagonist on pituitary Luteinizing hormone beta-bunit messager RNA in the rat**. *Aps/Aspet*, Montreal, QC, Canada, Abst. 1386, October 1988.

57. Poulin R, Lagacé L, Simard J, Petitclerc L, Labrie C, Pelletier G, Labrie F (1988) **Heterologous down-regulation of the estrogen receptor by androgens in the ZR-75-1 human breast cancer cell line**. *Satellite Symposium on Steroids Antagonists*, Kyoto, Japan, p. 7, 16 July 1988.

58. Poulin R, Lagacé L, Simard J, Petitclerc L, Labrie C, Pelletier G (1988) **e. L. F. Inhibition de l'expression du récepteur des estrogènes par les androgènes dans la lignée cellulaire de cancer du sein humain ZR-75-1**. *XXX^e Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, Abst. 103, October 1988.

59. Simard J, Labrie C, Labrie F (1988) **Synthetic "progestins" exert potent stimulatory effects on androgen- sensitive parameters in the rat prostate**. *70th Endocrine Society Meeting*, New Orleans, LO, USA, Abst. 720, June 8-11, 1988.

60. Simard J, Labrie C, Hubert JF, Labrie F (1988) **Multiple control of α- and β-subunits of luteinizing hormone mRNA levels in rat pituitary gland**. *31st Annual Meeting of the Canadian Federation of Biological Societies*, Université Laval, Quebec, QC, Canada, p. 287, June 15-18, 1988.

61. Simard J, Labrie C, Duval M, Zhao HF, Pelletier G, Labrie F (1988) **Androgenic activity of synthetic "progestins" on prostatic binding protein mRNA levels measured by in situ hybridization**. *8th International Congress of Endocrinology*, Abst. 16-19-097, July 1988.

62. Simard J, Hatton AC, Labrie C, Zhao HF, Poulin R, Petitclerc L, Labrie F (1988) **Modulation by sex steroids of human breast gross cystic disease fluid protein-15 mRNA levels in the ZR-75-1 human breast cancer cell line**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Ottawa, ON, Canada, Abst. C-214, 23-26 September 1988.

63. Simard J, Hatton AC, Labrie C, Petitclerc L, Zhao HF (1988) **e. L. F. Régulation de l'expression génétique d'un marqueur tumoral par les stéroïdes sexuels dans la lignée cellulaire de cancer du sein humain ZR-75-1**. *XXXe Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, Abst. 83, October 1988.

64. Simard J, Hatton AC, Labrie C, Zhao HF, Petitclerc L, Labrie F (1988) **Potent inhibitory effect of estrogens on breast gross cystic disease fluid protein-15 (GCDFP-15) mRNA levels in ZR-75-1 human breast cancer cells**. *Aps/Aspet*, Montreal, QC, Canada, Abst. 39.8, October 1988.

65. Simard J, Hatton AC, Labrie C, Dauvois S, Zhao HF, W., HD. Labrie F (1988) **Inhibitory effect of estrogens on GCDFP-15 mRNA levels in ZR-75-1 human breast cancer cells**. *Workshop on Biochemistry of Breast Cyst Fluid*, New York, NY, USA, December 1988.

66. Simard J, Labrie C, Hubert JF, Labrie F (1988) **Cumulative inhibitory effects of sex steroids on pituitary luteinizing hormone subunit messenger RNA levels**. *Canadian Physiological Society*, Mont-Tremblant, QC, Canada, Vol. 66, Abst. 5, Axxxvi, 1988.

67. Tong Y, Zhao HF, Simard J, Labrie C, Petitclerc L, Labrie F, Pelletier G (1988) **Regulation of prolactin mRNA levels by sex steroids in rat anterior pituitary gland**. *Aps/Aspet*, Montreal, QC, Canada, p. 138.1, October 1988.

68. Zhao HF, Labrie C, Simard J, Duval M, Pelletier G (1988) **Synthetic "progestins" cause accumulation of mRNA encoding prostatic binding protein in the rat**. *31st Annual Meeting of the Canadian Federation of Biological Societies*, Université Laval, Quebec, QC, Canada, p. 277, June 15-18, 1988.

69. Zhao HF, Labrie C, Simard J, Duval M, Pelletier G (1988) **Synthetic progestins cause accumulation of mRNA encoding prostatic binding protein in the rat**. *31st Annual Meeting of the Canadian Federation of Biological Societies*, Université Laval, Quebec, QC, Canada, p. 277, June 1988.

70. Zhao HF, Labrie C, Simard J, Pelletier G (1988) **e. L. F. Régulation de l'expression de gènes androgéno-sensibles par des "progestatifs" synthétiques dans la prostate de rat**. *XXXe Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, Abst. 107, October 1988.

71. Bérubé D, Luu-The V, Simard J, Gagné R, Labrie F (1989) **Localization of the 17β-estradiol dehydrogenase gene to bands q11-q12 of chromosome 17**. *10th Annual Meeting of the Human Gene Mapping*, New Heaven, CT, USA, Abst. A2685, June 10-17, 1989.

72. Bérubé D, Luu-The V, Simard J, Gagné R, Labrie F (1989) **The gene encoding human 3β-hydroxysteroid dehydrogenase/isomerase mapping to the p13 band of chromosome 1**. *10th Annual Meeting of the Human Gene Mapping*, New Heaven, CT, USA, Abst. A2686, June 10-17, 1989.

73. Bérubé D, Luu-The V, Simard J, Lachance Y, Gagné R, Labrie F (1989) **Localization of the human 17β-estradiol dehydrogenase and 3β-hydroxysteroid dehydrogenase/isomerase genes on human chromosomes**. *58th Annual Meeting of the Canadian Society for Clinical Investigation*, Edmonton, AB, Canada p. B29, Abst. C-159, September 22-25, 1989.

74. Couët J, Labrie C, Luu-The V, Zhao HF, Lachance Y, Geng GS, Simard J (1989) **e. L. F. Caractérisation de l'ARN messager encodant l'estradiol 17β-déshydrogénase**. *31e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Ste-Adèle, QC, Canada, p. 16A, Abst. 31, October 12-14, 1989.

75. Dauvois S, Simard J, Dumont M, Labrie F (1989) **Attenuation by insulin of the effect of progestins on cell growth and GCDFP-15 expression in ZR-75-1 human breast cancer cells**. *71st Annual Meeting of the Endocrine Society*, Seattle, WA, USA, p. 685, June 21-24, 1989.

76. Dauvois S, Dumont M, Simard J, Labrie F (1989) **Interaction between sex steroids and insulin on GCDFP-15 gene expression in human breast cancer ZR-75-1 cells**. *58th Annual Meeting of the Canadian Society for Clinical Investigation*, Edmonton, AB, Canada, p. B30, Abst. C-165, September 22-25, 1989.

77. Dumont M, Simard J, Dauvois S, Garcia T, Schachter B (1989) **e. L. F. Expression de la GCDFP-15: interaction entre les stéroïdes sexuels et corrélation avec l'expression des récepteurs des estrogènes et de la progestérone dans les cancers du sein humain**. *31e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Ste-Adèle, QC, Canada, p. 17A, Abst. 35, October 12-14, 1989.

78. Labrie C, Simard J, Bélanger A, Pelletier G, Labrie F (1989) **Influence of the duration of androgen deprivation on the sensitivity of the rat ventral prostate to dehydroepiandrosterone and androstenedione**. *First International Symposium on Steroid Formation, Degradation and Action in Normal, Peripheral and Neoplastic Tissues*, Taormina, Italy, March 14-18, 1989.

79. Labrie C, Simard J, Marchetti B, Pelletier G, Zhao HF, Bélanger A, Labrie F (1989) **Formation of active androgens from precursor adrenal steroids in peripheral tissues**. *First International Symposium on Steroid Formation, Degradation and Formation in Normal, Peripheral and Neoplastic Tissues*, Taormina, Italy, March 14-18, 1989.

80. Labrie C, Simard J, Zhao HF, Bélanger A, Pelletier G, Labrie F (1989) **Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate**. *First International Symposium on Steroid Formation, Degradation and Action in Normal, Peripheral and Neoplastic Tissues*, Taormina, Italy, March 14-18, 1989.

81. Labrie C, Simard J, Bélanger A, Pelletier G, Labrie F (1989) **Effet de l'absence chronique d'androgènes sur la sensibilité du tissu prostatique à l'action des androgènes et de leurs précurseurs chez le rat**. *57e Congrès de l'ACFAS*, Montreal, QC, Canada, p. 122, May 15-19, 1989.

82. Labrie F, Poulin R, Simard J, Zhao HF, Dumont M, Couët J, Labrie C, Dauvois S, Poirier D, Mérand Y (1989) **Interactions between estrogens, androgens, progestins and glucocorticoids in the ZR-75-1 human breast cancer cell line**. *First International Symposium on Steroid Formation, Degradation and Action in Peripheral Normal and Neoplastic Tissues*, Taormina, Italy, Abst. 27, March 14-18, 1989.

83. Labrie F, Simard J, Zhao HF, Dumont M, Couët J, Labrie C, Dauvois S, Poirier D, Mérand Y (1989) **Antiproliferative effects of androgens, progestins and glucocorticoids in the estrogen-sensitive ZR-75-1 human breast cancer cell line**. *First International Symposium on Steroid Formation, Degradation and Action in Normal, Peripheral and Neoplastic Tissues*, Taormina, Italy, March 14-18, 1989.

84. Labrie F, Simard J, Dauvois S, Labrie C, Poulin R, Dumont M, Hatton AC (1989) **Interactions between sex steroids on tumor marker and estrogen receptor expression and correlation with cell growth in ZR-75-1 human breast cancer cells**. *9th International Symposium of the Journal of Steroid Biochemistry*, Las Palmas, Spain, Abst. 27, May 28-31, 1989.

85. Labrie C, Zhao HF, Luu-The V, Simard J, Lachance Y, Couët J, Leblanc G, Dumont M, Labrie F (1989) **Characterisation of multiple 17β-estradiol dehydrogenase mRNAs in human placenta, prostate and ZR-75-1 breast cancer cells**. *32nd Annual Meeting of the Canadian Federation of Biological Societies*, Calgary, AB, Canada, p. 127, Abst. 439, June 14-17, 1989.

86. Luu-The V, Leblanc G, Côté J, Labrie C, Zhao HF, Couët J, Lachance Y, Simard J, Bérubé D, Lagacé L, Gagné R, Labrie F (1989) **Cloning, complementary DNA structure and predicted amino acid sequence of human 17β-dehydrogenase**. *First International Symposium on Steroid Formation, Degradation and Action in Peripheral Normal and Neoplastic Tissues*, Taormina, Italy, p. 95, March 14-18, 1989.

87. Luu-The V, Leblanc G, Côté J, Labrie C, Zhao HF, Lachance Y, Simard J, Lagacé L, Couët J, Labrie F (1989) **Isolement et caractérisation d'ADN complémentaire encodant l'estradiol déshydrogénase chez l'humain**. *57e Congrès de l'ACFAS*, Montreal, QC, Canada, p. 127, May 15-19, 1989.

88. Luu-The V, Leblanc G, Labrie C, Zhao HF, Lachance Y, Simard J, Lagacé L, Couët J, Labrie F (1989) **Molecular cloning, complementary DNA structure and predicted amino-acid sequence of human estradiol 17β-dehydrogenase, the key enzyme in estrogen biosynthesis**. *32nd Annual Meeting of the Canadian Federation of Biological Societies*, Calgary, AB, Canada, p. 121, Abst. 411, June 14-17, 1989.

89. Luu-The V, Zhao HF, Labrie C, Couët J, Simard J, Lachance Y, Leblanc G, Labrie F (1989) **Molecular cloning of two forms of cDNA encoding 17β-hydroxysteroid dehydrogenase**. *Assemblée annuelle de la Société des Obstétriciens et Gynécologues du Canada*, Quebec, QC, Canada, Abst. 95, June 20-21, 1989.

90. Luu-The V, Labrie C, Zhao HF, Couët J, Lachance Y, Simard J, Leblanc G, Côté J, Labrie F (1989) **Characterization of cDNAs for human estradiol 17β-dehydrogenase: evidence of two mRNA species with distinct 5' termini in human placenta**. *58th Annual Meeting of the Canadian Society for Clinical Investigation*, Edmonton, AB, Canada, p. B30, Abst. C-166, September 22-25, 1989.

91. Poulin M, Labrie C, Simard J, Pelletier A, Bélanger A (1989) **e. L. F. Régulation de gènes androgéno-dépendants prostatiques en fonction de l'âge et de la durée de la castration chez le rat**. *31e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Ste-Adèle, QC, Canada, p. 23A, Abst. 59, October 12-14, 1989.

92. Simard J, Labrie C, Mérand Y, Dufour JM, Lévesque C, Fournier A, Paquet J, and Labrie F (1989) **Pure antagonistic effect of a new steroidal antiestrogen in rat anterior pituitary cells in culture and in mouse uterus**. *First International Symposium on Steroid Formation, Degradation and Action in Normal, Peripheral and Neoplastic Tissues*, Taormina, Italy, March 14-18, 1989.

93. Simard J, Labrie C, Dufour JM, Lévesque C, Fournier A, Mérand Y, Paquette J, and Labrie F (1989) **Effet d'un antiestrogène stéroïdien dans les cellules adénohypophysaires de rat en culture et dans l'utérus de souris**. *57e Congrès de l'ACFAS*, Montreal, QC, Canada, p. 120, May 15-19, 1989.

94. Simard J, Dauvois S, Labrie C, Zhao HF, Dumont M, and Labrie F (1989) **Opposite effects of androgens, progestins, glucocorticoids and estrogens on gross cystic disease fluid protein-15 (GCDFP-15) expression and on cell growth in ZR-75-1 human breast cancer cells**. *32nd Annual Meeting of the Canadian Federation of Biological Societies*, Calgary, AB, Canada, p. 122, Abst. 412, June 14-17, 1989.

95. Simard J, Dauvois S, Labrie C, Poulin R, C., H. A., Dumont, M., and Labrie, F (1989) **Control of tumor marker, estrogen receptor expression and cell growth by sex steroids in ZR-75-1 human breast cancer cells**. *Assemblée annuelle de la Société des Obstétriciens et Gynécologues du Canada*, Quebec, QC, Canada, p. 89, June 20-21, 1989.

96. Simard J, Fournier A, Lévesque C, Paquet J, and Labrie F (1989) **Pure antiestrogenic activity of a new steroidal derivative in rat anterior pituitary cells in culture and in mouse uterus**. *71st Annual Meeting of the Endocrine Society*, Seattle, Washington, USA, p. 95, Abst. 290, June 21-24, 1989.

97. Tong Y, Zhao HF, Simard J, Labrie C, Labrie F, and Pelletier G (1989) **Sex steroid interactions in the control of prolactin mRNA levels in the male rat anterior pituitary gland as studied by in situ hybridization**. *Annual Meeting of the Histochemical Society*, Orlando, FL, USA, March 31-April 2, 1989.

98. Toranzo D, Dupont E, Simard J, Couët J, Labrie C, Labrie F, and Pelletier G (1989) **Regulation of luteinizing hormone-releasing hormone (LHRH) mRNA celluelar levels by sex steroids in the rat brain as studied by *in situ* hybridization**. *Annual Meeting of the Histochemical Society*, Orlando, FL, March 31-April 2, 1989.

99. Toranzo D, Dupont E, Simard J, Labrie C, Couët J, Labrie F, and Pelletier G (1989) **Contrôle des niveaux de l'ARN messager de la LHRH (luteinizing hormone-releasing hormone) par les stéroïdes sexuels dans le cerveau de rat**. *57^{e} Congrès de l'ACFAS*, Montreal, QC, Canada, p. 126, May 15-19, 1989.

100. Toranzo D, Dupont E, Simard J, Labrie C, Couët J, and Labrie F (1989) **e. P. G. Contrôle des niveaux de l'ARN messager de la LHRH (Luteinizing hormone-releasing hormone) par les stéroïdes sexuels dans le cerveau de rat.** *XIX^{ème} Colloque de la Société de Neuroendocrinologie Expérimentale*, Rouen, France, Abst. 165, September 12-15, 1989.

101. Bérubé D, Simard J, Labrie F, and Gagné R (1990) **Définition par hybridation in situ d'une délétion interstitielle d'un chromosome 1 survenue de nova chez un enfant**. *32^{e} Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, p. 31A, Abst. 82, September 27-29, 1990.

102. Couët J, Martel C, Zhao HF, Trudel C, Labrie C, Simard J, and Labrie F (1990) **Distribution tissulaire des différents types d'ARNm et de l'activité enzymatique de la 3β-hydroxystéroïde déhydrogénase/Δ5-Δ4 isomerase chez le rat**. *32^{e} Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, p. 20A, Abst. 38, September 27-29, 1990.

103. Dauvois S, Simard J, Haagensen DE, Lévesque C, and Mérand Y (1990) **Regulation of progesterone binding cyst protein GCDFP- 24 secretion by sex steroids in human breast cancer cells**. *The Canadian Physiological Society*, Vol. 20, p. 94, 1990.

104. Dauvois S. D. D., Simard J and Labrie, F (1990) **Effet des androgènes sur la croissance, la morphologie et la sécrétion de GCDFP-24 dans les cellules tumorales mammaires humaines MCF-7**. *58^{e} Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, p. 102, May 14-18, 1990.

105. de Launoit Y, Simard J, Dauvois S, Dufour M, and Labrie F (1990) **Inhibition of estrogen action on a novel biochemical marker, cell growth and cell kinetic parameters by androgens and the new pure anti-estrogen EM-139 in ZR-75-1 human breast cancer cells**. *The Canadian Society for Clinical Investigation*, Toronto, ON, Canada, Vol. 13, p. B29, Abst. 171, September 14-17, 1990.

106. de Launoit Y, Dauvois S, Dufour M, Simard J, and Labrie F (1990) **Blockade of estrogen-induced cell proliferation and cell kinetic parameters by the new steroidal pure antiestrogen EM-139 in ZR-75-1 human breast cancer cells**. *8th International Congress on Hormonal Steroids*, The Hague, The Netherlands, Vol. 36, p. 65S, Abst. 180, September 16-21, 1990.

107. de Launoit Y, Dauvois S, Dufour M, Simard J, and Labrie F (1990) **Differential antiproliferative effects of dihydrotestosterone and the new steroidal pure antiestrogen EM-139 on cell kinetic parameters in human breast cancer ZR-75-1 cells**. *13th Annual San Antonio Breast Cancer Symposium*, San Antonio, USA, TX, 2-3 November 1990, Vol. 16, p. 166, Abst. 85.

108. Labrie C, Luu-The V, Lachance Y, Simard J, Couët J, and Labrie F (1990) **Analyse des ARN messagers de la 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4- isomérase et de la 17β-hydroxystéroïde déshydrogénase dans les tissus hormono-sensibles chez l'humain**. *58^{e} Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, p. 105, May 14-18, 1990.

109. Labrie C, Trudel C, Martel C, Takahashi M, Dupont Zhao HF, Simard J, Luu-The V, Couët J, and Labrie F (1990) **Régulation de l'expression et de l'activité de l'enzyme 3β-hydroxystéroide déhydrogénase Δ5-Δ4-isomérase testiculaire et surrénalienne chez le rat**. *58e Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, p. 105, May 14-18, 1990.

110. Labrie C, Martel C, Couët J, Trudel C, Zhao HF, Luu-The V, Dupont E, Simard J, Pelletier G, and Labrie F (1990) **Control of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) expression in the rat testis and ovary**. *8th International Congress on Hormonal Steroids*, The Hague, Pays Bas, p. 84S, Abst. 232, September 16-21, 1990.

111. Labrie F, Bélanger A, Dupont A, Simard J, Luu-The V, and Labrie C (1990) **Endocrinology of prostate cancer**. *2nd International Symposium on GnRH Analogues in Cancer and Human Reproduction*, Vol. 4, p. 83, Abst. 145, Geneva, Switzerland, 1990.

112. Labrie F, Simard J, Dauvois S, de Launoit Y, and Poulin R (1990) **Effect of physiological concentrations of androgens on growth and gene expression in human breast cancer ZR-75-1**. *15th International Cancer Congress*, Hamburg, Germany, August 16-22, 1990.

113. Labrie F, Simard J, Dauvois S, Labrie C, and Dumont M (1990) **Potent and opposite effects of androgens on gross cystic disease fluid protein-15 (GCDFP-15) and GCDFP-24 expression and cell growth in human breast cancer ZR-75-1 cells**. *International Symposium on Benign Breast Disease and Chemoprevention of Breast Cancer*, Geneva, Switzerland, p. 27, December 6-8, 1990.

114. Lachance Y, Labrie C, Simard J, Luu-The V, and Labrie F (1990) **Structure of human 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene**. *The Canadian Society for Clinical Investigation,* Toronto, ON, Canada, Vol. 13, p. B29, Abst. 170, September 14-17, 1990.

115. Rhéaume E, Simard J, Kirkland K, Labrie F, and Luu-The V (1990) **Amplification sélective du gène encodant l'estradiol hydroxy-17β-déshydrogénase humaine**. *58e Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, p. 111, May 14-18, 1990.

116. Rhéaume E, Simard J, Kirkland KC, Morel Y, and Labrie F (1990) **Caractérisation des altérations génétiques associées à un déficit de l'activité 17β-hydroxystéroïde déshydrogénase causant un pseudo-hermaphrodisme masculin**. *32e Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, p. 18A, Abst. 29, September 27-29, 1990.

117. Simard J, Luu-The V, Leblanc G, Lachance Y, Zhao HF, and Labrie F (1990) **Caractérisation de la structure des gènes de l'hydroxy-17β-stéroïde déshydrogénase humaine**. *58e Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, p. 43, May 14-18, 1990.

118. Simard J, Dauvois S, Haagensen DE, and Mérand Y (1990) **Regulation of progesterone-binding cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: a new marker of steroid action**. *72nd Endocrine Society Meeting*, Atlanta, GA, USA, p. 353, Abst. 1316, June 20-23, 1990.

119. Simard J, Dauvois S, Haagensen DE, and Labrie F (1990) **Multiple hormonal control of progesterone-binding breast cyst protein GCDFP-24 secretion in human breast cancer cells**. *13th Annual San Antonio Breast Cancer Symposium*, San Antonio, Texas, USA, Vol. 16, p. 166, Abst. 88, November 2-3, 1990.

120. Simard J, Luu-The V, Lachance Y, and Leblanc G (1990) **Structure of two in tandem 17β-hydroxysteroid dehydrogenase genes**. *The Canadian Physiological Society*, Vol. 20, p. 155 *1990*.

121. Simard J, Zhao HF, Breton N, Trudel C, Labrie C, Rhéaume E, and Labrie F (1990) **Caractérisation de trois types d'ADN complémentaire encodant la 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase de rat**. *32e Réunion Annuelle du Club de Recherches Cliniques*, Pointe-au-Pic, QC, Canada, p. 19A, Abst. 35, September 27-29, 1990.

122. Simard J, Zhao HF, Labrie C, Trudel C, Rhéaume E, Dupont E, Pelletier G, Luu-The V, and Labrie F (1990) **Molecular cloning of rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase: structure of two types of cDNAs and differential expression of the corresponding mRNAs in the ovary**. *VIII Ovarian Workshop. Serono Symposia USA*, Maryville, Tennessee, USA, p. 47, Abst. 50, July 12-14, 1990.

123. Simard J, Dauvois S, Haagensen DE, and Labrie F (1990) **Multiple hormonal control of progesterone-binding breast cyst protein GCDFP-24 secretion in human breast cancer cells**. *13th Annual San Antonio Breast Cancer Symposium*, San Antonio, Texas, USA, November 2-3, 1990, Vol. 16, p. 166, Abst. 88.

124. Tong Y, Rhéaume E, Simard J, Dupont E, and Pelletier G (1990) **Localization of diazepam binding receptor (DBI) in the rat brain and pituitary by high resolution in situ hybridization**. *Society for Neuroscience*, St-Louis, Missouri, USA, p. 362, Abst. 157.4, October 28- November 2, 1990.

125. Trudel C, Zhao HF, Simard J, Labrie C, Breton N, Leblanc G, Luu-The V, and Labrie F (1990) **Caractérisation de deux types d'ADN complémentaire encodant l'hydroxy-3β-stéroïde déhydrogénase/Δ5-Δ4 isomerase dans l'ovaire de rat**. *58e Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, p. 44, May 14-18, 1990.

126. Zhao HF, Simard J, Labrie C, and Labrie F (1990) **Characterization of two types of rat cDNA encoding 3β-hydroxy-5-ene steroid dehydrogenase/Δ5-Δ4 isomerase**. *72nd Endocrine Society Meeting*, Atlanta, Georgia, USA, p. 246, Abst. 888, June 20-23, 1990.

127. Bérubé D, Simard J, Sandberg M, Grzeschik KH, Gagné R, Hansson V, and Jahnsen T (1991) **Assignment of the gene encoding the catalytic subunit Cbeta of cAMP-dependent protein kinase to the p36 band on chromosome 1**. *Eleventh International Workshop on Human Gene Mapping*, London, ON, Canada, p. 1, August 18-22, 1991.

128. Breton N, Rhéaume E, Zhao HF, Lachance Y, Trudel C, de Launoit Y, Dumont M, Luu-The V, Simard J, and Labrie F (1991) **Characterization of a new type of 3β-hydroxysteroid dehydrogenase cDNA in human adrenal**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Quebec, QC, Canada, Vol. 14, p. A33, Abst. 190, September 19-23, 1991.

129. Cossette LJ, Martinoli MG, Simard J, Chabot P, Pelletier G, and Vincent M (1991) **Transient expression of a new intermediate filament-associated protein during chick neurogenic differentiation**. *Third IBRO World Congress of Neuroscience*, Montreal, QC, Canada, p. 43, Abst. P3.58, August 4-9, 1991.

130. Couët J, Martel C, Trudel C, Zhao HF, Simard J, and Labrie F (1991) **Sexual dimorphic expression and activity of a newly characterized 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase in rat liver**. *22nd Canadian Physiological Society Meeting*, Ste-Adèle, QC, Canada, Vol. 21, p. 237, January 16-20, 1991.

131. Couture P, Simard J and Labrie F (1991) **Steroidal regulation of 17β-hydroxysteroid dehydrogenase activity in ZR-75-1 human breast cancer cells**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Quebec, QC, Canada, Vol. 14, p. A34, Abst. 195, September 19-23, 1991.

132. Couture P, Simard J, and Labrie F (1991) **Contrôle hormonal de l'activité 17β-hydroxystéroïde déshydrogénase dans les cellules cancéreuses mammaires humaines ZR-75-1**. *33e Réunion Annuelle du Club de Recherches Cliniques du Québe*c, Magog, QC, Canada, p. 25, Abst. 71, September 26-28, 1991.

133. de Launoit Y. and Simard J (1991) **Expression and site-directed mutagenesis of rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase cDNAs: crucial role of a 5' potential transmembrane domain**. *73rd Endocrine Society Meeting*, Washington, USA, p. 930, June 19-22, 1991.

134. de Launoit Y, Zhao HF, Labrie F, and Simard J (1991) **Structure-activity relationships of multiple rat 3β-hydroxysteroid dehydrogenases**. *Symposium on Molecular Basis of Reproductive Endocrinology*, Serono, Vancouver, BC, p. 23, Abst. 9, July 25-26, 1991.

135. Foss KB, Bérubé D, Simard J, Beebe SJ, Sandberg M, Grzeschik KH, Gagné R, Hansson V, and Jahnsen T (1991) **Localization of the catalytic subunit Cgamma of cAMP-dependent protein kinase on human chromosome q13**. *Eleventh International Workshop on Human Gene Mapping*, London, ON, Canada, p. 92, August 18-22, 1991.

136. Labrie F, Simard J, Luu-the V, and Pelletier G (1991) **Structure and regulation of tissue-specific expression of 3b-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase genes in human and rat steroidogenic and peripheral tissues**. *10th International Symposium Journal of Biochemistry and Molecular Biology*, Paris, France, Abst. 34, May 26-29, 1991.

137. Labrie F, Simard J, Luu-The V, and Pelletier G (1991) **Structure and control of expression of the 3β-HSD and 17β-HSD genes in classical steroidogenic and peripheral tissues: their role in intracrinology**. *Symposium on Molecular Basis of Reproductive Endocrinology*, Serono, Vancouver, BC, Canada, p. 10, July 25-26, 1991.

138. Labrie F, Luu-The V, Simard J, Lachance Y, Zhao HF, de Launoit Y, Labrie C, Martel C, Trudel C, Couët J, Dupont E, Pelletier G, Bélanger A, Dumont M, Rhéaume E, and Breton N (1991) **Structure and tissue-specific expression of multiple types of human and rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase (3β-HSD) and structure of human types I and II 3β-HSD genes**. *International Ares-Serono Symposium on Molecular View of Steroid Biosynthesis and Metabolism*, Jerusalem, Israel, p. 20, Abst. L-8, October 14-17, 1991.

139. Labrie F, Simard J, Luu-The V, Pelletier G, and Bélanger A (1991) **Structure and control of the expression of the androgen biosynthetic enzymes in gonadal and peripheral tissues**. *XV Meeting of the International Study Group for Steroid Hormones*, Rome, Italy, Vol. S14, p. 23, November 28-30, 1991.

140. Orstavik S, Sandberg M, Bérubé D, Natarajan V, Simard J, Walter U, Gagné R, Hansson V, and Jahnsen T (1991) **Localization of the human gene for type I cyclic GMP-dependent protein kinase to chromosome 10 at q11.2**. *Eleventh International Workshop on Human Gene Mapping*, London, ON, Canada, p. 106, August 18-22, 1991.

141. Rhéaume E, Leblanc JF, Labrie F, and Simard J (1991) **Detection of BglII restriction site polymorphism in human 3β-hydroxysteroid dehydrogenase genes**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Quebec, QC, Canada, p. A84, Abst. 518, September 19-23, 1991.

142. Rhéaume E, Breton N, Zhao HF, Dumont M, Lachance Y, de Launoit Y, Trudel C, Luu-The V, Simard J, and Labrie F (1991) **Isolement, structure et expression d'un nouveau type d'ADN complémentaire encodant la 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4 isomérase dans les gonades et les surrénales chez l'humain**. *33e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Magog, QC, Canada, p. 22, Abst. 57, September 26-28, 1991.

143. Simard J, de Launoit Y, and Veilleux R (1991) **Opposite action of androgens on the regulation of apoliprotein D secretion and cell cycle kinetic parameters in human prostatic cancer cells**. *73rd Endocrine Society Meeting*, Washington, USA, Abst. 1384, June 19-22, 1991.

144. Simard J, de Launoit Y, and Labrie F (1991) **Crucial role of a 5' potential membrane-spanning domain in rat 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Quebec, QC, Canada, p. A33, Abst. 191, September 19-23, 1991.

145. Simard J, Luu-The V, and Labrie F (1991) **Molecular characterization of sex steroid formation in normal and neoplastic cells**. *The 2nd Eastern Canadian Conference on Development and Cancer*, Montreal, QC, Canada, Abst. 40, September 23-25, 1991.

146. Simard J, de Launoit Y, Zhao HF, and Labrie F (1991) **Caractérisation fonctionnelle des isoenzymes de la 3β-hydroxystéroïde déshydrogénase**. *33e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Magog, QC, Canada, p. 22, Abst. 59, September 26-28, 1991.

147. Trudel C, Couët J, Martel C, Zhao HF, Simard J, and Labrie F (1991) **Dimorphisme sexuel dans l'expression et l'activité d'un type spécifique de 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4 isomérase (3β-HSD) dans le foie de rat**. *59e Congrès de l'ACFAS*, Sherbrooke, QC, Canada, p. 108, May 21-24, 1991.

148. Breton N, Turgeon C, Couët J, Labrie F, and Simard J (1992) **Structure et expression d'un gène encodant une nouvelle isoenzyme de la famille de la 3b-HSD chez le rat**. *60e Congrès de l'ACFAS*, Université de Montreal, QC, Canada, p. 119, May 11-15, 1992.

149. Breton N, Turgeon C, Couët J, Labrie Y, Labrie F, and Simard J (1992) **Characterization of the structure of a new member of the rat 3β-hydroxysteroid dehydrogenase gene family**. *9th International Congress of Endocrinology*, Nice, France, August 30- September 5, 1992.

150. Couët J, Labrie Y, Breton N, Trudel C, Martel C, Simard J, and Labrie F (1992) **Distribution tissulaire des différents ARNms encodant la 3β-hydroxystéroïde déshydrogénase chez le rat et régulation de cette enzyme dans la peau**. *60e Congrès de l'ACFAS*, Université de Montréal, QC, Canada, p. 119, May 11-15, 1992.

151. Couët J, Labrie Y, Martel C, Juneau C, Breton N, Luo S, and Simard J (1992) **Modulation of a newly characterized 3β-hydroxysteroid dehydrogenase /isomerase mRNA species in the rat placenta**. *Ninth International Congress of Endocrinology*, Nice, France, p. 508, Abst. P-15.04.023, August 30-September 5, 1992.

152. de Launoit Y, Sanchez-Garcia R, and Simard J (1992) **Characterization of the formation and degradation of androgens by recombinant members of the rat 3β-hydroxysteroid dehydrogenase family in intact mammalian cells in culture**. *74th Annual Meeting The Endocrine Society*, San Antonio, TX, USA, p. 89, June 24-27, 1992.

153. de Launoit Y, Poulin M, Labrie F, and Simard J (1992) **Cell-specific activation of human 17β-hydroxysteroid dehydrogenase II gene promoter**. *Ninth International Congress of Endocrinology*, Nice, France, p. 539, Abst. P-17.04.026, August 30- September 5, 1992.

154. Labrie F, Simard J, Bélanger A, Cusan L, and Dupont A (1992) **La peau, organe de synthèse des estrogènes et androgènes. Étude d'un nouvel antiandrogène dans l'hirsutisme et l'acné**. *20e Congrès Association des Dermatologistes et Syphiligraphes de la langue française*, Montreal, QC, Canada, June 8-11, 1992.

155. Labrie Y, Couët J, Martel C, Breton N, Juneau C, Simard J, and Labrie F (1992) **Modulation de l'expression dans le placenta de deux enzymes de la stéroïdogénèse durant la gestation chez le rat**. *60e Congrès de l'ACFAS*, Université de Montréal, QC, Canada, p. 121, May 11-15, 1992.

156. Labrie Y, Couët J, Martel C, Luo S, Simard J, Trudel C, and Labrie F (1992) **La corticostérone, l'hCG/LH et la prolactine ont des effets opposés dans la peau et le rein sur la régulation de la 3β-hydroxystéroïde déshydrogénase/isomérase chez le rat hypophysectomisé des deux sexes**. *XXXIVe Réunion Annuelle du Club de Recherches Cliniques du Québec*, Montebello, QC, Canada, p. 33, Abst. 124, October 9-10, 1992.

157. Martel C, Labrie C, Lévesque C, Mérand Y, Simard J, and Labrie F (1992) **Pure antagonistic activity of a new steroidal antiestrogen in human breast cancer cells and in mouse uterus**. *Ninth International Congress of Endocrinology*, Nice, France, p. 585, August 30-September 5, 1992.

158. Mebarki F, Rhéaume E, Morel Y, Simard J, Forest MG, David M, and Labrie F (1992) **Missense mutation ASN100-Ser in the 3β-hydroxysteroid dehydrogenase (3β-HSD) type II gene causes a male pseudo-hermaphoditism due to 3β-HSD deficiency**. *Ninth International Congress of Endocrinology*, Nice, France, p. 109, August 30-September 5, 1992.

159. Rhéaume E, Morel Y, Mebraki F, Zachman M, Forest MG, Simard J, and Labrie F (1992) **Homozygous nonsense mutation detected in two classical 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase**

deficient patients. *Ninth International Congress of Endocrinology*, Nice, France, p. 109, August 30-September 5, 1992.

160. Rhéaume E, Morel Y, Mebraki F, Zachman M, Forest MG, Simard J, and Labrie F (1992) **Homozygous nonsense mutation detected in two classical 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase deficient patients**. *Ninth International Congress of Endocrinology*, Nice, France, pp. Page 109, August 30-September 5, 1992.

161. Simard J, Rhéaume E, van Seters AP, Gordon RD, Zerah M, New MI, and Labrie F (1992) **Molecular basis of classical 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase deficiency**. *74th Annual Meeting The Endocrine Society*, San Antonio, Texas, USA, Abst. 560, June 24-27, 1992.

162. Simard J, Rhéaume E, de Launoit Y, Bettendorf M, Heinrich UE, and Labrie F (1992) **Missense mutation Ala244-Pro of type II 3β-hydroxysteroid dehydrogenase (3β-HSD) gene in a male with classical 3β-HSD deficiency**. *Ninth International Congress of Endocrinology*, Nice, France, p. 109, August 30-September 5, 1992.

163. Simard J, Rhéaume E, Sanchez R, Rosenfield RL, and Labrie F (1992) **Caractérisation de la substitution Tyr254 Asp dans le gène encodant la 3β-hydroxystéroïde déshydrogénase /Δ5-Δ4 isomérase (3β-HSD) de type II d'une patiente atteinte d'un déficit tardif sévère en 3β-HSD**. *XXXIVe Réunion Annuelle du Club de Recherches Cliniques du Québec*, Montebello, QC, Canada, p. 48, Abst. 214, October 9-10, 1992.

164. Blais Y, Sugimoto K, Carrière MC, Labrie F, and Simard J (1993) **L'effet antiprolifératif de l'interleukine-1α coïncide avec la stimulation de l'expression de l'apolipoprotéine D et de la GCDFP-15 dans les cellules humaines du cancer du sein ZR-75-1**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, Vol. 61, p. 36, May 17-21, 1993.

165. Blais Y, Sugimoto K, Carrière MC, Labrie F, and Simard J (1993) **Inhibition of estrogen-induced cell proliferation by interleukin-1α coincides with potent stimulation of apolipoprotein D and prolactin-inducible protein expression in human breast cancer cells**. *84th Annual Meeting of the American Association for Cancer Research*, Orlando, FL, USA, Vol. 34, p. 243, Abst. 1450, May 19-22, 1993.

166. Blais Y, Carrière MC, Sugimoto K, Simard J, and Labrie F (1993) **L'interleukine-6 inhibe la sécrétion de l'apolipoprotéine D et de la GCDFP-15 dans les cellules ZR-75-1 de cancer du sein humain**. *XXXVe Réunion annuelle du Club de Recherches Cliniques du Québec*, Pointe-au-Pic, QC, Canada, Vol. 9, p. 29, Abst. 120, September 30-October 2, 1993.

167. Brochu N, Turgeon C, Simard J, and Labrie F (1993) **Évaluation des activités enzymatiques responsables de la biosynthèse des stéroïdes sexuels dans les kératinocytes humains en culture primaire**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, Vol. 61, p. 110, May 17-21, 1993.

168. Brochu N, Turgeon C, Simard J, and Labrie F (1993) **Characterization of sex steroid biosynthetic activity in human keratinocytes in primary culture**. *37th Annual Meeting Canadian Federation of Biological Societies (CFBS)*, Windsor, ON, Canada, p. 120, Abst. 435, June 17-19, 1993.

169. Carrière MC, Blais Y, Sugimoto K, Labrie F, and Simard J (1993) **Inhibition de l'expression de l'apolipoprotéine D et de la GCDFP-15 par l'interleukine-6 dans les cellules du cancer du sein humain**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, Vol. 61, p. 110, May 17-21, 1993.

170. Carrière MC, Blais Y, Sugimoto K, Labrie F, and Simard J (1993) **Stimulation de l'expression de l'apolipoprotéine D et de la GCDFP-15 par l'interleukine-1a dans les cellules ZR-75-1 de cancer du sein humain**. *XXXVe Réunion annuelle du Club de Recherches Cliniques du Québec*, Pointe-au-Pic, QC, Canada, Vol. 9, p. 29, Abst. 122, September 30-October 2,1993.

171. Couët J, Martel C, Labrie Y, Chen C, Luo S, Simard J, and Labrie F (1993) **Hormonal control of 3β-hydroxysteroid dehydrogenase/5-ene-4-ene isomerase gene expression and enzymatic activity in the rat skin**. *11th International Symposium J. Steroid Biochem. Mol. Biol*., Tyrol, Austria, 1993, Abst. 67P, May 30-June 2, 1993.

172. Couët J, Labrie Y, Martel C, Gagné D, Simard J, and Labrie F (1993) **L'effet lutéolytique de la prolactine est dû principalement à son action inhibitrice sur la 3β-hydrosystéroïde déshydrogéanse/Δ5-Δ4 isomérase chez la rate hypophysectomisée**. *XXXVe Réunion annuelle du Club de Recherches Cliniques du Québec*, Pointe-au-Pic, QC, Canada, Vol. 9, Suppl.1, p. 29, Abst. 119, September 30-October 2, 1993.

173. Durocher F, Couët J, Labrie Y, Sanchez R, Turgeon C, Labrie F, and Simard J (1993) **Caractérisation structurale et fonctionnelle d'une nouvelle isoforme de l'enzyme 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4 isomérase chez le rat**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, Vol. 61, p. 24, May 17-21, 1993.

174. Durocher F, Sanchez R, Labrie Y, Samson C, Tremblay Y, Piché Y, Labrie F, and Simard J (1993) **Caractérisation structurale et fonctionnelle de la 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4 isomérase exprimée dans la glande surrénale chez le cobaye**. l*XXXVe Réunion annuelle du Club de Recherches Cliniques du Québec*, Pointe-au-Pic, QC, Canada, Vol. 9, Suppl.1, p. 29, Abst. 123, September 30-October 2, 1993.

175. Guérin SL, Eskild W, Simard J, and Hansson V (1993) **A member of the NF1 family binds to distinct cis-acting elements from the promoter and 5'-flanking region of the human CRBP1 gene. Transcription: factors, regulation and differentiation**. *Keystone Symposia on Molecular and Cellular Biology*, Keystone, CO, USA, 1993.

176. Heinrich U, Bettendorf M, Grulich-Henn J, Schonberg D, Simard J, and Labrie F (1993) **The heterogeneity of 3β-hydroxysteroid dehydrogenase (3β-HSD) deficiency-report of 4 cases**. *LWPES/ESPE Meeting*, San Francisco, CA, USA, Abst. 99, June 3-7, 1993.

177. Labrie F, Simard J, Luu-The V, and Bélanger A (1993) **Molecular biology of androgen and estrogen formation and degradation in peripheral intracrine tissue**. *11th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology*, Seefeld, Tyrol, Austria, p. 16, May 30-June 2, 1993.

178. Labrie F, Poulin R, Simard J, and Labrie C (1993) **Progestins and breast cancer**. *The Long-Term Effects of Estrogen Deprivation. Seventh Annual Symposium*, Victoria, BC, Canada, p. 60, July 24-27, 1993.

179. Labrie F, Simard J, Luu-The V, Poulin R, and Bélanger A (1993) **Molecular Biology of the Intracrine Formation of Estrogens and Androgens Regulating Breast Cancer Cell Growth**. *International Study Group of Steroid Hormones*, Vienna, Austria, p. 23, November 28-December 1, 1993

180. Labrie Y, Couët J, Simard J, and Labrie F (1993) **Régulation hormonale de l'expression du gène encodant la déhydroépiandrostérone sulfotransférase dans le foie du rat adulte**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, 1993, Vol. 61, p. 111, May 17-21, 1993.

181. Labrie Y, Couët J, Simard J, and Labrie F (1993) **Régulation de l'expression du gène encodant la déhydroépiandrostérone sulfotransférase par les stéroïdes sexuels et l'hormone de croissance dans le foie de rat adulte**. *XXXVe Réunion annuelle du Club de Recherches Cliniques du Québec*, Pointe-au-Pic, QC, Canada, Vol. 9, p. 29, Abst. 121, September 30-2 October 2, 1993.

182. Laflamme N, Rhéaume E, Sanchez R, Simard J, and Labrie F (1993) **Caractérisation fonctionnelle de la nutation A245P dans le gène encodant la 3β-hydroxystéroïde déshydrogénase/Δ5-Δ4 isomérase (3β-HSD) de type II chez un patient atteint d'un déficit en 3β-HSD**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, Vol. 61, p. 112, May 17- 21, 1993.

183. Martel C, Gagné D, Couët J, Labrie Y, Simard J, and Labrie F (1993) **Rapid modulation of ovarian 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene expression by prolactin and HCG in the**

hypophysectomized rat. *11th International Symposium J. Steroid Biochem. Mol. Biol*., Tyrol, Austria, Abst. 64P, May 30-June 2, 1993.

184. Martel C, Gagné D, Couët J, Labrie Y, Simard J, and Labrie F (1993) **Rapid modulation of ovarian 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase gene expression by prolactin and human chorionic gonadotropin in the hypophysectomized rat**. *Canadian Society for Clinical Investigation*, Vancouver, BC, Canada, Vol. 16, p. B39, Abst. 238, September 9-13, 1993.

185. Normand T, Narod S, Labrie F, and Simard J (1993) **Détection de 11 polymorphismes dans le gène de l'estradiol-17β-hydroxystéroïde déshydrogénase chez l'humain**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, p. 29, May 17-21, 1993.

186. Sanchez R, Simard J, and Labrie F (1993) **Puissant effet estrogénique de l'OH-tamoxifène dans les cellules humaines Ishikawa d'adénocarcinoma de l'endomètre**. *61e Congrès de l'ACFAS*, Rimouski, QC, Canada, Vol. 61, p. 114, May 17-21, 1993.

187. Sanchez R, Mont D, de Launoit Y, Labrie F, and Simard J (1993) **Le cholestérol déshydrogénase de nocardia possède une activité Δ5-3β-hydroxystéroïde déshydrogénase /Δ5-Δ4 isomérase**. *XXXVe Réunion annuelle du Club de Recherches Cliniques du Québec*, Pointe-au-Pic, QC, Canada, Vol. 9, p. 29, Abst. 118, September 30-October 2, 1993.

188. Simard J, Morel Y, Rhéaume E, Sanchez R, Mebarki F, Laflamme N, New MI, and Labrie F (1993) **Molecular basis of congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase deficiency**. *LWPES/ESPE Meeting*, San Francisco, CA, USA, Abst. 22, June 3-7, 1993.

189. Simard J, Normand T, Tonin P, and Narod S (1993) **Linkage of estradiol 17beta-hydroxysteroid dehydrogenase II gene with hereditary breast ovarian cancer locus *BRCA1* in the region 17q12-21**. *Endocrine Society*, Las Vegas, Nevada, USA, p. 127, Abst. 308, June 9-12, 1993.

190. Sugimoto K, Veilleux R, Labrie F, and Simard J (1993) **Inverse relationships between cell proliferation and basal or androgen-induced apolipoprotein D secretion in human LNCaP prostate cancer cells**. *37th Annual Meeting Canadian Federation of Biological Societies (CFBS),* Windsor, ON, Canada, p. 132, Abst. 502, June 17-19, 1993.

191. Blais Y, Carrière MC, Gingras S, Haagensen DE, Labrie F, and Simard J (1994) **Regulation of gross cystic disease fluid protein-15 (GCDFP-15) secretion by interleukins in human breast cancer cells**. *17th Annual San Antonio Breast Cancer Symposium*, San Antonio, TX, USA, December 8-10, 1994.

192. Blais Y, Carrière MC, Simard J, and Labrie F (1994) **Regulation of 17β-hydroxysteroid dehydrogenase activity by interleukin-4 and interleukin-6 in ZR-75-1 human breast cancer cells**. *76th Annual Meeting of the Endocrine Society*, Anaheim, CA, USA, p. 524, Abst. 1294, June 15-18, 1994.

193. Blais Y, Carrière MC, Simard J, and Labrie F (1994) **Régulation de l'activité 17β-hydroxystéroïde déshydrogénase par l'interleukine-4 et l'interleukine-6 dans les cellules ZR-75-1 de cancer du sein humain**. *36e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Ste-Adèle, QC, Canada, p. 38, Abst. 120, September 29 - October 1, 1994.

194. Brochu N, Turgeon C, Simard J, and Labrie F (1994) **Characterization and modulation of sex steroid metabolizing activity in human HaCaT and normal keratinocytes in primary culture**. *IX International Congress on Hormonal Steroids*, Dallas, TX, USA, p. 94, Abst. B104, September 24-29, 1994.

195. Couture P, Sanchez R, Govindan MV, Simard J, and Labrie F (1994) **Estrogen-receptor mediated transcription activation by C19-steroids**. *85th Annual Meeting of American Association for Cancer Research*, San Francisco, CA, USA, Vol. 35, p. 265, Abst. 1580, April 10-13, 1994.

196. Couture P, Simard J, Mooriani S, Vohl MC, Torres AL, Gagné C, Després JP, Labrie F, and Lupien PJ (1994) **Detection of a novel mutation Y468X in exon 10 of the low-density lipoprotein receptor gene causing heterozygous familial hypercholesterolemia among French Canadians**. *Annual Meeting of The*

American Society of Human Genetics, Montreal, QC, Canada, Vol. 55, p. A357, Abst. 2095, September 1994.

197. Durocher F, Morissette J, Labrie Y, Labrie F, and Simard J (1994) **Localization of the gene encoding human type II 17β-hydroxysteroid dehydrogenase by genetic mapping on chromosome 16q 24.1-24.2 region**. *IX International Congress on Hormonal Steroids*, Dallas, TX, USA, p. 99, Abst. B122, September 24-29, 1994.

198. Durocher F, Morissette J, Labrie Y, Labrie F, and Simard J (1994) **Genetic linkage mapping of the gene encoding human type II 17β-hydroxysteroid dehydrogenase on chromosome 16q 24.1-24.2 region**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Toronto, ON, Canada, Vol. 17, p. B31, Abst. 175, September 14-19, 1994.

199. Durocher F, Sanchez R, Laudet V, Labrie Y, Samson C, Tremblay Y, Labrie F, and Simard J (1994) **Structural and functional characterization of the guinea pig 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase expressed in the adrenal gland, and gonads**. *76th Annual Meeting of the Endocrine Society*, Anaheim, CA, USA, p. 498, Abst. 1192, June 15-18, 1994.

200. Durocher F, Tonin P, Narod S, Simard J, and Rommens J (1994) **Generation of a transcription map of the region containing the type 1 17β-hydroxysteroid dehydrogenase gene and the gene for hereditary breast-ovarian cancer, *BRCA1* on chromosome 17q12-21**. *LIX Cold Spring Harbor Symposium on Quantitative Biology. Molecular Genetics of Cancer*, Cold Spring Harbor, NY, USA, p. 49, June 1-8, 1994.

201. Labrie F, Simard J, Luu-The V, Bélanger A, and Labrie C (1994) **Molecular biology of the intracrine formation of androgens in the human prostate**. *International Symposium on Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects*, Milan, Italy, Vol. 17, p. 13, April 10-14, 1994.

202. Labrie F, Simard J, Luu-The V, Bélanger A, Lin SX, and Labrie C (1994) **Sources and roles of steroids in hormone-sensitive diseases and cancer**. *7th International Congress on Obesity*, Toronto, ON, Canada, Vol. 18, page 44, Abst. O170, August 20-25, 1994.

203. Labrie Y, Durocher F, Lachance Y, LeBlanc G, Turgeon C, Leblanc JF, Samson C, Labrie C, Simard J, and Labrie F (1994) **Structure of the human type II 17β-hydroxysteroid dehydrogenase gene**. *Abstracts of the IX International Congress on Hormonal Steroids 1994*. Abst. B123.

204. Labrie Y, Trudel C, Martel C, Simard J, and Labrie F (1994) **Modulation of type IV 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase mRNA levels by sex steroids and pituitary hormones in the rat skin**. *76th Annual Meeting of the Endocrine Society*, Anaheim, CA, USA, p. 499, Abst. 1194, June 15-18, 1994.

205. Luu-The V, Simard J, Labrie C, Bélanger A, and Labrie F (1994) **Molecular biology of steroidogenic enzymes in gonadal and peripheral tissues: intracrinology**. *XVI Int. Cancer Congress 1994*, New Delhi, India, October 30-November 5, 1994.

206. Rommens JM, Durocher F, Tonin P, LeBlanc JF, Samson C, McArthur J, Dion F, Allen T, Morgan K, Narod S, and Simard J (1994) **Generation of a transcription map from the 17q21 region containing the *BRCA1* locus**. *Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, p. A268, Abst. 1571, September 1994.

207. Sanchez, R., Rhéaume, E., Mébarki F, Carel JC, Chaussain JL, Morel Y, Labrie F, and Simard J (1994) **Identification and characterization of the G15D mutation found in a male patient with 3β-hydroxysteroid dehydrogenase (3β-HSD) deficiency: alteration of the putative NAD-binding domain of type II 3β-HSD**. *76th Annual Meeting of the Endocrine Society*, Anaheim, CA, USA, p. 510, Abst. 1238, 15-18 June 1994.

208. Simard J, Luu-The V, Labrie C, and Labrie F (1994) **Base moléculaire de la formation des stéroïdes sexuels dans les tissus périphériques: intracrinologie**. *19e Réunion des Endocrinologues de Langue Française*, Montreal, QC, Canada, September 22-24, 1994.

209. Simard J, Rhéaume E, Sanchez R, Mebarki F, Morel Y, Zerah M, New MI, and Labrie F (1994) **Molecular biology of 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase congenital deficiency**. *IX International Congress on Hormonal Steroids*, Dallas, Texas, USA, p. 50, Abst. S134, September 24-29, 1994.

210. Simard J, Rhéaume R, Sanchez R, Mebarki F, Morel Y, Zerah M, New MI, and Labrie, F (1994) **Relation between molecular defect and phenotypic manifestation of human 3β-hydroxysteroid dehydrogenase deficiency**. *International Symposium on Where Phenotype Does Not Match Genotype?* Voltera, Italy, p. 6, Abst. 5, October 13-14, 1994.

211. Tonin P, Moselehi R, Boyd N, Rosen B, Bellman S, Simard J, and Narod S (1994) **Linkage analysis of the *BRCA1* region on chromosome 17q12-21 in canadian breast, ovarian and breast-ovarian cancer families**. *LIX Cold Spring Harbor Laboratory Symposium on Quantitative Biology. Molecular Genetics of Cancer*, Cold Spring Harbor, NY, USA, p. 218, June 1-8, 1994.

212. Tonin P, Moslehl R, Boyd N, Rosen B, Bellman S, Vivier A, Ginsberg O, Durocher F, Simard J, and Narod S (1994) **Linkage analysis of chromosome 17q12-21 in canadian breast, ovarian and breast-ovarian cancer families**. *The Application of Molecular Biology to Cancer Control; New Avenues for Epidemiologic Research*, Montreal, QC, Canada, May 2, 1994.

213. Turgeon C, Simard J, and Labrie F (1994) **Characterization of sex steroid metabolism in MG63 human osteoblast-like cells in culture**. *IX International Congress on Hormonal Steroids*, Dallas, Texas, USA, pp. 94, Abst. B103, September 24-29, 1994.

214. Turgeon C, Simard J, and Labrie F (1994) **Formation et métabolisme des stéroïdes sexuels dans les cellules humaines MG63 d'ostéosarcome en culture**. *36e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Ste-Adèle, QC, Canada, p. 38, Abst. 122, September 29-October 1, 1994.

215. Turgeon C, Simard J, and Labrie F (1994) **Characterization of sex steroid metabolism in MG63 human osteoblast-like cells in culture: Intracrinology of bone-forming cells**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Toronto, ON, Canada, Vol. 17, p. B31, Abst. 179, September 14-19, 1994.

216. Vohl MC, Couture P, Moorjani S, Torres AL, Gagné C, Després JP, Lupien PJ, Labrie F, and Simard J (1994) **Rapid detection of three point mutations in the LDL receptor gene causing familial hypercholesterolemia among French Canadians**. *Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, Vol. 55, p. A247, Abst. 1447, September 1994.

217. Blais Y, Gingras S, Haagensen DE, Labrie F, and Simard J (1995) **Potent stimulatory effect of interleukin-13 on gross cystic disease fluid protein-15 secretion in human breast cancer cells**. *86th Annual Meeting American Association for Cancer Research*, Toronto, ON, Canada, Vol. 36, p. 256, Abst. 1525, 1995.

218. Blais Y, Zhao HF, Huber M, Labrie F, Simard J, and Poulin R (1995) **Stimulation of spermidine transport by interleukin-4 and interleukin-13 in ZR-75-1 human breast cancer cells**. *86th Annual Meeting of American Association for Cancer Research*, Toronto, ON, Canada, Vol. 36, p. 507, Abst. 3018, 1995.

219. Couture P, Moorjani S, Vohl MC, Gagné C, Labrie F, Lupien PJ, and Simard J (1995) **Identification of the mutation R329X in exon 7 of the low-density lipoprotein receptor gene in a French Canadian family with familial hypercholesterolemia**. *45th Annual Meeting of the American Society of Human Genetics*, Minneapolis, MN, USA, October 24-28, 1995.

220. Durocher F, Bélanger C, Labrie F, Tonin P, Morgan K, Narod SA, Shattuck-Eidens D, Neuhausen SL, Goldgar DE, and Simard J (1995) **Detection, haplotype and phenotype analyses of two common *BRCA1* mutations**. *2nd Joint Clinical Genetics Meeting*, Los Angeles, CA, USA, p. 108, Asbt. 64, March 6-9, 1995.

221. Durocher F, Morissette J, Dufort I, Simard J, and Luu-The V (1995) **Structural characterization and genetic mapping of the gene encoding human dehydroepiandrosterone sulfotransferase close to D19S412 on chromosome 19q13.4**. *77th Annual Meeting of the Endocrine Society*, Washington, USA, p. 624, Abst. P3-622, June 14-17, 1995.

222. Durocher F, Pelletier G, Bélanger C, Tonin P, Narod S, and Simard J (1995) **Localization of *BRCA1* gene expression and characterization of *BRCA1* mutations in canadian families**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Montreal, QC, Canada, p. B86, Abst. 573, September 13-17, 1995.

223. Durocher F, Shattuck-Eidens D, Skolnick MH, Goldgar DE, and Simard J (1995) **Detection of polymorphisms and missense mutations in *BRCA1* gene**. *45th Annual Meeting of the American Society of Human Genetics*, Minneapolis, MN, USA, October 24-28, 1995.

224. Durocher F, Simard J, and Pelletier G (1995) **Localisation de l'expression du gène *BRCA1* dans des tumeurs mammaires humaines et dans le testicule de rat par hybridation in situ**. *37e Réunion Annuelle du Club de Recherches Clinique du Québec*, Bromont, QC, Canada, p. B86, Abst. 106, September 28-30, 1995.

225. Durocher F, Simard J, and Pelletier G (1995) **Localization of *BRCA1* gene expression in the rat testis, ovary prostate and brain by in situ hybridization**. *77th Annual Meeting of the Endocrine Society*, Washington, USA, p. 448, Abst. P2-623, June 14-17, 1995.

226. Gingras S, Blais Y, Labrie F, and Simard J (1995) **Puissant effet stimulateur de l'interleukine-13 sur la sécrétion de la GCDFP-15 dans des lignées cellulaires de cancer du sein humain**. *37e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Bromont, QC, Canada, Abst. 107, September 28-30, 1995.

227. Labrie F, Bélanger A, Simard J, Luu-The V, and Labrie C (1995) **Intracrinology: the basis for the endocrine therapy of prostate cancer**. *5th International Conference of Anticancer Research*, Korfu, Greece, October 17-22, 1995.

228. Labrie F, Luu-The V, Simard J, Bélanger A, and Labrie C (1995) **Hormones and Cancer: Look to the Future**. *14th International Papillomavirus Conference*, Quebec, QC, Canada, June 23-28, 1995.

229. Labrie F, Luu-The V, Simard J, Bélanger A, Labrie C, Bernier F, Labrie Y, Durocher F, and Dufort I (1995) **Sources and roles of sex steroids in hormone-sensitive diseases and cancer**. *12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology*, Berlin, Germany, Abst. 12L, May 21-24, 1995.

230. Simard J, Bélanger C, MacArthur J, Tavtigian S, Samson C, Leblanc JF, Dumont M, Tranchant M, McSweeney D, Couch F, Weber B, Neuhaussen S, Goldgar D, Kamb A, Skolnick M, Labrie F, and Rommens J (1995) **Generation of a transcription map of the *BRCA2* region**. *45th Annual Meeting of the American Society of Human Genetics*, Minneapolis, MN, USA, October 24-28, 1995.

231. Simard J, Blais Y, Gingras S, Labrie C, Poulin R, and Labrie F (1995) **Inhibition of breast cancer cell growth**. *5th International Congress on Hormones and Cancer*, Quebec, QC, Canada, p. 35, Abst. S11, September 16-20, 1995.

232. Simard J, Luu-The V, Bélanger A, Pelletier G, and Labrie F (1995) **Molecular genetics and regulation of tissue-specific expression of the 3β-hydroxysteroid dehydrogenase gene family**. *77th Annual Meeting of the Endocrine Society*, Washington, DC, USA, p. 29, Abst. S23-1, June 14-17, 1995.

233. Simard J, Luu-The V, and Labrie F (1995) **Structure-function relationships and molecular genetics of the 3β-hydroxysteroid dehydrogenase family**. *International Symposium on DHEA Transformation into Androgens and Estrogens in Target Tissues: Intracrinology*, Quebec, QC, Canada, p. 35, Abst. S25, September 13-15, 1995.

234. Simard J, Sanchez R, and Rhéaume E (1995) **Molecular basis of human 3β-hydroxysteroid dehydrogenase deficiency**. *Annual Meeting of the Canadian Society for Clinical Investigation*, Montreal, QC, Canada, p. B37, Abst. 230, September 13-17, 1995.

235. Tonin PT, Simard J, LeBlanc G, Goldgar DE, Morgan JF, and Narod S (1995) **Mutation analysis of the *BRCA1* gene in 26 Canadian Breast, ovarian, breast and ovarian cancer families**. *86th Annual Meeting American Association for Cancer Research*, Toronto, ON, Canada, Vol. 36, p. 281, Abst. 1676, March 18-22, 1995.

236. Turgeon C, Sanchez R, Rhéaume E, Labrie F, and Simard J (1995) **Caractérisation du site de liaison du cofacteur de la 3β-HSD de type III chez le rat**. *37e Réunion Annuelle du Club de Recherches Cliniques du Québec*, Bromont, QC, Canada, Abst. 105, September 28-30, 1995.

237. Turgeon C, Sanchez R, Rhéaume E, Labrie F, and Simard J (1995) **Characterization of the unique cofactor specificity of liver-specific rat 3β-hydroxysteroid dehydrogenase by site-directed mutagenesis**. *77th Annual Meeting of the Endocrine Society*, Washington, DC, USA, p. 619, Abst. P3-603, June 14-17, 1995.

238. Couch F, Tavtigian S, Simard J, Rommens J, Neuhausen S, Peng Y, Kamb A, Skolnick M, Goldgar DE, and Weber B (1996) **Characterization of candidate genes from the *BRCA2* region of chromosome 13q12-13**. *AACR 87th Annual Meeting of American Association for Cancer Research*, Washington, DC, USA, p. 513, Abst. 3509, April 20-24, 1996.

239. Durocher F, Ouellette J, Richard V, Simard J, and Pelletier G (1996) **Tissue-distribution of the *BRCA1* gene expression in Macaca fascicularis**. *Eighteenth Conference of European Comparative Endocrinologists*, Rouen, France, p. 67, Abst. P227, September 1996.

240. Gingras S, Turgeon C, Labrie F, and Simard J (1996) **Induction of 3β-hydroxysteroid dehydrogenase/ isomerase activity in human breast cancer cell lines by interleukine-4 and interleukin-13**. *87th Annual Meeting of American Association for Cancer Research*, Washington, USA, p. 228, Abst. 1558, April 20-24, 1996.

241. Labrie F, Lin SX, Simard J, Luu-The V, Labrie C, and Breton R (1996) **Structure Function and Regulation of Human 17β-HSD Types I and II**. *2nd International Symposium on Molecular Steroidogenesis*, Monterey, CA, USA, p. 34, June 7-11, 1996.

242. Sanchez R, Simard J, Poirier D, Gauthier S, Singh MS, Mérand Y, and Labrie F (1996) **Pure antiestrogenic activity of EM-139 and EM-800 in human endometrial adenocarcinoma ishikawa cells**. *10th International Congress of Endocrinology*, San Francisco, CA, USA, Abst. P1-80, June 12-15, 1996.

243. Simard J, Durocher F, Labrie F, Tonin P, Narod S, and Rommens J (1996) **Génétique moléculaire des gènes de prédisposition au cancer du sein *BRCA1* et *BRCA2***. *Les journées de génétique humaine*, Montreal, QC, Canada, Abst. 44, June 18-19, 1996.

244. Simard J, Michaud D, Gauthier S, Singh SM, Mérand Y, and Labrie F (1996) **Characterization of the effects of the novel antiestrogen EM-800 on basal and estrogen-induced proliferation of T-47D, ZR-75-1 and MCF-7 human breast cancer cells in vitro**. *10th International Congress of Endocrinology*, San Francisco, CA, USA, p. 605, Abst. P2-804, June 12-15, 1996.

245. Simard J, Michaud D, Gauthier S, Singh SM, Mérand Y, and Labrie F (1996) **Long-lasting and potent inhibitory effect of the novel antiestrogen EM-800 on estrogen-induced proliferation of T-47D human breast cancer cells in vitro**. *10th International Congress of Endocrinology*, San Francisco, CA, USA, p. 606, Abst. P2-805, June 12-15, 1996.

246. Simard J, Michaud D, Singh M, and Labrie F (1996) **Comparison of in vitro effects of the pure antiandrogens OH-flutamide, casodex and nilutamide in mouse shionogi mammary carcinoma cells**

and ZR-75-1 human breast cancer. *10th International Congress of Endocrinology*, San Francisco, CA, USA, p. 605, Abst. P2-803, June 12-15, 1996.

247. Tonin P, Durocher F, Simard J, Latreille J, Mes-Masson AM, Provencher D, Narod S, and Ghadirian P (1996) **Genetic epidemiology of breast and ovarian cancer in french canadians: common *BRCA1* and *BRCA2* mutations**. *Les journées de génétique humaine*, Montreal, QC, Canada, Abst. 45, June 18-19, 1996.

248. Gingras S, Labrie F, and Simard J (1997) **Induction of 3β-hydroxysteroid dehydrogenase activity in normal human prostate epithelial cells by interleukin-4 and interleukine-13**. *79th Annual Meeting of The Endocrine Society*, Minneapolis, MN, USA, Abst. P1-295, June 11-14, 1997.

249. Labrie F, Labrie C, Bélanger A, Simard J, Mérand Y, Gauthier S, and Singh SM (1997) **A new orally active and pure antiestrogen: preclinical studies**. *Seventh International Congress on Anti-Cancer Treatment*, Paris, France, p. 58, Abst. 19, February 3-6, 1997.

250. Simard J (1997) **Structure and expression of mammalian homologues of the breast cancer susceptibility gene *BRCA2***. *Terry Fox Workshop on Cancer Genetics. Canadian Collaborative Group for Cancer Genetics*, Toronto, ON, Canada, May 31-June 1, 1997.

251. Simard J, Dumont M, Tranchant M, Samson C, Legris G, Desrochers M, Leblanc JF, Schroeder M, Baumgard M, Skolnick M, Tavtigian S, and Labrie F (1997) **Structure and expression of mouse and rat homologues of the breast cancer susceptibility gene *BRCA2***. *AACR Special Conference: Basic and Clinical Aspects of Breast Cancer*, Keystone, MB, Canada, March 7-12, 1997.

252. Simard J, Edwards S, Teare D, Durocher F, Easton D, Deamaley D, Shearer R, Ardern-Jones A, Dowe A, and UK Collaborators (1997) **Does the hereditary prostate cancer gene, HPC1, contribute to a large proportion of familial prostate cancer**. *47th Annual Meeting of American Society of Human Genetics*, Baltimore, USA, 1997, Abst. 345.

253. Simard J, Gingras S, Turgeon C, and Labrie F (1997) **Key role of cytokines in estrogen bioavailability in breast cancer**. *Institut de recherche internationale Servier*, Chantilly, France, April 24-26, 1997.

254. Simard J, Gingras S, Turgeon C, and Labrie F (1997) **Crucial role of cytokines in sex steroid formation in breast cancer cells**. *13th International Symposium on the Journal of Steroid Biochemistry & Molecular Biology*, Monaco, Abst. 30, May 25-28, 1997.

255. Singh SM, Caron B, Lourdusamy M, Paquet J, Girard M, Bouchard N, Dionne P, Coté J, Laplante S, Simard J, and Labrie F (1997) **Inhibition of Human Type I 5α-Reductase Activity and Shionogi Cell Proliferation by 17-(2', 3'α-Di/Tetra-hydropyran/furan-2'-spiro)-4-aza-5α-androstan-3-ones**. *8th Québec/Ontario Minisymposium in Biorganic and Organic Chemistry*, Université Laval, Quebec, QC, Canada, November 7-9, 1997.

256. Tonin PN, Mes-Masson AM, Provencher D, Foulkes WD, Simard J, Narod SA, and Ghadiran P (1997) **Mutation analysis of *BRCA1* and *BRCA2* in hereditary breast-ovarian cancer families of french-canadian descent**. *Terry Fox Workshop on Cancer Genetics. Canadian Collaborative Group for Cancer Genetics*, Toronto, ON, Canada, May 31-June 1 1997.

257. Desrochers M, Moisan AM, Alos N, Mebarki F, Turgeon C, Gingras S, Van Vliet G, Morel Y, and Simard J (1998) **Unexpected repercussions of missense mutations in type II 3β-hydroxysteroid dehydrogenase gene**. *80th Annual Meeting of the Endocrine Society*, New Orleans, LA, USA, Abst. P1-275, June 24-27, 1998.

258. Dumont M, Desrochers M, Bélanger C, Tranchant M, Samson C, Legris G, Skolnick M, Tavtigian S, Labrie F, and Simard J (1998) **Structure et expression du gène de prédisposition au cancer du sein *BRCA2* chez les mammifères**. *XXVe Forum des Jeunes Chercheurs de la Société Française de Biochimie et Biologie Moléculaire*, Université Laval, Quebec, QC, Canada, Abst. S-19, June 22-25, 1998.

259. Eeles RA, Edwards S, Teare D, Badzioch M, Durocher F, Simard J, Foulkes W, Hamoudi R, Gill S, Biggs P, Dearnaley D, Ardern-Jones A, Kelly J, Murkin A, Shearer R, and Easton D (1998) **Results from the CRC/BPG UK Familial Prostate Cancer Study**. *British Prostate Group Meeting*, Oxford, UK, October 18, 1998.

260. Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C, Schwerdtfeger A, Leblanc G, Martel C, Simard J, and Labrie F (1998) **Synthèse et propriétés d'analogues du EM-800, un antiestrogène non stéroïdien actif oralement. Influence de la nature de la fonction amine sur la chaîne latérale**. *66e Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, May 11-15, 1998.

261. Gingras S, Pfitzner E, Simard J, and Groner B (1998) **Interaction of Stat6 with p300/CBP during Interleukin-4 induction of transcription**. *Keystone Symposia on Molecular and Cellular Biology*, Tamarron, CO, USA, Abst. No. 217, February 3-8, 1998.

262. Gingras S, and Simard J (1998) **Induction of 3β-hydroxysteroid dehydrogenase (3β-HSD) by interleukin-4 (IL-4) and interleukin-13 (IL-13) in cell lines from peripheral tissues**. *Eighty-Ninth Annual Meeting AACR*, New Orleans, LA, USA, Abst. 3752, March 28-April 1 1998.

263. Gingras S, and Simard J (1998) **Induction de la 3β-hydroxystéroïde dehydrogenase (3β-HSD) par l'interleukine-4 et l'interleukine-13 dans des cellules dérivées de tissus périphériques**. *66e Congrès de l'ACFAS*, Université Laval, Quebec, QC, Canada, May 11-15, 1998.

264. Gingras S, and Simard J (1998) **Involvement of multiple signal transduction pathways in the stimulatory effect of interleukin-4 on 3β-hydroxysteroid dehydrogenase type 1 gene expression**. *Xth International Congress on Hormonal Steroids*, Quebec, QC, Canada, Abst. 59, June 17-21, 1998.

265. Labrie C, Bélanger A, Couillard S, Gauthier S, Giguère V, Luo S, Martel C, Mérand Y, Simard J, and Labrie F (1998) **Mechanism of Action of the Nonsteroidal Antiestrogen EM-800**. *Xth International Congress on Hormonal Steroids*, Quebec, QC, Canada, Abst. S1, June 17-21, 1998.

266. Moisan AM, Desrochers M, Gingras S, Alos N, Mébarki F, Turgeon C, Van Vliet G, Morel Y, and Simard J (1998) **Evidence of a novel mechanism involved in 3β-hydroxysteroid dehydrogenase deficiency**. *VIIIth Adrenal Cortex Conference*, Orford, QC, Canada, June 13-16, 1998.

267. Moisan AM, Peter M, Desrochers M, Durocher F, Tiulpakov A, Hamet P, and Simard J (1998) **Detection and functional characterization of the two novel mutations R96Q and A437E in the CYP17 gene**. *Xth International Congress on Hormonal Steroids*, Quebec, QC, Canada, Abst. 234, June 17-21, 1998.

268. Simard J, and Durocher F (1998) **Hérédité et cancer du sein: conduite à tenir avec les patientes porteuses de mutations dans les gènes *BRCA1* et *BRCA2***. *Colloque: Cancer du sein: 100 ans de progrès*, Hôtel Complexe Desjardins, Montreal, QC, Canada, April 3, 1998.

269. Simard J, Durocher F, Bolduc N, Samson C, Plante M, Otis H, Chiquette J, Deschênes L, and Laframboise R (1998) **Hérédité et cancer du sein: vers une approche intégrée**. *Les Journées Génétiques 98*, Hôtel Reine-Elizabeth, Montreal, QC, Canada, May 21-22, 1998.

270. Simard J, and Gingras S (1998) **Crucial role of interleukin-4 in sex steroid formation in breast and prostate cells**. *Breast and Prostate Cancer, Copper Mountain*, Colorado, USA, Abst. 226, February 21-26, 1998.

271. Carsol JL, Gingras S, and Simard J (1999) **Prolactin-inducible protein (PIP)/GCDFP-15 gene promoter: a model to study sex steroid and prolactin action on gene transcription in human breast cancer cells. *Reasons for Hope 1999***. *La recherche sur le cancer du sein: Raisons d'espérer. Conférence scientifique nationale*, Toronto, ON, Canada, June 17-19, 1999.

272. Côté S, Gingras S, and Simard J (1999) **Régulation de la 3β-hydroxysteroid dehydrogenase de type 2 par les facteurs de transcription STAT5 et STAT6**. *Journée de la recherche de la Faculté de médecine de l'Université Laval*, Centre des Congrès de Québec, QC, Canada, Abst.170, May 25, 1999.

273. Durocher F, Vézina H, Bolduc N, Samson C, Jomphe M, Dumont M, Desrochers M, Tranchant M, Larouche L, Stoppa-Lyonnet D, Chiquette J, Provencher L, Plante M, Easton D, Laframboise R, Bridge P, and Simard J (1999) **Molecular epidemiology of inherited breast and ovarian cancer among french canadians. *Reasons for Hope 1999***. *La recherche sur le cancer du sein: Raisons d'espérer. Conférence scientifique nationale*, Toronto, ON, Canada, June 17-19, 1999.

274. El-Alfy M, Berger L, Luu-The V, Simard J, and Labrie F (1999) **Immunocytochemical localization of estrogen receptors alpha and beta in human mammary gland. *Reasons for Hope 1999***. *La recherche sur le cancer du sein: Raisons d'espérer. Conférence scientifique nationale*, Toronto, ON, Canada, June 17-19, 1999.

275. Gingras S, and Simard J (1999) **Multiple signaling pathways mediate interleukin-4-induced 3β-hydroxysteroid dehydrogenase/Δ5-Δ4 isomerase type 1 gene expression in human breast cancer cells. *Reasons for Hope 1999***. *La recherche sur le cancer du sein: Raisons d'espérer. Conférence scientifique nationale*, Toronto, ON, Canada, June 17-19, 1999.

276. Gingras S, Turgeon C, Labrie F, and Simard J (1999) Crucial role of cytokines in sex steroid synthesis in breast cancer cells. *Reasons for Hope 1999. In: La recherche sur le cancer du sein: Raisons d'espérer. Conférence scientifique nationale*, Toronto, ON, Canada, June 17-19, 1999.

277. Labrie F, Bélanger A, Simard J, Labrie C, Luu-The V, Cusan L, and Lin SX (1999) **Intracrinologie: Recherche fondamentale et application dans les cancers hormono-sensibles**. *Journée de la recherche de la Faculté de Médecine de l'Université Laval*, Centre des Congrès de Québec, Quebec, QC, Canada, Abst. 42, May 25, 1999.

278. Moisan AM, Ricketts ML, Desrochers M, Gingras S, Alos N, Mébarki F, Turgeon C, Van Vliet G, Morel Y, and Simard J (1999) **Évidence d'un nouveau mécanisme responsable du déficit en 3β-hydroxystéroïde déshydrogénase**. *Journée de la recherche de la Faculté de Médecine de l'Université Laval*, Centre des Congrès de Québec, Quebec, QC, Canada, Abst. 171, May 25, 1999.

279. Simard J, Durocher F, Vézina H, Bolduc N, Samson C, Jomphe M, Dumont M, Desrochers M, Bridge P, Deschênes L, Provencher L, Plante M, Chiquette J, and Laframboise R (1999) **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire chez les Canadiennes françaises**. *Journées Scientifiques de l'IREP, Pavillon J.A. DeSève, Centre de recherche, Centre hospitalier de l'Université de Montréal*, Campus Notre-Dame, Montreal, QC, Canada, 1999.

280. Simard J, Vézina H, Durocher F, Plante M, Chiquette J, Dorval M, Voyer P, Lespérance B, Doyle C, Bessette P, Bridge P, Easton DF, Laframboise R. (1999) **Genetic and molecular epidemiology of hereditary breast and ovarian cancer in French Canadian women**. *Community Genetics.* 2 :151.

281. Simard J, Durocher F, Vézina H, Samson C, Tranchant M, Jomphe M, Chiquette J, Provencher L, Plante M, and Laframboise R (1999**) Low Proportion of *BRCA1* and *BRCA2* Mutations in French Canadian Breast Cancer Families**. *American Journal of Human Genetics, Annual Meeting 1999*, Chicago, USA, October 1999.

282. Simard J, Labrie C, Bélanger A, Michaud D, Gauthier S, Mérand Y, and Labrie F (1999) **Characterization of the effects of the novel antiestrogen EM-652 in human breast and endometrial ishikawa adenocarcinoma cells *in vitro. Reasons for Hope 1999***. *La recherche sur le cancer du sein: Raisons d'espérer. Conférence scientifique nationale*, Toronto, ON, Canada, June 17-19, 1999.

283. Simard J, Labrie C, and Raymond V (1999) **Génétique moléculaire des cancers hormono-dépendants et des maladies héréditaires complexes**. *Journée de la recherche de la Faculté de médecine de l'Université Laval*, Centre des Congrès de Québec, Quebec, QC, Canada, Abst. 47, May 25, 1999.

284. Labrie F, Labrie C, Bélanger A, and Simard J (2000) **EM-652 (SCH 57068), the First Complete Range SERM (CR-SERM) Having Activities Ranging From Pure Antiestrogenic to Complete Estrogen-Like in Different Tissues**. *Proceedings of the 19th Annual Meeting of the American Chemical Society*, 2000.

285. Labrie F, Labrie C, Bélanger A, and Simard J (2000) **Les Antiestrogènes Purs**. *E.R.P.M. 2000 (Les Estrogènes: de la recherche à la pratique médicale)*, Montpellier, France, March 16-17, 2000.

286. Labrie F, Luu-The V, Simard J, and Labrie C (2000) **17β-hydroxysteroid dehydrogenases: a series of key highly specific enzymes of sex steroid formation and inactivation in most human tissues**. *19th Joint Meeting of the British Endocrine Societies with the European Federation of Endocrine Societies*, Birmingham, UK, 2000.

287. Labrie F, Luu-The V, Simard J, Lin SX, Bélanger A and Labrie C (2000) **Production Intracellulaire d'Oestrogènes et Androgènes dans les Tissus Périphériques Cibles: Intracrinologie**. *E.R.P.M. (Les Estrogènes: de la recherche à la pratique médicale),* Montpellier, France, March 16-17, 2000.

288. Labrie F, Labrie C, Bélanger A, Simard J, Giguère V (2000) **EM-652 (SCH 57068), the first pure response-specific ER regulator (PURE-SERR) having activities ranging from pure antiestrogenic to complete estrogen-like effects in different tissues**. *19th Annual Meeting of American Chemical Society*, San Francisco, USA, March 24-28, 2000.

289. Martel C, Simard J, Labrie F, El-Alfy M, Labrie C (2000) **Effects of EM-652.HCI (SCH 57068.HCI), raloxifene and tamoxifen, administered alone or in combination, on rat endometrial epithelial height and vaginal weight**. *American Society of Clinical Oncology*, New Orleans, USA, May 20-23, 2000.

290. Carsol JL, Gingras S, and Simard J (2000) **Interaction fonctionnelle entre STAT5 et le récepteur des androgènes dans les cellules tumorales mammaires ZR-75-1**. *Journée de la recherche Faculté de médecine, Université Laval*, Quebec, QC, Canada, Abst. 175, May 30, 2000.

291. Moisan AM, Peter M, Durocher F, Hamet P, and Simard J (2000) **Identification de 9 nouvelles mutations dans le gène cyp17 chez 14 patients issus de 10 nouvelles familles atteints d'une forme d'hyperplasie congénitale des surrénales**. *Journée de la recherche Faculté de médecine, Université Laval*, Quebec, QC, Canada, Abst. 14, May 30, 2000.

292. Ricketts ML, Moisan AM, Desrochers M, Peter M, Morel Y, and Simard J (2000) **Identification de 8 mutations dans le gène HSD3B2 chez 11 patients atteints d'une forme d'hyperplasie congénitale des surrénales et comparaison des propriétés fonctionnelles de 25 mutations dans ce gène**. *Journée de la recherche Faculté de médecine, Université Laval*, Quebec, QC, Canada, Abst. 176, May 30, 2000.

293. Simard J, Laframboise R, Vézina H, Plante M, Chiquette J, Dumont M, Délos S, Samson C, Moisan AM, Malouin H, MacMillan A, Tranchant M, Larouche L, Provencher L, Dorval M, Stoppa-Lyonnet D, Bridge P, Easton D, Durocher F (2000) **Génétique et épidémiologie moléculaire des cancers héréditaires du sein et de l'ovaire chez les canadiennes françaises**. *Journée de la recherche Faculté de médecine, Université Laval*, Quebec, QC, Canada, May 30, 2000.

294. Côté S, Gingras S, Feltus A, Melner M, and Simard J (2000) **Stimulation par l'interleukine-4 de l'expression de la 3β-hydroxysteroid deshydrogénase type II dans l'ovaire: mécanismes d'action**. *Journée de la recherche Faculté de médecine, Université Laval*, Quebec, QC, Canada, Abst. 9, May 30, 2000.

295. Raymond V, Morissette J, Barden N, Laframboise R, Brown DJ, Savard P, Simard J (2000) **Programme de recherche en génomique humaine, Axe de génotypage et de séquençage à haut débit du Centre de recherche du CHUL**. *Journée de la recherche Faculté de médecine, Université Laval*, Quebec, QC, Canada, May 30, 2000.

296. Carsol JL, Gingras S, and Simard J (2000) **Functional Interaction between STAT5 and androgen receptor in ZR-75-1 breast cancer cells**. *The Endocrine Society's 82nd Annual Meeting*, Toronto, ON, Canada, 2000, Abst. 604.

297. Côté S, Feltus AF, Freeman M, Melner MH, and Simard J (2000) **IL-4 stimulation of ovarian 3β-hydroxysteroid dehydrogenase/Δ5-Δ4-isomerase type 2 gene expression: Mechanisms of activation**. *The Endocrine Society's 82nd Annual Meeting,* Toronto, ON, Canada, 2000, Abst. 1295.

298. Feltus FA, Côté S, Gingras S, Simard J, and Melner MH (2000) **Autocrine stimulation of adrenal 3β-hydroxysteroid dehydrogenase gene expression by glucocorticoids: Functional requirement for stat5 and glucocorticoid receptor interactions**. *The Endocrine Society's 82nd Annual Meeting*, Toronto, ON, Canada, 2000, Abst. 1532.

299. Melner MH, Côté S, Gingras S, Simard J, Nicholson W, Kovacs WJ, Feltus FA (2000) **The regulation of 3β–hydroxysteroid dehydrogenase gene expression: STAT proteins and autocrine steroid effects**. *IXth Adrenal Cortex Conference*, Toronto, ON, Canada, June 17-20, 2000.

300. Simard J, Ricketts ML, Moisan AM, Tardy V, Peter M, Morel Y (2000) **New insights into the molecular basis of 3β-HSD deficiency**. *IXth Adrenal Cortex Conference*, Toronto, ON, Canada, June 17-20, 2000.

301. Simard J, Vézina H, Durocher F, Plante M, Chiquette-Gagnon J, Dorval M, Voyer P, Lespérance B, Doyle C, Bessette P, Bridge P, Easton D, and Laframboise R (2000) **Genetic and Molecular Epidemiology of Hereditary Breast and Ovarian Cancer in French Canadian Women**. *International Conference on Community Genetics «From DNA to the Community»*, Jonquière, QC, Canada, June 20-22, 2000.

302. Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, Bélanger A (2000) **Intracrinology: Tissue-Specific Formation and Action of Sex Steroids**. *The Endocrine Society Annuel Meeting CMES Ancillary Symposium*, London, UK, June 21-24, 2000.

303. Simard J, Gingras S, Côté S (2000) **Multiple Signaling Pathways Mediate Interleukin-4-Induced Formation of Active Sex Steroids in Normal and Tumoral Target Tissues**. *14th International Symposium of the Journal of Steroid Biochemistry & Molecular Biology*, Quebec, QC, Canada, June 24-27, 2000.

304. Labrie F, Luu-The V, Bélanger A, Simard J, Labrie C, Lin SX (2000) **Intracrinology of adrenal and gonadal steroids**. *Teupitzer Colloquium*, Berlin, Germany, (532: 92-103) September 17-20, 2000.

305. Couture P, Simard J, Demers C, Callas PW, Jomphe M, Long GL, Rosendaal FR, Aiach M, Bovill EG (2000) **Evidence of a founder effect for the protein C gene 3363 inserted mutation in thrombophilic pedigrees of French origin**. *42nd American Society of Hematology Annual Meeting*, San Francisco, CA, USA, December 1-5, 2000.

306. Martel C, Gauthier S, Simard J, Mérand Y, Labrie F (2000) **Comparison of the antiestrogenic and estrogenic activities of EM-652.HC1 and lasofoxifene in human endometrial adenocarcinoma Ishikawa cells and in the ovariectomized mouse model**. *23rd Annual San Antonio Breast Cancer Symposium*, San Antonio, USA, p. 73, Abst. 270, December 6-9, 2000.

307. Dorval M, Maunsell E, Patenaude AF, Laframboise R, Durocher F, Chiquette J, Provencher L, Simard JR. (2000) **Elapsed time to disclosure of BRCA1/2 genetic testing result and participants' distress: preliminary finding from a research setting**. *Psycho-Oncology*. 9(5 suppl):no. 341.

308. Dorval M, Maunsell E, Morel S, Dugas MJ, Simard JR. (2001) **Elapsed time to disclosure of *BRCA1/2* genetic testing result and participants' distress: Preliminary finding from a research setting**. *Value in Health.* 4(6),437.

309. Tavtigian SV, Simard J, Skolnick MH, Neuhausen SL, Rommens J, Cannon Albright LA, Labrie F (2001) **Susceptibility genes for prostate cancer**. *11th International prostate cancer update*, Vail, Colorado, USA, January 31-February 4, 2001.

310. Simard J, Tavtigian SV, Labrie F, Skolnick MH, Neuhausen SL, Rommens J, Cannon Albright LA (2001) **A strong candidate prostate cancer predisposition gene at chromosome 17p**. *6th International Symposium on GnRH analogues in cancer and human reproduction*, Genève, Suisse, February 8-11, 2001.

311. Simard J, Gingras S, Côté S (2001) **Mécanismes d'action des cytokines dans la formation des stéroïdes sexuels dans les cellules de cancer du sein**. *Réunion scientifique de l'équipe de Physiopathologie Endocrinienne du Centre de recherche clinique de Sherbrooke*, Lac-Brome, QC, Canada, March 26, 2001.

312. Simard J, Dumont M, Délos S, Moisan AM, Samson C, Larouche L, MacMillan A, Babineau T, Malouin H, Tranchant M, Vézina H, Dorval M, Bessette P, Voyer P, Lépine J, Pichette R, Chiquette J, Plante M, Laframboise R, Bridge P, Easton D, and Durocher F (2001) **Molecular epidemiology of *BRCA1* and *BRCA2* mutations in high risk French Canadian breast / ovarian cancer families**. *10th International Congress of Human Genetics*, Vienna, Austria, May 15-19, 2001.

313. Simard J, Dumont M, Délos S, Moisan AM, Samson C, Larouche L, MacMillan A, Babineau T, Malouin H, Tranchant M, Vézina H, Dorval M, Bessette P, Voyer P, Lépine J, Pichette R, Lespérance B, Provencher L, Chiquette J, Plante M, Laframboise R, Easton D, Bridge P, the INHERIT BRCAs and Durocher F (2001) **Molecular epidemiology of *BRCA1* and *BRCA2* mutations in high risk french canadian breast / ovarian cancer families**. *Reasons for Hope 2001: New developments in breast cancer research. Second Scientific Conference sponsored by the Canadian Breast Cancer Research Initiative*, Quebec, QC, Canada, May 3-5, 2001.

314. Durocher F, Vézina H, Houde L, Szabo C, Dumont M, Délos S, Tranchant M, Jomphe M, Chiquette J, Plante M, Laframboise R, Stoppa-Lyonnet D, Nevanlinni H, Goldgar D, Easton D, Bridge P, INHERIT BRCAs and Simard J (2001) **Introduction and diffusion of the *BRCA1* mutation R1443X in the french canadian population**. *Reasons for Hope 2001: New developments in breast cancer research. Second Scientific Conference sponsored by the Canadian Breast Cancer Research Initiative*, Quebec, QC, Canada, May 3-5, 2001.

315. Vézina H, Durocher F, Houde L, Dumont M, Délos S, Jomphe M, Tranchant M, Chiquette J, Plante M, Laframboise R, Bridge P, INHERIT BRCAs and Simard J (2001) **Molecular and genealogical analyses of the *BRCA2* mutation 8765delAG in the French canadian population**. *Reasons for Hope 2001: New developments in breast cancer research. Second Scientific Conference sponsored by the Canadian Breast Cancer Research Initiative*, Quebec, QC, Canada, May 3-5, 2001.

316. Carsol JL, Gingras S, and Simard J (2001) **Synergistic action of prolactin and androgen on PIP/GCDFP-15 gene expression in human breast cancer cells: a unique model for functional cooperation between Stat5 and androgen receptor**. *Reasons for Hope 2001: New developments in breast cancer research. Second Scientific Conference sponsored by the Canadian Breast Cancer Research Initiative*, Quebec, QC, Canada, May 3-5, 2001.

317. Labrie F, Labrie C, Bélanger A, Simard J, Giguère V, Candas B (2001) **EM-652 (SCH 57068), its role in the future of women's health**. *Reasons for Hope 2001: New developments in breast cancer research. Second Scientific Conference sponsored by the Canadian Breast Cancer Research Initiative*, Quebec, QC, Canada, May 3-5, 2001.

318. Vézina H, Durocher F, Houde L, Szabo C, Dumont M, Delos S, Jomphe M, Chiquette J, Plante M, Laframboise R, Stoppa-Lyonnet D, Goldgar DE, Easton DF, Bridge PJ and Simard J (2001) **Introduction and diffusion of the *BRCA1* mutation R1443X in the French Canadian population**. *10th International Congress of Human Genetics*, Vienna, Austria, May 15-19, 2001.

319. Couture P, Simard J, Delage R, Jomphe M, Aiach M, Bovill EG, Demers C (2001) **Présence d'un effet fondateur pour la mutation 3363 insC dans le gène de la protéine C dans des familles thrombophiliques d'origine française**. In: *Journée de la recherche de la Faculté de médecine, Université Laval*, Quebec, QC, Canada, June 4, 2001.

320. Tavtigian SV, Simard J, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA (2001) **Novel prostate cancer susceptibility gene on 17p**. *Endo 2001*. Denver, Colorado, USA, June 20-23, 2001.

321. Demers C, Delage R, Vu L, Jacques L, Bovill EG, Aiach M, Simard J, and Couture P (2001) **The nature of the mutation in the protein C gene influences immunological plasma protein C levels in heterozygotes with type I protein C deficiency**. *XVIII Congress The International Society on Thrombosis and Haemostasis*, Paris, France, July 6-12, 2001.

322. Simard J (2001) **Advances and pitfalls in genetic screening for breast and prostate cancer susceptibilities.** *Biofuture 2001*, Toronto, ON, Canada, September 5-7, 2001.

323. Dumont M, Tavtigian SV, Frank D, Tranchant M, Moisan AM, Larouche L, Labrie F, Simard J (2001) **Caractérisation structurale et expression du gène de susceptibilité au cancer de la prostate Elac2 chez les mammifères**. *Club de recherches cliniques du Québec*, Val-des-Neiges, QC, Canada, September 22, 2001.

324. Simard J (2001) **Hereditary Susceptibility to Breast and Prostate Cancer**. *Partnership Group for Science & Engineering Symposium*, Ottawa, ON, Canada, October 17, 2001.

325. Bolduc C, St-Amand J, Larose M, Lafond N, Yoshioka M, Rodrigue MA, Barden N, Hudson T, Hallet M, Morissette J, Savard P, Poirier GG, Rivest S, Simard J, Luu-The V, Labrie C, Raymond V and Labrie F (2002) **Adipose tissue transcriptome studied by serial analysis of gene expression**. *9th International Congress on Obesity*, Sao Paulo, Brasil, August 26 2002.

326. Buhr K, Dugas MJ, Dorval M and Simard J (2002) **Validation of a measure of intolerance of uncertainty for women undergoing genetic testing for breast cancer susceptibility**. *Annual Conference of the Association for Advancement of Behavior Therapy*, Reno, NV, USA, November 2002.

327. Desbiens MC, Dorval M and Simard J (2002) **Utilisation d'une hormonothérapie de remplacement chez les femmes à haut risque de cancer du sein testée pour *BRCA1/2***. *Journée de la recherche de la Faculté de Pharmacie de l'Université Laval*, Quebec, QC, Canada, May 2002.

328. Durocher F, Vézina H, Dumont M, Houde L, Tranchant M, Bessette P, Bridge P, Brousseau C, Chiquette J, Delos S, Goldgar D, Jomphe M, Labrie Y, Laframboise R, Lajoie MA, Larouche L, Leblanc G, Lépine J, Lespérance B, Malouin H, Moisan AM, Nevanlinni H, Pichette R, Plante M, Plourde M, Provencher L, Rhéaume J, Samson C, Soucy P, Stoppa-Lyonnet D, Szabo C, Voyer P, INHERIT BRCAs and Simard J (2002) **Importance de l'effet fondateur de deux mutations inactivatrices dans les gènes *BRCA1/2* chez les familles Canadiennes Françaises à risque élevé**. *Quatrièmes Journées Génétiques du Réseau de médecine génétique appliquée du FRSQ*, Montreal, QC, Canada, May 23-24, 2002.

329. Gauthier G, Dorval M, Maunsell E, Simard J, Dorval M and INHERIT BRCAs (2002) **Les femmes ayant obtenu un résultat non-concluant à un test génétique de prédisposition au cancer du sein (*BRCA1/2*) sont-elles faussement rassurées?** *25ième Congrès annuel de la Société québécoise pour la recherche en psychologie*, Trois-Rivières, QC, Canada, November 2002.

330. Labrie C, Labrie F, Luu-The V, Bélanger A, Simard J and Candas B (2002) **DHEA and bone**. *International Congress and Hormones and Cancer*, Fukuoka, Japan, October 21-25, 2002.

331. Moisan AM, Dumont M, Tranchant M and Simard J (2002) **Analyse comparative des orthologues d'ELAC2 chez les primates et les rongeurs et mise en évidence d'un épissage alternatif chez les rongeurs**. *Journée de la recherche de la Faculté de médecine, Université Laval*, Quebec, QC, Canada, 28 May 2002.

332. Plourde M, Manhes C, Leblanc G, Durocher F and Simard J (2002) **Identification de polymorphismes dans le gène de la 17β-hydroxystéroïde déshydrogénase Type 2**. *Journée de la recherche de la Faculté de médecine, Université Laval*, Quebec, QC, Canada, May 28, 2002.

333. Rouleau I, Dorval M and Simard J (2002) **Variations in the use of hormone replacement therapy (HTR) among women at high risk of hereditary breast cancer undergoing *BRCA1/2* genetic testing (Preliminary Results)**. *Canadian Association of Psychosocial Oncology 2002 Conference*, Halifax, NS, Canada, May 2002.

334. Rouleau I, Dorval M and Simard J (2002) **Utilisation de l'hormonothérapie de substitution chez les femmes à haut risque de cancer du sein héréditaire se présentant pour un test de prédisposition génétique *BRCA1/2***. *70ième Congrès de l'AFCAS*, Quebec, QC, Canada, May 2002.

335. Ruel I, Couture P, Moisan AM, Gagné C, Simard J, Cohn J, Hegele R and Lamarche B (2002) **A novel mutation causing complete hepatic lipase deficiency among French-Canadians and its impact on lipoprotein metabolism**. *75e Conférence Annuelle de l'American Hear Association (AHA*), Chicago, Illinois, USA, November 2002.

336. Simard J (2002) **The Cancer Genomics Laboratory's Information Management System: An Essential Bioinformatic Tool for the INHERIT BRCAs Program**. *Second Annual INHERIT BRCAs Meeting and First National Heriditary Cancer Task Force*, Quebec, QC, Canada, November 24-26, 2002.

337. Simard J and Labrie F (2002) **Susceptibility Genes for Prostate Cancer**. *12th International Prostate Cancer Update*. Keystone, CO, USA, p. 197-211, February 6-10, 2002.

338. Simard J, Dumont M, El-Alfy M, Labrie F and Tavtigian S (2002) **Prostate Cancer Susceptibility Genes**. *International Congress on Hormonal Steroids and Hormones and Cancer*, Fukuoka, Japan, October 21-25, 2002.

339. Simard J (2002) **Building a Multidisciplinary Partnership Overview of the Research, the Team and the Key Issues**. *Twenty-second Annual Meeting Association for Politics and the Life Sciences*, August 11-14, 2002.

340. Simard J (2002) **Génétique du cancer du sein et du colon**. *Journées chirurgicales de l'Université Laval, Formation continue de la Faculté de médecine de l'Université Laval*, Quebec, QC, Canada, November 1-2, 2002.

341. Simard J, Moisan AM, Calemard-Michel L and Morel Y (2002) **Males with 17β-hydroxysteroid dehydrogenase deficiency**. *Hormonal & Genetic Basis of Sexual Differentiation Disorders*, Tempe, Arizona, USA, May 16-18, 2002.

342. Avard D, Brouillet F, Durocher F, Horsman D, Lespérance B and Simard J (2003) **Knowledge Transfer an Integral Part of INHERIT BRCAs**. *Third Scientific Conference of the Canadian Breast Cancer Research Alliance, Reasons for Hope*, Ottawa, ON, Canada, October 25-27, 2003.

343. Avard D and Simard J (2003) **Translating breast cancer research into policies and improved clinical services**. *Third Scientific Conference of the Canadian Breast Cancer Research Alliance, Reasons for Hope*, Ottawa, ON, Canada, October 25-27, 2003.

344. Desjardins S, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs and Durocher F (2003) **Analysis of ZBRK1 polymorphisms in high-risk non-*BRCA1/2* French-Canadian families**. *53rd American Society of Human Genetics*, Los Angeles, CA, USA, vol. 73, no. 356, November 4-8, 2003.

345. Dorval M, Gauthier G, Maunsell E, Simard J and INHERIT BRCAs (2003) **Are women with an inconclusive *BRCA1/2* genetic test result falsely reassured?** *6th World Congress in Psycho-Oncology*, Banff, AB, Canada, 12 (4 suppl) no. 166, April 2003.

346. Dorval M, Morel S, Maunsell E, Dugas MJ, Simard J and INHERIT BRCAs (2003) **Retention of pre-test *BRCA1/2* genetic counseling information up to one year following test result disclosure**. *8th International Meeting on Psycho-Social Aspects of Hereditary Cancer,* Barcelone, Spain, November 13-14, 2003.

347. Dorval M, Morel S, Maunsell E, Dugas M, Simard J and INHERIT BRCAs (2003) **When using the impact of events scale to assess psychological distress in the context of *BRCA1/2* testing, does the event matter?** *6th World Congress in Psycho-Oncology*, Banff, AB, Canada, 12 (4 suppl) no. 307, April 2003.

348. Dorval M, Rouleau I, Simard J and INHERIT BRCAs (2003) **Utilisation de l'hormonothérapie de substitution suite à un test génétique de susceptibilité cancer du sein *BRCA1/2***. *Congrès «Médicaments, pharmacie et société»*, Quebec, QC, Canada, January 2003.

349. Durocher F, Vézina H, Dumont M, Houde L, Szabo C, Tranchant M, Jomphe M, Chiquette J, Plante M, Laframboise R, Stoppa-Lyonnet D, Nevanlinni H, Goldgar D, Easton D, Bridge P, INHERIT BRCAs and

Simard J (2003) **Introduction et analyses généalogiques de deux mutations fondatrices dans *BRCA1* et *BRCA2* chez des familles Canadiennes-Françaises à risque élevé**. *Journée de la recherche, Faculté de médecine, Université Laval*, Quebec, QC, Canada, May 8, 2003.

350. Durocher F, Vézina H, Dumont M, Houde L, Szabo C, Tranchant M, Jomphe M, Chiquette J, Plante M, Laframboise R, Stoppa-Lyonnet D, Nevanlinni H, Goldgar D, Easton D, Bridge P, INHERIT BRCAs and Simard J (2003) **Molecular and genealogical analyses of the *BRCA1* R1443X founder mutation in high risk French-Canadian breast/ovarian cancer families**. *Genetics of complex diseases in isolated populations*, Sardinia, Italy, May 23-30, 2003.

351. Durocher F, Vézina H, Dumont M, Houde L, Szabo C, Tranchant M, Jomphe M, Chiquette J, Plante M, Laframboise R, Stoppa-Lyonnet D, Nevanlinni H, Goldgar D, Easton D, Bridge P, the INHERIT BRCAs and Simard J (2003) **Molecular and genealogical analyses of two germline *BRCA1/2* mutations in high risk French-Canadian breast/ovarian cancer families**. *Third Scientific Conference of the Canadian Breast Cancer Research Alliance, Reasons for Hope*, Ottawa, ON, Canada, October 25-27, 2003.

352. Gauthier S, Cloutier J, Dory YL, Fabre A, Mailhot J, Ouellet C, Schwerdtfeger A, Mérand Y, Martel C, Simard J, and Labrie F (2003) **Synthesis and structure-activity relationships of analogs of EM-652, a pure selective estrogen receptor modulator. Part 1: Study of nitrogen substitution**. *23rd ACS National Meeting American Chemical Soc*., Orlando, FL, USA, Abst. 224, April 7-11, 2003.

353. Godard B, Pratte A, Simard-Lebrun A, Malouin H, Simard J and INHERIT BRCAs (2003) **Characteristics of Individuals Who Refuse or Withdraw from Genetic Testing for Breast and Ovarian Cancer**. *8th International Meeting on Psycho-Social Aspects of Hereditary Cancer*, Barcelone, Spain, November 13-14, 2003.

354. Guénard F, Klappenburger S, Labrie Y, Simard J, Plante M, Têtu B and Durocher F (2003) **Prévalence des mutations dans les gènes *BRCA1* et *BRCA2* dans des cas de cancer de l'ovaire dans la population Canadienne-Française**. *Journée de la recherche, Faculté de médecine, Université Laval*, Quebec, QC, Canada, p. 58. Abst. 67, May 8, 2003.

355. Labrie F, Labrie C, Simard J and Bélanger A (2003) **New generation selective estrogen receptor modulators (SERMS)**. Stéroïdes sexuels: Le point sur l'action des estrogènes et des progestatifs. Palais des Congrès le Corum, Montpellier, France, March 31-April 1-2, 2003.

356. Guénard F, Labrie Y, Ouellette G, Houde M, Simard J, INHERIT BRCAs and Durocher F (2003) **Analysis of polymorphisms in genes encoding proteins interacting with *BRCA1* in high-risk non-*BRCA1/2* families**. *53rd American Society of Human Genetics*, Los Angeles, CA, USA, p. 231. Abst. 360, November 4-8, 2003.

357. Meijers-Heijboer H, Szabo C, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JGM, van den Ouweland AMW, Wagner TMU, Devilee P, Simard J, van't Veer LJ, Schutte M and Goldgar D (2003) **Are ATM mutations 7271T-G and IVS10-6T-G really high-risk breast cancer susceptibility alleles**? *Breast Cancer Linkage Consortium Meeting*, Madrid, Spain, June 2003.

358. Moisan AM, Fortin J, Dumont M, Samson C, Larouche L, INHERIT BRCAS and Simard J (2003) **No evidence of recurrent *BRCA1/2* genomic rearrangement in high risk French-Canadian breast/ovarian cancer families**. *Third Scientific Conference of the Canadian Breast Cancer Research Alliance, Reasons for Hope*, Ottawa, ON, Canada, October 25-27, 2003.

359. Moisan AM, Fortin J, Dumont M, Samson C, INHERIT BRCAS and Simard J (2003) **No evidence of recurrent *BRCA1/2* genomic rearrangement in high risk French-Canadian breast/ovarian cancer families**. *The 53rd American Society of Human Genetics Annual Meeting*, Los Angeles, CA, USA, p 241. Abst. 417, November 4-8, 2003.

360. Plourde M, Manhes C, Leblanc G, Durocher F, Dumont M, INHERIT BRCAs and Simard J (2003) **Identification of sequence variants in the 17□-hydroxysteroid dehydrogenase type 2 gene in French-Canadian high-risk breast cancer families**. *The 53rd American Society of Human Genetics Annual Meeting*, Los Angeles, CA, USA, Suppl. Vol. 73, Abst. 509, November 4-8, 2003.

361. Plourde M, Manhes C, Leblanc G, Durocher F, Simard J and INHERIT BRCAs (2003) Identification de polymorphismes dans le gène de la 17□-hydroxystéroïde déshydrogénase Type 2. *Journée de la recherche, Faculté de médecine, Université Laval*, Quebec, QC, Canada, p. 100. Abst. 152, May 8, 2003.

362. Rouleau I, Dorval M and INHERIT BRCAs (2003) **Hormone replacement therapy (HRT) utilization among women undergoing *BRCA1/2* genetic testing**. *6th World Congress in Psycho-Oncology, 2003*. 12(4 suppl) no. 541.

363. Rouleau I, Dorval M and INHERIT BRCAs (2003) **Hormone replacement therapy (HRT) use among women undergoing *BRCA1/2* testing**. *Canadian Journal of Clinical Pharmacology 2003,* 10(1) 69.

364. Simard J (2003) **Génomique: Enjeux cliniques et éthiques**. Congrès «*Médicaments, pharmacie et société*», Quebec, QC, Canada, January 23-25, 2003.

365. Simard J, Dumont M, Moisan AM, Brousseau C, Lajoie MA, Léger P, Malouin H, Rhéaume J, Labrie Y, Leblanc G, Ouellette G, Samson C, Soucy P, Tranchant M, Laframboise R, Plante M, Chiquette J, Provencher L, Lespérance B, Pichette R, Lépine J, Bessette P, Voyer P, Easton D, Bridge P, Durocher F et INHERIT BRCAs (2003) **Épidémiologie moléculaire des mutations *BRCA1* et *BRCA2* chez plus de 200 familles Canadiennes-Françaises à risque élevé**. *Journée de la recherche, Faculté de médecine, Université Laval*, Quebec, QC, Canada, May 8, 2003.

366. Simard J, Dumont M, Moisan AM, Durocher F, Brousseau C, Lajoie MA, Léger P, Malouin H, Rhéaume J, Labrie Y, Leblanc G, Ouelette G, Samson C, Soucy P, Tranchant M, Laframboise R, Plante M, Chiquette J, Provencher L, Lespérance B, Pichette R, Lépine J, Bessette P, Voyer P, Easton D, Bridge P and INHERIT BRCAs (2003) **Molecular epidemiology of *BRCA1* and *BRCA2* mutations in more than 200 high risk French Canadian breast/ovarian cancer families**. *Third Scientific Conference of the Canadian Breast Cancer Research Alliance, Reasons for Hope*, Ottawa, ON, Canada, October 25-27, 2003.

367. Szabo C, Coutanson C, Durocher F, Barjhoux L, Foretova L, Lubinski J, Bressac de Paillerets B, Lasset C, Lenoir G, Couch F, Stoppa-Lyonnet D, Sinilnikova O, Simard J, Goldgar D and the Breast Cancer Linkage Consortium (2003) **Contribution of Chek2 1100delC to familial breast cancer**. *Breast Cancer Linkage Consortium Meeting*, Familial Cancer 2: 217, no. 43, Madrid, Spain, June 2003.

368. Szabo C, Ginolhac S, Coupier I, Kadouri L, van Eijk R, Schreiber M, Plourde M, Csokay B, Olah E, Durocher F, Simard J, Wagner T, Eeles R, Abeliovich D, Peretz T, Stoppa-Lyonnet D, Sinilnikova O, Goldgar D, the Breast Cancer Linkage Consortium MOD-SQUAD and Devilee P (2003) **Androgen receptor CAG repeat length and *BRCA1* associated cancer risk: size does matter**. *Breast Cancer Linkage Consortium Meeting*, Familial Cancer 2: 217, no. 44, Madrid, Spain, June 2003.

369. Tavtigian SV, Simard J, Dumont M and Labrie F (2003) **Prostate Cancer Susceptibility Gene**. *7th International Symposium on GnRH analogues in cancer and human reproduction.* Amsterdam, Pays Bas, 6-9 February 2003.

370. Têtu R, Dorval M, Simard J. (2003) **Participation à l'étude STAR par les femmes à haut risque de cancer du sein héréditaire testées pour une prédisposition génétique liée à *BRCA1 et BRCA2***. *Journée de la recherche de la Faculté de Pharmacie de l'Université Laval*, Quebec, QC, Canada, April 2003.

371. Alamian A, Rouleau I, Simard J, INHERIT BRCAs, Dorval M (2004) **Use of Dietary Supplements Among Women Undergoing *BRCA1/2* Genetic Testing**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, October 7-8, 2004.

372. Bouchard K, Rouleau I, Maunsell E, Dugas MJ, Simard J, INHERIT BRCAs, Dorval M (2004) **Personal Cancer History and Psychological Distress Among Women Undergoing *BRCA1/2* Genetic Testing: Preliminary Findings**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, 7-8 October, 2004.

373. Desjardins S, Ouellet M, Labrie Y, Ouellette G, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2004) **Impact of *ZBRK1* Polymorphisms in High-Risk French-Canadian Breast Cancer Families Negative for Mutations in the Kown Susceptibility Genes *BRCA1/2***. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, October 7-8, 2004.

374. Desjardins S, Ouellet M, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2004) **Analyse de FANCA chez des familles à risque élevé de cancer du sein sans mutation *BRCA1/2***. *46e Réunion annuelle du Club de Recherches Cliniques du Québec,* Mont-Sainte-Anne, Beaupré, QC, Canada, September 23-25, 2004.

375. Desjardins S, Ouellet M, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2004) **Analyse des polymorphismes de ZBRK1 chez les familles canadiennes-françaises à risque élevé de cancer du sein négatives pour des mutations *BRCA1* et *BRCA2***. *6e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, June 3, 2004.

376. Desjardins S, Ouellet M, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2004) **FANCA sequence variations in high-risk non-*BRCA1/2* French Canadian families**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

377. Dumont M, Moisan AM, Tranchant M, Soucy P, Breton R, Labrie F, Tavtigian SV, Simard J (2004) **Structure of Primate and Rodent Orthologs of the Prostate Cancer Susceptibility Gene *ELAC2***. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, October 7-8, 2004.

378. Durocher F, Antoniou A, Smith P, Dumont M, Laframboise R, Chiquette J, Plante M, Simard J, Easton D, INHERIT BRCAs (2004) **Penetrance estimates of deleterous *BRCA1* and *BRCA2* mutations in high-risk French Canadian families**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

379. Durocher F, Vézina H, Houde L, Dumont M, Tranchant M, Gobeil L, Simard J, INHERIT BRCAs (2004) **Molecular and genealogical analyses of 8765de1AG, a *BRCA2* founder mutation in high-risk French Canadian families**. *The American Society of Human Genetics*, Toronto, Canada, October 26-30, 2004.

380. Durocher F. pour INHERIT BRCAs (2004) **Estimation de la pénétrance des mutations dans les gènes *BRCA1* et *BRCA2* chez des familles canadiennes-françaises à risque élevé**. *6e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, June 3, 2004.

381. Fortin J, Moisan AM, Dumont M, Labrie Y, Durocher F, INHERIT BRCAs, Simard J (2004) **Expression d'un nouveau transcrit de *BRCA1* incluant un exon supplémentaire conservant le cadre de lecture**. *46e Réunion annuelle du Club de Recherches Cliniques du Quebec,* Mont-Sainte-Anne, Beaupré, QC, Canada, September 23-25, 2004.

382. Guénard F, Labrie Y, Ouellette G, Joly Beauparlant C, Simard J, INHERIT BRCAs, Durocher F (2004) **Evaluation of the Role of PTEM in High-Risk, non *BRCA1/2* Breast Cancer Families from the French-Canadian Population**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, 7-8 October 2004.

383. Guénard F, Labrie Y, Ouellette G, Houde M, Simard J, INHERIT BRCAs, Durocher F (2004) **Analyse des polymorphismes du gène endocant l'ubiquitine ligase BARD1 chez des familles à risque élevé de cancer du sein**. *46e Réunion annuelle du Club de Recherches Cliniques du Québec,* Mont-Sainte-Anne, Beaupré, QC, Canada, September 23-25, 2004.

384. Guénard F, Labrie, Y, Ouellette G, Houde M, Simard J, INHERIT BRCAs, Durocher F (2004) **Analyse de polymorphismes de gènes encodant des protéines interagissant avec *BRCA1* dans des familles à haut risque, non porteuses de mutations dans les gènes *BRCA1* et *BRCA2***. *6e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, June 3, 2004.

385. Labrie Y, Durocher F, Soucy P, Labuda D, INHERIT BRCAs, Simard J (2004) **Characterization of ATR sequence variants in high-risk non *BRCA1/2* French Canadian families**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

386. Moisan AM, Fortin J, Dumont M, Labrie Y, Durocher F, INHERIT BRCAs and Simard J (2004) **Tissue-Specific Expression of a Novel Alternative Splice Variant in *BRCA1* Generating an Additional in Frame Exon**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, October 7-8 2004.

387. Moisan AM, Fortin J, Dumont M, Samson C, Larouche L, INHERIT BRCAs, Simard J (2004) **Absence d'évidence de réarrangement génomique récurrent dans *BRCA1* et *BRCA2* chez la population candienne française à risque élevé de cancer du sein et/ou de l'ovaire**. *46e Réunion annuelle du Club de Recherches Cliniques du Québec,* Mont-Sainte-Anne, Beaupré, QC, Canada, September 23-25 2004.

388. Moisan AM, Fortin J, Labrie Y, Durocher F, INHERIT BRCAs, Simard J (2004) **A new alternative splice variant in *BRCA1* generating and additional inframe exon**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

389. Plourde M, Leblanc G, Manhes C, Durocher F, Dumont M, Labuda D, INHERIT BRCAs and Simard J (2004) **Characterization of 17□-hydroxysteroid dehydrogenases sequence variants in French-Canadian high-risk breast cancer families**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier.* Montreal, QC, Canada, October 7-8, 2004.

390. Plourde M, Manhes C, Leblanc G, Durocher F, Dumont M, INHERIT BRCAs, Simard J (2004) **Identification de variant de séquence dans le gène encodant la 17□-hydroxtstéroïde déshydrogénase type 2 chez des familles canadiennes-françaises à risque élevé de cancer du sein**. *46e Réunion annuelle du Club de Recherches Cliniques du Québec,* Mont-Sainte-Anne, Beaupré, QC, Canada, September 23-25, 2004.

391. Pratte A, Godard B, Simard-Lebrun A, Simard J (2004) **Factors associated with refusal or withdrawal from genetic testing for breast and ovarian cancer**. *Genome Canada GE3LS Symposium 2004,* Vancouver, Canada, February 5-7, 2004.

392. Simard J for INHERIT BRCAs (2004) Molecular Epidemiology of *BRCA1* and *BRCA2* Mutations in French Canadian Breast/Ovarian Families. *Third Annual Future of Breast Cancer: An International Congress.* Southampton, Bermudes, 22-25 July 2004.

393. Simard J pour INHERIT BRCAs (2004) **Hérédité et cancer du sein: Réalisations et défis**. *6e Colloque du RQSS – Réseau québécois pour la santé du sein*, Montreal, QC, Canada, October 2, 2004.

394. Simard J, Dumont M, Moisan AM, Durocher F, Vézina H, Houde L, Laframboise R, Plante M, Chiquette J, Bessette P, Voyer P, Lépine J, Lespérance B, Pichette R, Parboosingh J, Bridge P, Smith P, Antoniou A, Easton D, Gaborieau V, Goldgar D and INHERIT BRCAs (2004) **Familial Breast/Ovarian Cancer in the French Canadian Founder Population**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17ièmes Entretiens du Centre Jacques Cartier,* Montreal, QC, Canada, October 7-8, 2004.

395. Simard J, Dumont M, Moisan AM, Durocher, F, Laframboise R, Plante M, Chiquette J, Lespérance B, Pichette R, Lépine J, Bessette P, Voyer P, Bridge P, Goldgar D and the INHERIT BRCAs (2004) **Molecular Epidemiology of *BRCA1* and *BRCA2* Mutations in French Canadian Breast/Ovarian Families**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

396. Simard, J (2004) **INHERIT BRCAs: Réalisations et défis**. La génétique humaine au Québec – Qui fait quoi? *Cinquièmes Journées Génétiques 2004 du RMGA, Réseau de Médecine Génétique Appliquée,* Montreal, QC, Canada, May 17-18, 2004.

397. Simard J (2004) **Les enjeux du partage des résultats de recherche: L'expérience d'INHERIT BRCAs**. *Symposium GE^{3}DS, La recherche en génétique et en génomique: droits et responsabilités,* Montreal, QC, Canada, December 2-3, 2004.

398. Smith P, Spurdle A, Harrington PA, Durocher F, Hughes D, Ginolhac S, Sinilnikova O, Szabo C, Labrie J, Coupier I, Stoppa-Lyonnet D, Peock S, Cook M, Hopper JL, Simard J, Goldgar DE, Dunning AM, Chenevix-Trench G, Easton DF, ABCFS, AJBCS, EMBRACE, kConFab, GGC-France, INHERIT BRCAs collaborators (2004) **Analysis of polymorphisms in DNA repair genes as modifiers of breast cancer risk in *BRCA1* and *BRCA2* carriers**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

399. Tremblay JJ, Martin LJ, Taniguchi H, Simard J and Viger R (2004) **GATA Factors and Ophan Nuclear Receptors Cooperate to Synergistically Activate the Human *HSD3B2* Promoter**. *The Endocrine Society's 86th Annual Meeting*, New Orleans, LA, USA, June 16-19, 2004.

400. Vallée M, Rouleau I, Plante M, Chiquette J, Simard J, INHERIT BRCAs, Dorval M (2004) **Comparison in the Use of Hormone-Replacement Therapy Among Women Tested for *BRCA1/2* Mutations Before and After The Publication of the Women's Health Initiative**. *Oncogenetics: Achievements and Challenges. Oncogénétique: Réalisations et Défis, 17^{ièmes} Entretiens du Centre Jacques Cartier,* Montreal, QC, Canada, October 7-8, 2004.

401. Vézina H, Durocher F, Houle L, Dumont M, Tranchant M, Gobeil L, Simard J, INHERIT BRCAs (2004) **Molecular and genealogical analyses of 8765de1AG, a *BRCA2* founder mutation in high-risk French Canadian families**. *The American Society of Human Genetics*, Toronto, ON, Canada, October 26-30, 2004.

402. Desjardins M, Labrie Y, Ouellette G, Ouellet M, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2005) **Distribution et comparaison des haplotypes de ZNF350/ZBRK1 dans la susceptibilité au cancer du sein**. *7^{ième} Journée de la recherche de la Faculté de médecine.* Pavillon Alphonse Desjardins, Cité universitaire, Université Laval, Quebec, QC, Canada, May 25, 2005.

403. Desjardins S, Ouellet M, Labrie Y, Ouellette G, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2005) **Distribution et comparaison des haplotypes de ZBRK1/ZNF350 dans la susceptibilité au cancer du sein**. *Journées CREMO 2005, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval*, Lac-Beauport, QC, Canada, April 11-12, 2005.

404. Desjardins S, Ouellet M, Labrie Y, Ouellette G, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2005) **Distribution et comparaison des haplotypes de ZNF350/ZBRK1 chez des individus atteints de cancer du sein provenant de familles à risque élevé et chez des individus contrôles**. *73^{e} Congrès de l'ACFAS*, Université du Québec à Chicoutimi, QC, Canada, May 9-13, 2005.

405. Dorval M, Davilmar A, Rouleau I, Maunsell E, INHERIT BRCAs Simard J (2005) **Men undergoing *BRCA1/2* genetic testing: Who are they and why do they do it?** *The Second Annual Conference of the American Psychosocial Oncology Society (APOS)*, Phoenix, Arizona, USA, January 27-29, 2005.

406. Guénard F, Ouellette G, Labrie Y, Joly-Beauparlant C, Simard J, INHERIT BRCAs, Durocher F (2005) **Évaluation de la contribution du gène PTEN dans la susceptibilité génétique au cancer du sein chez les familles Canadiennes Françaises à risque élevé**. *7^{ième} Journée de la recherche de la Faculté de médecine.* Pavillon Alphonse Desjardins, Cité universitaire, Université Laval, Quebec, QC, Canada, May 25, 2005.

407. Guénard F, Ouellette G, Labrie Y, Joly-Beauparlant C, Simard J, INHERIT BRCAs, Durocher F (2005) **Évaluation de la contribution du gène PTEN dans la susceptibilité génétique au cancer du sein chez les familles Canadiennes Françaises à risque élevé**. *Journées CREMO 2005, Centre de Recherche en*

Endocrinologie Moléculaire et Oncologique de l'Université Laval, Lac-Beauport, QC, Canada, April 11-12, 2005.

408. Guénard F, Ouellette G, Labrie Y, Joly-Beauparlant C, Simard J, INHERIT BRCAs, Durocher F (2005) **Évaluation de la contribution du gène PTEN dans la susceptibilité génétique au cancer du sein chez les familles Canadiennes Françaises à risque élevé**. *73e Congrès de l'ACFAS*, Université du Québec à Chicoutimi, QC, Canada, May 9-13, 2005.

409. Moisan AM, Fortin J, Dumont M, Samson C, INHERIT BRCAs, Simard J (2005) **Absence d'évidence de réarrangement génomique récurrent dans *BRCA1* et *BRCA2* chez la population canadienne française à risque élevé de cancer du sein et/ou de l'ovaire**. *Journées CREMO 2005, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval*, Lac-Beauport, QC, Canada, April 11-12, 2005.

410. Moisan AM, Fortin J, Dumont M, Samson C, INHERIT BRCAs, Simard J (2005) **Absence d'évidence de réarrangement génomique récurrent dans *BRCA1* et *BRCA2* chez la population canadienne française à risque élevé de cancer du sein et/ou de l'ovaire**. *7ième Journée de la recherche de la Faculté de médecine.* Pavillon Alphonse Desjardins, Cité universitaire, Université Laval, Quebec, QC, Canada, May 25, 2005.

411. Plourde M, Leblanc G, Manhes C, Durocher F, Samson C, Dumont M, Soucy P, Labuda D, INHERIT BRCAs, Simard J (2005) **Caractérisation de variants de séquences dans les gènes encodant les 17□□hydroxysteroïde déshydrognases chez les familles Canadiennes Françaises à risque élevé de cancer du sein**. *Journées CREMO 2005, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval*, Lac-Beauport, QC, Canada, April 11-12, 2005.

412. Vallée MH, Rouleau I, Plante M, Chiquette J, Simard J, INHERIT BRCAs, Dorval M. (2005) **Comparison in the use of hormone replacement therapy among women tested for *BRCA1/2* mutations before and after the publication of the Women's Health Initiative**. *The 29th Annual Meeting of the Association of Preventive Oncology (ASPO),* San Francisco, CA, USA, March 13-15, 2005.

413. Desjardins S, Labrie Y, Ouellette G, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2006) **Analysis of *FANCF* sequence variations and promoter hypermethylation in breast cancer**. *Raisons d'espérer, Quatrième Congrès Scientifique*, Montreal, QC, Canada, May 6-8, 2006.

414. Durocher F, Antoniou AC, Smith P, Simard J, INHERIT BRCAs, Easton DF (2006) ***BRCA1/2* predictions using BOADICEA and BRCAPRO and penetrance estimation in French-Canadian families**. *Raisons d'espérer, Quatrième Congrès Scientifique*, Montreal, QC, Canada, May 6-8, 2006.

415. Durocher F, Labrie Y, Soucy P, Sinilnikova O, Labuda D, Bessette P, Chiquette J, Laframboise R, Lépine J, Lespérance B, Pichette R, Plante M, Tavtigian SV, Simard J (2006) **Characterization of ATR sequence variants in high-risk non-*BRCA1/2* French-Canadian families**. *Raisons d'espérer, Quatrième Congrès Scientifique*, Montreal, QC, Canada, May 6-8, 2006.

416. Guénard F, Labrie Y Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2006) **A screen for germline mutations in the *PTEN* gene in high-risk non-*BRCA1/BRCA2* breast cancer families**. *Raisons d'espérer, Quatrième Congrès Scientifique*, Montreal, QC, Canada, May 6-8, 2006.

417. Plourde M, Samson C, Leblanc G, Manhes C, Durocher F, Soucy P, Dumont M, Labuda D, Luu-The V, INHERIT BRCAs, Simard J (2006) **Sequence variant characterization in genes encoding types 1, 2, 7 and 12 17b-hydroxysteroid dehydrogenases in high-risk French-Canadian families with breast and ovarian cancer**. *Raisons d'espérer, Quatrième Congrès Scientifique*, Montreal, QC, Canada, May 6-8, 2006.

418. Simard J, Dumont M, Moisan AM, Gaborieau V, Vézina H, Durocher F, Chiquette J, Plante M, Avard D, Bessette P, Brousseau C, Dorval M, Houde L, Lajoie MA, Leblanc G, Lépine J, Lespérance B, Malouin H, Parboosingh J, Pichette R, Provencher L, Rhéaume J, Sinnett D, Samson C, Simard JC, Tranchant M, Voyer P, INHERIT BRCAs, Easton DF, Tavtigian SV, Knoppers BM, Laframboise R, Bridge P, Goldgar D (2006)

Characteristics of French-Canadian high-risk breast and/or ovarian cancer families: *BRCA1* and *BRCA2* mutation prevalence and evaluation of a multi-step testing approach. *Raisons d'espérer, Quatrième Congrès Scientifique*, Montreal, QC, Canada, May 6-8, 2006.

419. Desjardins S, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2006) **Analyse des variants de séquence de *FANCF* et de l'hyperméthylation du promoteur chez des familles Canadiennes françaises à risque élevé de cancer du sein**. *8e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 31, 2006.

420. Guénard F, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2006) **Évaluation de la contribution du gène *PTEN* dans la susceptibilité génétique au cancer du sein chez les familles Canadiennes françaises à risque élevé**. *8e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 31, 2006.

421. Desjardins S, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2006) **Analyse de *FANCF* chez des familles Canadiennes françaises à risque élevé de cancer du sein sans mutation *BRCA1/2***. *Dans: Médecine Sciences, supplément no 2, volume 22, Club de Recherches Cliniques du Québec,* Lac-à-l'Eau-Claire, QC, Canada, September 21-23, 2006.

422. Guénard F, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2006) **Analyse de l'implication du gène *PTEN* dans la susceptibilité génétique au cancer du sein chez les familles Canadiennes françaises à risque élevé**. *Dans: Médecine Sciences, supplément no 2, volume 22, Club de Recherches Cliniques du Québec,* Lac-à-l'Eau-Claire, QC, Canada, September 21-23, 2006.

423. Desjardins S, Ouellette G, Labrie Y, Labuda D, Simard J, Durocher F (2006) **Determination of *FANCF* sequence variation in high-risk non-*BRCA1/2* breast cancer families and promoter hypermethylation**. *FA Meeting: Eighteenth Annual International Fanconi Anemia Research Fund Scientific Symposium*, Bethesda, Maryland, USA, October 19-22, 2006.

424. Dorval M, Power T, Maunsell E, Dugas M, Patenaude AF, Simard J. (2006) **Cancer risk management behaviors of French Canadian women following BRCA1/2 genetic testing**. *Psycho-Oncology*. 15(2 suppl): no. 537.

425. Power T, Dorval M, Maunsell E, Dugas M, Patenaude AF, Simard J. (2006) **Evolution of psychological distress among French Canadian women who undergo *BRCA1/2* genetic testing**. *Psycho-Oncology*. 15 (2 suppl): no.873.

426. Desjardins S, Ouellette G, Labrie Y, Ouellet M, Simard J, INHERIT BRCAs, Durocher F (2007) **Analyse de variants de séquence et d'épissage de FANCA chez des familles à risque élevé de cancer du sein**. (Poster) *Journées ENDOMOL 2007, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval et Centre de Recherche sur les Maladies Lipidiques de l'Université Laval*, Quebec, QC, Canada, May 14-15, 2007.

427. Desjardins S, Ouellette G, Labrie Y, Ouellet M, Simard J, INHERIT BRCAs, Durocher F (2007) **Analyse de variants de séquence et d'épissage de FANCA chez des familles à risque élevé de cancer du sein**. (Poster) *9e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 29, 2007.

428. Desjardins S, Belleau P, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2007) **ZNF350/ZBRK1 haplotypes in high-risk non-BRCA1/2 families of French Canadian origin**. (Poster) *HMG2007, HUGO's 12th Human Genome Meeting*, Montreal, QC, Canada, May 21-24, 2007.

429. Ferland, A, Tranchant M, Plourde M, Soucy P, INHERIT BRCAs, Simard J (2007) **Caractérisation des variants de séquence du gène encodant la 17b-hydroxystéroïde-déshydrogénase de type 5 chez les femmes Canadiennes-françaises atteintes d'un cancer du sein provenant de familles à risque élevé**. (Poster) *Journées ENDOMOL 2007, Centre de Recherche en Endocrinologie Moléculaire et Oncologique*

de l'Université Laval et Centre de Recherche sur les Maladies Lipidiques de l'Université Laval, Quebec, QC, Canada, May 14-15, 2007.

430. Ferland, A, Tranchant M, Plourde M, Soucy P, INHERIT BRCAs, Simard J (2007) **Caractérisation des variants de séquence du gène encodant la 17b-hydroxystéroïde-déshydrogénase de type 5 chez les femmes Canadiennes-françaises atteintes d'un cancer du sein provenant de familles à risque élevé**. (Poster) *9e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 29, 2007.

431. Guénard F, Labrie Y, Ouellette G, Joly-Beauparlant C, INHERIT BRCAs, Simard J, Durocher F (2007) **Germline mutations in *BRIP1/FANCJ* are rare in non-*BRCA1/BRCA2* French Canadian Breast Cancer Families**. (Poster) *HMG2007, HUGO's 12th Human Genome Meeting*, Montreal, QC, Canada, May 21-24, 2007.

432. Guénard F, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2007) **Analyse mutationnelle du gène de susceptibilité au cancer du sein *BRIP1/FANCJ* chez des familles Canadiennes Françaises à risque élevé**. (Poster) *Journées ENDOMOL 2007, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval et Centre de Recherche sur les Maladies Lipidiques de l'Université Laval*, Quebec, QC, Canada, May 14-15, 2007.

433. Guénard F, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2007) **Analyse mutationnelle du gène de susceptibilité au cancer du sein *BRIP1/FANCJ* chez des familles Canadiennes Françaises à risque élevé**. (Poster) *9e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 29, 2007.

434. Joly-Beauparlant C, Desjardins S, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2007) **Analyse des variants de sequence de NBS1 chez des familles Canadiennes-Françaises à risqué élevé de cancer du sein**. (Poster) *Journées ENDOMOL 2007, Centre de Recherche en Endocrinologie Moléculaire et Oncologique de l'Université Laval et Centre de Recherche sur les Maladies Lipidiques de l'Université Laval*, Quebec, QC, Canada, May 14-15, 2007.

435. Joly-Beauparlant C, Desjardins S, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2007) **Analyse des variants de sequence de NBS1 chez des familles Canadiennes-Françaises à risqué élevé de cancer du sein**. (Poster) *9e Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 29, 2007.

436. Antoniou AC, Sinilnikova OM, Simard J, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, GEMO, Rebbeck TR, MAGIC, Godwin A, Jakubowska A, Peock S, EMBRACE, Schmutzler RK, kConFaB, Offit K, Friedman E, Rennert G, Andrulis IL, Hogervorst F, Devilee P, Greene MH, Benìtez J, Szabo CI, Nevanlina H, Hamann U, Arason A, Radice P, Caligo M, Borg A, Lindblom A, Gerdes AM, Couch F, Easton DF, Chenevix-Trench G on behalf of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) (2007) **Identification of modifiers of BRCA1/2: results from combined analysis from the Consortium of Investigators of Modifiers of *BRCA1/2***. (Oral) *Genemappers 2007*, Brisbane, Autralia, August 29-31, 2007.

437. Antoniou AC, Sinilnikova OM, Simard J, Léoné M, Dumont M, Neuhausen SL, Struewing JP, Stoppa-Lyonnet D, Barjhoux L, Hughes DJ, Coupier I, Belotti M, Lasset C, Bonadona V, Bignon YJ, GEMO, Rebbeck TR, Wagner T, Lynch HT, Domchek SM, Nathanson KL, Garber JE, Weitzel J, Narod SA, Tomlinson G, Olopade OI, Godwin A, Isaacs C, Jakubowska A, Lubinski J, Gronwald J, Górski B, Byrski T, Huzarski T, Peock S, Cook M, Baynes C, Gray J, Daly PA, Dorkins H, EMBRACE, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Niederacher D, Deissler H, Spurdle AB, Chen X, Waddell N, Cloonan N, kConFab, Kirchhoff T, Offit K, Friedman E, Kaufmann B, Laitman Y, Galore G, Rennert G, Lejbkowicz F, Raskin L, Andrulis IL, Ilyushik E, Ozcelik H, Devilee P, Wreeswijk MPG, Greene MH, Prindiville SA, Osorio A, Benítez J, Zikan M, Szabo CI, Kilpivaara O, Nevanlina H, Hamann U, Durocher F, Arason A, Couch FJ, Easton DF, Chenevix-Trench G on behalf of the Consortium of Investigators of Modifiers of *BRCA1/2*. (2007) ***RAD51* 135G>C modifies breast cancer risk among *BRCA2* mutation**

carriers: results from a combined analysis of 19 studies. (Oral) *2007 Annual Meeting of The American Society of Human Genetics*, San Diego, California, USA, October 23-27, 2007.

438. Durocher F, Guénard F, Desjardins S, Labrie Y, Ouellette G, Joly Beauparlant C, Dumont M, INHERIT BRCAs, Simard J (2008) **Evaluation of candidate breast cancer susceptibility genes among French Canadian families with high risk of breast cancer**. (Oral) *Canadian Breast Cancer Alliance – Reasons for Hope 2008,* Vancouver, BC, Canada, April 25-27, 2008.

439. Ferland A, Plourde M, Soucy P, Tranchant M, Durocher F, INHERIT BRCAs, Simard J (2008) **Mutation analysis and sequence variant characterization of candidate genes involved in sex steroid synthesis and metabolism, in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer**. (Poster) *Canadian Breast Cancer Alliance – Reasons for Hope 2008,* Vancouver, BC, Canada, April 25-27, 2008.

440. Desjardins S, Joly Beauparlant C, Labrie Y, Ouellette G, Labuda D, Simard J, INHERIT BRCAs Durocher F (2008) **Role of NBN/NBS1 sequence variants in high-risk breast cancer families of French Canadian origin**. (Poster) *1st Annual Canadian Human Genetics Conference*, Quebec, QC, Canada, April 9-12, 2008.

441. Guénard F, Joly Beauparlant C, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2008) **Evaluation of the contribution of the breast cancer susceptibility gene *FANCJ* in non-*BRCA1/BRCA2* French Canadian families with high risk of breast cancer**. (Poster) *1st Annual Canadian Human Genetics Conference*, Quebec, QC, Canada, April 9-12, 2008.

442. Joly Beauparlant C, Desjardins S, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2008) **Analyses of sequence and splicing variants of the FANCC gene in a cohort of French Canadian women with high-risk of breast and ovarian cancer**. (Poster) *1st Annual Canadian Human Genetics Conference*, Quebec, QC, Canada, April 9-12, 2008.

443. Joly Beauparlant C, Desjardins S, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2008) **Analyse de la contribution des variants de séquence et d'épissage du gène FANCC chez des familles canadiennes-françaises à risque élevé pour le cancer du sein**. (Poster) *7ièmes Journées génétiques RMGA*, Quebec, QC, Canada, May 14-16, 2008.

444. Desjardins S, Joly Beauparlant C, Labrie Y, Ouellette G, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2008) **Le risque de cancer du sein chez les familles à risque élevé québécoises: implication des variants de séquences de NBN/NBS1**. (Poster) *7ièmes Journées génétiques RMGA*, Quebec, QC, Canada, May 14-16, 2008.

445. Guénard F, Beauparlant C, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2008) **Implication de FANCJ dans la susceptibilité génétique au cancer du sein chez les familles à risque élevé canadiennes-françaises**. (Poster) *7ièmes Journées génétiques RMGA*, Quebec, QC, Canada, May 14-16, 2008.

446. Joly Beauparlant C, Desjardins S, Ouellette G, Labrie Y Simard J, INHERIT BRCA, Durocher F (2008) **Étude des variants de séquence et d'épissage du gène FANCC sur la susceptibilité au cancer du sein chez des familles canadiennes-françaises à risque élevé**. (Poster) *10ième Journée de la recherche, Faculté de médecine, Université Laval,* Quebec, QC, Canada, May 27, 2008.

447. Guénard F, Joly Beauparlant C, Ouellette G, Labrie Y, Labuda D, Simard J, INHERIT BRCAs, Durocher F (2008) **Risque de cancer du sein chez les familles canadiennes françaises à risque élevé: Implication du gène FANCJ**. (Poster) *10ième Journée de la recherche, Faculté de médecine*, Université Laval, Quebec, QC, Canada, 27 May 2008.

448. Desjardins S, Joly Beauparlant C, Labrie Y, Ouellette G, Simard J, INHERIT BRCAs, Durocher F (2008) **Implication des variants de séquences de NBN/NBS1 dans la susceptibilité au cancer du sein**. (Poster) *10ième Journée de la recherche, Faculté de médecine*, Université Laval, Quebec, QC, Canada, May 27, 2008.

449. Dorval M, Bouchard K, Maunsell E, Camden S, Simard J (2008) **Perceived impact of BRCA1/2 testing on familial relationships and association with psychological distress**. (Abstract) *European Journal of Human Genetics*. 16 (Suppl 2): 459.

450. Dorval M, Bouchard K, Côté C, Camden S, Simard J. (2009) **Long-term stability of knowledge acquired during genetic counselling for breast/ovarian cancer susceptibility**. (Abstract) *Current Oncology*. 16; 355.

451. Bouchard K, Badaroudine F, Chiquette J, Plante M, Maunsell E, Camden S, Simard J, INHERIT BRCAs, Dorval M (2009) **Psychological distress in women initiating BRCA1/2 genetic testing: Comparison with control population**. (Poster) *11th International Meeting on Psychosocial Aspects of Genetic Testing for Hereditary Cancer, Canadian Association of Psychosocial Oncology*, Toronto, ON, Canada, April 23-24, 2009.

452. Bouchard K, Dubé M, Chiquette J, Plante M, Maunsell E, Camden S, Simard J, INHERIT BRCAs, Dorval M (2009) **Health behaviours in women initiating BRCA1/2 genetic testing: Comparison with control population**. (Poster) *11th International Meeting on Psychosocial Aspects of Genetic Testing for Hereditary Cancer, Canadian Association of Psychosocial Oncology*, Toronto, ON, Canada, April 23-24, 2009.

453. Dorval M, Bouchard K, Côté C, Camden S, Simard J (2009) **Long-term stability of knowledge acquired during genetic counselling for breast/ovarian cancer susceptibility**. (Abstract) 16:355. *11th International Meeting of Psychosocial Aspects of Genetic Testing for Hereditary Cancer, Canadian Association of Psychosocial Oncology*, Toronto, ON, Canada, April 23-24, 2009.

454. Lapointe J, Abdous B, Camden S, Bouchard K, Simard J, Dorval M (2009) **Family cluster effect on psychosocial variables in families at high risk for hereditary breast/ovarian cancer**. (Poster) *11th International Meeting on Psychosocial Aspects of Genetic Testing for Hereditary Cancer, Canadian Association of Psychosocial Oncology*, Toronto, ON, Canada, April 23-24, 2009.

455. Lapointe J, Abdous B, Camden S, Bouchard K, Simard J, Dorval M (2009) **Effet de plan dans la mesure de variables psychosociales chez les familles canadiennes-françaises à haut risque de cancer héréditaire du sein et de l'ovaire**. (Poster) *9e édition de la Journée recherche de la Faculté de pharmacie de l'Université Lava*l, Quebec, QC, Canada, April 15, 2009.

456. Lapointe J, Bouchard K, Simard J, Dorval M (2009) **Family Communication following BRCA1/2 Genetic Testing: Project Overview**. (Oral) *Meeting of the CIHR Team in Familial Risks of Breast Cancer*. Quebec, QC, Canada, April 14-15, 2009.

457. Lapointe J, Abdous B, Camden S, Bouchard K, Simard J, Dorval M (2009) **Effet de plan dans la mesure de variables psychosociales chez les familles canadiennes-françaises à haut risque de cancer héréditaire du sein et de l'ovaire**. (Poster) *20e Journée hospitalo-universitaire du CHA*, Quebec, QC, Canada, May 21, 2009.

458. Lapointe J, Abdous B, Camdem S, Bouchard K, Simard J, Dorval M (2009) **Family cluster effect on psychosocial variables in families at high risk for hereditary breast/ovarian cancer**. (Abstract) Published in March 2010. *Chronic Diseases in Canada (CDIC) Journal*. 30(2). *The Canadian Society of Epidemiology and Biostatistics National Student Conference*, Ottawa, ON, Canada, May 23-24, 2009.

459. Lapointe J, Abdous B, Camdem S, Bouchard K, Simard J, Dorval M (2009) **Family cluster effect on psychosocial variables in families at high risk for hereditary breast/ovarian cancer**. (Poster) *The Canadian Society of Epidemiology and Biostatistics National Student Conference*, Ottawa, ON, Canada, May 23-24, 2009.

460. Joly Beauparlant C, Desjardins S, Ouellette G, Labrie Y, Simard J, INHERIT BRCAs, Durocher F (2009) **Le gène FANCC et le cancer du sein: Analyse des variants de séquence et d'épissage chez des familles canadiennes-françaises à risque élevé**. (Poster) 11ième Journée de la recherche, Faculté de médecine, Université Laval, Quebec, QC, Canada, June 2, 2009.

461. Hamdi Y, Ferland A, Soucy P, Tranchant M, Simard J (2009) **Caractérisation des variants de séquence du gène encodant la 17B-hydroxystéroïde déshydrogénasede type 5 chez des femmes atteintes d'un cancer du sein provenant de familles à risque élevé**. (Poster) *Club de Recherches Cliniques du Québec, 51^{e} réunion annuelle*, Quebec, QC, Canada, September 24-26, 2009.

462. Joly Beauparlant C, Desjardins S, Ouellette G, Labrie Y, Simard J, INHERIT BRCAs, Durocher F (2009) **Implication du gene FANCC dans la susceptibilité au cancer du sein: analyse de variants de séquence et d'épissage**. (Poster) *Club de Recherches Cliniques du Québec-51^{e} réunion annuelle,* Quebec, QC, Canada, September 24-26, 2009.

463. Larouche G, Bouchard K, Camden S, Simard J, Dorval M (2009) **Concordance entre deux mesures de perception du risque de cancer suite à un test *BRCA1/2***. (Poster) *Journée scientifique du 1er cycle de la Faculté de médecine et des sciences de la santé (FMSS) de l'Université de Sherbrooke*, Sherbrooke, QC, Canada, September 25, 2009.

464. Dorval M, Bouchard K, Côté C, Camden S, Simard J (2009) **Long-term stability of knowledge acquired during genetic counseling for breast/ovarian cancer susceptibility**. (Abstract) *Current Oncology,* 16(5), 103. *The Third International Symposium on hereditary breast and ovarian cancer*, Montreal, QC, Canada, October 14-16, 2009.

465. Dorval M, Bouchard K, Côté C, Camden S, Simard J (2009) **Long-term stability of knowledge acquired during genetic counseling for breast/ovarian cancer susceptibility**. (Poster) *The Third International Symposium on hereditary breast and ovarian cancer*, Montreal, QC, Canada, October 14-16, 2009.

466. Jbilou J, Côté S, Mathieu M, Blouin-Bougie J, Amara N, Landry R, Simard J (2009) **Familial Genetic Risk for Breast Cancer Risk Prediction and Risk Communication: Health professionals' perspective**. (Oral) Annual meeting of the CIHR Team on Familial Genetic Risk for Breast Cancer, Quebec, QC, Canada, October 15, 2009.

467. Dorval M, Noguès C, Logeat C, Berthet P, Chiquette J, Gauthier-Villars M, Lasset C, Picard C, Plante M, INHERIT BRCAs, GENEPSO Cohort, Simard J, Julian Reynier C (2010) **Two-year follow-up of breast and ovarian cancer screening practices of non-carriers from BRCA-mutation positive families: a comparative study between France and Quebec**. (Poster) *European Meeting of Psychosocial Aspects of Genetics (EMPAG)*, Gothenburg, Sweden, June 12-15, 2010.

468. Hamdi Y, Ferland A, Soucy P, Tranchant M, Simard J (2010) **Caractérisation des variants de séquence du gène encodant la 17B-hydroxystéroïde déshydrogénase de type 5 chez des femmes atteintes d'un cancer du sein provenant de familles à risque élevé**. (Poster) *Journées génétiques 2010, Réseau de médecine génétique appliquée (RMGA)*, Quebec, QC, Canada, May 3-5, 2010.

469. Hamdi Y, Soucy P, Tranchant M, Reimnitz G, Dubois S, Simard J (2010) **Modificateurs de risque du cancer du sein chez les porteuses de mutations dans les gènes BRCA1/2 : Rôle des polymorphismes fonctionnels de la région promotrice des gènes candidats**. (Poster) *Journées scientifiques du Centre de recherche en Endocrinologie moléculaire et oncologique et en Génomique Humaine (CREMOGH) et de l'Axe Endocrinologie et Génomique,* Quebec, QC, Canada, October 28-29, 2010.

470. Jbilou J, Landry R, Amara N, Simard J (2010) **Risk Prediction and Risk Communication for Familial Genetic Risk for Breast Cancer: Health professionals' perspective**. (Poster) EACH 2010 '*International Conference on Communication in Healthcare*', Verona, Italy, September 7, 2010.Lapointe J, Abdous B, Camden S, Bouchard K, Simard J, Dorval M (2010) **Effet de plan dans la mesure de variables psychosociales chez les familles canadiennes-françaises à haut risque de cancer héréditaire du sein et de l'ovaire**. (Abstract) *Revue d'Épidémiologie et de Santé Publique*. 58(Supp.2) A1-4, published in September 2010. Quebec, QC, Canada, September 15-17, 2010.

471. Lapointe J, Bouchard K, Simard J, Dorval M (2010) **Incidence and correlates of positive and negative effects of *BRCA1/2* genetic testing on familial relationships: A three-year follow-up study**. (Abstract)

Psycho-Oncology.19 (Supp.2) A-51, published on May 20, 2010. *IPOS 12th World Congress/CAPO*, Quebec, QC, Canada, May 25-27, 2010.

472. Lapointe J, Bouchard K, Simard J, Dorval M (2010) **Incidence and correlates of positive and negative effects of BRCA1/2 genetic testing on familial relationships: A three-year follow-up study**. (Oral) *PORT Annual Meeting*. Quebec, QC, Canada, May 25, 2010.

473. Lapointe J, Abdous B, Camden S, Bouchard K, Simard J, Dorval M (2010) **Effet de plan dans la mesure de variables psychosociales chez les familles canadiennes-françaises à haut risque de cancer héréditaire du sein et de l'ovaire**. (Abstract) *Revue d'Épidémiologie et de Santé Publique*. 58(Supp.2) A1-4, published in Septembre 2010. Quebec, QC, Canada, September 15-17, 2010.

474. Lapointe J, Abdous B, Camden S, Bouchard K, Simard J, Dorval M (2010) **Effet de plan dans la mesure de variables psychosociales chez les familles canadiennes-françaises à haut risque de cancer héréditaire du sein et de l'ovaire**. (Oral) *IVème Congrès International d'Épidémiologie «Du Nord au Sud» & XVème actualités du Pharo*. Marseille, France, September 15, 2010.

475. Larouche G, Bouchard K, Camden S, Simard J, Dorval M (2010) **Concordance entre deux mesures de perception du risque de cancer suite à un test de prédisposition génétique au cancer du sein (*BRCA1/2*)**. (Poster) *Journée de la recherche de la Faculté de pharmacie de l'Université Laval*, Quebec, QC, Canada, April 13, 2010.

476. Jbilou J, Amara N, Landry R, Simard J (2011) **Genetic counseling for familial breast cancer: From theory to practice and the other way back!** (Oral) *2nd Annual meeting of the CIHR Team on Familial Genetic Risk for Breast Cancer*, Quebec, Canada, March 21, 2011.

477. Larocque M, Jbilou J, Amara N, Landry R, Simard J (2011) **Preventing breast cancer among women with low literacy level: A scoping review of the literature**. (Poster) *22ème Concours des jeunes chercheuses et chercheurs FESR*, March 23, 2011, Quebec, QC, Canada. (Winner of the 2nd price of the best research project + grant for attendance to ACFAS 2011).

478. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Validité des données auto-rapportées sur l'utilisation de la mammographie chez des femmes testées pour les gènes *BRCA1/2***. (Oral) *Conférence des étudiants de l'Unité de recherche en santé des populations (URESP)*, Quebec, QC, Canada, March 29, 2011.

479. Larouche G, Bouchard K, Côté C, Camden S, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following BRCA1/2 genetic testing may be overestimated**. (Poster) *12th International meeting on psychosocial aspects of hereditary cancer (IMPAHC)*, Amsterdam, The Netherlands, April 27-29, 2011.

480. Larouche G, Bouchard K, Côté C, Camden S, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following *BRCA1/2* genetic testing may be overestimated**. (Abstract) *Familial Cancer*. 2011.10(Suppl 2):S94, published April 1, 2011, *12th International meeting on psychosocial aspects of hereditary cancer (IMPAHC)*, Amsterdam, The Netherlands, April 27-29, 2011.

481. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Validité des données auto-rapportées sur l'utilisation de la mammographie chez des femmes testées pour les gènes BRCA1/2** / **Self-reported mammography use following *BRCA1/2* genetic testing may be overestimated.** (Poster) *Journée de la recherche de la Faculté de pharmacie de l'Université Laval*, Quebec, QC, Canada, April 21, 2011.

482. Lapointe J, Bouchard K, Godard B, Chiquette J, Simard J, Dorval M (2011) **Cancer-related life events may facilitate family communication of genetic information following *BRCA1/2* testing**. (Abstract) *Familial Cancer*. 2011-10(Suppl 2):S94, published on April 1, 2011. *12th International meeting on psychosocial aspects of hereditary cancer (IMPAHC)*, Amsterdam, The Netherlands, April 27-29, 2011.

483. Lapointe J, Bouchard K, Godard B, Chiquette J, Simard J, Dorval M (2011) **Cancer-related life events may facilitate family communication of genetic information following *BRCA1/2* testing**. (Poster) *Annual Conference of the Canadian Association of Psychosocial Oncology*, Toronto, ON, Canada, May 4-6, 2011.

484. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following *BRCA1/2* genetic testing may be overestimated**. (Poster) *Annual Conference of the Canadian Association of Psychosocial Oncology*, Toronto, ON, Canada, May 4-6, 2011.

485. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following *BRCA1/2* genetic testing may be overestimated.** (Poster) *Journée hospitalo-universitaire du Centre hospitalier affilié universitaire de Québec*, Quebec, QC, Canada, May 19, 2011.

486. Hamdi Y, Soucy P, Goldgar D, Feng BJ, Reimnitz G, Tranchant M, Sinilnikova O, Simard J (2011) **Gènes modificateurs de risque du cancer du sein chez les porteuses de mutations dans les gènes BRCA1/2 : Rôle des polymorphismes fonctionnels de la région promotrice des gènes candidats**. (Poster) *13ième Journée annuelle de la recherche, Faculté de médecine*, Université Laval, Quebec, QC, Canada, June 9, 2011.

487. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following BRCA1/2 genetic testing may be overestimated**. (Poster) *Canadian Society for Epidemiology & Biostatistics; National Student Conference*, Montreal, QC, Canada, June 19-20, 2011.

488. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following BRCA1/2 genetic testing may be overestimated**. (Abstract) *Journal of population therapeutics and clinical pharmacology. 2011,* 19 May 18(2):e300. Colloque annuel *Réseau Québécois de Recherche sur l'usage des médicaments (RQRUM)*, Montreal, QC, Canada, May 19, 2011.

489. Larouche G, Bouchard K, Desbiens C, Simard J, Chiquette J, Dorval M (2011) **Self-reported mammography use following BRCA1/2 genetic testing may be overestimated**. (Poster) Colloque annuel *Réseau Québécois de Recherche sur l'usage des médicaments (RQRUM)*, Montreal, QC, Canada, June 1-2, 2011.

490. Hamdi Y, Soucy P, Goldgar D, Feng BJ, Reimnitz G, Tranchant M, Sinilnikova O, Simard J (2011) **Gènes modificateurs de risque du cancer du sein chez les porteuses de mutations dans les gènes *BRCA1/2* : Rôle des polymorphismes fonctionnels de la région promotrice des gènes candidats**. (Poster) *Club de Recherches Cliniques du Québec-53ième réunion annuelle* (CRCQ), Ste-Adèle, QC, Canada, September 22-24, 2011.

491. Antoniou AC, Mulligan AM, Couch FJ, Barrowdale D, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Robson M, Sherman M, Spurdle AB, Wappenschmidt B, McGuffog L, Simard J, Chenevix-Trench G, Easton DF, Andrulis IL on behalf of CIMBA (2011) **Common breast cancer susceptibility alleles are associated with tumor subtypes in *BRCA1* and *BRCA2* mutation carriers: results from the Consortium of Investigators of Modifiers of *BRCA1/2***. (Oral) *12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, October 11-15, 2011.

492. Couch FJ, Gaudet MM, Antoniou AC, Ramus SJ, Kuchenbacker K, Soucy P, Beesley J, Wang X, Kirchhoff T, McGuffog L, Barrowdale D, Sinilnikova OM, Goldgar D, Peock S, Wappenschmidt B, Hogervorst F, Jakubowska A, Neuhausen SL, Borg A, Gerdes AM, Osório A, Andrulis IL, Domchek SM, Radice P, Easton DF, Chenevix-Trench G, Offit K, Simard J on behalf of CIMBA. (2011) **Common variation at the *C19orf62* and *ZNF365* loci is associated with breast and ovarian cancer risk in *BRCA1* and *BRCA2* mutation carriers** (Oral) *12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, October 11-15, 2011.

493. Hamdi Y, Soucy P, Goldgar D, Feng BJ, Reimnitz G, Tranchant M, Pastinen T, Cassart P, Ouimet M, Sinnett D, Verny-Pierre C, Barjhoux L, Stoppa-Lyonnet D, GEMO Study Collaborators, Sinilnikova O, Simard J (2011) **Identification of functional polymorphisms at the 4q21 locus associated with modification of breast cancer risk in *BRCA2* mutation carriers**. (Poster) *12th International Congress of Human Genetics / 61st Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, October 11-15, 2011.

494. Jbilou J, Landry R, Amara N, Simard J (2011) **Improving quality of genetic counseling for familial risk for breast cancer: A systematic review of the literature**. (Poster) *12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, October 11-15, 2011.

495. Ramus SJ, Antoniou AC, Kuchenbaecker K, Soucy P, McGuffog L, Healey S, Sinilnikova OM, Radice P, Goldgar D, Peock S, Schmutzler R, Stoppa-Lyonnet D, Rookus M, Jakubowska A, kConFab, Simard J, Easton DF, Couch FJ, Chenevix-Trench G on behalf of the Consortium of Investigators of Modifiers of BRCA1/2 (2011) **Ovarian cancer susceptibility loci and risk of ovarian cancer in *BRCA1* and *BRCA2* carriers**. (Oral) *12th International Congress of Human Genetics/61st Annual Meeting of The American Society of Human Genetics*, Montreal, QC, Canada, October 11-15, 2011.

496. Dorval M, Foulkes W, Hamet P, Chiquette J, Simard J, Wong N, Côté S, El Haffaf Z, Rhéaume J, Pelletier S (2012) **Cancer Screening practices of non-carriers from BRCA1/2 mutation-positive families: Study protocol**. (Abstract) *Current Oncology* 2012; 19(2):e90. *4th International Symposium on Hereditary Breast and Ovarian Cancer: From Theory to Practice*, Montreal, QC, Canada, April 25-27, 2012.

497. Dorval M, Foulkes W, Hamet P, Chiquette J, Simard J, Wong N, Côté S, El Haffaf Z, Rhéaume J, Pelletier S (2012) **Cancer Screening practices of non-carriers from BRCA1/2 mutation-positive families: Study protocol**. (Poster) *4th International Symposium on Hereditary Breast and Ovarian Cancer: From Theory to Practice*, Montreal, QC, Canada, April 25-27, 2012.

498. Hamdi Y, Soucy P, Goldgar D, Feng B-J, PastinenT, Reimnitz G, Tranchant M, Dumont M, Dubois S, Sinnett D, Cassart P, Ouimet M, Leclerc M, Lakhal Chaieb MHL, Stoppa-Lyonnet D, Verny-Pierre C, Barjhoux L, GEMO Study Collaborators, Sinilnikova O, Simard J (2012) (Poster) **New Putative Functional Polymorphisms at the 4q21 Locus Associated With Modification of Breast and Ovarian Cancer Risk in BRCA2 Mutation Carriers**. *4th International Symposium on Hereditary Breast and Ovarian Cancer: From Theory to Practice*, Montreal, QC, Canada, April 25-27, 2012.

499. Lapointe J, Bouchard K, Godard B, Chiquette J, Simard J, Dorval M (2012) **Cancer-related life events may facilitate family communication of genetic information following BRCA1/2 testing**. (Poster) *Journée de la recherche de la Faculté de Pharmacie de l'Université Laval*. Quebec, QC, Canada, April 12, 2012.

500. Larouche G, Côté C, Simard J, Desbiens C, Chiquette J, Dorval M (2012) **Use of Quebec Health Insurance Board (RAMQ) data to assess adherence to screening recommendations following BRCA1/2 testing**. (Poster) *Journée de la recherche de la Faculté de Pharmacie de l'Université Laval*. Quebec, QC, Canada, April 12, 2012.

501. Larouche G, Côté C, Simard J, Desbiens C, Chiquette J, Dorval M (2012) **Use of Quebec Health Insurance Board (RAMQ) data to assess adherence to screening recommendations following BRCA1/2 testing**. (Abstract) *Current Oncology* 2012;19(2):e91, April 25-27, 2012.

502. Larouche G, Côté C, Simard J, Desbiens C, Chiquette J, Dorval M (2012) **Use of Quebec Health Insurance Board (RAMQ) data to assess adherence to screening recommendations following BRCA1/2 testing**. (Poster) *4th International Symposium on Hereditary Breast and Ovarian Cancer: From Theory to Practice*. Montreal, QC, Canada, April 25-27, 2012.

503. Larouche G, Bouchard K, Camden S, Simard J, Dorval M (2012) **Using two complementary approaches to assess lifetime breast cancer risk perception may be relevant**. (Poster) *Annual conference of the Canadian Association of Psychosocial Oncology (CAPO)*. Vancouver, BC, Canada, April 25-27, 2012.

504. Larouche G, Côté C, Simard J, Desbiens C, Chiquette J, Dorval M (2012) **Potentiel des données de la RAMQ pour décrire la prise en charge suite au test génétique BRCA1/2**. (Oral) *Conférence des étudiants de l'Unité de recherche en santé des populations (URESP)*. Quebec, QC, Canada, April 3, 2012.

505. Larouche G, Côté C, Simard J, Desbiens C, Chiquette J, Dorval M (2012) **Use of Quebec Health Insurance Board (RAMQ) data to assess adherence to screening recommendations following BRCA1/2 testing**. (Poster) *Journée hospitalo-universitaire du centre de recherche affilié universitaire de Québec*; Quebec, QC, Canada, May 17, 2012.

506. Simard J, Antoniou A, Easton D, Chenevix-Trench G on behalf of CIMBA (2012) **Genetic Modifies of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers**. (Oral) *RMGA Journées génétiques*, Montreal, QC, Canada, May 22-24, 2012.

507. Wang X, McGuffog L, Lee A, Gaudet MM, Kuchenbaecker KB, Soucy P, Simard J, Offit K, Easton DF, Chenevix-Trench, Couch FJ, Consortium of Investigators of Modifiers of BRCA1/2 (2012) **Genome-wide association in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.** (Oral) *ASHG 2012 Annual Meeting*, San Francisco, CA, USA, November 5-9, 2012.

508. Kuchenbaecker K, Gaudet M, Vijai J, Klein R, Kirchhoff T, McGuffog L, Barrowdale D, Dunning A, Lee A, Hall P, Couch F, Simard J, Altshuler D, Easton D, Chenevix-Trench G, Antoniou A, Offit K, Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) Collaborators (2012) **Identification of the first locus to modify breast cancer risk specifically in BRCA2 mutation carriers**. (Oral) *ASHG 2012 Annual Meeting*, San Francisco, USA, November 5-9, 2012.

509. Couch J, Garcia-Closas M, Lindstrom S, Michailidou K, Schmidt MK, Brook M, Orr N, Slager S, Hunter DJ, Simard J, Benitez J, Dunning A, Sherman ME, Chenevix-Trench G, Chanock SJ, Hall P, Pharoah P, Vachon C, Easton DF, Haiman CA, Kraft P for BPC3 TNBCC, and BCAC (2012) **1150T Genome-wide association studies ifentify four novel ER-negative specific breast cancer risk loci**. (Oral) *ASHG 2012 Annual Meeting*, San Francisco, CA, USA, November 5-9, 2012.

510. Dorval M, Foulkes W, Hamet P, Chiquette J, Simard J, Larouche G, Wong N, Côté S, El Haffaf Z, Rhéaume J, Pelletier S (2013) **Cancer screening practices of non-carriers from BRCA1/2 mutation-positive families: Study protocol**. (Poster) *CAPO (Canadian Association of Psychosocial Oncology)*, Ottawa, ON, Canada, April 24-26, 2013.

511. Leclerc M, Lakhal-Chaieb L, Simard J (2013) **Ascertainment-adjusted SNP-breast cancer association analysis of correlated age-at-onset outcomes in BRCA1/2 data with non-proportional hazards**. (Poster) 2e Réunion canadienne sur la génétique humaine et la génétique statistique (*2nd Canadian Human and Statistical Genetics Meeting*), Estérel, Quebec, QC, Canada, April 21-24, 2013.

512. Leclerc J, Bouchard K, Chiquette J, Simard J, Dorval M (2013) **Utilisation en ligne de modèles de prédiction du risque de cancer du sein: Point de vue de femmes ayant une histoire familiale**. (Poster) *81e Congrès de l'Association francophone pour le savoir : Savoirs sans frontières*, Quebec, QC, Canada, May 6-10, 2013.

513. Renault AL, Tavtigian S, Lesueur F, Le Calvez-Kelm F, Dumont M, Tranchant M, Reimnitz G, The Breast Cancer Family Registry, Simard J (2013) **Association entre les variants rares du gène *Abraxas* et la susceptibilité au cancer du sein : une étude cas/contrôles**. (Poster) *Journée annuelle de la recherche de la Faculté de médecine 2013*, Université Laval, Quebec, QC, Canada, May 30, 2013.

514. Larouche G, Chiquette J, Plante M, Simard J, Dorval M (2013) **Why is it so challenging to have data about the uptake of screening and risk reduction measures in BRCA1/2 mutation carriers in Canada?**

(Poster) *Journée scientifique des étudiants du Centre de recherche sur le cancer / Axe oncologie*, Quebec, QC, Canada, August 21-22, 2013.

515. Larouche G, Chiquette J, Plante M, Simard J, Dorval M (2013) **Limited usefulness of public health insurance administrative databanks to assess clinical management of BRCA1/2 mutation carriers in Canada**. (Poster) *Colloque Annuel du Regroupement Québécois de Recherche sur l'Usage des Médicaments (RQRUM)*, Montreal, QC, Canada, September 17-18, 2013.

516. Larouche G, Chiquette J, Plante M, Simard J, Dorval M (2013) **Limited usefulness of public health insurance administrative databanks to assess clinical management of BRCA1/2 mutations carriers in Canada**. (Abstract) *J Popul Ther Clin Pharmacol.* 2013; 20(3):3266-e304, September 12, 2013.

517. Amos CI, Antoniou AC, Berchuck A, Chenevix-Trench G, Couch FJ, Eeles RA, Esserman LJ, Gayther SA, Goh CL, Goldgar DE, Gruber SB, Haiman CA, Hall P, Hunter DJ, Kote-Jarai Z, Lepage PK, Lindstrom S, McKay J, Milne RL, Peters U, Pharaoh PD, Phelan CM, Schumacher FR, Sellers TA, Simard J, Wang Z, Seminara D, Chanock SJ, Easton DF, Henderson BE (2013) **A comprehensive genetic analysis of common cancer risk through the development of the GAME-ON Oncochip.** (Oral) Presenter: Amos CI. *63rd Annual Meeting of the American Society of Human Genetics,* Boston, Massachusetts, USA, October 22-26, 2013.

518. Simard J on the behalf of the *Personalised Risk Stratification for Prevention and Early Detection* Project. (2013) **Towards a Comprehensive Understanding of the Inherited Genetic Suceptibility to Breast Cancer**. (Oral) *Canadian Cancer Research Conference (CCRA)*, Toronto, ON, Canada, November 4-6, 2013.

519. Joly Y and Simard J (2013) **Cancer genomics: Access to genetic information by life insurers.** (Oral) *Canadian Cancer Research Conference* (CCRA), Toronto, ON, Canada, November 4-6, 2013.

520. Leclerc J, Bouchard K, Chiquette J, Larouche G, Glendon G, Maugard CM, Simard J, Dorval M (2013) **Online Use of Breast Cancer Risk Prediction Tools: Views of Women With a Family History of Breast Cancer**. (Poster) *Canadian Cancer Research Conference* (CCRA), Toronto, ON, Canada, November 5, 2013.

521. Leclerc J, Bouchard K, Simard J, Dorval M (2014) **Profilage génétique et cancer du sein : Attitudes des femmes de la population générale**. (Poster) *14e Journée de la Recherche de la Faculté de Pharmacie de l'Université Laval*, Quebec, QC, Canada, April 17, 2014.

522. Guedaoura S, Pelletier S, Foulkes W, Hamet P, Chiquette J, Wong N, El Haffaf Z, Simard J, Dorval M (2014) **Do BRCA1/2 non-carriers contribute to their doctors' awareness of their genetic status and does this influence their own follow-up?** (Poster) *5th International Symposium on Hereditary Breast and Ovarian Cancer: Twenty Years of Advances*, Montreal, QC, Canada, April 23-25, 2014.

523. Leclerc J, Bouchard K, Chiquette J, Larouche G, Glendon G, Maugard CM, Simard J, Dorval M (2014) **Online Use of Breast Cancer Risk Prediction Tools: Views of Women With a Family History of Breast Cancer**. (Poster) *5th International Symposium on Hereditary Breast and Ovarian Cancer*, Montreal, QC, Canada, April 23-25, 2014.

524. Larouche G, Chiquette, J, Simard J, Dorval M (2014) **La fréquence de la mammographie n'est pas influencée par le test génétique BRCA1/2 chez les non-porteuses de mutations familiales**. (Poster) *Journée de la recherche de la Faculté de pharmacie de l'Université Laval,* Quebec, QC, Canada, April 17, l 2014.

525. Larouche G, Chiquette, J, Simard J, Dorval M (2014) **No Change in the Rate of Bilateral Mammographies After BRCA1/2 Testing Among True Non-Carriers**. (Poster) *5th International Symposium on Hereditary Breast and Ovarian Cancer*, Montreal, QC, Canada, April 23-25, 2014.

526. Larouche G, Chiquette, J, Simard J, Dorval M (2014) **No Change in the Rate of Bilateral Mammographies After BRCA1/2 Testing Among True Non-Carriers**. (Abstract) *Curr Oncol.* 2014;

21:e373 *5th International Symposium on Hereditary Breast and Ovarian Cancer*, Montreal, QC, Canada, April 23-25, 2014.

527. Larouche G, Chiquette, J, Simard J, Dorval M (2014) **No Change in the Rate of Bilateral Mammographies After BRCA1/2 Testing Among True Non-Carriers**. (Poster) *Canada's 3rd Applied Research in Cancer Control (ARCC) Conference,* Toronto, ON, Canada, May 11-12, 2014.

528. Leclerc M, Simard J, Lakhal-Chaieb L (2014) **Ascertainment-Adjusted SNP Set Analysis for Clustered Age-at-Onset Outcomes**. (Oral) *Société statistique du Canada* (SSC) 2014 Annual Meeting, Toronto, ON, Canada, May 25-28, 2014.

529. Gagnon J, Lévesque E, Knoppers BM, Lespérance B, Simard J (2014) **Risk Stratification of Women at Intermediate or High Risk of Breast Cancer: Developing a Consensus Framework for Screening & Prevention** (Poster) *18th SIS World Congress on Breast Healthcare*, Orlando, Floride, USA, October 16-19, 2014.

530. Renault A-L, Lesueur F, Soucy P, Hamdi Y, Coulombe Y, Gobeil S, Le Calvez-Kelm F, Vallée M, The Breast Cancer Family Registry, Hopper JL, Andrulis IL, Southey MC, John EM, Masson J-Y, Tavtigian SV, Simard J (2014) ***ABRAXAS* (*FAM175A*) and breast cancer susceptibility: no evidence of association in the Breast Cancer Family Registry** (Poster) *ASHG 2014*, San Diego, CA, USA, October 18-22, 2014.

531. Gagnon J, Lévesque E, Knoppers BM, Lespérance B, Simard J (2015) **Recommendations of the Clinical Advisory Committee on breast cancer screening and prevention in the context of risk stratification implementation: changes to come in current policies** (Poster) *ACMG Annual Clinical Genetics Meeting*, Salt Lake City, USA, March 25-27, 2015.

532. Simard J (2015) **Personalised Risk Stratification for Prevention and Early Detection of Breast Cancer (PERSPECTIVE)** (Oral) *18th Meeting of the Breast Cancer Association Consortium (BCAC*), Porto, Portugal, June 3-6, 2015.

533. Simard J (2015) **Functional regulatory SNPs in candidate genes and modification of breast and ovarian cancer risk in BRCA1/2 mutation carriers** (Oral) *16th Meeting of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)*, Porto, Portugal, June 8-9, 2015.

534. Edwards S, Dunning A, Michailidou K, Kuchenbaecker K, Thompson D, French J, Beesley J, Healy C, Kar S, Pooley K, Dicks E, Barrowdale D, Sinnott Armstrong N, Cowper-Sallari R, Hillman K, Kaufmann S, Sivakumaran H, Moradi Marjaneh M, Lopez-Knowles E, Dowsett M, Pharoah P, Simard J, Hall P, Garcia-Closas M, Vachon C, Chenevix-Trench G, Antoniou A, Easton D (2015) **Five independent 6q25 breast cancer risk variants regulate ESR1 and RMND1 and display genotype-phenotype correlations**. (Oral/Program # 5) *Annual Meeting of the American Society of Human Genetics (ASHG) 2015*, Baltimore, MD, USA, October 7, 2015.

535. Kuchenbaecker K, Simard J, Offit K, Couch F, Easton D, Chenevix-Trench G, Antoniou AC on behalf of CIMBA (2015) **Predicting breast and ovarian cancer risks for *BRCA1* and *BRCA2* mutation carriers using polygenic risk scores** (Abrégé) AACR Annual Meeting, 18-22 avril 2015.

536. Kuchenbaecker K, Simard J, Offit K, Couch F, Easton D, Chenevix-Trench G, Antoniou AC, on behalf of CIMBA (2015) **Predicting breast and ovarian cancer risks for female *BRCA1* and *BRCA2* mutation carriers using common genetic variants.** (Poster/Program # 2626T) *Annual Meeting of the American Society of Human Genetics (ASHG) 2015*, Baltimore, MD, USA, October 8, 2015.

537. Michailidou K, Lindstrom S, Dennis J, Simard J, Kraft P, Easton DF; on behalf of the Breast Cancer Association Consortium (BCAC), Discovery, Biology, and Risk of Inherited Variants in Breast Cancer (DRIVE) and PErsonalised Risk Stratification for Prevention and Early deteCTIon of breast cancer (PERSPECTIVE) (2015) **Meta-analysis of OncoArray, iCOGS and GWAS data from more than 220,000 women identifies more than 50 novel breast cancer susceptibility loci.** (Oral/Program # 3)

Annual Meeting of the American Society of Human Genetics (ASHG) 2015, Baltimore, MD, USA, October 7, 2015.

538. Ottini L, Lecarpentier J, Kuchenbaecker K, Thomassen M, Offit K, Schmutzler R, Couch F, Simard J, Easton D, Chenevix-Trench G, Antoniou AC on behalf of CIMBA (2015) **Common genetic variants modify breast and prostate cancer risks for male *BRCA1* and *BRCA2* mutation carriers: implications for risk prediction.** (Oral/Program # 8) *Annual Meeting of the American Society of Human Genetics (ASHG) 2015*, Baltimore, MD, USA, October 7, 2015.

539. Durand PJ, Bérubé MC, Simard J, Thériault P, De Koninck M, Glenn J, Blackburn R, Courtemanche J, Côté L (2015) **Production d'un Code de professionnalisme à la Faculté de médecine de l'Université Laval** (Oral) *2016 Canadian Conference on Medical Education (CCME) "Accountability from Self to Society"*, Montreal, QC, Canada, April 16-19, 2016.

540. Pouliot M-C, Joly-Beauparlant C, Labrie Y, Simard J, Droit A, Durocher F (2016) **RNA sequencing in High Risk French Canadian Breast Cancer Families** (Poster) *BRCA: Challenges and Opportunities, The Sixth International Symposium on Hereditary Breast and Ovarian Cancer*, Montreal, QC, May 10-13, 2016.

541. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, García-Closas M, Schmidt MK, Antoniou AC, Simard J, on behalf of the Breast Cancer Association Consortium (BCAC) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2016) **A GWAS including 30,882 estrogen receptor negative or *BRCA1* mutation-related breast cancer cases and 110,088 controls identifies 10 new susceptibility variants.** (Abstract) *Familial Aspects of Cancer Meeting*, Kingscliff, Australia, August 2016.

542. Feng B-J, Callis Duffin K, Krueger G, Kohlmann W, Schiffman J, Schmidt M, Meindl A, Berruti R, Schmutzler R, Hahnen E, Vallée M, Droit A, Easton D, Tavtigian S, Simard J and Goldgar D (2016) **VICTOR: a pipeline for Variant Interpretation in Clinical Testing or Research** (Poster) *TBC 2016 (Translational Bioinformatics Conference)*, Jeju Island, South Korea, October 15-17, 2016.

543. Beesley J, Kar S, McCue KI, Michailidou K, Kuchenbaecker KB, Fachal L, Glubb DM, Lemaçon A, Droit A, Soucy P, Dunning AM, French JD, Kraft P, Schmidt MK, Antoniou AC, Milne RL, Simard J, Easton DF, Edwards SL, Chenevix-Trench G, Consortium of Investigators of Modifiers of BRCA1/2 and Breast Cancer Association Consortium (2016) **Functional annotation of breast cancer risk-associated loci identified using the OncoArray.** (Oral – PgmNr 48) *2016 Annual Meeting of The American Society of Human Genetics (ASHG),* Vancouver, BC, October 19, 2016.

544. Feng B-J, Callis Duffin K, Krueger GG, Kohlmann W, Schiffman JD, Schmidt M, Meindl A, Berruti R, Schmutzler R, Hahnen E, Vallée M, Droit A, Easton DF, Tavtigian S, Simard J, Goldgar DE (2016) **VICTOR: A pipeline for Variant Interpretation in Clinical Testing Or Research** (Poster – PgmNr 1671) *2016 Annual Meeting of The American Society of Human Genetics (ASHG),* Vancouver, BC, October 21, 2016.

545. Lemaçon A, Allen J, Soucy P, Beesley J, Kraft P, Bader G, Dunning A, Michailidou K, Chenevix-Trench G, Milne R, Kuchenbaecker KB, Antoniou AC, Easton D, Simard J, Droit A, BCAC, CIMBA (2016) **Variant EXplOreR: Integrative environment for functional understanding of complex trait susceptibility loci. Application in breast cancer fine-mapping analysis.** (Poster 2824/W) *2016 Annual Meeting of The American Society of Human Genetics (ASHG),* Vancouver, BC, October 19, 2016.

546. Milne RL, Kuchenbaecker KB, Michailidou K, Beesley J, Kar S, Lindström S, Hui S, Lemaçon A, Soucy P, Droit A, Bader GD, Pharoah PDP, Couch FJ, Easton DF, Kraft P, Chenevix-Trench G, Garcia-Closas M, Schmidt MK, Antoniou AC, Simard J, on behalf of the Breast Cancer Association Consortium (BCAC) and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). (2016) **A GWAS including 30,882 estrogen receptor negative or BRCA1 mutation-related breast cancer cases and 110,088 controls**

identifies 10 new susceptibility variants. (Oral – PgmNr 48) 2016 Annual Meeting of *The American Society of Human Genetics (ASHG),* Vancouver, BC, October 21, 2016.

547. Wolfson M, Gribble S, Antoniou A, Easton D, Pashayan N, Lee A, Simard J (2016) **Estimating the joint distribution of rare variants, polygenic risk and family history to support analysis of the prospective benefits of risk-based mammographic screening.** (Poster / Poster Talk (Oral) – PgmNr 190) *2016 Annual Meeting of The American Society of Human Genetics (ASHG),* Vancouver, BC, October 18, 2016.

548. Wu L, Long J, Guo X, Kraft P, Milne R, Michailidou K, Beesley J, Dunning A, Pharoah P, Simard J, Chenevix-Trench G, Easton D, Zheng W, on behalf of the Breast Cancer Association Consortium (2016) **Identification of novel susceptibility loci and genes for breast cancer risk: A large transcriptome-wide association study in 119,000 cases and 101,000 controls of European descent** (Oral) – PgmNr 189) *2016 Annual Meeting of The American Society of Human Genetics (ASHG),* Vancouver, BC, October 21, 2016.

549. Ho WK, Mariapun S, Dennis J, Wang Q, Bolla M, Mohd Taib NA, Hartman M, Miao H, Yip C-H, Breast Cancer Consortium, Simard J, Easton D, Teo S-H, Antoniou A (2016) **Breast cancer risk assessment using common genetic variants in Malaysian and Singaporean Chinese population.** (Abstract) *AACR Conference on Improving Cancer Risk Prediction for Prevention and Early Detection*, Orlando, Florida, USA, November 16-19, 2016.

550. Simard J (2017) **The PERSPECTIVE project.** *20th Meeting of the Breast Cancer Association Consortium* (BCAC), Limassol, Cyprus, January 9-12, 2017.

551. Simard J (2017) **Development of statistical methods to test the association between multiple censored phenotypes and SNPs sets in the presence of clustering.** *18th Meeting of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA),* Limassol, Cyprus, January 13-14, 2017.

552. Shu X, Wu L, Khankari NK, Michailidou K, Bolla MK, Wang Q, Dennis J, Shu X-O, Simard J, Easton DF, Zheng W, on behalf of the Breast Cancer Association Consortium (2017) **Association between insulin resistance and breast cancer risk: A Mendelian randomization analysis of data from 228,000 women of European descent.** (Abstract) *American Association Cancer Research (AACR) Annual Meeting 2017*, Washington, D.C., É.-U., April 1-5, 2017.

553. Schmidt MK, Guo Q, Dörk T, Eccles D, Keeman R, Simard J, Kraft P, Easton DF, Pharoah PP on behalf of the Breast Cancer Association Consortium (2016) **Genome-wide association studies of breast cancer prognosis.** (Abstract) *American Association Cancer Research (AACR) Annual Meeting 2017*, Washington, D.C., É.-U., April 1-5, 2017.

554. Ducy M, Coulombe Y, Rodrigue A, Margaillan G, Couturier A, Pauty J, Castroviejo-Bermejo M, Cruz C, Serra V, Simard J, Masson J-Y (2017) **Caractérisation fonctionelle de variations dans *PALB2*, un gène de susceptibilité au cancer du sein.** *Journée du département de Biologie Moléculaire, Biochimie Médicale et Pathologie*, Québec, Canada, April 24, 2017.

555. Ducy M, Rodrigue A, Margaillan G, Coulombe Y, Simard J, Masson J-Y (2017) **Caractérisation fonctionelle de variations dans *PALB2*, un gène de susceptibilité au cancer du sein.** *Journée du CHU de Québec*, Québec, Canada, May 25, 2017.

556. Blouin-Bougie J, Jbilou J, Amara N, Simard J. **To what extent do patients' factors matter in genetic counselling practices? A scoping literature review on providers' point of view.** *Administrative Science Association of Canada (ASAC) 2017 - Health Care Management Division,* Montreal, Canada, May 29-June 1, 2017.

557. Rodrigue A, Coulombe Y, Margaillan G, Ducy M, Soucy P, Caron M-C, Couturier A.M, Pauty J, Joshi N, Buisson R, Zou L, Dellaire G, Carvalho MA, Monteiro A.N.A, Simard J, Masson J-Y (2017) **Regulation and functional analysis of the *PALB2* tumor suppressor.** *Functional Analysis of Sequence Variants in Hereditary Breast and Ovarian Cancer Genes - Improving Genetic Counseling and Cancer Treatment Strategies*, Amsterdam, The Netherlands, May 31–June 2, 2017.

558. Middha P, Lindström S, Jung A, Garcia-Closas M, Guénel P, Kraft P, Simard J, Easton D, Milne RL, Chang-Claude J for the Breast Cancer Association Consortium (2017) **Gene-environment interactions between 65 newly identified breast cancer susceptibility loci and non-genetic risk factors in association with breast cancer risk.** (Abstract) *International Genetic Epidemiology Society Meeting*, Cambridge, UK, September 9-11, 2017.

559. Mavaddat N, Michailidou K, Kraft P, Garcia-Closas M, Simard J, Easton DF on behalf of the Breast Cancer Association Consortium (2017) **An improved polygenic risk score for risk prediction in breast cancer.** (Abstract) *International Genetic Epidemiology Society Meeting*, Cambridge, UK, September 9-11, 2017.

560. Simard J (2017) **The PERSPECTIVE Project.** *BRIDGES annual meeting,* Santiago de Compostela, Spain, September 12-13, 2017.

561. Simard J (2017) **Comprehensive functional assays to evaluate variants impact: *PALB2* a prototype of *in vitro* and *in cellulo* approaches.** *ENIGMA Consortium annual meeting,* Santiago de Compostela, Spain, September 14-16, 2017.

562. Simard J (2017) **Genome Canada Personalised Health Competition.** *21th Meeting of the Breast Cancer Association Consortium* (BCAC), Santiago de Compostela, Spain, September 15-17, 2017.

563. Ducy M, Rodrigue A, Coulombe Y, Margaillan G, Soucy P, Dellaire G, Serra V, Simard J, Masson J-Y (2017) **Caractérisation fonctionelle de variations dans *PALB2*, un gène de susceptibilité au cancer du sein.** *59e réunion annuelle du Club de Recherches Cliniques du Québec,* Magog-Orford, Canada, October 12-14, 2017.

564. Ahearn T, Zhang H, Lecarpentier J, Michailidou K, Milne R, Couch F, Simard J, Kraft P, Easton D, Pharoah P, Schmidt M, Garcia-Closas M, Chatterjee N on behalf of the Breast Cancer Association Consortium (2017) **Novel analysis incorporating multiple tumor characteristics provide evidence of highly heterogeneous associations for known breast cancer risk loci.** *2017 Annual Meeting of The American Society of Human Genetics (ASHG),* Orlando, USA, October 17-21, 2017.

565. Fachal L, Aschard H, Allen J, Barnes D, Beesley J, Ghoussaini M, Kahr S, Carroll JS, Kristensen VN, Chenevix-Trench G, Antoniou A, Simard J, Kraft P, Easton DF, Dunning A on behalf of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), and the Breast Cancer Association Consortium (BCAC) (2017) **Fine-mapping analysis of 152 breast cancer risk loci from OncoArray and iCOGS data.** *2017 Annual Meeting of The American Society of Human Genetics (ASHG),* Orlando, USA, October 17-21, 2017.

566. Zhang H, Lecarpentier J, Ahearn T, Michailidou K, Milne R, Kraft P, Simard J, Pharoah P, Schmidt M, Easton D, Chatterjee N, Garcia-Closas M for the Breast Cancer Association Consortium (2017) **Genome-wide association study (GWAS) identifies 9 novel breast cancer loci from analyses accounting for subtype heterogeneity.** *2017 Annual Meeting of The American Society of Human Genetics (ASHG),* Orlando, USA, October 17-21, 2017.

567. Wolfson M, Gribble S, Pashayan N, Antoniou A, Easton D, van Katwyk S, Lee A, Simard J (2017) **Combining individual-level dynamics of union formation and dissolution and fertility with microsimulation modeling to infer the joint distribution of family pedigrees and genetics risks for breast cancer.** *XXVIII IUSSP International Population Conference.* Cape Town, South Africa, October 29-November 4, 2017.

568. Rodrigue A, Coulombe Y, Marguillan G, Ducy M, Soucy P, Couturier AM, Pauty J, Buisson R, Joshi N, Caron M-C, Zou L, Dellaire G, Carvalho MA, Monteiro A, Simard J, Masson J-Y (2017) **Functional analysis of the *PALB2* tumor suppressor.** *4th Canadian Cancer Research Conference.* Vancouver, Canada, November 5-7, 2017.

569. Baxter J, Dryden N, Fedele V, Johnson N, Maguire S, Orr N, Fletcher O, The Breast Cancer Association Consortium. **Common genetic variants at the breast cancer risk region 2q35 map to putative IGFBP5**

enhancers. *European Association for Cancer Research*. Amsterdam, The Netherlands, 30 june – 3 july 2018. ESMO Open Jul 2018, 3 (suppl 2) A248; doi:10.1136/esmoopen-2018-EACR25.586.

570. Middha P, Mavaddat N, Milne RL, Simard J, Schmidt MK, Kraft P, Pharoah PDP, Easton DF, Garcia-Closas M, Chang-Claude J on behalf of Breast Cancer Association Consortium (2018) **Combined association of a polygenic risk score with 313 genetic variants and established environmental risk factors in relation to breast cancer risk**. *The 2018 Annual Meeting of the International Genetic Epidemiology Society*. San Diego, CA, October 13-16, 2018. doi:10.1002/gepi.22163.

571. Zhang Y, Wilcox A, Kote Jarai Z, Eeles R, Haiman C, Easton D, Kraft P, Simard J, Landi M, Amos C, McKay J, Pharoah P, Sellers T, Berchuck A, Jenkins M, Hoffmeister M, Campbell P, O'Mara TO, Spurdle A, Thompson D, Iles M, Bondy M, Wrensch M, Wiencke J, Purdue M, Scelo G, Brennan P, Chanock S, Chatterjee N, Garcia Closas M (2018) **Estimation of the polygenetic architecture of ten cancers and its implications for future discoveries.** *2018 Annual Meeting of The American Society of Human Genetics (ASHG)*. San Diego, USA, October 16-20, 2018.

572. Garcia-Closas M, Chatterjee N, Ahearn T, Antoniou A, Chang-Claude J, Chenevix-Trench G, Couch F, Fejerman L, Garver J, Gillanders L, Haiman C, Kraft P, Milne R, Orr N, Palmer J, Pharoah P, Schmidt M, Simard J, Zhang W, Easton D, Chanock S (2018) **The Confluence Project: Uncovering Breast Cancer Genetics.** *NCI Cohort Consortium Meeting.* Rockville, Maryland, USA, November 28-30, 2018.

573. Pal Choudhury P, Wilcox A, Gao C, Carter B, Husing A, Brook M, Eriksson M, Martin K, Scott C, Shi M, Aheran T, Jones M, Orr N, Schoemaker M, Czene K, Chang-Claude J, Simard J, Easton D, Schmidt MK, Sandler D, Weinberg CR, Vachon C, Milne R, Hall P, Swerdlow A, Kaaks R, Barrdahl M, Gaudet M, Antoniou A, Kraft P, Garcia-Closas M, Chatterjee N (2019) **Validation of breast cancer risk model incorporating classical risk factors and polygenic risk scores in 14 prospective cohort studies in 6 countries.** (Oral) *American Association for Cancer Research (AACR) Annual Meeting*. Georgia, Atlanta, USA, March 29 – April 3, 2019.

574. Jung AY, Ahearn TU, Behrens S, Zhang H, Middha P, Schmidt M, Chatterjee N, Garcia-Closas M, Chang-Claude J, Simard J, on behalf of BCAC (2019) **Evaluating multiple tumor markers in a novel analysis of reproductive factors and breast cancer risk.** *American Association for Cancer Research (AACR) Annual Meeting*. Georgia, Atlanta, USA, March 29 – April 3, 2019.

575. Morra A, Jung AY, Behrens S, Yang R, Eliassen H, Holmes M, Garcia-Closas M, Schmidt MK, Chang-Claude J, on behalf of the BCAC (2019) **Breast cancer risk factors and survival by tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.** *American Association for Cancer Research (AACR) Annual Meeting.* Georgia, Atlanta, USA, March 29 – April 3, 2019.

576. Kar S, Lindström S, Dennis J, Michailidou K, Hung R, Easton D.F., Simard J, Spurdle A, O'Mara T, Eeles R, Pasaniuc B, Kraft P, Pharoah P, on behalf of BCAC, OCAC, ECAC, GAME-ON, PRACTICAL, CAPS and PEGASUS consortia (2019) **Genome-wide association meta-analysis of over 237,000 breast, prostate, ovarian and endometrial cancer cases and 317,000 controls identifies 128 regions containing associations with multiple cancers.** *American Society of Human Genetics (ASHG) Annual Meeting.* Houston, Texas USA, October 14 - 19, 2019.

577. Lévesque E, James J*, Knoppers BM*, Andrulis I, Brooks J, Chiquette J, Dorval M, Esserman L, Eisen A, Eloy L, Joseph G, Koenig B, Madlensky L, Nabi H, Shieh Y, Stockley T, Ziv E, Blackmore K, Caruncho M, Lambert-Côté L, Riddle L, Stover Fiscalini A, Tong B, Turgeon A, van't Veer L, Chiarelli AM, Simard J (2020) **Polygenic Risk Scores and the Return of Breast Cancer Risk Results: Canada – United States Experience** (Oral). *BRCA 2020 Symposium.* Montreal, Québec, Canada, May 5 – 8, 2020.

578. Simard J, Chiarelli AM, Antoniou AC, Blackmore K, Brooks J, Chiquette J, Després P, Dorval M, Easton DF, Eisen A, Eloy L, Hagan J, Joly Y, Knoppers BM, Lambert-Côté L, Lévesque E, Mittmann N, Nabi H, Pashayan N, Stockley T, Turgeon A, Wolfson M on behalf of PERSPECTIVE I&I. **Risk-based breast cancer screening: Strategies adopted in the PERSPECTIVE I&I study to address implementation challenges.** *BRCA 2020 Symposium.* Montréal, QC, May 5-8, 2020.